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DEPRESSIVE DISORDERS AND CHRONIC COMORBID DISEASE 
STATES – A PHARMACOEPIDEMIOLOGICAL EVALUATION 
 
SUMMARY 
 
The treatment of Depressive Disorders in patients with chronic comorbid 
disease states warrants careful consideration of the risk-benefit ratio 
pertaining to the pharmacokinetic and pharmacodynamic characteristics of the 
antidepressant being considered, against the physiological susceptibilities of 
the patient; potential drug-drug interactions and depressive symptoms. 
 
The primary aim of this study was to investigate the relationship between 
Depressive Disorders and the most frequently diagnosed chronic comorbid 
disease states in a depressed South African study population; and to 
comment on the appropriateness of antidepressants prescribed to these 
patients.   
 
This retrospective drug utilisation study consisted of two parts:  the first part 
focused on the prevalence of the most frequently diagnosed chronic 
comorbidities in a depressed South African population (N = 21 171).  The 
three most prevalent chronic comorbid disease states were Hypertension 
(52.87%), Lipid Disorders (20.40%) and Arthritis (16.70%).  The second 
part of the study included an assessment of the antidepressants prescribed to 
depressed patients in 2004 (N = 6 150).  Emphasis was placed on the 
suitability of antidepressants selected for depressed adult patients (18 years 
of age and older) with comorbid Hypertension, Lipid Disorders or Arthritis. 
   
SSRIs were prescribed most frequently to the depressed patients during 2004 
(59.67%).  SSRIs are the suggested first-line treatments for depressed 
patients with multiple chronic comorbid disease states.  However, of the 
SSRIs, fluoxetine has the least favourable pharmacokinetic profile and was 
found to be the antidepressant prescribed most often.   
 
 xxv
Amitriptyline, which was the TCA prescribed most frequently, produces the 
greatest degree of anticholinergic, sedative and hypotensive effects, relative 
to other agents in the same antidepressant class.  Thus, it is not 
recommended as a first-line antidepressant, especially in depressed patients 
with comorbidities. 
 
This study identifies potential areas of intervention regarding antidepressant 
prescribing in depressed individuals with chronic comorbid disease states and 
offers recommendations to promote the selection of optimal, individualised 
drug treatment strategies for these patients. 
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INTRODUCTION AND PROBLEM STATEMENT 
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1.1 INTRODUCTION 
 
A pharmacoepidemiological evaluation involves the application of 
epidemiological methods to pharmacological matters (International Society for 
Pharmacoepidemiology, 2007).  This dissertation focuses on the following two 
pharmacoepidemiological aspects regarding a sample of depressed patients 
registered with a chronic pharmaceutical benefit management company in 
South Africa:  the nature and prevalence of chronic comorbid disease states; 
and antidepressant prescribing trends relative to the most common 
comorbidities identified.  This chapter provides an outline of the background to 
the study; problem statement; primary aim and objectives; and chapter layout. 
 
1.2 BACKGROUND TO THE STUDY 
 
Researchers have shown that individuals born in this era are more likely to 
suffer from Depressive Disorders at some stage during their lives than those 
who were born in earlier times (Kessler, Berglund, Demler, Jin, Koretz, 
Merikangas, Rush, Walters & Wang, 2003a).  The World Health Organization 
(WHO) estimates that Depressive Disorders currently affect 340 million 
people worldwide (WHO, 2003).  In the United States (US), it is further 
estimated that 12% and 7% of females and males, respectively, will 
experience a depressive episode in any given year (Narrow, 1998).  However, 
this varies amongst surveys and nations.  For example, South Africa is a 
middle income, developing country and it has been suggested that the 
prevalence of mental disease states amongst South Africans is linked to the 
political and social history of the country.  The influence of apartheid, high 
poverty and unemployment rates (estimated to be 30% and 50%, 
respectively) and the burden of Human Immunodefiency Virus/Acquired 
Immunodefiency Syndrome (HIV/AIDS) amongst South Africans, all impact 
significantly on mental health.  In South Africa, the prevalence of Depressive 
Disorders reportedly ranges from 14% to 49%.  (Triant, 2002.)  
 
Depressive Disorders are known to affect more women than men and many 
studies have deduced, more specifically, that rates of Depressive Disorders 
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for females are twice as high as for males (Kamlet, Paul, Greenhouse, Kupfer, 
Frank & Wade 1995; Kornstein, 2001; Kessler, 2003).  It has been proposed 
that approximately 70% of females are more likely to suffer from Depressive 
Disorders over their lifespan when compared with males (Kessler et al., 
2003a).  The two perspectives discussed most frequently in order to explain 
this gender-related difference, include:   the female reproductive physiology 
and the woman’s status, roles and life’s situations (Norman, 2004).  
Conversely, studies have failed to yield consistent results regarding the 
relationship between age and Depressive Disorders (Stordal, Mykletun & 
Dahl, 2003).  Some studies have depicted a positive relationship in this regard 
(Pillay & Sargent, 1999; Schnittker, 2005).  It has been suggested that 
changes in physical health are responsible for a significant increase in 
depressive symptoms in the elderly (defined as individuals aged 65 years and 
older) (Schnittker, 2005).  Furthermore, Mirowsky and Ross (1992) suggested 
that there would be fewer depressive symptoms in elderly individuals if age-
related changes in physical health were not considered.       
 
Researchers have demonstrated that patients with chronic disease states are 
more susceptible towards the development of a future Depressive Disorder 
than individuals without these disease states (McCoy, 1996; Patten, 2001; 
Carnethon, Kinder, Fair, Stafford & Fortmann, 2003; Kanner, 2003; Katon, 
2003; Yates, Mitchell, Rush, Trivedi, Wisiniewski, Warden, Hauger, Fava, 
Gaynes, Husain & Bryan, 2004; Patten, Beck, Kassam, Williams, Barbui & 
Metz, 2005).  On the other hand, depressed patients have been shown to 
exhibit a high prevalence of chronic comorbid disease states (Wells, Rogers, 
Burnam, Greenfield & Ware, 1991; Barbee, 1998; Krishnan & Clary, 2000; 
Lespẻrance, Frasure-Smith, Juneau & Thẻroux, 2000; Ohira, Iso, Satoh, 
Sankai, Tanigawa, Ogawa, Imano, Sato, Kitamura & Shimamoto, 2001; van 
Manen, Bindels, Dekker, IJzermans, van der Zee & Schadé, 2002; Katon, 
2003; Golden, Williams, Ford, Yeh, Paton Sanford, Nieto & Brancati, 2004; 
Cankurtaran, Halil, Yavuz, Dagli, Cankurtaran & Ariogul, 2005).  On average, 
depressed patients are diagnosed with two chronic comorbid disease states 
(Katon, 2003).   
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Studies focusing on patients with specific illnesses have identified a 
relationship between Depressive Disorders and the following disease states:  
Hypertension (Jonas, Franks & Ingram, 1997; Dorsey, Rodriguez & 
Brathwaite, 2002; Kessler, Ormel, Demler & Stang, 2003b; Meyer, Armenian, 
Eaton & Ford, 2004; Cankurtaran et al., 2005; Patten et al., 2005); Arthritis 
(Marsh, 1997; Taal, Rasker & Timmers, 1997; Kessler et al., 2003b); 
Menopause (Cohen, Soares, Vitonis, Otto & Harlow, 2006); Diabetes 
Mellitus (Kovacs, Goldston, Obrosky & Bonar, 1997; Lustman, Griffith & 
Clouse, 1997; Anderson, Freedland, Clouse & Lustman, 2001; Pincus & 
Pettit, 2001; Kanner, 2003; Cankurtaran et al., 2005); Thyroid Disorders 
(Burmeister, Ganguli, Dodge, Toczek, DeKosky & Nebes, 2001; Sintzel, 
Mallaret & Bougerol, 2004; Thomsen, Kvist, Andersen & Kessing  2005; 
Patten et al., 2005; Gülseren, Gülseren, Hekimsoy, Cetinay, Ozen & 
Tokatlioglu, 2006); Allergic Rhinitis (Cuffel, Wamboldt, Borish, Kennedy & 
Crystal-Peters, 1999); Lipid Disorders (Kinder, Carnethon, Palaniappan, 
King & Fortmann, 2004; Nakao & Yano, 2004; Petrlova, Rosolova, Hess, 
Podlipny & Simon, 2004); Thrombo-Embolic Prophylaxis (Frasure-Smith, 
Lespẻrance & Taljic, 1995; Musselman, Evans & Nemeroff, 1998; Krishnan et 
al., 2000; Nemeroff & Musselman, 2000); Psychiatric Disorders (Kanner, 
2003); Neurological Disease States (Mayberg & Solomon, 1995 [Parkison’s 
Disease]; Whyte & Mulsant, 2002; Berg, Palomaki, Lehtihalmes, Lonnqvist & 
Kaste, 2003 [Stroke]; Kanner, 2003 [Epilepsy]; Cankurtaran et al., 2005 
[Alzheimer’s Disease]; and HIV/AIDS (Perkins, Stern, Golden, Murphy, 
Naftolowitz & Evans, 1994; Dew, Becker, Sanchez, Caldararo, Lopez, Wess, 
Dorst & Banks, 1997; Bing, Burnam, Longshore, Fleishman, Sherbourne, 
London, Turner, Eggan, Beckman, Vitiello, Morton, Orlando, Bozzette, Ortiz-
Barron & Shapiro, 2001).   
 
Depressive Disorders are highly recurrent (Pincus et al., 2001; Keller & 
Berndt, 2002) and are not likely to resolve spontaneously without proper 
treatment (Keller, Lavori, Mueller, Endicott, Coryell, Hirschfeld & Shea, 1992).   
There are various treatment modalities available for the management of 
Depressive Disorders, but psychotherapy and pharmacotherapy are utilised 
most frequently (APA, 2000).  In depressed patients with chronic co-existing 
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disease states, the use of psychotherapy on its own may be an advantageous 
treatment modality because of the avoidance of adverse effects and potential 
drug interactions (MacHale, 2002).  Cognitive Behavioural Therapy (CBT) is a 
psychological treatment approach that has been demonstrated to exhibit 
equal efficacy to pharmacological agents (DeRubeis, Gelfand, Tang & 
Simons, 1999).  Furthermore, depressed patients with specific chronic 
comorbid disease states have been shown to benefit from the use of CBT 
(Lustman, Griffith, Freedland, Kissel & Clouse, 1998 [Diabetes Mellitus]; 
Grover, Kumaraiah, Prasadrao & D’souza, 2002 [Asthma]; Alpay & Cassem, 
2000; Sharpe, Sensky, Timberlake, Ryan & Allard, 2003 [Arthritis]). 
 
The following pharmacological treatments are currently available for the 
management of Depressive Disorders:  non-selective monoamine re-uptake 
inhibitors; selective serotonin reuptake inhibitors (SSRIs); monoamine oxidase 
inhibitors (MAOIs); ‘other antidepressants’; ‘combination antidepressant-
antipsychotic drug treatments’; and antidepressants prescribed with 
augmenting therapies, such as lithium or thyroid hormone (Nemeroff, 2006).  
The selection of a suitable antidepressant for depressed patients with chronic 
comorbid disease states requires careful consideration of the risk-benefit ratio 
regarding the pharmacokinetic and pharmocodynamic properties of the 
medication being considered, versus the physiological susceptibilities of the 
patient; potential drug-drug interactions and depressive symptoms (Beliles & 
Stoudemire, 1998; MacHale, 2002).  Based on results from reputable clinical 
trials, possible side effects, cost-effectiveness, safety and tolerability profiles, 
and patient preference, the American Psychiatric Association (APA, 2000) 
suggests the use of the following antidepressants (only those available in 
South Africa are listed here):  SSRIs, venlafaxine and bupropion (venlafaxine 
and bupropion are classified as ‘other antidepressants’).  More specifically, 
numerous studies recommend the use of SSRIs as first-line agents for 
depressed patients with multiple comorbidities; for example, Hypertension 
(Guck, Kavan, Elsasser & Barone, 2001; MacHale, 2002; Hayes, 2004); and 
Arthritis (Alpay et al., 2000).  Additionally, Beliles and Stoudemire (1998) 
advise the use of an antidepressant with a reasonably short half-life in 
depressed patients with comorbidities.  Of the SSRIs, citalopram and 
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sertraline exhibit the most favourable pharmacokinetic profiles, which include 
short to intermediate half-lives and a poor propensity towards drug-drug 
interactions (Hirschfeld, 2001).  In contrast, fluoxetine has a long half-life and 
is more likely to be involved in drug-drug interactions than many other 
antidepressants (Kando, Wells & Hayes, 2002).  This is a major concern in 
patients with multiple comorbid disease states and complex drug regimens 
involving different drug treatments (Kairuz, Zolezzi & Fernando, 2005).  South 
African drug utilisation reviews analysing antidepressant prescribing patterns 
in depressed patients, have identified fluoxetine as the most commonly 
prescribed agent for the treatment of Depressive Disorders (Truter & Kotze, 
1996; Van Schalkwyk, 2005).  In addition to the unfavourable pharmacokinetic 
profile of fluoxetine, studies have shown that it has adverse effects in terms of 
the management of numerous chronic comorbid disease states, such as, 
Diabetes Mellitus (Kando et al., 2002; MacHale, 2002; South African 
Medicines Formulary [SAMF], 2005) and Hyperlipidaemic Disorders 
(Nicholas, Ford, Esposito, Ekstrom & Golden, 2003).   
 
Venlafaxine and bupropion have been shown to display comparable efficacy 
rates to the SSRIs (Thase, Haight, Richard, Rockett, Mitton, Modell, 
VanMeter, Harriett & Wang, 2005; Nemeroff, 2006).  Moreover, these newer 
antidepressants do not partake in significant drug-drug interactions (Forstein, 
Cournos, Douaihy, Goodkin, Wainberg & Wapenyi, 2000) and have been 
proposed to offer considerable advantages over the older agents in 
depressed patients with certain chronic concomitant disease states.  
Examples of such disease states include:  Diabetes Mellitus (Musselman, 
Betan, Larsen & Phillips, 2003) and Myocardial Infarction [MI] (Glassman, 
Roose & Bigger, 1993). 
 
Recent studies conducted in South Africa have demonstrated that tricyclic 
antidepressants (TCAs) are still frequently prescribed pharmacological agents 
for the treatment of Depressive Disorders (Kairuz, Truter, Hugo & Foxcroft, 
2003; Bellingan, 2004; Van Schalkwyk, 2005).  This class of antidepressants 
is associated with an adverse side effect and safety profile and elevated rates 
of non-compliance (Roose, 2003).  As a result, TCAs are no longer 
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considered as first-line agents for the treatment of Depressive Disorders 
(Quitkin, 2002).  Of particular concern, is the prescription of TCAs (especially, 
amitriptyline) and fluoxetine in depressed patients with prevalent chronic 
comorbid disease states.  For example, Hypertension and Hyperlipidaemia 
are frequently diagnosed chronic disease states in South Africans (Steyn, 
Bradshaw, Norman, Bradley & Laubscher, 2005; Heart Foundation - South 
Africa, 2006).  Furthermore, researchers have established that these disease 
states are associated with Depressive Disorders (Jonas et al., 1997; Dorsey 
et al., 2002; Kessler et al., 2003b; Meyer et al., 2004; Cankurtaran et al., 
2005; Patten et el., 2005 [Hypertension]; Kinder et al., 2004; Nakao et al., 
2004; Petrlova et al., 2004 [Lipid Disorders]).  TCAs may change the following 
cardiovascular parameters:  heart rate and rhythm, electrical conduction, 
myocardial contractility and blood pressure (Roose & Dalack, 1992).  Also, 
antidepressant-antihypertensive drug interactions may result in an enhanced 
or reduced blood pressure lowering effect (Lucas, 1999; APA, 2000).  With 
regard to depressed patients diagnosed with comorbid Hyperlipidaemic 
Disorders, current research has shown that elevated lipid levels may be 
associated with treatment failure to fluoxetine (Nicholas et al., 2003).  
 
The empirical component of the study consists of two parts, namely:  an 
investigation into the prevalence of the most frequently diagnosed chronic co-
existing disease states in a depressed South African study population; and a 
drug utilisation review of the antidepressants prescribed to patients diagnosed 
with one or more Depressive Disorders in the year, 2004.  The analyses will 
be repeated for different age groups selected for this study (0 to 17 years, 18 
to 34 years, 35 to 54 years, 55 to 64 years and 65 years and older), since 
depressed children and adolescents (0 to 17 years of age), for example, 
would be expected to present with different comorbidities and antidepressant 
prescribing patterns to elderly depressed patients.  Therefore, these 
independent analyses will allow for distinctions to be made across the age 
groups.  Comparisons will be made with literature findings in order to further 
elucidate the nature of the relationship between Depressive Disorders and the 
specified chronic comorbid disease states.  In addition, antidepressant 
prescribing trends observed in depressed adult patients (individuals aged 18 
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years and older) diagnosed with one or more of the most prevalent chronic 
concomitant disease states (identified in the first part of the study) will be 
evaluated against literature recommendations, and thus, allow for the 
identification of potentially inappropriate prescribing trends.   
       
1.3 MOTIVATION FOR THE STUDY AND PROBLEM STATEMENT 
 
The risk of developing Depressive Disorders secondary to a chronic disease 
state or alternatively, developing a chronic disease state secondary to a 
Depressive Disorder, has been investigated for many years already (Katon, 
2003).  However, the relationship between Depressive Disorders and chronic 
co-existing disease states is complex and appears to be attributable to 
Depressive Disorders precipitating chronic disease states and similarly, to 
chronic disease states exacerbating depressive symptoms (Chapman, Perry 
& Strine, 2005).  It is imperative to understand this complex interrelationship 
since Depressive Disorders and chronic comorbidities are increasingly being 
recognised as major impediments to health.  For example, the impact of 
Depressive Disorders alone may be illustrated by the expectation that such 
disorders will be second only to Cardiovascular Disease (CVD) with regards 
to their contribution to the global burden of disease by 2020 (Chapman et al., 
2005).  Additionally, the association between Depressive Disorders and 
chronic co-existing disease states has significant implications for both the 
treatment of the Depressive Disorder and the management of comorbidities.     
 
The motivation for conducting this study stems from the fact that there is a 
paucity of research available in South Africa regarding the treatment of 
Depressive Disorders in depressed patients with chronic comorbid disease 
states.  Appropriate antidepressant selection is fundamental because 
numerous studies have identified a significant improvement in the 
management of the comorbid disease state, as well as, patient functionality 
and quality of life, in patients treated adequately for Depressive Disorders 
(Carney, Freedland, Eisen, Rich & Jaffe, 1995; Alexopoulos, Kiosses, Choi, 
Murphy & Lim, 2002; Lustman & Clouse, 2005).  Therefore, an investigation of 
the antidepressant prescribing patterns for South African depressed patients 
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with concomitant chronic disease states would provide data to review the 
suitability of the medications selected.   
 
1.4 PRIMARY AIM AND OBJECTIVES 
 
The primary aim of this pharmacoepidemiological study is to investigate the 
relationship between Depressive Disorders and the most frequently 
diagnosed chronic comorbid disease states in a depressed South African 
study population; and to comment on the appropriateness of antidepressants 
selected for these patients.  The specific research objectives pertaining to the 
epidemiological review are to: 
 
• conceptualise the literature regarding the aetiology and diagnosis of 
Depressive Disorders; prevalence of Depressive Disorders and 
factors affecting prevalence; nature and prevalence of commonly 
occurring chronic comorbid disease states; and the implications of 
being diagnosed with a chronic disease state and comorbid 
Depressive Disorders;     
• elucidate the nature of the relationship between Depressive 
Disorders and commonly occurring chronic comorbid disease 
states; 
• establish the prevalence of Depressive Disorders relative to age 
and gender in the study population; 
• provide an overview of the number of chronic comorbid disease 
states per depressed patient in the study population;  
• investigate the prevalence and nature of chronic comorbid disease 
states in depressed patients; 
• determine the prevalence and nature of chronic comorbid disease 
states in specified age groups; and 
• investigate the impact of age on the chronic comorbid disease state 
prevalence.  
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The specific research objectives applicable to the pharmacological evaluation 
(empirical analysis pertains to the year, 2004) are as follows: 
 
• conceptualise the management of Depressive Disorders in the 
presence of commonly occurring chronic comorbid disease states; 
• provide an overview of the number of active ingredients prescribed 
per depressed patient; 
• evaluate the frequency of the most commonly prescribed 
medications in depressed patients; 
• provide an overview of the drugs prescribed for the management of 
Depressive Disorders in depressed patients; 
• review the drugs prescribed for the management of Depressive 
Disorders in the specified age groups; 
• provide general comment regarding antidepressant prescribing 
trends in relation to the five comorbidities identified to be most 
prevalent in each of the specified age groups;  and 
• investigate changes in antidepressant prescribing patterns relative 
to the prevalence of the three most frequently diagnosed chronic 
co-existing disease states in adult depressed patients.  
 
1.5 CHAPTER LAYOUT 
 
The first chapter provides an outline of the background to the study; a 
description of the motivation and problem statement; and a list of the primary 
aim and research objectives.   
 
Chapter two is an overview of Depressive Disorders and chronic comorbid 
disease states.  The purpose of this chapter is to investigate the nature of the 
relationship between Depressive Disorders and chronic co-existing disease 
states.  
 
The literature pertaining to the management of Depressive Disorders (with the 
main focus on pharmacological treatments) in patients with prevalent chronic 
comorbid disease states is examined in Chapter three. 
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Chapter four describes the methods utilised to undertake this study and 
includes an overview of the processes involved in the assembly of applicable 
information for the literature chapters; and the collection, verification and 
analysis of data.  In addition, the statistical analyses and limitations of the 
study are outlined in this chapter. 
 
The results of this study are presented in Chapters five and six.  The 
observations regarding the prevalence of Depressive Disorders and the 
nature of the chronic comorbid disease states are presented in Chapter five.  
Chapter six, in turn, depicts the findings relating to the appropriateness of 
antidepressant prescribing trends in the presence of prevalent chronic 
comorbid disease states. 
   
Chapter seven summarises the chief findings of the study and provides 
recommendations, which are based on the most significant observations of 
this study. 
 
 
  
 
 
 
CHAPTER 2 
 
DEPRESSIVE DISORDERS AND CHRONIC COMORBID 
DISEASE STATES 
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2.1 INTRODUCTION 
 
The World Health Organization estimates that Depressive Disorders currently 
affect 340 million people worldwide (WHO, 2003).  Depressed patients have 
been found to exhibit a higher prevalence of certain chronic comorbid disease 
states than their non-depressed counterparts (Wells et al., 1991).  Similarly, 
patients with chronic disease states are more likely to suffer from a 
Depressive Disorder than individuals without these disease states (Patten, 
2001; Patten et al., 2005).  Several studies have shown that the effects of 
Depressive Disorders and chronic comorbid disease states on symptom 
burden, functionality and quality of life, are synergistic (Berardi, Menchetti, De 
Ronchi, Rucci, Leggieri & Ferrari, 2002; Harpole, Williams, Olsen, 
Stechuchak, Oddone, Callahan, Katon, Lin, Grypma & Unűtzer, 2005).   
 
This review conceptualises the literature pertaining to the relationship that 
exists between Depressive Disorders and chronic comorbid disease states.  It 
provides an overview of the following aspects:  
 
• definition of Mood Disorders;  
• various aetiologies of Depressive Disorders;  
• prevalence of Depressive Disorders and factors affecting 
prevalence;  
• chronic disease states commonly comorbid with Depressive 
Disorders and discussions pertaining to the possible link between 
Depressive Disorders and these comorbidities; and  
• implications of being diagnosed with a Depressive Disorder and one 
or more co-existing disease states.   
 
2.2 DEFINITION OF MOOD DISORDERS  
 
Mood Disorders (Affective Disorders) constitute a collection of mental 
disorders characterised by states of changing moods (depression or mania) 
which fall beyond the bounds of normal oscillations from sadness to elation 
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(US Department of Health and Human Services, 1999).  Mood is defined as ‘a 
pervasive and sustained emotion that, in the extreme, markedly affects the 
person’s perception of the world and ability to function adequately in society’ 
(Kando et al., 2002).  A Mood Disorder occurs when a disturbance in mood is 
accompanied by specific associated symptoms that impair the person’s ability 
to perform for a certain period of time (Kando et al., 2002).   
 
The four principal Mood Disorders are listed below, followed by a brief 
explanation of each disorder:   
 
• Major Depressive Disorder (also known as MDD or Unipolar Major 
Depression) 
• Bipolar Disorders (also referred to as Manic Depression or Bipolar 
Affective Disorder) 
• Dysthymia 
• Cyclothymia 
 
Major Depressive Disorder differs both qualitatively and quantitatively from 
normal states of dysphoria (negative mood state).  Normal states of sadness 
and grief are not as insidious or as lengthy as the mood disturbance that is 
evident in MDD.  In addition to this difference, normal states of dysphoria are 
seldom accompanied by some of the following symptoms of MDD:  
hopelessness, poor concentration, suicidal thoughts, psychotic symptoms 
(delusions and hallucinations) and inability to experience pleasure.  (Kalia, 
2005.) 
 
Bipolar Disorder is a recurring Mood Disorder characterised by the presence 
of one or multiple episodes of mania or mixed episodes of mania and 
depression (Kalia, 2005).  It is a cyclic disorder that can be differentiated from 
MDD by the presence of manic, hypomanic (milder than manic and not 
psychotic), or mixed episodes during the course of the disease (Kando et al., 
2002). 
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Dysthymia is a chronic form of Depression and is characterised by fewer 
acute but longer-lasting symptoms than MDD (US Department of Health and 
Human Services, 1999). 
 
Cyclothymia is a disorder that encompasses manic and depressive states that 
are not of the required intensity or duration to be categorised as either Bipolar 
Disorder or MDD (US Department of Health and Human Services, 1999). 
 
According to the Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition, text revision (DSM-IV-TR®, 2000), Mood Disorders are categorised as 
either Depressive Disorders (MDD, Dysthymia and Depressive Disorder Not 
Otherwise Specified); Bipolar Disorders (Bipolar I Disorder, Bipolar II 
Disorder, Cyclothymia and Bipolar Disorder Not Otherwise Specified); Mood 
Disorder Due to a General Medical Condition and Substance-induced Mood 
Disorder.  Depressive Disorders will form the principal focus of this study.   
 
2.3 AETIOLOGY OF DEPRESSIVE DISORDERS 
 
A Depressive Disorder is a multifactorial disorder with many aetiological 
variables.  This section discusses the various aetiological factors involved in 
the development of a Depressive Disorder.  Table 2.1 outlines these factors 
and provides a few examples of each. 
 
2.3.1 Environmental Factors 
 
The role of life events (with reference to current, major socio-economic 
changes in the individual’s life) and social stress in the development of 
Depressive Disorders has been studied extensively over the years.  Such 
research has deduced that the risk of Depressive Disorders increases after 
stressful life events and that these occurrences are the cause of many cases 
of depressive episodes.  (Shah, 2002.) However, not all people suffer from 
Depressive Disorders during or after such situations.  Most people adapt to 
the challenges of life and only experience a mild and temporary state of 
dysphoria.  Conversely, other individuals who are exposed to these identical 
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psychosocial challenges will experience a major depressive episode (MDE).  
(Kando et al., 2002.) This suggests that there are numerous other causative 
and modifying factors that are involved in predicting the risk of developing a 
clinical Depressive Disorder.  This point was reinforced by calculating the so-
called ‘population attributable risk’, which is an estimate of the proportion of 
the Depressive Disorders that can be attributed to life situations, to be 40% 
(Shah, 2002).   
 
TABLE 2.1 
AETIOLOGICAL FACTORS INVOLVED IN THE DEVELOPMENT OF 
DEPRESSIVE DISORDERS  
   
Aetiological factors Examples 
1. Environmental Factors • Sexual abuse during childhood, exposure to a disturbed 
family environment, loss of parents prematurely, 
predisposing personality characteristics, traumatic and 
difficult life experiences, poor social support and marital 
hardship (Kendler, Gardner & Prescott, 2002).   
• Substance misuse.  (Kendler et al., 2002). 
2. Genetic Factors • A family history of Major Depressive Disorder 
(US Department of Health and Human Services, 1999).  
3. Iatrogenic Causes • Beta-blockers (Cankurtaran et al., 2005). 
• Corticosteroids (Bonala, Pina, Silverman, Amara, 
Bassett & Schneider, 2003). 
4. Chronic Comorbid 
Disease States 
• Coronary Heart Disease (CHD) (McCoy, 1996). 
• Diabetes Mellitus (Kovacs et al., 1997; Lustman et al., 
1997; Anderson et al., 2001; Pincus et al., 2001; 
Kanner, 2003; Cankurtaran et al., 2005). 
5. Neurochemical Theories • Monoamine Hypothesis (Kalia, 2005). 
• Hypothalamic-Pituitary-Adrenal (HPA) dysfunction 
(Gums & Terpening, 2002). 
6. Other Hypotheses • Fatty acid theory (Maes & Smith, 1998; Maes, 
Christophe, Delanghe, Altamura, Neels & Meltzer, 
1999). 
 
 
 17
2.3.2 Genetic Factors 
 
Genetic predisposition to Depressive Disorders and other Psychiatric 
Disorders has been recognised for over 50 years.  It has been established, by 
means of twin studies and studies on adopted children, that hereditability 
accounts for approximately 60% of all severe Mood Disorders.  (Shah, 2002.) 
Researchers have shown that first-degree relatives of individuals with Mood 
Disorders are two to four times more susceptible to also suffering from a 
Mood Disorder (US Department of Health and Human Services, 1999).  
However, this alone, does not prove a genetic association, so it can therefore 
be suggested that the link may be more environmental than genetic in origin, 
since these relatives typically live in the same environment, are exposed to 
similar stressors and have comparable principles to the individual suffering 
from the Mood Disorder.  An early study (1986) used the term ‘genetic control 
of exposure to the environment’ to describe a possible synergistic relationship 
between genotype and environmental factors when it comes to increasing the 
risk for a MDE.  ‘Genetic control of exposure to the environment’ refers to the 
situation in which persons, who have a significant genetic risk, allow 
themselves to be involved in lifetime traumas and divorce.  Such 
circumstances subsequently enhance the predisposition towards Depressive 
Disorders.  (Kendler & Eaves, 1986.) 
  
From a simple genetic theory perspective, it is well-known that an exclusively 
hereditary trait, that is evident in one individual of a pair of identical 
(monozygotic) twins, should also always be found in the other twin.  In same-
sex fraternal twins, termed dizygotic twins, the hereditary trait should only 
appear 50% of the time.  Studies performed on both sets of twins have 
revealed that the prevalence concordance for Mood Disorders is greater 
among identical twins than fraternal twins.  More specifically, this proportion 
was found to be two to one, for monozygotic and dizygotic twins, respectively.  
(US Department of Health and Human Services, 1999.) Such studies may 
serve as tools to distinguish environmental factors from genetic influences in 
order to establish their association to Depressive Disorders.   
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Research has not yet been able to identify precisely which inherited genes are 
implicated.  The discovery of a difference in the polymorphism of a gene 
(involved in transporting serotonin in depressed individuals), has been put 
forward to explain one of the possible mechanisms of genetic involvement in 
the aetiology of Depressive Disorders.  However, further studies were unable 
to yield the same results on a consistent basis. This could imply that multiple 
genes are implicated.  (Shah, 2002.)   
 
2.3.3 Iatrogenic Causes 
 
The DSM-IV-TR® (2000) defines a ‘Substance-Induced Mood Disorder’ as 
follows:  ‘the essential feature of Substance-Induced Mood Disorder is a 
prominent and persistent disturbance in mood that is judged to be due to the 
direct physiological effects of a substance’.  A ‘substance’ can refer to many 
different aspects, but medication would be an example of a substance that is 
relevant in this case.  Such a disorder must begin during the time when the 
patient is receiving the medication or during withdrawal (if there is a 
withdrawal syndrome associated with the medication).  The substance-
induced mood symptoms will normally disappear within days or weeks of 
cessation of the medication.  However, if the symptoms persist beyond four 
weeks post-cessation of medication, then other aetiological factors should be 
evaluated.  (DSM-IV-TR®, 2000.) 
 
The following studies highlight the association between certain medications 
and depressive symptoms: 
 
• A recent study found that a significant percentage of hypertensive patients 
had a comorbid Depressive Disorder and it has been proposed that 
antihypertensive medications, such as beta-blockers, methyldopa and 
clonidine, could have resulted in the development of Depressive 
Disorders (Cankurtaran et al., 2005). 
• It is believed that all antiepileptic drugs can result in psychiatric symptoms 
in epileptic patients.  However, the extent to which they elicit such 
symptoms varies from drug to drug.  (McConnell & Duncan, 1998.) Many 
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earlier studies have shown that phenobarbitone can result in a Depressive 
Disorder (Collaborative Group for Epidemiology of Epilepsy, 1986; 
McConnell et al., 1998).  Research has also shown that tiagabine, 
vigabatrin, felbamate and topirimate may result in depressive symptoms 
(Ring & Reynolds, 1990; Kanner & Palac, 2000).  Although antiepileptics 
with mood-stabilising effects (for example, carbamazepine or valproic acid) 
are not associated with depressive symptoms to such a great extent, in 
comparison with other antiepileptics, they do occasionally result in 
depressive episodes.   
• Studies have identified a link between corticosteroid use in asthmatics and 
Depressive Disorders (O’Byrne & Pederson, 1998; Bonala et al., 2003).  
The last 20 years has seen a significant increase in the use of inhaled 
corticosteroids, because more potent devices, with delivery systems of 
superior efficacy, have been developed.  Although high doses of inhaled 
corticosteroids have been associated with positive effects on lung 
functioning, such doses were found to impact negatively on psychological 
status.  (Bonala et al., 2003.) Patten (2000) conducted a large-scale study 
in 73 402 members of a Canadian community to determine the prevalence 
of Depressive Disorders amongst individuals taking corticosteroids.  The 
study found that the prevalence of MDD was much higher in those 
individuals taking corticosteroids (11.1%) than in those individuals in the 
community who were not taking corticosteroids (4.1%).   
 
Other medications that have been associated with Depressive Disorders 
include the following:  aminophylline, theophylline, metoclopramide, 
benzodiazepines, propranolol, reserpine, anti-parkinsonian drugs, cimetidine, 
hydralazine, oestrogens, progesterone, tamoxifen, vinblastine, vincristine and 
dextropropoxyphene (MacHale, 2002; Alexopoulos, 2005). 
 
2.3.4 Chronic Comorbid Disease States 
 
Comorbidity may be defined as the co-existence of two disorders or 
syndromes in the same patient (Krishnan, Delong, Kraemer, Carney, Spiegal, 
Gordon, McDonald, Dew, Alexopoulos, Buckwalter, Cohen, Evans, 
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Kaufmann, Olin, Otey & Wainscott, 2002).  Chronic disease states are strong 
psychological stressors and are also associated with risk factors that 
predispose patients to develop comorbid Depressive Disorders.  Patients with 
severe, chronic and often fatal disease states, for example, Neurological and 
Cardiovascular Disease States, are more susceptible to suffering from a co-
existing Depressive Disorder.  (McCoy, 1996.) 
 
A conceptual model was devised for the purpose of illustrating the complex 
interrelationship that exists between Depressive Disorders and other chronic 
disease states. More specifically, this model (presented in Figure 2.1) 
explores the interactions between risk factors for Depressive Disorders and 
chronic disease states.  Figure 2.1 illustrates three known risk factors for 
developing Depressive Disorders, namely:  genetic vulnerability, childhood 
adversity and stressful life events.  It then goes on to show that those who are 
vulnerable to Depressive Disorders because of childhood adversity could also 
experience maladaptive attachment as a consequence.  Maladaptive 
attachment, in turn, may result in such individuals withdrawing themselves 
from society and experiencing difficulty in co-operating with physicians.  Both 
childhood adversity and Depressive Disorders are also associated with 
biobehavioural risk factors for chronic disease states.  Conversely, the 
consequences of chronic disease states (severe symptoms and impaired 
functionality), together with the indirect pathophysiologic effects of theses 
disorders on the brain, may also cause Depressive Disorders.  (Katon, 2003.)   
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Genetic Vulnerability   Maladaptive    Depressive        Biobehavioural             Chronic  
Childhood Adversity   Attachment    Anxiety       Risks for Chronic         Disease States 
(loss, neglect, abuse)      Disorders       Disease States: - Diabetes    
Adverse Life Events           -  Obesity  - Heart Disease 
      -  Sedentary  
          lifestyle 
      -  Smoking 
      -  Chronic stress 
             -  Metabolic 
                Syndrome 
 
 
Self-care of Chronic Disease State   Consequences of Chronic Disease States 
-  Collaboration with physicians   -  Symptom burden  
-  Exercise     -  Functional impairment 
-  Diet      -  Quality of life 
-  Medication adherence    -  Biologic changes in the brain 
-  Monitoring symptoms/signs of exacerbation       secondary to chronic illness 
-  Quitting smoking 
 
 
 
 
FIGURE 2.1 
A CONCEPTUAL MODEL TO ILLUSTRATE THE ASSOCIATION BETWEEN DEPRESSIVE 
DISORDERS AND CHRONIC COMORBID DISEASE STATES (Source:  Adapted from 
Katon, 2003) 
 
2.3.5 Neurochemical Theories 
 
Many people believe that Depressive Disorders are due solely to a 
biochemical imbalance, however, the mere fact that there is not a single drug 
to correct this imbalance, indicates that there cannot be a single final common 
pathway involved in the biochemical aetiology of Depressive Disorders.  Even 
though it can be clearly seen that there are many other predisposing factors 
involved, it is not yet possible to ascertain the exact influence of these other 
factors on neurochemical function.  (Shah, 2002.) 
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2.3.5.1 The Monoamine Hypothesis  
 
The Monoamine Hypothesis was the prevailing aetiological hypothesis for 
Depressive Disorders for many years.  This theory originated in the early 
1950s as a result of several observations that were made.  (Shah, 2002.) The 
earliest clinical report was made by Freis in 1954, where he noted that five 
hypertensive patients who were on high doses of the antihypertensive drug, 
reserpine, developed a Depressive Disorder.  Reserpine induces Depressive 
Disorders by depleting the neuronal storage granules of the following 
monoamines:  serotonin and dopamine; and noradrenaline and adrenaline 
(brain catecholamines).  Since then, pharmacological studies have found that 
the administration of drugs that facilitate monoamine transmission, for 
example, TCAs, alleviate depressive symptoms.  (Kalia, 2005.) However, 
there are many shortcomings to the Monoamine Hypothesis (US Department 
of Health and Human Services, 1999; Kalia, 2005):  
 
• Firstly, the monoamine neurotransmitter system is not the only system that 
is altered in Depressive Disorders.  For instance, gamma-aminobutyric 
acid (GABA) and ACh systems have also been implicated.   
• Secondly, although antidepressants that enhance monoamine 
transmission may alleviate the signs of Depressive Disorders, this does 
not necessarily mean that they correct the underlying aetiological defect.  
In other words, alleviation of depressive symptoms by these drugs does 
not mean that Depressive Disorders are caused by defective monoamine 
transmission.  
• Thirdly, defects in monoamine synthesis or excessive degradation of 
monoamines, is not linked to Depressive Disorders on a consistent basis.   
• The other more obvious limitation of the Monoamine Hypothesis is that it 
does not take into consideration the influence of psychosocial factors on 
the development or exacerbation of an existing Depressive Disorder.  
• Lastly, this hypothesis could not explain why the therapeutic effect of most 
antidepressant drugs was only evident after at least two weeks of 
administration, despite these drugs displaying an almost immediate effect 
at their pharmacological sites of action.   
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2.3.5.2 Dysregulation of Endocrine Systems 
 
It has been found that many endocrine systems function differently in the 
presence of a Depressive Disorder.  The HPA axis has been the system of 
greatest research focus because it is the chief endocrine stress system and 
its ability to actively adapt to chronic stress, is very important.  Corticotropin 
releasing hormone (CRH) is secreted by the hypothalamus and stimulates the 
release of corticotropin by the pituitary gland.  Corticotropin, in turn, stimulates 
the synthesis and release of cortisol from the adrenal cortex.  (Gums et al, 
2002.) Excessive cortisol secretion and failure of dexamethasone to suppress 
cortisol, led researchers to conclude that depressed patients have 
dysregulation of the HPA axis (Gillespie & Nemeroff, 2005).  Altered 
functioning of the HPA axis manifests itself in the form of hypercortisolism 
(high cortisol levels) and adrenal hyperplasia (Shah, 2002).  Depressed 
patients have been shown to have elevated levels of CRH in their 
cerebrospinal fluid (Gillespie et al., 2005).  Studies have utilised animal 
models to determine the effects of high cortisol levels on the brain.  The 
outcomes of these studies have shown that high cortisol levels are associated 
with neuronal damage, especially within the hippocampal region of the brain.  
It can therefore be assumed that depressed individuals might also show 
changes in the hippocampus.  This hippocampal change has, in fact, been 
recently demonstrated and the extent of the alteration might be linked to the 
degree of memory impairment evident in patients diagnosed with Depressive 
Disorders.  Furthermore, depressed patients seem to exhibit a blunted 
response to CRH.  There are also many neurotransmitters that influence the 
HPA axis, such as serotonin, noradrenaline, ACh and opioids.  This becomes 
important when one considers the effects of neurotransmitter-enhancing 
antidepressants on the treatment of Depressive Disorders.  (Shah, 2002.) 
 
2.3.6 Other Hypotheses and Latest Developments 
 
The abovementioned theories fall short of providing complete and adequate 
explanations for Depressive Disorders and this encouraged further research 
into other possible mechanisms. It has, for example, been proposed that 
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impaired fatty acid metabolism could provide another link to Depressive 
Disorders (Maes et al., 1998; Maes et al., 1999).  Evidence from studies 
investigating the relationship between fatty acids and Depressive Disorders, 
suggests that low concentrations of fatty acids or minimal intake of fatty acids 
is associated with depressive symptoms.  Depressed patients are believed to 
have reduced omega-3 polyunsaturated fatty acids in plasma, serum 
phospholipids, or red cell membranes.  It has also been found that a higher 
intake of fish in the diet correlates with a reduced risk of developing MDD.  
(Maes et al., 1999.) Maes and Smith (1998), however, suggested that 
changes in omega-3 polyunsaturated fatty acids could elicit alterations in 
serotonin receptor number and function and in this indirect way, contribute to 
the development of Depressive Disorders.     
 
The past five years have noticed an unparalleled advance in knowledge 
pertaining to the neurobiology of Depressive Disorders.  There have been 
considerable improvements in genomics, imaging and the identification of 
important neural systems involved in emotion, cognition and behaviour.  
Moreover, genetic differences associated with most Psychiatric Disorders are 
being recognised and researchers are embarking on the innovation of reliable 
tests that can be used to ensure early detection of risk and disease.  Recent 
neuroimaging studies of depressed patients have revealed many 
abnormalities in regional cerebral blood flow and glucose metabolism in 
different areas of the brain, including the limbic cortex, prefrontal cortex, 
hippocampus, amygdala and anterior cingulated cortex.  Anatomical studies 
involving imaging of the hippocampus, amygdala and prefrontal cortex, as 
well as neurochemicals in the brain, (for example, neurotropic factor, which is 
associated with many Psychiatric Disorders) have presented proof regarding 
the aetiology of Depressive Disorders.  This recently acquired knowledge 
plays an important role in creating more selective and effective drug 
treatments for Depressive Disorders.  (Kalia, 2005.) 
 
It is evident that the aetiology of Depressive Disorders is complex and cannot 
be explained by a single social, biological or developmental theory.  However, 
because this study focuses on the interrelationship between Depressive 
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Disorders and chronic comorbid disease states, the aetiological influence of 
chronic disease states on Depressive Disorders is of paramount importance.  
Krishnan and others (2002) analysed various epidemiological studies of 
comorbid Depressive Disorders and offered the following suggestion, based 
on the results of such studies:  regardless of the underlying aetiology, the 
severity of a chronic disease state is the variable that is most closely related 
to the frequency of depressive symptoms and episodes.  This could imply that 
chronic disease states may have a profound impact on the development of a 
comorbid Depressive Disorder and thus, highlights the need to investigate the 
link between Depressive Disorders and other chronic disease states, which is 
essentially, one of the main focuses of this study. 
 
2.4 DIAGNOSIS OF MOOD DISORDERS IN PATIENTS WITH CHRONIC 
DISEASE STATES 
 
The International Statistical Classification of Diseases and Related Health 
Problems, Tenth Revision (ICD-10) is the official coding system utilised 
throughout most of the world.  The DSM-IV-TR® is the official coding system 
in use in America.  It was developed in close co-ordination with the ICD-10 
coding system, so as to allow for the DSM-IV® codes and terms to be 
completely compatible with those present in the ICD-10 document.  In order to 
facilitate the use of the DSM-IV® system internationally, the APA presents the 
DSM-IV® classification with the ICD-10 codes.  There are many sections to 
the DSM-IV® diagnostic system, but for the purposes of this study, only the 
Mood Disorders section will be discussed in more detail.  The Mood Disorders 
section describes diagnostic criteria for disorders that have a mood 
disturbance as the main feature.  This section is further subdivided into three 
parts, namely: mood episodes, Mood Disorders and specifiers.  The first part 
offers a description of mood episodes (major depressive episode, manic 
episode, mixed episode and hypomanic episode), which is intended to 
facilitate the diagnoses of various Mood Disorders.  The second component 
provides a description of the different Mood Disorders, such as MDD, 
Dysthymia and Bipolar I Disorder.  The diagnostic criteria for the majority of 
the Mood Disorders are based on the presence or absence of mood episodes.  
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The third part gives details about the specifiers that describe either the most 
recent mood episode or the course of recurrent episodes.  Examples include 
severity, psychotic, remission and chronic specifiers.  (DSM-IV-TR®, 2000.)  
 
Of the various Mood Disorders (listed in Section 2.1), MDD and Mood 
Disorder Due to a General Medical Condition are the two disorders that apply 
to this study and therefore, warrant further explanation.  MDD is characterised 
by the presence of one or more major depressive episodes.  Table 2.2 
outlines the DSM-IV-TR® criteria for the diagnosis of a MDE.  The main 
feature of a MDE is the presence of either depressed mood or the loss of 
interest or pleasure in nearly all activities for a period of at least two weeks.  In 
addition to this, the person must also experience at least four of the symptoms 
depicted in Table 2.2, which range from weight changes and alterations in 
sleeping habits, to feelings of worthlessness and recurrent thoughts of 
suicide.  In order to be regarded as a symptom of a MDE, the symptom must 
either be newly present or it must be obvious that the symptom has 
exacerbated, when compared with the individual’s status prior to the episode.  
These symptoms must also persist for most of the day, practically every day, 
for a minimum of two consecutive weeks.  The episode must be associated 
with clinically significant distress or impaired ability to perform normal daily 
functions, for example on a social or occupational level.  In less severe cases, 
the individual may be able to carry out daily activities in an apparently normal 
manner, but this requires a markedly increased contribution.  (DSM-IV-TR®, 
2000.)   
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TABLE 2.2 
DSM-IV-TR® CRITERIA FOR MAJOR DEPRESSIVE EPISODE 
 
A:   Five (or more) of the following symptoms have been present during the same two-week period 
and represent a change from previous functioning; at least one of the symptoms is either (1) 
depressed mood or (2) loss of interest or pleasure.  (Note:  Do not include symptoms that are 
clearly due to a general medical condition, or mood-incongruent delusions or hallucinations.)   
 
1. Depressed mood most of the day nearly every day (as indicated by either subjective report 
or observation made by others). 
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day (as indicated by either subjective report or observation made by others). 
3. Significant weight loss when not dieting or weight gain (for example, a change of more than 
5 % of body weight in a month), or decrease or increase in appetite nearly every day. 
4. Insomnia or hypersomnia nearly every day. 
5. Psychomotor agitation or retardation nearly every day (observable by others, not merely 
subjective feelings of restlessness or being slowed down). 
6. Fatigue or loss of energy nearly every day. 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) 
nearly every day (not merely self-reproach or guilt about being sick). 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (as indicated 
by either subjective report or observation made by others). 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a 
specific plan, or a suicide attempt or a specific plan for committing suicide. 
 
B: The symptoms do not meet criteria for a mixed episode.  
C: The symptoms cause clinically significant distress or impairment in social, occupational, or other 
important areas of functioning. 
D: The symptoms are not due to the direct physiological effects of a substance (for example, a drug 
of abuse, a medication) or a general medical condition (for example, Hypothyroidism). 
E:  The symptoms are not better accounted for by bereavement (that is, after the loss of a loved 
one), the symptoms persist for longer than two months or are characterised by marked 
functional impairment, morbid pre-occupation with worthlessness, suicidal ideation, psychotic 
symptoms, or psychomotor retardation.  
 
(Source:  Adapted from the DSM-IV-TR®, 2000) 
 
A Mood Disorder Due to a General Medical Condition is described in the 
DSM-IV-TR® (2000) as being ‘characterised by a prominent and persistent 
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disturbance in mood that is judged to be a direct physiological consequence 
of a general medical condition’ (for example, Multiple Sclerosis, Stroke and 
Hypothyrodism).  It is important to distinguish between medically ill patients 
with comorbid Depressive Disorders and those who simply experience a 
transient dysphoria (which is to be expected in response to a severe chronic 
disease state).  Lack of compliance to medication or displaying disinterest 
towards receiving treatment, could be key indicators of Depressive Disorders.  
When physical symptoms are disproportionate to the disease or when the 
symptoms impact significantly on the patient’s ability to function normally, a 
Depressive Disorder should also be suspected.  A family history of the patient 
also needs to be evaluated, since this could also assist in determining 
whether a comorbid Depressive Disorder exists.  (DSM-IV-TR®, 2000.) 
 
It is difficult to identify Depressive Disorders in physically ill patients because 
side-effects of medication and symptoms of the disease (for example, fatigue 
and insomnia), may mimic symptoms of the Depressive Disorder.  The 
following symptoms are believed to be more specific to depressed patients 
and can be used as discriminators of Depressive Disorders from chronic 
disease states: recurrent suicidal thoughts, loss of social interest, crying, 
continuous dissatisfaction, indecisiveness, sense of failure and psychomotor 
retardation. However, in patients with Parkinson’s Disease or 
Hypothyroidism, psychomotor retardation cannot be used as a distinguishing 
symptom since it is ambiguous whether this symptom is a consequence of the 
medical illness or a possible comorbid Depressive Disorder.  (DSM-IV-TR®, 
2000.) Besides for the assumption that symptoms are due to the chronic 
disease state rather than the comorbid Depressive Disorder, there are other 
factors that may complicate the diagnosis.  For example, the belief (both 
patient and physician) that Depressive Disorders are inevitable in old age and 
should therefore be expected.  Also, the stigma associated with a mental 
disease state discourages patients to report symptoms and to seek help.  
(Cankurtaran et al., 2005.)   
 
Individuals who have chronic disease states co-existing with Depressive 
Disorders, are of the perception that their general health is poor.  These 
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patients tend to intensify physical symptoms of their disease state.  They 
become progressively unwilling to co-operate and this has a negative effect 
on the ability to achieve a favourable outcome with regards to treatment of the 
medical illness.  (McCoy, 1996.) If the underlying Depressive Disorder goes 
unnoticed, it may seem as if there is an exacerbation of the chronic disease 
state, which consequently leads to implementation of expensive and 
unnecessary diagnostic tests and treatments.  Even if the chronic disease 
state is treated adequately, if the Depressive Disorder is left untreated, it will 
still limit the patient’s functionality (McCoy, 1996).    
 
A few studies have attempted to devise the best method for diagnosing 
Depressive Disorders in patients with other chronic disease states; however, 
there is still a lot of debate concerning the issue.  Some of these studies set 
out to evaluate the symptom presentation of MDD, in individuals with one or 
more comorbidities and compared these symptom patterns with those 
displayed by MDD patients without chronic disease states.  These studies 
revealed the following:  depressed patients with comorbid chronic disease 
states have a more chronic form of Depressive Disorder; take longer to 
recover; and show greater resistance to standard antidepressant treatments, 
than depressed patients with no comorbidities.  (Yates et al., 2004.) 
 
2.5 PREVALENCE OF DEPRESSIVE DISORDERS AND FACTORS 
AFFECTING  PREVALENCE 
 
The World Health Organization determined that mental illness is one of the 
greatest causes of disability universally (WHO, 2000).  Furthermore, five out 
of the ten leading causes of disability worldwide can be attributed to 
Psychiatric Disorders.  The following Psychiatric Disorders are implicated:  
MDD, Schizophrenia, Bipolar Disorder, Alcohol Use Disorder and Obsessive 
Compulsive Disorder.  The WHO Global Burden of Disease Study ranked 
Depressive Disorders as the most burdensome universal disease states in 
middle-aged people.  It also estimated that Depressive Disorders would 
become the second leading cause of disease burden worldwide and the 
leading cause in developed countries within the next two decades.  (Murray & 
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Lopez, 1996.) It is noteworthy to mention that the median age of onset of 
Depressive Disorders is in the mid-20s, which is no less than two decades 
earlier than the median age of onset of chronic disease states that have been 
found to exhibit similar prevalence rates and impairments to Depressive 
Disorders.  However, unlike the majority of chronic disease states, Depressive 
Disorders occur during a time in an individual’s life when it may have a 
detrimental effect on educational attainment, occupational entry, marital 
stability and parenting.  (Kessler, McGonagle, Zhao, Nelson, Hughes, 
Eshleman, Wittchen & Kendler, 1994.)   
 
A number of large-scale epidemiological studies of Depressive Disorders, 
conducted throughout the world, have been performed in the past few 
decades.  These studies involved large samples of participants 
(approximately 4 000 to 20 000 individuals) in the general population.  Table 
2.3 summarises the prevalence findings of these large-scale epidemiological 
surveys. 
 31 
TABLE 2.3 
RESULTS OF LARGE-SCALE EPIDEMIOLOGICAL STUDIES FOR THE PREVALENCE OF DEPRESSIVE DISORDERS  
 
Epidemiological Study 
Prevalence of 
MDE* in One 
Year (%) 
Lifetime 
Prevalence 
Sample Size Age Range 
Epidemiologic Catchment Area Study (ECA) – 1980 – 1983 (American study) 
(Narrow, Rae, Robins & Regier, 2002). 
1.7 - 3.4 3 – 5.9 20 000 ≥ 18 years of age 
Edmonton Survey of Psychiatric Disorders – 1983 – 1986 (Canadian study) 
(Patten et al., 2005). 
4.6 8.6 3 956 > 18 years of age 
The National Comorbidity Survey (NCS) – 1990 - 1992  
(conducted in America) (Kessler et al., 1994). 
8.6 14.9 8 018 15 – 54 years of age 
The Netherlands Mental Health Survey and Incidence Study (NEMESIS) – 
1996 (Bijl, Ravelli & van Zessen, 1998). 
 
5.8 
15.4 7 076 18 – 64 years of age 
The Canadian Community Health Survey (CCHS) – 2000-2001  
(Patten et al., 2005).  
7.4 Not measured 115 071 ≥ 18 years of age 
The National Comorbidity Survey Replication (conducted in America from 
2001-2002).  The NCS-R aimed to revise information on the prevalence of 
Psychiatric Disorders (Kessler et al., 2003a).  
6.6 
(representing an 
estimated 13 to 
14 million 
American adults) 
 
16.2 
(representing an 
estimated 33 to 
35 million 
American 
adults) 
9 090 ≥ 18 years 
 * MDE refers to a Major Depressive Episode.
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Narrow (1998) estimated that 12% of females and 7% of males will 
experience a depressive episode in any given year.  However, this varies 
amongst surveys and nations.  For example, in the US, between 3.4% 
(Narrow et al., 2002) and 6.6% (Kessler et al., 2003a) of adults (taking the 
genders together) over 18 years of age, are estimated to suffer from a MDE in 
any given year.  Depressive Disorders affect one in 40 adults throughout 
Europe at any given time and one in 20 adults for at least a few weeks in any 
year (Paykel, Brugha & Fryers, 2005).  In South Africa, the prevalence of 
Depressive Disorders reportedly ranges between 14% and 49% (Triant, 
2002).  The following studies have been conducted in South African 
communities and the majority of the observed prevalence percentages fall 
within the range reported by Triant (2002):   
 
• Thom and others (1993) determined the prevalence of Psychiatric 
Disorders (Alcohol, Depressive, Anxiety and Adjustment disorders) at a 
primary care clinic in Soweto, Johannesburg, to be 14.38%.  
• A study conducted in Pietermaritzburg determined the prevalence of 
Depressive Disorders to be 28% (Pillay et al., 1999). 
• The prevalence of Depressive Disorders (includes MDD [Partial 
Remission], Dysthymia; and Minor Depression) amongst 222 patients 
admitted to the Lotus River Community Centre in the Cape Flats was 
determined to be 32%.  In addition to this, 13% were noted to meet criteria 
for MDD.  (Triant, 2002.) 
 
Kessler (2003) estimates the lifetime risk for at least one MDD for the total US 
population to be 16%.  Numerous studies have shown that the prevalence of 
Depressive Disorders in adults seems to be increasing in many countries 
(Murray et al., 1996; Kessler et al., 2003a).  The large-scale epidemiological 
surveys listed in Table 2.3, were tabulated in chronological order and it is 
evident that, on the whole, prevalence rates for MDD have increased over the 
years.  Two successive National Ambulatory Care Surveys that were 
conducted among adult patients in 1992 to 1993 and 1996 to 1997, 
respectively, showed that there was an increase in the prevalence of 
Depressive Disorders from the 1992 to 1993 study to the 1996 to 1997 study.  
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The diagnosis of Depressive Disorders increased in the second survey in all 
cases, from 10.9 % (1992 to 1993) to 11.3% for whites (1996 to 1997), 4.2% 
(1992 to 1993) to 5.5% (1996 to 1997) for blacks and from 4.8% (1992 to 
1993) to 8.3% (1996 to 1997) for Hispanics.  (Skaer, Sclar, Robison & Galin, 
2000.) This highlights the significant influence of changing environmental 
conditions on the prevalence of Depressive Disorders, since the gene pool 
and population distribution of sex hormones could not have changed 
significantly during such a short period of time.  It is more likely for people who 
are born in this era to suffer from MDD at some point in their lives than it was 
for people who were born in earlier times (Kessler et al., 2003a).  To further 
reinforce this point, in 1999, it was estimated that internationally, one in six 
people would suffer from MDD.  Additionally, MDD is expected to become the 
second most significant source of disability on a global level, by 2020 
(Davidson & Meltzer-Brody, 1999).   
 
An estimated 40% of depressed patients will meet diagnostic criteria for 
Depressive Disorders one year after the first episode and 15% to 20% will 
remain depressed for two years.  It has also been estimated that 60% of those 
patients who have an initial depressive episode, will experience a second one; 
and that the risk of recurrence increases with each subsequent episode 
(Pincus et al., 2001.) About 40% of untreated patients with MDD will display 
depressive symptoms a year later.  This indicates that Depressive Disorders 
are not likely to resolve spontaneously without appropriate treatment.  (Keller 
et al., 1992.) Furthermore, a recent 15-year follow-up study (where subjects 
reported different degrees of treatment) found that a great percentage (85%) 
of the participants with MDD suffered from recurrent Depressive Disorders 
(Keller et al., 2002). 
 
2.5.1 Factors Affecting the Prevalence of Depressive Disorders 
 
There are many factors that may influence the prevalence of Depressive 
Disorders.  Age and Gender provide two examples that are applicable to the 
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specific objectives of the study (listed in Section 1.4) and are discussed in the 
following section.   
 
2.5.1.1 Age 
 
The relationship between age and Depressive Disorders remains 
controversial (Stordal et al., 2003).  Jorm (2000) reviewed epidemiological 
studies across the adult life span in order to ascertain whether old age 
reduces the risk of Depressive Disorders and Anxiety.  This particular study 
reported that although many studies pertaining to Depressive Disorders show 
that there is an initial incline across age groups, followed by a decline, this 
pattern is not universal and the peak age varies considerably from study to 
study.  On the other hand, research has also consistently shown that there is 
in fact a steep increase in depressive symptoms in late life (Schnittker, 2005).  
For example, in Pietermaritzburg, South Africa, a study demonstrated that 
there was a positive relationship between Depressive Disorders and age 
(Pillay et al., 1999).  Changes in physical health contribute significantly to an 
increase in depressive symptoms in old age (Schnittker, 2005).  Snowdon 
(2001) reviewed various studies pertaining to age and Depressive Disorders 
and concluded the following:  Many studies found no age difference; the ECA 
study showed that those between the ages of 25 and 44 years were the most 
depressed; two studies found prevalence to peak at 55 to 64 years; and 
another one found those between the ages of 60 and 69 years to be the most 
depressed (Snowdon, 2001). 
 
It has been suggested that if age-related changes in physical health could be 
excluded, there would actually be fewer depressive symptoms associated with 
old age than earlier in life (Mirowsky et al., 1992).  Such physical changes, 
however, cannot be ignored, so Mirowsky and Ross (1992), after 
incorporating these changes into their study, found middle-aged individuals to 
be the least depressed and those over 80 years, to be the most depressed.  It 
can therefore be seen, that age cannot be considered as an independent 
factor influencing the prevalence of Depressive Disorders.     
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Elderly depressed patients frequently suffer from chronic comorbid disease 
states.  Examples include:  CHD, Cancer, Diabetes Mellitus and Hypertension 
(Harpole et al., 2005).  Approximately 88% of individuals who are 65 years of 
age or older, suffer from one or multiple chronic conditions.  Furthermore, it 
has been estimated that a quarter of these individuals will suffer from more 
than four chronic disease states and it is well known that comorbid illness is 
associated with Depressive Disorders.  (Hoffman, Rice & Sung, 1996.) 
Individuals over 70 years of age, who suffer from a chronic disease state, 
have been found to be more prone to Depressive Disorders (McCoy, 1996; 
Taylor, McQuoid & Krishnan, 2004).  A number of studies performed in elderly 
patients in primary care settings (most with chronic concomitant disease 
states) revealed that the prevalence of Depressive Disorders amongst them 
ranged from 10% to 25% (Cankurtaran et al., 2005).  A recent study identified 
the risk of developing Depressive Disorders to be higher in the elderly when 
chronic disease states result in a new decrease in functioning (Katon, 2003).  
Schnittker (2005) analysed the relationship between chronic disease states 
(such as Cancer, Chronic Obstructive Pulmonary Disease (COPD), Diabetes 
Mellitus, Hypertension, Arthritis, Heart Diseases and Stroke) and symptoms of 
Depressive Disorders amongst a large, nationally representative sample of 
Americans over the age of 50 years.  The study evaluated the effects of age 
on depressive symptoms and found the trend to be consistent with previous 
findings; that is, that an increase in age is associated with an increase in 
depressive symptoms.  This study (like Mirowsky and Ross [1992]) also found 
that, although in all cases age is associated with an increase in depressive 
symptoms, fewer of these symptoms would be evident had it not been for 
increases in disability (Schnittker, 2005).  
 
Failure to yield consistent results pertaining to the link between age and 
Depressive Disorders may indicate that the impact of age on the prevalence 
of Depressive Disorders is influenced by many other factors.  For example, 
Stordal and others (2003) found that the following factors influenced the 
interrelationship between age and Depressive Disorders:  gender, race, 
marital status, education, employment status, income, household, life event, 
social support, carer role and the number of chronic disease states present.   
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2.5.1.2 Gender 
  
Depressive Disorders are known to affect more women than men and many 
studies have deduced, more specifically, that the rates of Depressive 
Disorders evident in women are twice as high as those observed in men.  
(Kamlet et al., 1995; Kornstein, 2001; Kessler, 2003) The National 
Comorbidity Survey found the prevalence of MDD to be 21.3% for women and 
12.7% for men (Kessler, McGonagle, Swartz, Blazer & Nelson, 1993).  An 
earlier study (1979) conducted in Uganda, found the prevalence of Depressive 
Disorders to be 23% for females and 14% for males (Orley & Wing, 1979), 
which is very similar to the results yielded by the American researchers in the 
National Comorbidity Survey.  Therefore, it is apparent that this gender-
related difference in the prevalence of Depressive Disorders has been 
consistently recognised in various studies (older and recent studies) 
conducted on a global level.  Various surveys of Depressive Disorders have 
shown that this gender-associated difference in prevalence rates begins to 
surface in adolescence, at about 10 to 14 years of age (Kessler & Walters, 
1998; Angold, Costello & Worthman, 1998; Angold, Costello, Erkanli & 
Worthman, 1999; Kessler, 2003).  
 
Many studies have examined the possible explanations for a higher 
prevalence of Depressive Disorders amongst females and have offered the 
following proposals:   
 
• Many women report depressive symptoms during Menopause, oral 
contraceptive use and the use of Hormone Replacement Therapy (HRT).  
These experiences, together with the age range during which the gender 
differences first emerge, are all associated with changes in the levels of 
sex hormones and therefore posed questions about the role that sex 
hormones have to play in the higher prevalence of Depressive Disorders in 
females.  In addition to this, the period during which the risk for Depressive 
Disorders is at its greatest in females, is between the ages of Menarche 
and Menopause, which further suggests that hormonal influences may 
play a role in the risk for Depressive Disorders in women.  (Cohen, Soares 
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& Joffe, 2005.) However, comprehensive surveys are yet to find a link 
between these hormonal factors and the prevalence of Depressive 
Disorders in women (Kessler, 2003).  
• Kornstein (2001) explained the higher prevalence of Depressive Disorders 
in females, relative to males, in terms of the following three factors:   
i) Females seek help for Depressive Disorders more readily than 
males do or they are more likely to respond to questioning about the 
condition in a way that reports their current and past depressive 
episodes. 
ii) Biological theories have considered variations in brain structure and 
function, which suggest differences in reproductive hormones 
amongst females and males. 
iii) Psychosocial factors such as differences in socialisation, stress, 
coping techniques and styles.   
 
Although each of the aforementioned factors is likely to contribute to the 
different rates of Depressive Disorders evident in females and males, the two 
most frequently discussed perspectives include:  The female reproductive 
physiology and the woman’s status, roles and life’s circumstances (Norman, 
2004).  In addition to having a higher prevalence rate of Depressive Disorders, 
females seem to be more adversely affected by the disease state than males. 
They have a younger age of onset, greater family history of Mood Disorders, 
greater disease severity (more symptoms reported), reduced quality of life and 
poorer social adjustment, in comparison to males (Kornstein, Schatzberg, 
Thase, Yonkers, McCullough, Keitner, Gelenberg, Ryan, Hess, Davis, 
Harrison & Keller, 2000).  Some studies have revealed that there are no 
gender differences in recurrence and chronicity of Depressive Disorders 
(Kessler et al., 1993).  In contrast, other studies found that females have a 
more chronic case of the disease state and that they are more susceptible to 
relapses, with episodes occurring more frequently and lasting longer than in 
males (Ernst & Angst, 1992; Winokur, Coryell, Keller, Endicott & Akiskal, 
1993).  
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The association between Depressive Disorders and Obesity has been found 
to be influenced by gender.  In women with a Body Mass Index (BMI) of 
greater than or equal to 30kg/m2, the lifetime prevalence of Depressive 
Disorders was found to be 50% higher than in non-obese women.  (Becker, 
Margraf, Turke, Soeder & Neumer, 2001.) On the other hand, in men, BMI 
was not identified as an influential factor of psychological well-being.  Having 
said this though, men who are obese around the abdominal area have been 
shown to display more depressive symptoms than men who carry less weight 
around that area (Rosmond, Lapidus, Marin & Bjorntorp, 1996).  In 2003, a 
five-year observational study was performed in 2 000 adults diagnosed with 
MDD.  Even after controlling for variables such as gender, marital status, 
social support, education, physical health troubles and functional limitations, 
this study deduced that obesity was linked with an enhanced risk of 
Depressive Disorders five years later (Roberts, Deleger, Strawbridge & 
Kaplan, 2003).  However, more current research has demonstrated that most 
obese individuals do not suffer from Mood Disorders, albeit reports of a 
possible interrelationship between the two conditions (McElroy, Kotwal, 
Malhotra, Nelson, Keck & Nemeroff, 2004; Johnston, Johnson, McLeod & 
Johnston, 2004).  Licinio and Wong (2003) postulated that Obesity and 
Depressive Disorders could stem from a common pathophysiology, since the 
neurotransmitters, serotonin and noradrenaline, have a role to play in 
influencing both mood and body weight.   
 
2.6 DISEASES COMMONLY CO-EXISTING WITH DEPRESSIVE 
DISORDERS 
 
2.6.1 Prevalence of Depressive Disorders with Chronic Comorbid 
Disease States 
 
Researchers have been examining the risk of developing Depressive 
Disorders secondary to a chronic disease state or conversely, developing a 
chronic disease state secondary to Depressive Disorders, for many years 
already.  For example, in 1988, the ECA study deduced that patients 
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diagnosed with one of eight chronic disease states* had a 41% greater risk 
(relative to those individuals with no chronic disease states) of developing any 
recent mental disorder and that depressed patients, on average, suffer from 
two chronic disease states (Wells, Golding & Burnam, 1988).  Depressed 
patients exhibit a high prevalence, namely 65% to 71%, of any of eight 
common chronic disease states* (Wells et al., 1991).   
 
A review conducted by the Agency for Health Care Policy and Research 
[AHCPR] (now known as the Agency for Health Care Research and Quality or 
AHRQ), stipulated that between 12% and 38% of patients with a general 
medical condition will also have a clinically significant Depressive Disorder 
(AHCPR, 1993).  More recently, Patten (2001) determined that there was a 
greater risk of developing Depressive Disorders with basically any chronic 
disease state in 4% of patients with one or more multiple conditions, 
compared with 2.8% of patients with no disease state.  Many researchers 
have identified enhanced prevalence rates of Depressive Disorders in 
numerous specific chronic disease states, ranging from 20% to 50% (Yates et 
al., 2004).  The CCHS (2000 to 2001) found the prevalence of MDD to be 
65.7% in patients with any chronic disease state.  This value was almost 
double the prevalence rate evident in individuals with no chronic condition 
(34.3%).  (Patten et al., 2005.) Studies focusing on patients with particular 
disease states, such as CHD, MI, HIV-related Disease, Diabetes Mellitus, 
Cancer, Asthma, COPD, Hypertension, Epilepsy and Neurological Disease 
States (Parkinson’s Disease, Alzheimer’s Disease, Vascular Depression and 
Stroke) have all found a consistently higher occurrence of Depressive 
Disorders in these patients, relative to individuals without these disease 
states.  Table 2.4 summarises the prevalence ranges of Depressive Disorders 
in patients with specific chronic disease states.  These percentages were 
obtained from various studies conducted over the years. 
 
 
 
                                            
* Eight chronic disease states:  Arthritis, Hypertension, Diabetes Mellitus, CVD, Neurological 
Disease State, Lung Disease, Cancer and Physical Handicap.   
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TABLE 2.4 
PREVALENCE RATES OF COMORBID DEPRESSIVE DISORDERS IN 
PATIENTS WITH SPECIFIED CHRONIC DISEASE STATES 
 
Chronic Disease State 
Prevalence Range of Major 
Depressive Disorder (%) 
Reference 
Hypertension 
13.9 
(study conducted from  
2000 - 2001) 
77.3 
Patten et al., 2005 
 
 
Cankurtaran et al., 2005 
CHD 
18 - 50  
 
32.6 
Fielding, 1991;  Roose, Dalack & 
Woodring, 1991 
Cankurtaran et al., 2005 
Post-MI 
36.5 
18 
 
 
>45   
(of patients admitted for a MI) 
40 
16 - 26 
Koenig, 1998 
van Melle, de Jonge, Kuyper, Honig, 
Schene, Crijns, van den Berg, van 
Veldhuisen & Ormel, 2006 
Krishnan et al., 2000 
 
Pincus et al., 2001 
Guck et al., 2001 
Arthritis 
15.7 
55.6 
Patten et al., 2005 
Unűtzer, Patrick, Diehr, Simon, 
Grembowski & Katon, 2000 
Diabetes Mellitus 
≥ 15 (Type II) 
27.5 (Type I) 
11 - 15 (Type II) 
27 
17 * 
23.4  
Lustman et al., 1997 
Kovacs et al., 1997 
Anderson et al., 2001 
Pincus et al., 2001 
Kanner, 2003 
Cankurtaran et al., 2005 
Thyroid conditions 
5.2  
(Thyroid condition unspecified.) 
Patten et al., 2005 
 
Asthma 
16  * 
45 
1 - 45 a 
2.9 
Kanner, 2003  
Pincus et al., 2001 
Opolski & Wilson, 2005 
Cankurtaran et al., 2005 
 
 
 
 41
TABLE 2.4 
PREVALENCE RATES OF COMORBID DEPRESSIVE DISORDERS IN 
PATIENTS WITH SPECIFIED CHRONIC DISEASE STATES (CONTINUED) 
 
Chronic Disease State 
Prevalence Range of Major 
Depressive Disorder (%) 
Reference 
Anxiety Disorders 
57.4 
(Lifetime prevalence percentage 
estimated to be as high as 74%) 
Zimmerman, McDermut & Mattia,  
2000  
Alzheimer’s disease b 12.5 Cankurtaran et al., 2005 
Epilepsy 
20 - 55  
(in patients with recurrent seizures) 
 
3 - 9  
(in patients with controlled Epilepsy) 
 
29 *  
(reported to have suffered from at 
least 1 depressive episode)  
Indaco, Carrieri, Nappi, Gentile & 
Striano, 1992;  Baker, Jacoby & 
Chadwick, 1996;   
O’Donoghue, Goodridge, Redhead, 
Sander & Duncan, 1999; Lambert & 
Robertson, 1999  
Kanner, 2003 
Parkinson’s disease b 
 
4 - 70 McNamara, 1991;  Cummings, 1992;  
Mayberg et al., 1995 
Stroke 
25 - 30  
20 c 
30  
40 
15 - 25  
50  
(reported depressive symptoms) 
Clothier & Grotta, 1991  
Robinson, 1998  
Roose, Glassman & Seidman, 2001 
Pincus et al., 2001 
Whyte et al., 2002 
Berg et al., 2003 
HIV or AIDS  
8 (at start of study) 
10 (at 6-month follow-up) 
36 
33  
(of an American population sample 
of HIV-infected individuals) 
Perkins et al., 1994 
 
Dew et al., 1997 
Bing et al.,  2001 
 
* Results of a population-based survey (involving 181 000 participants) that analysed 
the lifetime prevalence of Epilepsy, Depressive Disorders, Asthma and Diabetes 
Mellitus were reported in 2002.  Epileptic patients constituted 2 281 members of the 
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sample size and 29% of these individuals were found to have suffered from at least a 
single depressive episode.  This is more than three times greater than the prevalence 
of Depressive Disorders in healthy participants (8.7%).  Additionally, it is noteworthy 
that the prevalence of a co-existing Depressive Disorder in diabetic and asthmatic 
patients (17% and 16%, respectively) was almost half of the corresponding percentage 
for epileptic patients.  (Kanner, 2003.) 
 
a Opolski and Wilson (2005) came to this value by reviewing several studies (1994 to 
2001) performed in asthmatic patients.  This range is wide, therefore making it difficult 
to draw distinct conclusions.  Furthermore, although many studies have shown that 
the prevalence of Depressive Disorders is in fact higher in individuals with Asthma 
than those without Asthma, some researchers have found no proof of this.  It has been 
suggested that these differences may be attributed to the different sampling methods 
utilised by the various investigators.  (Adams, Wilson, Taylor, Daly, Tursan 
d’Espaignet, Dal Grande & Ruffin, 2004.) 
 
b The prevalence of Depressive Disorders in patients with the following Neurological 
Disease states has proven to be variable, with wide prevalence ranges:  Parkinson’s 
Disease and Alzheimer’s Disease.  For this reason, in order to work with consistent 
figures that are of a narrower prevalence range, estimates were made.  It can be 
assumed that about half of patients suffering from Neurological Disease States exhibit 
depressive symptoms and that the prevalence of MDD falls approximately in the 
abovementioned ranges (National Institute of Mental Health [NIMH], 2002).    
 
c This is the mean point prevalence that was calculated utilising the results of studies 
conducted in several countries. 
 
Individuals with chronic disease states or Depressive Disorders may enhance 
the predisposition risk of developing the other disease state.  Table 2.5 
depicts the bidirectional risk estimates for the co-existence of Depressive 
Disorders and the specified chronic comorbid disease states. 
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TABLE 2.5  
ESTIMATES OF THE RISK INVOLVED IN DEVELOPING EITHER A 
DEPRESSIVE DISORDER OR CHRONIC COMORBID DISEASE STATE 
 
Chronic 
Comorbid 
Disease State 
Bidirectional Prevalence Risk Estimates Associated with the  
Co-existence of Depressive Disorders and a Specified Chronic 
Comorbid Disease State 
CVDs 
• Multiple large-scale studies have constantly demonstrated that depressed 
individuals are more prone to the development of a CVD in the following years, 
than their non-depressed counterparts (Frasure-Smith et al., 1995; Lespẻrance 
et al., 2000).  For example, the risk amongst depressed patients, for the 
development of a CVD, has been calculated to be 1.6 times greater than in 
individuals without Depressive Disorders, which is greater than the risk 
presented by passive smoking (Rugulies, 2002). 
 
• Studies have shown that individuals with Hypertension are more prone to the 
development of Depressive Disorders.  A study performed in 444 patients over 
58 years of age (151 patients with no mental disorder and 293 diagnosed with 
Unipolar Depression using DSM-IV® criteria) showed the prevalence of 
Hypertension in depressed individuals to be 42%.  This was almost double the 
prevalence of Hypertension observed in non-depressed patients (25%).  
(Bosworth, Bartash, Olsen & Steffens, 2003.) A study performed in 273 
depressed patients (193 females and 80 males), determined the prevalence of 
Hypertension to be 77.3% amongst these patients (Cankurtaran et al., 2005). 
  
• The prevalence of Depressive Disorders in CHD patients has been shown to be 
at least three times higher than the prevalence of Depressive Disorders in 
individuals without Cardiac Disease States (Krishnan et al., 2000).  Freedland 
and others (1992) deduced that approximately half of depressed CVD patients 
suffered from previous depressive episodes, which, in the majority of cases, 
began prior to the onset of the CVD. 
 
• In 1996, a study showed that MDD increased the incidence of MI over a 13-year 
period, by approximately 37% (Krishnan et al., 2000).  
 
• It has been estimated that one in three patients will suffer from a Depressive 
Disorder at some stage during the 12-month post-MI period (Lespẻrance, 
Frasure-Smith & Taljic, 1996). 
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TABLE 2.5  
ESTIMATES OF THE RISK INVOLVED IN DEVELOPING EITHER A 
DEPRESSIVE DISORDER OR CHRONIC COMORBID DISEASE STATE 
(CONTINUED) 
 
Chronic 
Comorbid 
Disease State 
Bidirectional Prevalence Risk Estimates Associated with the  
Co-existence of Depressive Disorders and a Specified Chronic 
Comorbid Disease State 
Diabetes 
Mellitus 
• Diabetic patients (Type I and Type II) are twice as likely to suffer from MDD as 
non-diabetic individuals (Anderson et al., 2001; Lustman et al., 2005).  
 
• Depressed individuals, who display depressive symptoms in the ‘highest 
quartile’, have a 63% higher risk of developing Diabetes Mellitus than those 
depressed patients with symptoms in the ‘lowest quartile’ (Golden et al., 2004).  
A 21-year follow up study performed in the US, identified depressive symptoms 
as an independent risk factor for the development of Diabetes Mellitus 
(Carnethon et al., 2003). 
Arthritis 
• Patients with Arthritis have been reported to be two to three times more likely to 
develop MDD, relative to individuals without Arthritis (Dickens, McGowan, 
Clarke-Carter & Creed, 2002). 
Asthma 
• Almost half of patients who suffer from Asthma may also experience depressive 
symptoms that are clinically significant (Mancuso, Peterson & Charlson, 2000).  
Anxiety 
Disorders 
• Earlier studies estimated that in any given year, between 30% and 40% of 
depressed adults may also have a comorbid Anxiety Disorder and that the 
lifetime prevalence is approximately 47% (Kessler, Nelson, McGonagle, Edlund, 
Frank & Leaf, 1996; Barbee, 1998). 
Epilepsy 
• It has been frequently documented that Epilepsy is a risk factor for Depressive 
Disorders.  On the other hand, more recent surveys have shown that the risk of 
developing Epilepsy is four to six times greater if there is a history of Depressive 
Disorders.  (Kanner, 2003.)   
Stroke 
• Research has shown that severely depressed patients are approximately twice 
as likely to have a stroke within 10 years, when compared with those depressed 
patients with fewer symptoms (Ohira et al., 2001).  
HIV-Disease 
• Patients with HIV infection have been associated with a two-fold higher rate of 
Depressive Disorders than individuals without this disease state (Dew et al., 
1997).  The lifetime prevalence rates of Depressive Disorders in HIV-infected 
individuals have ranged from 22% to 45% (Dew et al., 1997; Kelly, Otto-Salaj, 
Sikkema, Pinkerton & Bloom, 1998).   
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2.6.2 Proposed Explanations for the Link between Depressive 
Disorders and Chronic Comorbid Disease States 
 
A conceptual model (see Figure 2.1) attempted to explain the possible link 
between Depressive Disorders and chronic disease states.  A complex 
relationship exists between Depressive Disorders and chronic comorbidities 
and this association appears to be due to Depressive Disorders exacerbating 
chronic disease and to chronic disease states precipitating symptoms of 
Depressive Disorders (Chapman et al., 2005).  A study performed by Katon 
(2003) proposed that the higher prevalence of Depressive Disorders observed 
in patients with chronic disease states may be attributable to a number of 
factors, including, but not limited to the following: 
 
• Depressive Disorders enhance the risk of developing certain chronic 
disease states. 
• The occurrence of a chronic disease state triggers a psychological reaction 
that can develop into a co-existing Depressive Disorder.  A Depressive 
Disorder could be a consequential response to complications of adverse 
symptoms of the disease state. 
• The side-effects of the medication used to treat the chronic disease state 
may lead to Depressive Disorders.  
• Some chronic disease states (for example, Stroke and Multiple Sclerosis) 
have direct pathophysiological effects on the brain.  For example, the 
higher prevalence of Depressive Disorders in patients with Neurological 
Disease States may be due to the direct effects that such disorders have 
on neural circuits associated with regulating mood.  Other disease states 
may induce indirect physiological changes that could lead to the 
development of Depressive Disorders.  The enhancement of cytokine 
levels, or other inflammatory mediators that influence the brain, provides 
an example of such a physiological change.  
 
Although the abovementioned possible explanations for an association 
between Depressive Disorders and chronic disease states are logical, they 
are generalised and therefore, individual disease states and theories need to 
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be discussed in more detail in order to define the interrelationship more 
clearly.  The following section presents the literature findings regarding the 
nature of the relationship between Depressive Disorders and prevalent 
chronic comorbid disease states. 
 
2.6.2.1 The Theory of Vascular Depression 
 
Some researchers have noted that Depressive Disorders secondary to 
chronic disease states seem to be more strongly associated with 
environmental factors than with a family history of Depressive Disorders.  In 
light of this observation, it may be proposed that a chronic disease state 
(environmental factor) has a more pronounced influence on the 
pathophysiology of a comorbid Depressive Disorder.  However, it has also 
been demonstrated that genetic risks for late-onset Depressive Disorders 
(initial onset after 65 years of age) may be associated with a genetic risk for 
Vascular Disease (Yates et al., 2004.) Studies demonstrated that such late-
onset Depressive Disorders may be attributable to more of a vascular cause 
than Depressive Disorders of early-onset (Shah, 2002).  This was deduced 
after magnetic resonance imaging (MRI) procedures revealed that patients 
with late-onset Depressive Disorders displayed greater vascular-related 
changes.  For example, ‘discrete high intensity signals in white matter’, known 
as white matter hyperintensities on MRI, were found to be ‘sclerotic lesions 
around the vasculature’ when a post-mortem was performed (Krishnan, Hays 
& Blazer, 1997).  In addition to this finding, greater treatment resistance; more 
deaths from CVDs and significant cognitive impairment; constitute other 
observations noted in patients with late-onset Depressive Disorders, which 
suggests the presence of a disease process (Shah, 2002).  For example, the 
association between Depressive Disorders and the vascular system has been 
examined and this gave rise to an influential theory known as the theory of 
Vascular Depression.  This theory states that Cerebrovascular Disease 
States, such as Diabetes Mellitus, Hypertension and CHD, alter the 
structure of the brain and impair neurological functioning.  By altering 
neurological functioning, such disease states interfere with the regulation of 
serotonin and noradrenaline.  Thus, this theory suggests that Vascular 
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Depression exacerbates and contributes to the maintenance of depressive 
symptoms by the abovementioned mechanisms.  The theory of Vascular 
Depression has contributed to our understanding of the high comorbidity that 
exists between Depressive Disorders and Diabetes Mellitus, Hypertension 
and CHD.  (Schnittker, 2005.) Furthermore, the theory corresponds with many 
important clinical features of late-onset Depressive Disorders, such as its 
greater chronicity, diminished response to treatment and lower familial 
concordance (Alexopoulos, 2005). 
 
2.6.2.2 Harmful Lifestyle Influences and Cardiac Risk Factors 
 
Several studies have demonstrated that depressed patients exhibit higher 
rates of harmful lifestyle risk factors, such as smoking, sedentary lifestyle and 
obesity (Carney, Freedland, Miller & Jaffe, 2002; Katon, Lin, Russo, von Korff, 
Ciechanowski, Simon, Ludman, Bush & Young, 2004).  This enhances the risk 
of developing a chronic disease state, such as Diabetes Mellitus, 
Hypertension or other CVDs (Katon, 2003; Cankurtaran et al., 2005). 
 
It is well-established that genetic predispositions, lifestyle choices and chronic 
disease states increase the risk of CVDs.  More recently, research has 
focused on establishing a correlation between Depressive Disorders as a risk 
factor for not only the development of CVD, but also for death after onset of 
Coronary Vascular Disease.  A quantitative review of 10 controlled 
observational studies was performed (1993 to 2000) for the purposes of 
evaluating the link between Depressive Disorders and the onset of Coronary 
Disease.  This analysis revealed that as a group, these 10 studies suggest 
that Depressive Disorders pose a significant risk factor for the onset of 
Coronary Disease in patients without clinically apparent CVD.  (Wulsin & 
Singal, 2003.)  
 
Katon (2003) found that more than 60% of diabetic patients with comorbid 
Depressive Disorders displayed cardiac risk factors.  This was approximately 
double the risk associated with Depressive Disorders in individuals without 
Diabetes Mellitus (35%).  The significance of this can be demonstrated by the 
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finding that 70% to 80% of diabetic patients die from Cardiac Disease States.  
(Katon, 2003.) A recent study conducted in 4 225 diabetic patients (1 215 with 
current Cardiovascular Disease [CVD+] and 3 010 without an existing 
Cardiovascular Disease [CVD-]) explored the relationship between comorbid 
Depressive Disorders and risk factors for Cardiac Disease States.  Those 
diabetic patients with Depressive Disorders (14.2% of CVD+ patients and 
10.6% of CVD- patients) were twice as likely to have four or more cardiac risk 
factors as their non-depressed counterparts.  These risk factors included 
smoking, Hypertension, elevated low-density lipoprotein, triglyceride (TG) and 
glycosylated haemoglobin (HbA1c) levels, sedentary lifestyle, BMI and 
microalbuminaemia or macroalbuminaemia.  Another finding of this study was 
that depressed diabetic patients without CVD were significantly more likely to 
have a BMI of greater than or equal to 30kg/m2, to smoke, to follow a more 
sedentary lifestyle and to have HbA1c levels of greater than 8%, than non-
depressed diabetic patients without a CVD.  Similarly, diabetic patients with a 
co-existing Depressive Disorder and CVD were more likely to have a BMI of 
greater than or equal to 30kg/m2, to lead a more sedentary lifestyle and to 
have TG levels of greater than 400mg/dl in comparison with non-depressed 
diabetic patients with CVD.  Therefore, this study concluded that depressed 
diabetic patients with or without CVD exhibit a higher number of CVD risk 
factors than their non-depressed counterparts.  (Katon et al., 2004.) 
 
Depressive Disorders have been linked with the Metabolic Syndrome in 
females younger than 40 years of age.  Since the Metabolic Syndrome is a 
risk factor for the development of CVD among women, it can be seen that if a 
Depressive Disorder is recognised early and treated accordingly, the CVD risk 
amongst women can be reduced.  (Kinder et al., 2004.)  
 
 
 
 
 
 
 49
2.6.2.3 Defining the Relationship between Depressive Disorders and 
Cardiovascular Events 
 
Several possible theories have been proposed to define the relationship 
between Depressive Disorders and cardiac events: 
 
• It has been deduced that certain antidepressants, especially TCAs and 
MAOIs, have toxic effects on the heart (Glassman et al., 1993; Cohen, 
Gibson & Alderman, 2000).  Cohen and colleagues (2000) suggested that 
the significant cardiac morbidity and mortality associated with co-existing 
Depressive Disorders might be due to the antidepressant drug treatment, 
rather than as a result of the Depressive Disorder itself.  However, other 
researchers have opposed this proposal and offered noteworthy 
explanations as to why the abovementioned theory cannot hold true for a 
large percentage of cardiac morbidity and mortality cases: 
i) The relationship between Depressive Disorders and cardiac 
mortality was identified long before antidepressant treatments were 
even developed (Fuller, 1935). 
ii) A small percentage of antidepressant-related cardiotoxic reactions 
are severe or fatal (Herbert et al., 1993). 
iii) SSRIs are the agents of choice for cardiac patients with comorbid 
Depressive Disorders as a result of few cardiotoxic effects (Sheline, 
Freedland & Carney, 1997). 
iv) Physicians often fail to diagnose comorbid Depressive Disorders in 
patients with CVDs.  Even in cases where the Depressive Disorder 
is identified, in many instances, antidepressants are not prescribed.  
(Sheline et al., 1997.) 
• Depressive Disorders are associated with many of the important cardiac 
risk factors, such as Hypertension, smoking, Diabetes Mellitus and 
reduced functionality (Carney et al., 2002). 
• It has been postulated that a Depressive Disorder correlates with Cardiac 
Disease State severity.  This implies that cardiac patients with comorbid 
Depressive Disorders could display poorer medical outcomes than non-
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depressed patients, simply because they have a CVD that is more severe.  
(Carney et al., 2002.) 
• Studies have shown that Depressive Disorders are predictors of cardiac 
morbidity and mortality, regardless of age.  There is also proof that the 
cardiac mortality risk is greater amongst those patients with early-onset 
Depressive Disorders than those with late-onset disorders.  (Lespẻrance et 
al., 1996.)  
• Patients with CHD and a co-existing Depressive Disorder were found to be 
less compliant with pharmacological cardiac programmes (Carney et al., 
1995) and lifestyle interventions to reduce risk factors (Ziegelstein, 
Fauerbach, Stevens, Romanelli, Richter & Bush, 2000) than non-
depressed cardiac patients.  These findings might suggest that lack of 
adherence to both pharmacological and non-pharmacological therapies 
could possibly contribute significantly to a greater risk of cardiac morbidity 
and mortality in depressed patients with comorbid CVDs. 
• It has been established that Depressive Disorders cause dysregulation of 
the sympathetic nervous system and the HPA axis.  Enhanced 
sympathetic activity and decreased parasympathetic activity may increase 
the risk of myocardial ischaemia, ventricular fibrillation, ventricular 
tachycardia and sudden cardiac death in patients with CVDs.  (Carney et. 
al, 1995.) Modification of normal endocrine functioning leads to less heart 
rate variability and raised plasma and serum levels of cortisol, 
catecholamines and their metabolites.  Experimental research has shown 
that raised plasma catecholamine levels leads to increased platelet 
aggregation.  This may increase the risk for Thrombosis and Infarction, 
since platelet aggregation lowers the myocardial ischaemic threshold 
(Nemeroff et al., 2000.) 
• Serotonin is an active neurotransmitter that has an important role to play in 
Depressive Disorders.  It has also been shown to enhance platelet activity 
and therefore may predispose the patient to a CVD.  Serotonin is stored in 
platelets and is released during an ischaemic attack.  Its release initiates a 
series of processes that lead to platelet aggregation and thrombus 
formation.  (Krishnan et al., 2000.) The significantly higher morbidity and 
mortality rates evident in depressed patients, render it necessary to 
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analyse the role that serotonin has to play in Vascular Disease States.  
The effect of serotonin may be supported by the following experimental 
findings:  Biochemical studies have deduced that non-depressed cardiac 
patients display higher levels of markers of platelet activation than those 
evident in individuals without Cardiac Disease States (Musselman, Tomer, 
Manatunga, Knight, Porter, Kasey, Marzec, Harker & Nemeroff, 1996; 
Musselman et al., 1998).  Depressed patients with CVDs were shown to 
display much higher levels of these markers, as well as a higher serotonin 
receptor density.  For example, depressed patients had a platelet 
activation and responsiveness rate that was 41% higher than the rate 
evident in non-depressed patients (Musselman et al., 1996).  Therefore, it 
has been suggested that depressed individuals may be at a greater risk of 
platelet activation as a consequence of serotonin, and this may cause 
coronary artery vasoconstriction (Musselman et al., 1998). 
• It is becoming more common to view CHD as a chronic inflammatory 
response to endothelial injuries (Ross, 1999).  Depressive Disorders may 
result in recurrent damage to the vascular endothelium, which 
consequently triggers this inflammatory process.  Furthermore, a 
Depressive Disorder is a chronic, recurring disease and so each new 
episode could add to, and therefore promote, the endothelial damage.  
(Judd, 1997.) Depressive Disorders may contribute to the initiation of the 
inflammatory response by encouraging undesirable lifestyle habits, such 
as smoking (Miller, Cohen & Herbert, 1999); causing dysregulation of 
cortisol and catecholamine secretion (Owens, Plotsky & Nemeroff, 1995); 
or enhancing the predisposition to infection by latent pathogens that could 
damage the vessel wall (Herbert et al., 1993).  A recent study suggested 
that Depressive Disorders maintain the inflammatory process by 
increasing resistance to the glucocorticoid hormones that exert an anti-
inflammatory effect; however, there has not been satisfactory proof of this, 
as yet (Miller, Cohen & Ritchey, 2002). 
 
Hypertension, Lipid Disorders and Diabetes Mellitus have been 
recognised as prevalent disease states amongst South Africans (Levitt, 
Unwin, Bradshaw, Kitange, Mbanya, Mollentze, Omar, Motala, Joubert, 
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Masuki  & Machibya, 2000; Steyn et al., 2005; Heart Foundation - South 
Africa, 2006).  For this reason, the association between Depressive Disorders 
and these chronic comorbid disease states will be further investigated in the 
sections to follow (Sections 2.6.2.4 [Hypertension]; 2.6.2.5 [Lipid Disorders] 
and 2.6.2.6 [Diabetes Mellitus]).  
 
2.6.2.4 The Relationship between Hypertension and Depressive 
Disorders 
 
Studies evaluating the relationship between Depressive Disorders and 
Hypertension have yielded conflicting results.  Some prospective studies 
indicated that depressed patients are more likely to develop subsequent 
Hypertension (Jonas et al., 1997; Meyer et al., 2004), whereas other 
researchers have found no link between the two disease states (Vogt, Pope, 
Mullooly & Hollis, 1994).  Jonas and others (1997) suggested that the inability 
to yield consistent results among the prospective studies is due to inadequate 
follow-up time, insufficient study population size and a shortage of well-
validated standardised measures.  Shrivastava and Kochar (2002) conducted 
an extensive literature review regarding the relationship between 
Hypertension and Depressive Disorders and made the following deductions: 
 
• Neurohormonal mechanisms or lifestyle behaviours associated with 
Depressive Disorders, may lead to the development of Hypertension.  The 
neurohormonal system plays a vital role in blood pressure regulation and 
is affected by various sources of input.  The noradrenergic system 
influences blood pressure regulation and it is thought that Depressive 
Disorders are coupled with dysregulation of this system.  It has been 
postulated that the efficacy of the alpha2-adrenergic receptor is 
compromised in depressed patients.  The suboptimal efficacy could result 
from decreased sensitivity of the receptor or less adrenergic activity in the 
central nervous system (CNS).  Activation of alpha2-adrenergic receptors 
in the hypothalamus results in an inhibitory effect on sympathetic nervous 
activity.  Therefore, it follows that reduced responsiveness of these 
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receptors, will lead to enhanced sympathetic activity, which in turn, will 
lead to a blood pressure increase.   
• Researchers have also found that depressed patients exhibit other 
abnormalities involving the noradrenergic system, such as erratic 
noradrenaline secretion and irregular circadian pattern of its secretion.  
Studies have shown that an increase in mean arterial pressure and heart 
rate in depressed patients can be attributed to an enhanced sympathetic 
nervous system output in these individuals.  It can thus be speculated that 
the increased sympathetic activity evident in depressed patients is merely 
a non-specific stress reaction associated with Depressive Disorders.  This 
supposition cannot hold true, however, since studies have demonstrated 
that patients with Panic Disorder (a disorder associated with a lot of 
distress) do not exhibit raised plasma noradrenaline levels or enhanced 
noradrenaline output.   
 
2.6.2.5 The Relationship between Lipid Disorders and Depressive 
Disorders 
  
Research conducted for the purposes of establishing a connection between 
Depressive Disorders and cholesterol levels, have produced conflicting 
results, with some studies indicating an inverse relationship (Morgan, 
Palinkas, Barrett-Connor & Wingard, 1993); others displaying enhanced 
cholesterol levels amongst depressed patients (Kinder et al., 2004; Nakao et 
al., 2004; Petrlova et al., 2004); and still others not finding any significant 
relationship (Brown, Salive, Harris, Simonsick, Guralnik & Kohout, 1994; 
McCallum, Simons, Simons & Friedlander, 1994).  
 
In terms of lipid homeostasis, studies have noted the following abnormalities 
in depressed individuals:  reduced concentration of vitamin E; enhanced 
activity of enzymes taking part in the oxidation and peroxidation of lipids; and 
lower serum concentrations of high-density lipoprotein-cholesterol 
(Papakostas, Öngür, Iosifescu, Mischoulon & Fava, 2004). 
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2.6.2.6 The Relationship between Diabetes Mellitus and Depressive 
Disorders 
 
It has been proposed that Depressive Disorders may contribute to the 
development of Diabetes Mellitus; however, this relationship is more 
pronounced when there are many depressive symptoms present.  
Furthermore, a study revealed that this marked association was only evident 
in individuals with less than a high school education.  (Carnethon et al., 2003.) 
This could suggest that low socioeconomic status may be an individual risk 
factor for the development of Diabetes Mellitus in patients with many 
depressive symptoms.   
 
There seems to be a chronological relationship between Depressive Disorders 
and the commencement of Type I and Type II Diabetes Mellitus.  This stems 
from the observation that although Depressive Disorders often precede the 
onset of Type II Diabetes Mellitus, it usually occurs many years after the 
onset of Type I Diabetes Mellitus.  (Talbot & Nouwen, 2000.) It has therefore 
been stated that Depressive Disorders play a role in the development or 
exacerbation of diabetic complications by means of its metabolic and 
behavioural effects (Lustman et al., 2005).  The relationship between 
Depressive Disorders and Diabetes Mellitus seems to be bidirectional since, 
as mentioned previously, the difficulties associated with suffering from a 
chronic disease state (like Diabetes Mellitus), may lead to the development of 
a comorbid Depressive Disorder (Talbot et al., 2000). 
 
The interrelationship between Diabetes Mellitus and Depressive Disorders 
has also been attributed to poor metabolic control.  Figure 2.2 illustrates this 
hypothesis.   
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DEPRESSIVE DISORDERS 
 
 
 
have been associated with: 
• cortisol irregularities 
• weight gain 
• poor compliance to medicine regimens 
• insulin resistance 
       exacerbates 
 
` 
Interferes with satisfactory glycaemic control 
 
 
 
HYPERGLYCAEMIA (affects mood) 
 
 
 
Antidepressants 
Exacerbation of Diabetes Mellitus 
 
FIGURE 2.2 
A PROPOSED EXPLANATION FOR THE RELATIONSHIP BETWEEN DEPRESSIVE 
DISORDERS AND DIABETES MELLITUS (Source:  Adapted from Lustman et al., 2005) 
 
The interaction between Depressive Disorders and Diabetes Mellitus is 
governed by both psychological and biological variables.  The hyperglycaemic 
effects of antidepressants; diet and weight changes and lack of physical 
activity are associated with chronic Depressive Disorders and have been 
linked to the development of Type II Diabetes Mellitus.  (Eaton, Armenian, 
Gallo, Pratt & Ford, 1996.) Additionally, biochemical changes associated with 
Depressive Disorders, such as enhanced sympathetic and adrenal activity, 
also contribute and the overall effects of these factors are an increase in the 
blood glucose levels and negative alteration of glucose tolerance (Surwit, 
Schneider & Feinglos, 1992).  Depressive Disorders may impair the 
carbohydrate disposition loads through the release of counter-regulatory 
hormones.  This, in turn, enhances the risk for the development of Type II 
Diabetes Mellitus.  On the other hand, hyperglycaemia may lead to stimulation 
of the nervous system and this makes the individual more vulnerable to 
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environmental stress, which enhances their susceptibility towards the 
development of a Depressive Disorder.  (Lustman et al., 2005.) 
  
2.6.2.7 The Relationship between Arthritis and Depressive Disorders 
 
Arthritis is a commonly occurring chronic disease state in the elderly and its 
prevalence has been shown to increase sharply with an increase in age (Lin, 
Katon, Von Korff, Tang, Williams, Kroenke, Hunkeler, Harpole, Hegel, Arean, 
Hoffling, Della Penna, Langston & Unűtzer, 2003).  Symptoms of Depressive 
Disorders have been consistently linked with functional disability (Lin, Von 
Korff, Russo, Katon, Simon, Unűtzer, Bush, Walker & Ludman, 2000; Lin et 
al., 2003). 
 
The association between Arthritis and Depressive Disorders seems to stem 
from the chronic pain experienced by arthritic patients (Dickens et al., 2002).  
However, the aetiological nature of this relationship between Depressive 
Disorders and pain, in patients with Arthritis, has not been investigated 
extensively.  Studies that have been conducted in this regard have yielded 
inconsistent findings.  Dickens and colleagues (2002) performed an extensive 
literature review into Depressive Disorders in patients with Arthritis and found 
that the variability in the results may be attributed to the following aspects:  
differences in samples and measures utilised; and the mutual association of 
Depressive Disorders and Arthritis with regard to the extent of physical 
disability, disease activity and duration of disease state.  This study also 
assessed the extent to which sociodemographic variables (age, sex and 
socioeconomic status) may influence the degree of Depressive Disorders.  It 
was established that sociodemographic variables did not reduce the 
magnitude of the effect size for Depressive Disorders.  Thus, the enhanced 
likelihood of a Depressive Disorder amongst patients with Arthritis was 
suggested to have been due to the arthritic condition and not the 
sociodemographic differences.  (Dickens et al., 2002.)  
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2.6.2.8 The Relationship between Menopause and Depressive 
Disorders  
 
Cohen and others (2005) reviewed the current literature pertaining to 
Depressive Disorders during the menopausal transition and deduced the 
following:  some studies have suggested that sleep disturbances (that are 
associated with hot flushes) indirectly result in the development of Depressive 
Disorders during the menopausal transition; and other studies have suggested 
that the occurrence of Depressive Disorders during this period may be 
attributable to the sensitivity of the brain to alterations in the levels of 
reproductive hormones (for example, estrogen) that occur during the 
menopausal transition phase.      
 
2.6.2.9 The Relationship between Hypothyroidism and Depressive 
Disorders 
  
 Depressive Disorders and other Psychiatric Disorders have been associated 
with Hypothyroidism (Burmeister et al., 2001; Sintzel et al., 2004).  For 
example, a meta-analysis of six studies showed that the prevalence of 
subclinical Hypothyroidism was as follows:  52% (patients with treatment-
resistant Depressive Disorders); 8% to 17% (patients with uncomplicated 
Depressive Disorders); and 5% in the overall study population (Sintzel et al., 
2004).  It has been suggested that the relationship between Hypothyroidism 
and Depressive Disorders may be explained by the changes at the 
serotonergic and noradrenergic receptor level (Burmeister et al., 2001). 
 
2.6.2.10 The Relationship between Asthma and Depressive Disorders 
 
The link between Asthma and Depressive Disorders is not precisely known, 
however many theories have been proposed, namely:   
 
• Some researchers attribute the association to common physiological 
causes.  This includes impaired voluntary activation of the diaphragm in 
depressed asthmatic patients, or a muscarinic imbalance that connects 
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Depressive Disorders and smooth muscle bronchoconstriction (Mancuso 
et al., 2000).   
• It has been proposed that Asthma and concurrent Depressive Disorders 
co-exist independently (Mancuso et al., 2000).   
• It has also been postulated that Depressive Disorders occur secondary to 
Asthma because of the drugs used to treat Asthma (Mancuso et al., 2000). 
• Mrazek (2003) proposed that the stress associated with having Asthma 
might contribute to the existence of the depressive symptoms evident in 
asthmatic patients, to a certain extent.  However, it seems as though it is 
the symptoms of Asthma (as opposed to the diagnosis thereof) that is 
linked to Depressive Disorders and Anxiety (Janson, Bjornsson, Hetta & 
Boman, 1994).  A recent study performed in a sample of South Western 
Nigerians with Asthma, proved to be in agreement with this hypothesis, 
because it was found that 87.5% of those individuals who had more 
frequent Asthma attacks, presented with depressive and anxiety 
symptoms.  This contrasts with 25% of those asthmatic patients who had 
less frequent attacks.  (Erhabor, Kuteyi & Obembe, 2002.) Furthermore, 
Goldney and colleagues (2003) also suggested that those patients who 
experienced severe symptoms associated with Asthma, such as dyspnoea 
and nocturnal awakening, were at a greater risk of developing MDD.  
• It has been shown that the airways react to changes in emotional status.   
Such changes have been linked to greater instability of the airways, as 
well as exacerbation of the Asthma condition.  (Lehrer, Feldman, Giardino, 
Song & Schmaling, 2002.) The association between Asthma and 
Depressive Disorders, however, can be described as being complex and 
controversial.  Whereas some studies have demonstrated that an increase 
in depressive symptoms is associated with worse forced expiratory volume 
in one second (FEV1) values, others have stated that there is no 
correlation between depressive symptoms and FEV1 (Mancuso et al., 
2000).   
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2.6.2.11 The Relationship between Neurological Disease States and 
Depressive Disorders 
 
Neurological Disease States have been linked to (but not necessarily limited 
to) the following aetiologies of Depressive Disorders: 
 
• Depressive Disorders may be a psychological reaction to disability (Katon, 
2003). 
• It was previously mentioned that the higher prevalence of Depressive 
Disorders in patients with Neurological Disease States may be as a 
consequence of the direct effects that such disorders impart on neural 
circuits associated with mood regulation.  It therefore comes as no surprise 
that the following theories have been put forward to ascertain whether 
Depressive Disorders occur as a result of the neurodegenerative 
processes that are characteristic in such Neurological Disease States:   
i) Cerebrovascular Disease States may cause ‘leukoencephalopathy 
and degeneration of subcorticol structures’, which have been linked 
to the development of Depressive Disorders of late-onset (Krishnan, 
McDonald, Doraiswamy, Tupler, Husain, Boyko, Figiel & Ellinwood, 
1993).  Depressive Disorders may be more likely to develop after a 
Stroke when the left hemisphere of the brain has been affected 
(Narushima, Kosier & Robinson, 2003).   
ii) Degeneration of the brain-stem monoamine afferents (especially 
those areas with an abundance of serotonin and noradrenergic 
neurons) has been demonstrated to exhibit a certain degree of 
correlation with Depressive Disorders (Forstl, Burns, Luthert, 
Cairns, Lantos & Levy, 1992). 
iii) Studies have shown that the following factors are linked to a higher 
incidence of Depressive Disorders in patients with Parkinson’s 
Disease:  depleted levels of the serotonin metabolite, 5-
hydroxyindole acetic acid, in the cerebrospinal fluid (Mayeux, Stern, 
Williams, Cote, Frantz & Dyrenfurth, 1986); right-sided motor 
symptoms (Starkstein, Preziosi, Bolduc & Robinson, 1990); and 
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‘akinetic rigid subtype’ (Starkstein, Petracca, Chemerinski, Teson, 
Sabe, Merello & Leiguarda, 1998).    
 
In terms of the individual Neurological Disease States, it appears as though 
Epileptic Disorders have been studied most extensively.  The following section 
outlines the literature findings regarding the relationship between Depressive 
Disorders and Epilepsy: 
 
• It was previously noted that Depressive Disorders are risk factors for the 
development of Epilepsy.  Conversely, Epilepsy is a risk factor for the 
development of a Depressive Disorder (refer to Table 2.5).  This suggests 
that there could be a bidirectional relationship between the two disease 
states or that both conditions are associated with common pathogenic 
pathways (Kanner, 2003).  Depressive Disorders are associated with 
reduced serotonergic and noradrenergic activity.  Similarly, reduced 
activity of these same neurotransmitters (serotonin and noradrenaline) has 
been linked with promoting the stimulation of seizure foci, which worsens 
the severity of seizures and enhances susceptibility towards seizures.  
(Jobe, Dailey & Wernicke, 1999.)  
• Depressive Disorders constitute the most frequently diagnosed Psychiatric 
Disorders in epileptic patients.  The following factors are believed to 
influence the prevalence of comorbid Depressive Disorders in patients with 
Epilepsy (Kanner, 2003): 
i) Familial Predisposition 
A family history of Depressive Disorders has been identified in 
depressed patients with Epilepsy.  From as early as 1987, 
Robertson and colleagues noted that more than half of patients 
diagnosed with Epilepsy reported a family history of mental illness, 
with Mood Disorders occurring most commonly. 
ii) The Origin of the Seizure Focus 
It has been shown that seizures stemming from the temporal and 
frontal lobe regions of the brain are more strongly associated with 
Depressive Disorders.  Prevalence rates of Depressive Disorders in 
such instances have been found to range from 19% to as high as 
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65% in various earlier studies.  (Blumer, 1991; Mendez, Doss, 
Taylor & Salguero, 1993.) 
iii) Dysfunction of the Temporal Lobe 
Gilliam and Kanner (2002) provided additional and more recent 
proof pertaining to the interrelationship between temporal lobe 
dysfunction and Depressive Disorder severity.  This study confirmed 
what earlier studies stated, that is, that temporal lobe dysfunction is 
in fact associated with a higher prevalence of Depressive Disorders. 
iv) Dysfunction of the Frontal Lobe 
Research has indicated that Temporal Lobe Epilepsy may result in 
frontal lobe dysfunction (Menzel, Grunwald, Klemm, Ruhlmann, 
Elger & Biersack, 1998).  This is relevant, since it has been 
speculated that compromised frontal lobe functioning may be 
associated with reduced serotonergic transmission and this can 
consequently enhance the susceptibility towards Depressive 
Disorders (Kanner, 2003). 
 
2.6.2.12 The Relationship between HIV-Disease and Depressive 
Disorders 
 
It has been observed that Depressive Disorders and stress are associated 
with a reduction in the number of NK and CD8+ T cells (Herbert et al., 1993).  
These cells are important for controlling the progression of disease states and 
therefore, it can be stated that Depressive Disorders may influence disease 
progression in patients with HIV/AIDS by affecting cell-mediated immune 
functioning.  On the other hand, plasma cobalamin levels in patients 
diagnosed with HIV have been correlated with an enhanced prevalence of 
Depressive Disorders.  (Baldewicz, Goodkin, Blaney, Shor-Posner, Kumar, 
Wilkie, Baum & Eisdorfer, 2000.) The following HIV medications have side-
effects that may result in Depressive Disorders:  interleukin, steroids, 
interferon, efavirenz, zidovudine, stavudine, zalcitabine and vinblastine (Roy, 
2006).  Thus, it is evident that there may be a two-way relationship between 
Depressive Disorders and HIV-Disease (Baldewicz et al., 2000).   
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2.7 THE IMPLICATIONS OF SUFFERING FROM A DEPRESSIVE 
DISORDER AND CHRONIC COMORBID DISEASE STATES  
 
Research has shown that 70% of patient consultations with primary care 
physicians pertain to chronic disease states (Veale, 2003).  This highlights the 
increasingly important role that chronic disease state management is 
assuming in the delivery of health care.  A study conducted by Wells and 
Shelbourne (1999) established that, generally speaking, on a physical, mental 
and emotional level, depressed patients function at lower levels than 
individuals suffering from 11 other common chronic disease states.    
 
According to the conceptual model (refer to Figure 2.1), the management of 
chronic disease states requires the implementation of multiple measures in 
order to optimise treatment outcomes.  This often entails, but is not limited to, 
the following:  collaboration with the patient’s physician; compliance to 
medication regimens; self-monitoring activities (for example, frequent blood 
pressure and/or glucose monitoring); and lifestyle adjustments to reduce 
adverse health risks (smoking and drinking cessation, alteration of the 
patient’s diet).  Depressive Disorders result in greater symptom burden, 
reduced functionality and decreased quality of life.  (Katon, 2003.)  
Furthermore, several studies have shown that the effects of Depressive 
Disorders and chronic co-existing disease states on symptom burden, 
functionality and quality of life, are synergistic (Berardi et al, 2002; Harpole et 
al., 2005).  For example, the detrimental impact of Depressive Disorders on a 
patient’s co-operation with the attending physicians; frequency of preventative 
medical care visits; compliance to self-care regimens; and the direct 
pathophysiologic effects of Depressive Disorders, may enhance morbidity and 
mortality in patients with chronic disease states and comorbid Depressive 
Disorders (Katon, 2003).  
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Sections 2.7.1 to 2.7.3 further describe the implications of being diagnosed 
with a Depressive Disorder and one or more chronic comorbid disease states 
in terms of the following: 
 
• non-compliance with treatment regimens; 
• outcomes from chronic comorbid disease states; and 
• financial and occupational implications. 
 
2.7.1 Non-compliance with Pharmacological and Non-pharmacological 
Therapies 
 
A recent study revealed that medically ill patients with comorbid Depressive 
Disorders were three times more likely to be non-compliant with medical 
treatment regimens than their non-depressed counterparts.  It has been 
hypothesised that a ‘feedback loop’ may explain the association between 
Depressive Disorders, chronic disease states and non-compliance.  This 
‘feedback loop’ may be interpreted as follows:  Depressive Disorders result in 
lack of compliance to treatment programmes.  Non-compliance, in turn, further 
exacerbates the chronic disease state, which consequently worsens the 
Depressive Disorder; and so the cycle continues.  (Di’Matteo, Lepper & 
Croghan,  2000.) 
 
In order to establish the impact that Depressive Disorders have on 
compliance, various studies have focused on depressed individuals with 
particular chronic comorbid disease states.  These studies yielded the 
following results: 
   
• Diabetic patients with Depressive Disorders were found to be less 
adherent to a healthy diet and less diligent with regard to collecting 
monthly repeats of medication, than non-depressed diabetics (Katon, 
2003). 
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• Cardiac patients with comorbid Depressive Disorders were found to be 
less compliant with their daily dose of aspirin, relative to their non-
depressed counterparts (Katon, 2003).    
• Post-MI Depressive Disorders have been associated with poorer 
adherence to lifestyle recommendations and this may, as a result, increase 
the likelihood of future cardiac episodes (Ziegelstein et al., 2000).   
• Asthmatic patients with comorbid Depressive Disorders have also been 
found to be less compliant with their medication regimens than asthmatic 
patients without a Depressive Disorder (Cluley & Cochrane, 2001).   
• Studies conducted in HIV-infected patients deduced that Depressive 
Disorders were related to a lack of compliance to Highly Active 
Antiretroviral Therapy (HAART) (Katon, 2003).    
 
2.7.2 The Detrimental Effects of Depressive Disorders and Chronic 
Comorbid Disease States on Outcomes  
 
Many studies have demonstrated that Depressive Disorders impact negatively 
on outcomes from chronic comorbid disease states (Vali & Walkup, 1998; 
Krishnan et al., 2000; Harpole et al., 2005).  Table 2.6 depicts examples of the 
negative effects that comorbid Depressive Disorders have on outcomes from 
comorbidities that are frequently associated with Depressive Disorders. 
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TABLE 2.6 
THE EFFECTS OF DEPRESSIVE DISORDERS AND CHRONIC COMORBID   
DISEASE STATES ON DISEASE STATE OUTCOMES 
 
Chronic Comorbid 
Disease States 
Impact on Outcomes from Chronic Comorbid 
Disease States  
CHD and Depressive 
Disorders 
Patients have functional disability, worse results after coronary 
artery bypass procedures, poorer prognoses following an 
episode of Unstable Angina and greater mortality than those 
CHD patients without Depressive Disorders (Krishnan et. al., 
2000).   
MI and Depressive 
Disorders 
 
Depressed patients who have had a MI were demonstrated to 
have displayed a greater number of chronic comorbidities and 
cardiac complications than non-depressed individuals who 
had suffered from a MI (Watkins, Schneiderman, Blumenthal, 
Sheps, Catellier, Taylor & Freedland, 2003).  The mortality 
rate of depressed patients six months following a MI was 
calculated to be five times higher than in post-MI patients 
without Depressive Disorders (Krishnan et al., 2000).  
Frasure-Smith and others (1995) evaluated the influence of 
Depressive Disorders on an 18-month prognosis after MI and 
revealed that the mortality risk of cardiac patients is four times 
greater in the presence of co-existing Depressive Disorders.   
Diabetes Mellitus and 
Depressive Disorders 
Depressive Disorders impair glycaemic control in diabetics 
(Lustman, Griffith, Gavard & Clouse, 1992; Harpole et al., 
2005); increase the risk for the development of a Stroke 
(Harpole et al., 2005) and have been associated with a greater 
occurrence of diabetic complications, such as nephropathy 
and neuropathy (Egede, 2004).   
Arthritis and 
Depressive Disorders 
It has been shown that patients with Arthritis and a 
concomitant Depressive Disorder, exhibit restrictive activity 
(Vali et al., 1998). 
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TABLE 2.6 
THE EFFECTS OF DEPRESSIVE DISORDERS AND CHRONIC COMORBID   
DISEASE STATES ON DISEASE STATE OUTCOMES (CONTINUED) 
 
Chronic Comorbid 
Disease States 
Impact on Outcomes from Chronic Comorbid 
Disease States  
Epilepsy and 
Depressive Disorders 
Gilliam and Kanner (2002) deduced that a Depressive 
Disorder is one of the most significant factors to exhibit a 
negative effect on the quality of life of patients with refractory 
Epilepsy.  This variable was found to have had a more 
profound impact on the quality of life of these patients than 
the frequency and severity of seizures.    
Asthma and Depressive 
Disorders 
Asthmatic patients with co-existing Depressive Disorders 
have been shown to report more respiratory symptoms and to 
have poorer Asthma outcomes than asthmatic patients 
without Depressive Disorders.  A study performed in 230 
asthmatic patients between the ages of 18 and 62 years, 
showed that those patients with a greater number of 
depressive symptoms had poorer functional status and 
quality of life scores than those patients with fewer 
depressive symptoms. (Mancuso, et al., 2000.) Furthermore, 
a study calculated that asthmatic patients experienced 
impaired physical or psychological health for an average of 
10 days per month, which is almost twice as many days 
reported by individuals without Asthma (Ford, Mannino, 
Homa, Gwynn, Redd, Moriarty & Mokdad, 2003).   
Stroke and Depressive 
Disorders 
Depressive Disorders occurring after a stroke have been 
associated with impaired rehabilitative responses for up to 
two years following the occurrence of the Stroke (Gillen, 
Tennen, McKee, Gernert-Dott & Affleck, 2001; House, Knapp, 
Bamford & Vail, 2001).  In addition to enhancing stroke 
morbidity, Depressive Disorders also increase Post-Stroke 
mortality (Ramasubbu & Patten, 2003). 
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2.7.3 The Financial and Occupational Implications of Being Diagnosed 
with a Depressive Disorder and One or More Chronic Comorbid 
Disease States 
 
Studies have shown that Depressive Disorders increase medical care costs 
by 50% to 100% on all levels, including prescriptions, primary care 
consultations, emergency room visits, hospital days, laboratory tests and 
mental health consultations (Katon, Lin, Russo, Unűtzer, 2003).  The 
economic implications of suffering from a chronic disease state and comorbid 
Depressive Disorder can be illustrated by the results of a multinational study 
that was conducted in Barcelona (Spain); Be’er Sheva (Israel); Seattle 
(America); Melbourne (Australia); Porto Alegre (Brazil) and Saint Petersburg 
(Russia).  This study deduced that comorbidity increased the health care 
costs at five of six study sites, by 17% to 46% (Chisholm, Diehr, Knapp, 
Patrick, Treglia & Simon, 2003).  This emphasises the profound financial 
consequences that are imposed by the presence of a comorbid Depressive 
Disorder, when compared with those associated with the chronic disease 
state alone.   
 
An American study revealed that being diagnosed with three or more chronic 
co-existing disease states (Psychiatric or Physical Disorders) resulted in a 
greater number of absent days from work and cut-back days than the total 
sum of the individual effects of each disease state (Katon, 2003).  Another 
study was conducted in 1 801 geriatric primary care patients with severe 
Depressive Disorders in order to determine the relative association of 
Depressive Disorder severity and chronicity; and other comorbidities; on 
quality of life, disability, physical and psychological functioning.  The results of 
this study revealed that as the severity of the Depressive Disorder increased, 
so the quality of life, physical and psychological functioning decreased, while 
disability increased.  This study also revealed that the severity of a Depressive 
Disorder impacts more drastically on quality of life, functional status and 
disability in depressed elderly patients, than the majority of chronic disease 
states.  (Noël, Williams, Unűtzer, Worchel, Lee, Cornell, Katon, Harpole & 
Hunkeler, 2004.) This comparison reinforces the importance of adequately 
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recognising and treating late-life Depressive Disorders in patients with 
comorbid disease states.  In addition, Depressive Disorders may be one of the 
few chronic disease states that can be successfully treated (Noël et al., 2004).  
This stems from the realisation that most chronic disease states can only be 
managed (as opposed to treated) in order to prevent further exacerbations or 
complications.  Therefore, it is evident that Depressive Disorders exert a 
significant effect on the patient’s and his/her family’s quality of life, normal 
daily activities, general health of the population and health-system expenses.   
 
2.8 CONCLUSION 
 
This chapter reviewed the complex relationship between Depressive 
Disorders and prevalent chronic comorbid disease states.  This association 
appears attributable to Depressive Disorders precipitating chronic disease 
states and conversely, to chronic disease states exacerbating symptoms of 
Depressive Disorders.  There is a paucity of research pertaining to the nature 
of the relationship between Depressive Disorders and chronic co-existing 
disease states in South Africa.   Therefore, there is a need for such studies to 
be conducted in order to recognise common or alternatively, different trends to 
those identified by researchers in other countries.  This will assist in providing 
a better understanding of the intricate nature of the association between 
Depressive Disorders and certain chronic comorbid disease states.   
 
Without adequate treatment, Depressive Disorders characteristically assume 
a chronic course and are expected to be second only to Heart Disease in the 
global burden of disease by 2020 (Chapman et al., 2005).  It is well-known 
that depressed patients exhibit a greater burden of chronic comorbid disease 
states than those without Depressive Disorders (Callahan, Keterson & 
Tierney, 1997).  This highlights the importance of adequately treating 
Depressive Disorders in patients with specific chronic comorbidities.  Chapter 
3 will discuss the treatment of Depressive Disorders. 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
TREATMENT OF DEPRESSIVE DISORDERS IN PATIENTS 
WITH PREVALENT CHRONIC COMORBID DISEASE STATES 
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3.1 INTRODUCTION 
 
The initial selection of antidepressant medication will depend on the following 
factors:  possible side effects, patient preference; safety and tolerability 
profiles; chronic comorbid disease states; results from reputable clinical trials; 
history of familial response to antidepressants; the possibility of drug-drug 
interactions; and cost of the medication (APA, 2000; MacHale, 2002; Kando et 
al., 2002).  More precisely, choosing a suitable antidepressant for a patient 
with one or more comorbid disease states requires an evaluation of the risk-
benefit ratio pertaining to the pharmacokinetic and pharmocodynamic 
properties of the medication being considered against the following 
parameters:  patient’s physiological susceptibilities, potential drug-drug 
interactions and symptoms of the individual’s Depressive Disorder (Beliles et 
al., 1998; MacHale, 2002).   
 
This chapter will discuss the treatment phases for Depressive Disorders and 
outline the various modalities available for the management of Depressive 
Disorders.  Thereafter, this review will focus more specifically on the 
pharmacological treatment of Depressive Disorders and provides an overview 
of the following:   
 
• classification of antidepressants;  
• treatment considerations in special populations (children, adolescents 
and the elderly); and  
• factors that need to be considered with regard to the treatment of 
Depressive Disorders when specified chronic disease states co-exist. 
 
3.2 TREATMENT OF DEPRESSIVE DISORDERS 
 
3.2.1 Treatment Phases for Depressive Disorders 
The APA (2000) divides the treatment of Depressive Disorders into three 
phases, namely:  acute, continuation and maintenance phases.  Figure 3.1 
outlines the three treatment phases. 
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FIGURE 3.1 PHASES OF TREATMENT FOR DEPRESSIVE DISORDERS (Source:  
Adapted from Ratcliffe & Weinberger, 2003)  
 
• The acute phase refers to the first six to 12 weeks of therapy and the aims 
at this stage are to reduce symptoms and improve functionality.  This is 
done in an attempt to produce remission of the current episode, which is 
essentially the main goal of the acute phase.  Usually after about three 
months of treatment, most patients will exhibit complete remission of the 
current depressive episode or at least a noticeable reduction in symptoms.  
However, there are many factors that will cause response rates to vary 
significantly amongst patients, including the severity of the Depressive 
Disorder, environment and treatment methods.  (APA, 2000; Ratcliffe et 
al., 2003.)   
• The continuation phase follows the acute phase and consists of about 
four to nine months of therapy post-remission.  Treatment during this 
phase aims to prevent relapse.  The APA (2000) guideline recommends 
that all patients who have received acute phase treatment should be 
placed on continuation phase therapy in order to minimise the risk of 
relapse, even if the patient shows complete remission of depressive 
symptoms in the first three months.  According to the United Kingdom’s 
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(UK) National Institute for Clinical Excellence (NICE) Guidelines for the 
management of Depressive Disorders in Primary and Secondary Care 
(2004), antidepressants should be prescribed for a minimum of six months 
following remission of a depressive episode.  Generally speaking, the 
dosage of antidepressant medication used during the acute phase of 
treatment is also used in the continuation phase (APA, 2000).   
• The maintenance phase (one or more years) intends to prevent 
recurrence of a new depressive episode in susceptible patients.  
Susceptible patients include individuals with a history of chronic 
Depressive Disorders.  Some patients may even require chronic, indefinite 
therapy, although there is insufficient information on the optimal duration of 
chronic treatment or the physiological and mental implications of long-term 
antidepressant therapy.  (APA, 2000.) The NICE Guidelines (2004) 
recommend that patients who have experienced two or more episodes of 
Depressive Disorders in the recent past, with severe functional impairment 
during the depressive episodes, should continue antidepressant therapy 
for two years.  Additionally, the age of the patient, chronic comorbid 
disease states and other risk factors, need to be considered when a 
decision needs to made regarding the use of maintenance treatment 
beyond the recommended two year period (NICE Guidelines, 2004).  It has 
been estimated that 50% to 85% of patients with a single episode of MDD 
will experience at least one more episode (Keller et al., 2002).  This is why 
the maintenance phase of treatment is so important with regard to 
preventing recurrences of depressive episodes.  In general, the treatment 
that was found to be effective in the acute and continuation phases should 
also be used in the maintenance phase.  Furthermore, antidepressant 
medications should be used at the same dosages as in the acute and 
continuation phases of treatment.  (APA, 2000.)        
 
3.2.2 Treatment Modalities for the Management of Depressive Disorders 
 
The treatment modalities utilised for the treatment of Depressive Disorders 
are summarised in Table 3.1 and are discussed in the following section. 
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TABLE 3.1 
INITIAL TREATMENT MODALITIES FOR THE ACUTE PHASE OF 
DEPRESSIVE DISORDERS 
 
Treatment Modality Indications 
Pharmacotherapy 
• Patient preference is considered. 
• It is indicated for moderate to severe Depressive Disorders unless 
Electroconvulsive Therapy (ECT) is scheduled. 
• Antipsychotics and antidepressants are indicated for Psychotic Depressive 
Disorders. 
Psychotherapy 
• Patient preference is considered. 
• It is indicated for patients with mild to moderate Depressive Disorders. 
• It is useful in depressed patients with the following clinical features:  major 
psychosocial stressors, intrapsychic conflict, difficulty with interpersonal 
relationships, or the presence of one or more comorbid disease states. 
Combination 
Therapy 
(Pharmacotherapy and 
Psychotherapy) 
• The effects of psychotherapy and pharmacological treatments are deemed 
to be synergistic. 
Useful in: 
• Depressed patients (moderate to severe Depressive Disorders) with 
psychosocial stressors, interpersonal difficulties or a comorbid disease 
state; 
• patients with a history of partial response to sufficient trials of single 
treatment options; and 
• non-compliant patients. 
Electroconvulsive 
Therapy (ECT) 
ECT is a safe and effective treatment modality for specific severe mental 
disorders and is considered for: 
• Depressed patients with severe symptoms and impaired functionality; 
• patients with psychotic or catatonic symptoms; 
• very medically ill patients who cannot tolerate antidepressant treatments; 
• patients who are suicidal or nutritionally compromised secondary to refusal 
of food; 
• patients who require a quick response; 
• treatment resistance; and 
• circumstances in which risks of other treatments exceed possible benefits. 
 
(Source:  Adapted from:  Klapheke (1997); APA, 2000; Kando et al., 2002; Zisselman, Kelly, 
Cutillo-Schmitter, Payne & Denman, 2001) 
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3.2.2.1 Pharmacotherapy 
 
Various meta-analyses of randomised trials, reviewing the efficacy of 
antidepressant drug treatments versus placebo, have yielded consistent 
findings, that is, that the response rate to active drug is noticeably higher.  In 
addition to this, response rates to active antidepressant therapy do not vary 
across diverse patient populations and generally range from 50% to 70%.  
Conversely, placebo response rates vary significantly and may range from 
20% to 60%.  (Simon, 2002.) It is well-known that antidepressants of different 
classes and within the same class are comparatively effective (APA, 2000; 
NICE Guidelines, 2004), so this raises the question of why there are so many 
different classes of antidepressants necessary for the treatment of depressive 
symptoms.  The answer lies in the fact that patient response to treatment 
varies considerably from one individual to the next (Nielsen, Witek & Hurwitz, 
2000).  If a depressed patient fails to respond to a specific antidepressant or 
antidepressant class, this is not a prediction of a future failed response to 
either a different medication within the same class (in cases where a particular 
agent failed to elicit a response), or a different class (when various agents 
within the same class have not yielded a satisfactory response) (Kando et al., 
2002).  
 
The various pharmacological treatments available for the management of 
Depressive Disorders will be discussed in Section 3.2.3.   
 
3.2.2.2 Psychotherapy 
 
Although psychotherapy may be a useful first-line therapy in patients with mild 
to moderate Depressive Disorders, it is not recommended as monotherapy in 
the maintenance phase to prevent recurrence (Blackbum & Moore, 1997).  
However, the advantage of considering the use of psychotherapy on its own 
for the treatment of Depressive Disorders in patients with comorbidities, is the 
avoidance of potential drug interactions or adverse side effects of 
antidepressants that may lead to exacerbation of the co-existing chronic 
disease states (MacHale, 2002).  Psychological treatment modalities (such as 
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Cognitive Behavioural Therapy [CBT] and Interpersonal Therapy [IPT]) have 
been shown to be useful in the management of Depressive Disorders in 
patients with specific comorbid disease states, for example:  Diabetes 
Mellitus (Lustman et al., 1998), Asthma (Grover et al., 2002); COPD (Kunik, 
Braun, Stanley, Wristers, Molinari, Stoebner & Orengo, 2001); Rheumatoid 
Arthritis (Alpay et al., 2000; Sharpe et al., 2003); Cancer (Fawzy, Fawzy, 
Arndt & Pasnau, 1995) and HIV/AIDS (Nemeroff, Heim, Thase, Klein, Rush, 
Schatzberg, Ninan, McCullough, Weiss, Dunner, Rothbaum, Kornstein, 
Keitner & Keller, 2003).  In addition, CBT is a non-pharmacological method 
that has been found to be equally as effective as pharmacological therapies 
for the treatment of Depressive Disorders (DeRubeis et al., 1999).  
 
3.2.2.3 Combination Therapy 
 
It has been estimated that 75% of depressed patients are treated with 
pharmacotherapy and only 60% with psychotherapy (Olfson, Marcus, Druss & 
Pincus, 2002).  Additionally, the same study deduced that from 1987 to 1997, 
the number of patients receiving antidepressant treatments doubled, whereas 
there was a 15% decline in the number of individuals receiving 
psychotherapy.  Thase (2000) stipulated that the implementation of combined 
psychotherapy and pharmacotherapy might be more effective than either 
modality on its own.  The APA (2000), in turn, has deduced that 
pharmacotherapy and psychotherapy have comparable efficacies; however, 
this institution still suggests that pharmacological treatment may be more 
useful for more severe cases, especially in the acute phase. 
 
3.2.3 Pharmacological Treatment of Depressive Disorders 
 
This section lists the various antidepressant classes available in South Africa 
and provides a description of the efficacy, safety and pharmacokinetic profiles 
of each class.      
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3.2.3.1 Classification of Antidepressants 
 
One method of classifying antidepressants is by the presumed mechanism of 
drug action (Kando et al., 2002).  Table 3.2 classifies the various 
antidepressants available in South Africa, according to the fourth and fifth 
levels of the ATC Classification System.  Currently, the pharmacological 
approaches available for the treatment of Depressive Disorders include:  non-
selective monoamine re-uptake inhibitors; SSRIs; MAOIs; ‘other 
antidepressants’; ‘combination antidepressant-antipsychotic drug treatments’; 
and antidepressants prescribed with augmenting therapies, such as lithium or 
thyroid hormone (Nemeroff, 2006).  
 
Studies conducted in primary care patients have consistently found that 50% 
or more of patients receiving antidepressant treatments, were receiving doses 
that were lower than those suggested by expert guidelines (Wells, Katon, 
Rogers & Camp, 1994 [America]; Dunn, Donoghue, Ozminkowski, 
Stephenson & Hylan, 1999 [UK]).  Therapeutic dosages may be titrated 
gradually over the initial weeks of antidepressant treatment.  However, this 
process may vary amongst depressed individuals depending on the age of the 
patient, the presence of comorbid disease states and the side effects 
experienced.  (APA, 2000.)  
 
The following individuals should be initiated on lower dosages than those 
depicted in Table 3.2:  the elderly, patients with Panic Disorder, significant 
Anxiety Disorder or Liver Disease; and depressed individuals with general 
comorbidity.  Patients with co-existing chronic disease states are more 
sensitive to the side effects of antidepressants.  As a result, treatment for 
Depressive Disorders should be initiated at lower dosages; and then 
increased gradually according to individual patient response.  (MacHale, 
2002.) Elderly patients should be treated with approximately one-half of the 
doses listed in Table 3.2 (APA, 2000; Kando et al., 2002); except in cases 
where such dosage adjustments are not stipulated.   
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TABLE 3.2 
ATC CLASSIFICATION AND RECOMMENDED ADULT DOSAGES OF 
ANTIDEPRESSANTS 
 
 
Active Ingredients (Trade names) 
 
ATC 
Classification 
Initial 
Dosage  
(mg/d) 
Usual Dose 
Range 
(mg/d) 
Non-selective Monoamine Re-uptake Inhibitors N06AA   
Imipramine (Tofranil®, Ethipramine®) N06AA02 50 - 75 100 - 300 
Clomipramine (Anafranil®, Equinorm®) N06AA04 50 - 75 100 - 250 
Trimipramine (Surmontil®, Tydamine®) N06AA06 50 -75 75 - 150 
Lofepramine (Emdalen®) N06AA07 70 - 210 70 - 140 
Amitriptyline (Tryptanol®, Sandoz-Amitriptyline®, 
Trepiline®) N06AA09 50 - 75 100 - 300 
Dothiepin (Prothiaden®, Sandoz-Dothiepin®, Thade ®) N06AA16 50 - 75 75 - 150 
Maprotiline (Ludiomil ®)  N06AA21 50 - 75 100 - 225 
Nortriptyline (Aventyl ®) * N06AA10 25 - 50 50 - 150 
Desipramine (Pertofran®) *    
Selective Serotonin Re-uptake Inhibitors (SSRIs) N06AB   
Fluoxetine (Prozak®, Nuzak®, ProHexal®, Lilly-
Fluoxetine®, Sandoz-Fluoxetine®,  
A-Lennon Fluoxetine®, Lorien®, Ranflocs®)
N06AB03 10 - 20  
10 - 80 
 
Citalopram (Cipramil®, Cilift®, CitaloHEXAL®,  
Depramil®, Talomil®) N06AB04 20 20 - 60 
Paroxetine (Aropax®, Deparoc®) N06AB05 20 20 - 50 
Sertraline (Zoloft®, Serlife®) N06AB06 50 100 - 200 
Fluvoxamine (Luvox®) N06AB08 50 50 - 300 
Escitalopram (Cipralex®) N06AB10 10 10 - 20 
Monoamine Oxidase Inhibitors (MAOIs) N06AF   N06AG   
Tranylcypromine (Parnate®) [Non-selective inhibitor] N06AF04 20 20 - 60 
Moclobemide (Aurorix®, Clorix®, Depnil®) [Monoamine 
Oxidase A inhibitor] N06AG02 150 300 - 600 
Other Antidepressants N06AX   
Mianserin (Lantonon®) N06AX03 30 - 40 30 - 60 
Trazodone (Molipaxin®) N06AX05 50 - 150 150 - 400 
Nefazodone (Serzone®) * N06AX06 200 300 - 600 
Mirtazapine (Remeron®) N06AX11 15 15 - 45 
Bupropion, Sustained Release (Wellbutrin SR®) N06AX12 150 150 - 300 
Venlafaxine, Extended Release (Efexor XR®) N06AX16 75 75 - 225 
Reboxetine (Edronax®) N06AX18 8 8 - 10 
Duloxetine (Cymbalta®) N06AX20 60 60 
 
* These are discontinued medications, but have been included in this review of the 
literature because these agents were available during 2004, which is the year of drug 
prescribing that was analysed for this study (Refer to Chapter 6). 
 
(Source:  Adapted from Kando et al., 2002; APA, 2000; South African Medicines Formulary 
[SAMF], 2005; MIMS Medical Specialities, 2006) 
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3.2.3.2 Non-selective Monoamine Re-uptake Inhibitors  
 
Except for maprotiline, all of the other non-selective monoamine re-uptake 
inhibitors are TCAs.  A recent study pooled the results of various studies 
which compared the efficacy of antidepressant treatments versus placebo for 
the management of Depressive Disorders.  The authors of this study deduced 
that TCAs exhibited superior efficacy, relative to placebo (Arrol et al., 2005).  
The TCAs have an adverse side effect and safety profile and are associated 
with elevated rates of non-compliance (Roose, 2003).  Table 3.3 summarises 
the most prominent side effects that have been coupled with the use of TCAs. 
 
In turn, Table 3.4 contrasts the potential of the individual TCAs to result in 
anticholinergic effects, orthostatic hypotension and sedation.  Maprotiline is a 
tertracylic antidepressant that has less of an inhibitory effect on serotonin re-
uptake relative to the inhibition of NA re-uptake (Kando et al., 2002).  In terms 
of the frequency of commonly occurring side effects linked with the 
administration of maprotiline, the following has been reported:  common 
(sedation); less common (anticholinergic effects, orthostatic hypotension and 
weight gain); and low (cardiac arrhythmias) (Majeroni & Hess, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79
TABLE 3.3 
MOST COMMMONLY OCCURRING SIDE EFFECTS RELATED TO TCA 
USE 
  
 
Side effect Implications 
Anticholinergic  
Effects 
• Anticholinergic effects include the following:  dry mouth, constipation, 
tachycardia and sexual dysfunction. 
• Some patients develop a certain degree of tolerance, however, few 
anticholinergic symptoms that impair functioning or influence compliance, may 
require treatment. 
• The elderly or medically ill patients may experience exacerbated 
anticholinergic delirium. 
Cardiovascular  
Effects 
• TCAs cause alpha-adrenergic blockade, which causes cardiovascular effects, 
such as orthostatic hypotension and tachycardia. 
Sedation 
• TCAs display affinity towards histaminergic receptors and as a consequence, 
induce varying degrees of sedation. 
• Tertiary amines (for example, amitriptyline, imipramine, dothiepin, 
clomipramine and trimipramine) produce more sedation than secondary 
amines (which are not available in South Africa; and include the following 
TCAs:  nortriptyline, desipramine and protriptyline). 
• Sedation generally reduces within the first few weeks of therapy. 
• This side effect may be useful in depressed patients with insomnia, as the 
medication can be administered as a single dosage at night. 
Weight Gain 
• It has been suggested that the ability of TCAs to result in weight gain, occurs 
secondary to their histaminergic properties. 
• There is a varying extent of weight gain associated with the use of different 
TCAs.  For example, amitriptyline results in more weight gain than some of 
the other TCAs.  In addition, the degree of weight gain is also dose-
dependent and is reversible upon cessation of treatment with TCAs.  
(Source:  Adapted from APA, 2000; SAMF, 2005) 
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TABLE 3.4 
RELATIVE CHARACTERISTICS OF THE TCAs  
 
Side effect 
Relative Characteristics of the TCAs 
         High                                    Low 
Anticholinergic Effects 
 
 
 
 
Potential for Sedation 
 
 
Orthostatic 
Hypotension 
 
 
lofepramine 
desipramine 
notriptyline 
dothiepin 
imipramine 
amitriptyline 
clomipramine 
trimipramine 
lofepramine 
desipramine 
 
dothiepin 
imipramine 
clomipramine 
nortriptyline 
amitriptyline 
trimipramine 
 
lofepramine 
nortriptyline 
amitriptyline 
clomipramine 
dothiepin 
desipramine
imipramine 
 
(Source:  Adapted from Majeroni et al., 1998; SAMF 2005)  
 
The TCAs are hepatically metabolised via the cytochrome P450 (CYP450) 
system and may, therefore, interact with other medications that alter liver 
enzyme activity or hepatic blood flow.  Additionally, TCAs are highly protein-
bound, which means that protein displacement reactions could occur with the 
co-administration of other extensively protein-bound medications.  Maprotiline 
is involved in similar drug-drug interactions to the TCAs.  (Kando et al., 2002.)   
 
3.2.3.3 Monoamine Oxidase Inhibitors 
 
Tranylcypromine and moclobemide are the only MAOIs marketed in South 
Africa (MIMS Medical Specialities, 2006).  Tranylcypromine is a non-selective 
inhibitor of MAO A and MAO B (Potter & Hollister, 2001).  The most commonly 
occurring side effect of this class of antidepressants is postural hypotension.  
Although anticholinergic side effects (particularly constipation and dry mouth) 
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are common with the use of MAOIs, relative to the TCAs, these effects are 
mild.  Tranylcypromine has been associated with insomnia because it may 
exert a stimulating effect.  (Kando et al., 2002.)  
 
Inhibition of the MAO enzyme continues even after drug levels are no longer 
detectable in the plasma.  For example, the effect of tranylcypromine is 
believed to persist for seven days after cessation of therapy (Potter et al., 
2001).  Therefore, conventional pharmacokinetic parameters are not useful for 
determining dosages.   
 
There has been a renewed interest in the use of MAOIs for the treatment of 
Depressive Disorders (Amsterdam & Chopra, 2001).  However, MAOIs exhibit 
the potential for drug-drug interactions and necessitate adherence to certain 
dietary restrictions, which render this class of antidepressants less useful for 
the treatment of Depressive Disorders (Balon, Mufti & Arfken, 1999).   
 
Since their advent in the 1950s, TCAs and MAOIs were the chief 
pharmacological agents prescribed for the treatment of Depressive Disorders 
for three decades (Nemeroff, 2006).  These agents are no longer considered 
as first-line agents for the treatment of Depressive Disorders; however, they 
may be used for treatment-resistant Depressive Disorders (Quitkin, 2002; 
Nemeroff, 2006).  Newer medications, such as the SSRIs and agents 
categorised as ‘other antidepressants’, have vastly simplified the treatment of 
Depressive Disorders.    
 
3.2.3.4 Selective Serotonin Re-uptake Inhibitors (SSRIs) 
 
The SSRIs are considered to be first-line agents for the treatment of 
Depressive Disorders because of:  improved tolerability, reduced potential for 
cardiovascular side effects and superior safety in cases of overdose, relative 
to the TCAs (Judd & Boyce, 1999).  The SSRIs that are currently available in 
South Africa include:  fluoxetine, paroxetine, sertraline, citalopram, 
fluvoxamine and escitalopram (SAMF, 2005; MIMS Medical Specialities, 
2006).     
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Substantial research has been conducted on the SSRIs as a class.  The focus 
of much of this research has been on making comparisons with other 
antidepressant classes regarding efficacy.  Such studies have found that 
SSRIs have comparable efficacy with other classes of antidepressants (APA, 
2000; Taylor & Stein, 2005).  For example, on the whole, the literature shows 
that TCAs and SSRIs exhibit similar rates of efficacy, with a few differences in 
subtypes of Depressive Disorders (Nemeroff, 2006).  Various earlier and more 
recent studies have shown that individual SSRI agents are superior to placebo 
in all cases (Pande & Sayler, 1993 [fluoxetine]; Ottevanger, 1994 
[fluvoxamine]; Nemeroff, 1994 [paroxetine]).  Research has also shown that 
individual drugs within the SSRI class are in fact equipotent (Newhouse, 
Krishnan, Doraiswamy, Richter, Batzar & Clary, 2000).  On the other hand, a 
few comparative studies demonstrated that sertraline and escitalopram have 
slight advantages when compared with fluoxetine and citalopram, respectively 
(Nemeroff, 2006).   
   
Table 3.5 summarises the most frequently reported side effects associated 
with the use of SSRIs.  Generally speaking, the SSRIs exhibit a low affinity for 
histamine, muscarinic and alpha1-adrenergic receptors, therefore eliciting 
fewer anticholinergic and cardiovascular adverse effects in comparison to the 
TCAs (Kando et al., 2002).  Overall, the side effect profile of the SSRIs and 
other newer antidepressants is favourable (Majeroni et al., 1998).  With 
extended periods of treatment (three months or longer), the patient will 
develop tolerance to most of the adverse effects that may have been evident 
when treatment was initiated.  Conversely, some adverse effects (for 
example, weight gain) may become more pronounced with time due to the 
fact that patients may be less willing or able to withstand these effects for long 
periods.  Having said this, however, the SSRIs and other newer 
antidepressants are more advantageous with regard to weight gain than the 
TCAs and MAOIs.  (Hirschfeld, 1999.)    
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TABLE 3.5  
SIDE EFFECTS OCCURRING MOST FREQUENTLY WITH SSRI USE 
 
Side Effect Implications 
Gastro- 
intestinal 
Symptoms  
• Nausea, diarrhoea and vomiting are more strongly associated with the administration of 
SSRIs than TCAs, but these effects are influenced by the dosage prescribed and seem to 
diminish over the first weeks of treatment (APA, 2000). 
Sexual 
Dysfunction 
• Sexual dysfunction may occur with practically any antidepressant, but this adverse effect 
appears to be more common with SSRIs (APA, 2000; SAMF, 2005). 
• If it has definitely been established that sexual dysfunction is a side effect of the SSRI (as 
opposed to being attributable to the underlying Depressive Disorder), the following strategies 
may be implemented in order to counteract this adverse effect:  wait to see if tolerance 
develops with continued use; lower the dosage; cease treatment with the SSRI; or use an 
alternative antidepressant, such as bupropion or mirtazapine (which do not cause significant 
sexual dysfunction) (Musselman et al., 2003). 
Insomnia/ 
Activation 
• SSRIs have been shown to precipitate agitation, restlessness and sleep disturbances.  
Similar to the gastrointestinal effects, these symptoms also tend to dissipate with time.  
(APA, 2000.) 
• If the SSRI is initiated at a low dosage, the potential anxiety side effect may be curtailed 
(APA, 2000).   
• Insomnia may be managed by adding trazodone at bedtime (APA, 2000). 
Neurological 
Effects 
• At the start of treatment, SSRIs may worsen certain types of headaches, such as, migraines.  
Conversely, some studies have suggested that longer term treatment with SSRIs may then 
actually assist in preventing and treating migraines.  (APA, 2000.) 
• Extrapyramidal symptoms, such as parkinsonism, tardive dyskinesia and dystonias, have 
been reported with SSRI use.  These effects occur more frequently in elderly individuals, 
especially patients with Parkinson’s Disease.  (APA, 2000; SAMF, 2005.) 
Weight 
Changes 
• Some SSRIs have been associated with weight loss; for example, fluoxetine and others; 
such as paroxetine, have been known to cause weight gain (Bourin, Chue & Guillon, 2001).   
• After the acute treatment phase, the literature is conflicting regarding whether weight gain is 
a consequent side effect of SSRI use (APA, 2000).  
Serotonin 
Syndrome 
• The serotonin syndrome is characterised by excessive serotonergic activity and the 
symptoms include:  diarrhoea, flushing, abdominal pain, sweating, hyperthermia, tremor, 
changes in mental status, cardiovascular shock; and may possibly be fatal (APA, 2000). 
• Even though the serotonin syndrome can occur when SSRIs are used as sole therapies, it is 
more common when many serotonergic medications are co-administered (for instance, 
when SSRIs and MAOIs are co-prescribed) (APA, 2000). 
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One of the most renowned characteristics of the SSRIs is their potential to 
interact with other drugs on a pharmacokinetic level.  Since depressed 
patients with co-existing disease states would be expected to be taking 
multiple medications, the pharmacokinetic capabilities of this class of 
antidepressants needs to be evaluated: 
 
• Fluoxetine has a longer half-life (two to five days in young healthy 
individuals) than many of the other newer antidepressants (Kando et al., 
2002).  Moreover, its clinically active metabolite, norfluoxetine (half-life of 
seven to nine days), further extends the half-life of fluoxetine and, as a 
result, washout periods are much longer for this antidepressant 
(Hirschfeld, 1999).  In contrast, the half-lives of paroxetine and sertraline 
are approximately 24 hours (Kando et al., 2002).  The half-life of 
citalopram is about 36 hours and plasma levels have been observed to 
peak within two to four hours following administration (Hiemke & Härtter, 
2000; Kando et al., 2002).  Excluding fluvoxamine and citalopram, all of 
the SSRIs display high protein-binding properties (Kando et al., 2002). 
• Of the SSRIs, sertraline and citalopram have the most favourable 
pharmacokinetic profiles, which include:  short to intermediate half-lives; 
no clinically relevant active metabolites; linear kinetics; and poor potential 
for drug-drug interactions (Hirschfeld, 1999).  In addition to these SSRIs, 
escitalopram is not likely to partake in clinically significant pharmacokinetic 
interactions (Kando et al., 2002).   
 
Table 3.6 compares the inhibitory potential of the various SSRIs on the 
CYP450 enzymes.  It is evident that fluvoxamine is the only SSRI that interacts 
extensively with the CYP450IA2 isoenzyme.  Most of the other SSRIs have an 
inhibitory action on CYP450IID6.  Specific drug-drug interactions which are 
applicable to depressed patients with prevalent comorbid disease states will 
be discussed in Section 3.4. 
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TABLE 3.6 
POTENTIAL OF SSRIs TO INHIBIT THE CYP450 ENZYMES  
 
Antidepressant 
Cytochrome P450 Enzyme 
IA2 IIC IID6 IIIA4 
Fluoxetine 
Norfluoxetine * 
0 ++ ++++ 
++++ 
++ 
++ 
Sertraline 
N-desmethylsertraline * 
0 ++ 
++ 
+ 
++ 
+ 
+ 
Paroxetine 0 0 ++++ 0 
Fluvoxamine ++++ ++ 0 ++ 
Citalopram 0 0 0 +++ 
 
* Major metabolites 
 
(Source:  Adapted from Kando et al., 2002) 
 
3.2.3.5 Other Antidepressants 
    
Nefazodone has been withdrawn from the market because of concerns 
relating to hepatotoxicity (Canadian Medical Association or its Licensors, 
2003).  For example, a study analysing the World Health Organization’s 
database of adverse drug reports, identified a high frequency of hepatic injury 
reports associated with the use of nefazodone (Spigset, Hagg & Bate, 2003).  
However, discussions pertaining to the use of nefazodone have been included 
in this study because this antidepressant was prescribed to depressed 
patients in the study population for the time period analysed (refer to Chapter 
6).  Although the potential benefits of nefazodone and trazodone in the 
treatment of severe Depressive Disorders have not been properly examined, 
these antidepressants have displayed efficacy in the management of various 
subtypes of Depressive Disorders (Nemeroff, 2006).     
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Venlafaxine is a novel antidepressant in terms of structure and, unlike the 
TCAs, has practically zero affinity for muscarinic, alpha1-adrenergic and 
histaminergic receptors.  It causes potent inhibition of serotonin and 
noradrenaline re-uptake and is a weak inhibitor of dopamine re-uptake. 
(Ballenger, 1996.) Numerous clinical studies have compared the efficacy of 
venlafaxine in the treatment of MDD and overall, have deduced that this 
antidepressant displays comparable efficacy to the SSRIs (Costa e Silva, 
1998; Nemeroff, 2006).  It is noteworthy to mention that although the 
probability of a 50% improvement in symptoms of Depressive Disorders is the 
same for venlafaxine and SSRIs, studies have shown that there is a greater 
probability of remission amongst depressed patients treated with venlafaxine 
(Thase, Entsuah & Rudolph, 2001; Entsuah, Huang & Thase, 2001).  For 
instance, one study (involving an evaluation of a collection of remission rates) 
found that venlafaxine was associated with superior remission rates compared 
with placebo and individual SSRIs (paroxetine, fluvoxamine and fluoxetine) 
(Thase et al., 2001).  However, Burke (2004) identified numerous limitations to 
the separate trials (for example, no placebo comparisons in some studies) 
that were selected for the study by Thase and others (2001).  The following 
unfavourable effects have been associated with venlafaxine use:  fatality 
potential in overdose (similar to TCAs) (Cheeta, Schifano, Oyefeso, Webb & 
Ghodse, 2004); and cardiovascular effects, such as prolongation of the QT 
interval (Blythe & Hackett, 1999). 
 
Like venlafaxine, duloxetine inhibits the re-uptake of serotonin and 
noradrenaline (Stewart, Wohlreich, Mallinckrodt, Watkin & Kornstein, 2006).  
Double-blind, placebo-controlled studies have demonstrated that duloxetine 
(60 to 80mg/day) displayed ‘significant efficacy’ when compared with placebo 
(Goldstein, Lu, Detke, Wiltse, Mallinckrodt & Demitrack, 2004; Stewart et al., 
2006).  However, there have been no clinical trials of duloxetine in the 
treatment of patients with severe Depressive Disorders published as yet 
(Nemeroff, 2006).   
 
Bupropion has been demonstrated to be effective for the treatment of severe 
Depressive Disorders (Reimherr, Cunningham, Batey, Johnston & Ascher, 
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1998) and has been linked with comparable remission rates to the SSRIs 
(Thase et al., 2005).  Bupropion was not available to South African prescribers 
during 2004, which was the year for which drug utilisation trends were 
assessed for this study (Refer to Chapter 6).  In spite of this, it is important to 
mention the advent of new antidepressants, like bupropion, since, in the past, 
antidepressant drug selection was limited by the almost sole availability of the 
TCAs; and newer medications may be advantageous for the treatment of 
Depressive Disorders in patients with concomitant disease states.   
 
Mirtazapine has displayed equal efficacy to TCAs in treating patients with 
severe Depressive Disorders (Benkert, Muller & Szegedi, 2002).  It has 
minimal anticholinergic and anti-adrenergic properties and as a result, this 
antidepressant is only associated with marginal cholinergic blocking side 
effects and orthostatic hypotension (Beliles et al., 1998).   
 
Table 3.7 lists the most frequently occurring side effects noted with reference 
to the administration of the ‘other antidepressants’.  Thereafter, the inhibitory 
ability of the individual agents (in this antidepressant class) on the CYP450 
enzymes is compared in Table 3.8.   
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TABLE 3.7 
MOST FREQUENTLY OCCURRING SIDE EFFECTS ASSOCIATED WITH 
THE ADMINISTRATION OF ‘OTHER ANTIDEPRESSANTS’ 
 
‘Other 
Antidepressant’ 
Most Common Side Effects 
Trazodone 
• may cause sedation at low doses and may therefore be useful in depressed patients 
with comorbid Insomnia (Mendelson, Roth, Cassella, Roehrs, Walsh, Woods, Buysse 
& Meyer, 2004);  
• may cause sexual dysfunction (APA, 2000); and 
• is associated with fewer anticholinergic side effects than most of the TCAs. Despite 
eliciting less anticholinergic effects than most TCAs, trazodone may result in postural 
hypotension (especially in the elderly) (Majeroni et al., 1998). 
Nefazodone 
• better side effect profile than trazodone (nefazadone and trazodone are chemically 
related) (Rickels, Schweizer, Clary, Fox & Weise, 1994); 
• sexual dysfunction rarely reported (Majeroni et al., 1998); 
• marginal adrenergic activity and almost no cardiotoxicity (Majeroni et al., 1998); less 
anticholinergic activity than other antidepressants (Taylor, Carter, Eison, Mullins, 
Smith, Torrente, Wright & Yocca, 1995); and 
• frequently occurring adverse effects include:  orthostatic hypotension, dizziness, light-
headedness, somnolence, dry mouth and asthenia (Davis, Whittington & Bryson, 
1997).   
Venlafaxine 
• similar side effect profile to the SSRIs (APA, 2000); 
• may lead to blood pressure increases (APA, 2000; Johnson, Whyte, Mulsant, Pollock, 
Weber, Begley & Reynolds, 2006); and 
• gastrointestinal side effects (Sáiz-Ruiz, Ibáñez, Díaz-Marsá, Arias, Padin, Martin-
Carrasco, Montes, Ferrando, Carrasco, Martin-Ballesteros, Jordá & Chamorro, 2002). 
Mirtazapine 
• weight gain, sedation and dry mouth (Fava, 2000; Sussman, Ginsberg & Bikoff, 2001; 
APA, 2000); and 
• may increase serum cholesterol levels in a few patients (APA, 2000). 
Bupropion 
• neurological effects (for example, headache and seizures) (APA, 2000); 
• insomnia; gastrointestinal effects (APA, 2000); and 
• may induce psychotic symptoms (due to dopaminergic activity) (APA, 2000). 
Reboxetine 
• dry mouth, constipation, enhanced perspiration, insomnia, tachycardia, sexual 
dysfunction and urinary retention (APA, 2000). 
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TABLE 3.8 
INHIBITORY POTENTIAL OF ‘OTHER ANTIDEPRESSANTS’ ON THE 
CYP450 ENZYMES  
 
Antidepressant 
Cytochrome P450 Enzyme 
IA2 IIC IID6 IIIA4 
Nefazodone 0 0 0 ++++ 
Venlafaxine 0 0 0 0 
Bupropion 0 0 0 0 
Mirtazapine 0 0 0 0 
Reboxetine 0 0 0 0 
 
(Source:  Adapted from Kando et al., 2002) 
 
The half-life of duloxetine has been shown to range between eight and 17 
hours (approximately 12 hours) (Sharma, Goldberg & Cerimele, 2000) and it 
is predominantly hepatically metabolised via CYP450IID6 and CYP450IA2 
(Skinner, Kuan, Pan, Sathirakul, Knadler, Gonzales, Yeo, Reddy, Lim, Ayan-
Oshodi & Wise, 2003).  Bupropion is metabolised by CYP450IIB6 and does not 
interact with many medications (Beliles et al., 1998), which renders it quite 
safe in terms of the potential for drug interactions with other agents. 
 
The metabolic pathway of mirtazapine is mediated by many CYP450 enzymes, 
namely:  CYP450IA2, CYP450 IID6 and CYP450IIIA3/4.  In vitro studies have 
demonstrated that mirtazapine may be less likely to elicit drug-drug 
interactions with other medications exhibiting CYP450 induction or inhibition.  
This is because other medications are reliant on solely one CYP450  isoenzyme 
for their biotransformation, whereas mirtazapine depends on several of the 
CYP450  isoenzymes.  (Preskorn, 1994.) With reference to the inhibitory 
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potential of the SSRIs (refer to Table 3.6) versus the ‘other antidepressants’ 
(see Table 3.8), it is clear that the SSRIs have more pronounced activity, 
which could point towards a relatively greater degree of drug-drug interactions 
when co-administered with other medications utilising the same metabolic 
pathways. 
 
3.3 Treatment Considerations in Special Populations 
 
3.3.1 Treatment of Depressive Disorders in Children and Adolescents 
 
Evidence-based guidelines for the treatment of Depressive Disorders in 
children and adolescents, is limited.  Consequently, choices regarding 
treatment options are commonly based on ‘clinical consensus and the 
extrapolation of data from adults’.  (APA, 2000.) However, this could provide 
complexities, since, for example, antidepressant medications that have been 
found to be effective in adults, may not have been shown to be as efficacious 
in children and adolescents (APA, 2000).   
 
The use of psychotherapy as an initial treatment modality may be useful in 
children and adolescents with mild to moderate Depressive Disorders; or it 
can be used to augment pharmacotherapy in patients with more severe 
Depressive Disorders (Son & Kirchner, 2000; NICE Guidelines, 2005).  There 
are no other existing definitive treatments for the management of Depressive 
Disorders in children and adolescents and this is why antidepressants are 
being utilised (Kando et al., 2002).  The TCAs and SSRIs are two feasible 
antidepressant choices in younger depressed patients (Kando et al., 2002).  It 
has been suggested that SSRIs may be effective and tolerated better in young 
people.  Therefore, the use of SSRIs amongst younger patients has 
increased.  (Hayes, 2004.) However, SSRIs have been associated with an 
enhanced suicidal risk (Whittington, Kendall, Fonagy, Cottrell, Cotgrove & 
Boddington, 2004).  For this reason, Whittington and others (2004) evaluated 
the risk-benefit profile for each of the SSRIs in children by means of a meta-
analysis of various studies conducted before April 2003.  This study found that 
fluoxetine may have a ‘favourable risk-benefit profile’ for the management of 
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Depressive Disorders in children and adolescents.  Conversely, risks 
pertaining to the use of paroxetine and sertraline were found to outweigh the 
benefits of utilising these antidepressant treatments (when published and 
unpublished data were considered collectively).  Fluoxetine is the only SSRI 
approved by the US Food and Drug Administration (FDA) Centre for Drug 
Evaluation and Research for the treatment of Depressive Disorders in children 
(Hayes, 2004) and a recent study proposed that it was superior to placebo in 
children and adolescents diagnosed with MDD (Garland, 2004).  The 
aforementioned study concluded that the risks associated with SSRI use 
(except for fluoxetine) might offset the benefits of this class of antidepressants 
in younger depressed patients.  A British expert working group, namely, the 
Committee on Safety of Medicines (CSM), discourages the use of the 
following agents as new therapies in children and adolescents:  sertraline, 
citalopram, escitalopram, paroxetine, fluvoxamine and venlafaxine.  Albeit 
this, child and adolescent psychiatrists may prescribe other SSRIs (other than 
fluoxetine) in specific circumstances; for example, where a young patient 
cannot tolerate the use of fluoxetine.  (NICE Guidelines, 2005.) Except for 
fluoxetine, three antidepressants are approved by the FDA for the following 
uses in children:  Enuresis (imipramine); and Obsessive Compulsive 
Disorder (clomipramine [in children aged 12 years or older] and fluvoxamine 
[in children aged eight years or older]) (Hayes, 2004).   
 
Amongst adolescents with Depressive Disorders, suicide is a chief concern, 
thus, toxicity in overdose is critical (Kando et al., 2002).  For example, TCAs 
have been demonstrated to be fatal in overdose (Kerr, McGuffie & Wilkie, 
2001) whereas SSRIs are safer in comparison (Kando et al., 2002).  The 
Treatment for Adolescents with Depression Study (TADS) recently found that 
Depressive Disorders in adolescents may be effectively treated with a 
combination of fluoxetine treatment and CBT [response rate was more than 
double for active treatment versus placebo] (March, Silva, Petrycki, Curry, 
Wells, Fairbank, Burns, Domino, McNulty, Vitiello & Severe, 2004).      
 
In children (especially) and adolescents (to a less extent), heterocyclic 
antidepressants are metabolised more rapidly than in adults (Majeroni et al., 
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1998).  This is relevant because fast hepatic metabolism of serotonergic 
parent compounds, such as amitriptyline and imipramine, results in a higher 
noradrenergic (due to noradrenergic active metabolites) to serotonergic 
activity than is evident in adults (Ryan, 1992).  The noradrenergic system only 
develops properly (on a functional and anatomical level) in early adulthood 
(Ryan, 1992), so this shift towards a greater relative noradrenergic to 
serotonergic activity may have important implications for the pharmacological 
treatment of Depressive Disorders in young patients.  Ryan (1992) 
recommended that if the administration of these drugs results in prolongation 
of the PR interval or increases in blood pressure, then dose reductions or 
cessation of treatment should be implemented.  This is because the use of 
such antidepressant treatments in children has been associated with reports 
of sudden cardiac death. 
 
Children and adolescents should be initiated on lower dosages of 
antidepressants (when compared with those prescribed for adults); however, 
adult dosages of TCAs are ordinarily required in adolescents (Kando et al., 
2002).  The anticholinergic and potentially cardiotoxic effects of the TCAs 
have shifted this class of antidepressants to a second-line treatment for 
Depressive Disorders in children and adolescents.  In spite of this, TCAs may 
be useful in depressed children with multiple concomitant disease states, such 
as ADHD and Enuresis.  (Son et al., 2000.)   
 
3.3.2 Treatment of Depressive Disorders in the Elderly 
 
Age-related pharmacokinetic and pharmacodynamic changes in the elderly 
warrant careful dosing of antidepressant medication.  For example, the elderly 
have a higher percentage of fat, less total body water and less muscle mass 
than younger individuals and this could increase the levels of lipophilic drugs 
in the brain (Kompoliti & Goetz, 1998).  Studies have suggested that the 
following pharmacodynamic aspects may be responsible for a possible 
enhanced response (sensitivity) to medications in the elderly:  receptor 
number changes, alterations in receptor affinity, changes at the post-receptor 
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level and impaired homeostatic mechanisms (Feely & Coakley, 1990; Swift, 
1990; Hammerlein, Derendorf, & Lowenthal, 1998).  
 
The factors that need to be considered regarding the choice of antidepressant 
medication in the elderly are basically the same as for younger depressed 
patients (Reynolds, Frank, Perel, Imber, Cornes, Miller, Mazumdar, Houck, 
Dew, Stack, Pollock & Kupfer, 1999).  According to Rabheru (2004), the 
treatment of Depressive Disorders in the elderly should have as its main goal; 
the achievement of remission instead of merely a response.  It has been 
demonstrated that antidepressants are just as effective in elderly individuals 
as in younger depressed patients (Salzman, Wong & Wright, 2002; 
Alexopoulos, 2005).  Research has shown that SSRIs and serotonin 
noradrenaline re-uptake inhibitors (such as, venlafaxine and duloxetine) are 
the antidepressants of choice in the elderly, followed by bupropion and 
mirtazapine (Hayes, 2004; Alexopoulos, 2005).  As stated by an expert 
consensus guideline regarding the use of pharmacological treatments 
amongst elderly patients, venlafaxine may be used as an alternative to SSRIs 
in patients who do not respond; or as a first-line antidepressant for patients 
with severe Depressive Disorders (Alexopoulos, Katz, Reynolds, Carpenter, 
Docherty & Ross, 2001).  Having said this, however, a recent study 
demonstrated that almost 30% of patients receiving treatment with venlafaxine 
stopped therapy as a result of adverse effects (Oslin, Ten Have, Streim, 
Datto, Weintraub, DiFilippo & Katz, 2003).  Therefore, it is evident from these 
two studies, conducted by Alexopoulos and others (2001) and Oslin and 
colleagues (2003), that certain antidepressants that may appear to be safe 
amongst elderly patients in the community, may not be as safe in their frail 
counterparts (Hayes, 2004).   
 
Table 3.9 summarises the research findings regarding the use of various 
antidepressants in elderly depressed patients. 
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TABLE 3.9 
LITERATURE FINDINGS FOR ANTIDEPRESSANT USE IN THE ELDERLY 
 
Antidepressant Class 
Research Findings Pertaining to the Use of Specific 
Antidepressants in Elderly Patients 
Non-selective 
Monoamine Re-uptake 
Inhibitors 
 
• It is more likely for an elderly individual taking an antidepressant that is 
strongly associated with orthostatic hypotension and anticholinergic 
symptoms (for example:  amitriptyline and imipramine) to experience 
these effects, than a younger depressed patient (APA, 2000; MacHale, 
2002).  Alexopoulos and colleagues (2001) do not recommend the use of 
maprotiline, amitriptyline and imipramine in elderly depressed 
patients.  
 
• Desipramine and nortriptyline, on the other hand, exhibit a weaker 
propensity towards causing orthostatic hypotension and anticholinergic 
effects (refer to Table 3.4); and are therefore the preferred TCAs in 
elderly depressed patients.  If the use of sensible alternative 
antidepressants (to SSRIs and venlafaxine) is warranted in severe cases 
of Depressive Disorders in elderly patients, nortriptyline followed by 
desipramine, may be used.  (Alexopoulos et al., 2001.)   
 
• Reynolds and others (1999) demonstrated that nortriptyline and IPT 
were effective maintenance treatment options in elderly patients with 
recurrent MDD. 
SSRIs 
• Recent research has shown that the various SSRIs are equipotent with 
regard to the treatment of Depressive Disorders in the elderly (Newhouse 
et al., 2000; Hayes, 2004).  However, the safety and efficacy of SSRIs in 
elderly depressed patients with comorbidities, has only been 
demonstrated recently.  For example, Krishnan and colleagues (2001) 
showed that sertraline is safe, well tolerated and efficacious in 
depressed elderly patients with a co-existing vascular comorbidity, such 
as Hypertension.  Fluoxetine and sertraline have been shown to be less 
likely to cause orthostatic hypotension than certain TCAs (APA, 2000). 
 
• The Syndrome of Inappropriate Antidiuretic Hormone is a common side 
effect of SSRIs and may be associated with confusion and seizures, 
when severe (Bouman, Pinner & Johnson, 1998). 
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TABLE 3.9 
LITERATURE FINDINGS FOR ANTIDEPRESSANT USE IN THE ELDERLY 
(CONTINUED) 
 
Antidepressant Class 
Research Findings Pertaining to the Use of Specific 
Antidepressants in Elderly Patients 
MAOIs 
• MAOIs are only used in elderly depressed patients who are resistant to 
other treatments (Kando et al., 2002).  In fact, the expert consensus 
panel suggests that tranylcypromine be avoided in the elderly 
(Alexopoulos et al., 2001). 
Other 
Antidepressants: 
 
Trazodone 
• Trazodone may lead to orthostatic hypotension and cause exacerbation 
of arrhythmias (Majeroni et al., 1998).  The majority of elderly individuals 
cannot tolerate the dosages of trazodone that are recommended for the 
optimal treatment of Depressive Disorders (Majeroni et al., 1998); 
therefore, this antidepressant is not recommended (Alexopoulos et al., 
2001). 
Bupropion 
• Bupropion is less likely to cause orthostatic hypotension than TCAs with 
prominent anticholinergic activity (APA, 2000). 
Mirtazapine 
• Since weight loss has been noted to be a problem amongst elderly 
patients, it may be useful to prescribe an antidepressant that is 
associated with weight gain, for example, mirtazapine (APA, 2000). 
Venlafaxine 
• Studies have shown that almost a quarter of elderly patients treated with 
SSRIs or venlafaxine, develop hyponatraemia (Kirby, Harrigan & Ames, 
2002).   
 
Antidepressants should be initiated at low dosages in elderly depressed 
patients (Majeroni et al., 1998; Alexopoulos, 2005); however, the final 
dosages should be comparable to the ones used in younger patients 
(Alexopoulos, 2005).  When treatment with an antidepressant has 
commenced, it needs to be administered for a minimum of four to six weeks 
before the effectiveness of the medication is assessed (Alexopoulos et al., 
2001, NICE Guidelines, 2004).  If there has been an incomplete response 
within the six weeks of initiating therapy, treatment should be continued for 
another six weeks (NICE Guidelines, 2004).  Alternatively, if the patient’s 
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response to the antidepressant is not satisfactory, the dose may be increased.  
Thereafter, if the patient’s response is still poor, another agent may be added 
to augment the response to existing treatment.  (Alexopoulos, 2005.)   
 
Some depressed elderly patients with chronic comorbid disease states may 
require more aggressive antidepressant treatment (Hayes, 2004).  A study 
performed in 498 elderly depressed patients with common chronic comorbid 
disease states (Heart Disease, Diabetes Mellitus, Arthritis and Hypertension), 
yielded the following results with regard to the proportion of the study 
population that received adequate treatment for Depressive Disorders:  34% 
of cardiac patients; 46% of diabetic patients; 33% of arthritic patients; 39% of 
hypertensive patients; and 34% overall (Harman, Edlund, Fortney & Kallas, 
2005).  It was deduced that less than half of the patients in this study 
conducted by Harman and others (2005) were treated properly for Depressive 
Disorders.  This is not promising since research has found that the recovery 
rates amongst patients (with comorbid disease states) who received optimal 
treatment for Depressive Disorders were greater than those evident in 
depressed patients who were not prescribed antidepressant treatments (at all 
or at suboptimal dosages) (MacHale, 2002, Hayes, 2004).  For example, a 
study involving an analysis of the Cochrane database, found that the recovery 
rate in depressed patients (with concurrent chronic disease states) receiving 
antidepressants (at appropriate dosages), was three times greater than the 
rate evident in patients taking placebo (Hayes, 2004). 
 
Depressed elderly individuals with comorbid disease states may benefit 
significantly from the use of psychostimulants, such as methylphenidate and 
dextroamphetamine, for the management of Depressive Disorders.  Picket 
and colleagues (1990), for example, showed that more than half of elderly 
depressed patients, who were receiving psychostimulant therapy, displayed a 
rapid improvement in depressive symptoms.   
 
The recurrence rate of Depressive Disorders amongst elderly patients in 
remission (post-cessation of treatment) is high (Hayes, 2004).  Reynolds and 
colleagues (1999) evaluated the use of maintenance therapies for recurrent 
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Depressive Disorders and made the following recommendations regarding the 
prevention of relapse:  physicians should identify the susceptibility of older 
persons with Depressive Disorders and promote an aggressive, but closely 
monitored treatment strategy; encourage the use of maintenance treatment, 
regardless of the number of previous depressive episodes; and contemplate 
increasing the antidepressant dosage. 
 
3.4 Treatment of Depressive Disorders in the Presence of Commonly 
Occurring Comorbid Disease States 
 
In Chapter 2, the most prevalent comorbidities in depressed patients were 
identified and included the following chronic disease states:  Cardiovascular 
Disease States (such as Lipid Disorders and Hypertension), Diabetes 
Mellitus, Arthritis, Menopause, Hypothyroidism, Asthma, Psychiatric 
Disorders, Neurological Disease States and HIV-Disease.  This section 
reviews the research findings pertaining to the use of various antidepressants 
for the treatment of Depressive Disorders in the presence of the 
aforementioned commonly occurring co-existing disease states. 
 
3.4.1 Treatment of Depressive Disorders and Comorbid Cardiovascular 
Disease States 
 
3.4.1.1 TCAs:  Implications for Cardiovascular Disease States 
  
Research has observed the following with reference to the use of TCAs in 
depressed patients with comorbid Cardiovascular Disease States: 
 
• Cardiovascular side effects of TCAs include changes in the following:  
heart rate and rhythm, electrical conduction, myocardial contractility and 
blood pressure (Roose et al., 1992).   
• Studies have found that there were higher morbidity and mortality rates 
amongst post-MI patients who were receiving Type IC and Type IA 
antiarrhythmics, when compared with individuals who were not prescribed 
these medications (Glassman et al., 1993).  This is noteworthy because, in 
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addition to the anticholinergic and anti-adrenergic effects (Beliles et al., 
1998), TCAs are Type IA antiarrhythmics and may therefore increase 
mortality in depressed patients with comorbid Ischaemic Heart Disease 
[IHD] (Glassman et al., 1993).  Despite the enhanced risks associated with 
TCA use in patients with CVDs, some TCAs have been used to treat MDD 
in depressed patients with certain types of IHD (Nelson, Kennedy, Pollock, 
Laghrissi-Thode, Narayan, Nobler, Robin, Gergel, McCafferty & Roose, 
1999).  If treatment with a TCA is necessary, nortriptyline may be a 
favourable choice since it causes less orthostatic hypotension than the 
other agents in the same antidepressant class (McCoy, 1996). 
 
3.4.1.2 SSRIS:  Implications for Cardiovascular Disease States 
 
The prescription of SSRIs in depressed patients with comorbid Cardiovascular 
Disease States warrants the following considerations: 
 
• SSRIs have been demonstrated to be safer and more effective than other 
antidepressants, such as TCAs, in patients with CVDs (Roose, Glassman, 
Attia, Woodring, Giardina & Bigger, 1998; Roose, Laghrissi-Thode, 
Kennedy, Nelson, Bigger, Pollock, Gaffney, Narayan, Finkel, McCafferty & 
Gergel, 1998; Glassman, O’Connor, Califf, Swedberg, Schwartz, Bigger, 
Krishnan, van Zyl, Swenson, Finkel, Landau, Shapiro, Pepine, Mardekian, 
Harrison, Barton & McIvor, 2002; MacHale, 2002; Hayes, 2004).  For 
example, studies have found that the effects of SSRIs on the comorbid 
CVD in terms of the blood pressure, heart rate and conduction, are 
‘clinically benign’ (Roose et al., 1998; Glassman et al., 2002).    
• The concomitant administration of an SSRI with CBT has been found to be 
one of the most effective treatment options for depressed patients with a 
co-existing CVD (Guck et al., 2001). 
• SSRIs should be considered as first-line medications for the treatment of 
Depressive Disorders in patients post-MI because they are devoid of 
quinidine-like antiarrhythymic effects (Glassman et al., 1993). 
• SSRIs have been linked to minimal cardiotoxic effects.  However, it was 
not until the Sertraline Heart Attack Randomised Trial (SADHART) that the 
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safety and efficacy of SSRIs in post-MI or Unstable Angina patients were 
known (Glassman et al., 2002).  This study (performed in 269 outpatients 
with MDD who had been hospitalised for MI or Unstable Angina in the 
previous month) demonstrated that sertraline was of superior efficacy, 
relative to placebo, in the treatment of recurrent Depressive Disorders in 
the study population.  Furthermore, another study evaluating the 
SADHART trial study population found that there was a more pronounced 
positive influence on the quality of life of patients receiving sertraline 
treatment, when compared with placebo (Swenson, O’Connor, Barton, Van 
Zyl, Swedberg, Forman, Gaffney & Glassman, 2003). 
• It is well-established that Depressive Disorders are associated with 
enhanced platelet aggregation (Carney et al., 1995; Frasure-Smith et al., 
1995; Musselman et al., 1998; Nemeroff et al., 2000; Krishnan et al., 2000) 
and it is the effect of the SSRIs (sertraline in particular) on platelet 
function that is believed to combat cardiovascular morbidity and mortality 
(Serebruany, O’Connor & Gurbel, 2001).  Some studies have suggested 
that SSRIs normalise the activation of the platelets (Sauer, Berlin & 
Kimmel, 2001; Serebruany et al., 2001; Serebruany, Glassman, Malinin, 
Nemeroff, Musselman, Van Zyl, Finkel, Krishnan, Gaffney, Harrison, Califf 
& O’Connor, 2003).  Furthermore, SSRIs may exhibit additional antiplatelet 
effects in cardiac patients receiving Thrombo-embolic Prophylaxis (Roose 
et al., 1998).  Therefore, it has been suggested that the antiplatelet and 
endothelium-protective properties of the SSRIs may be advantageous in 
depressed patients with co-existing acute coronary events (Serebruany et 
al., 2003).  For example, a study conducted by Nelson and others (1999), 
showed that paroxetine was well-tolerated and effective in patients with 
IHD. 
• All SSRIs have the ability to cause inhibition of the CYP450 IID6  isoenzyme 
(Beliles et al., 1998).  Certain beta-blockers (for example, propranolol and 
timolol) are also metabolised by CYP450IID6 (Beliles et al., 1998) and 
therefore, co-administration with an SSRI, may lead to enhanced levels of 
these drugs.  In order to avoid the drug-drug interaction between certain 
beta-blockers and SSRIs, it has been recommended that beta-blockers 
that undergo little or no hepatic biotransformation, such as atenolol and 
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nadolol, be used (Beliles et al., 1998).  Since sertraline is the weakest 
inhibitor of the CYP450 IID6  isoenzyme (Beliles et al., 1998), it may be the 
SSRI of choice in depressed patients receiving beta-blocker therapy.   
 
3.4.1.3 ‘Other Antidepressants’:  Implications for Cardiovascular 
Disease States 
 
The literature findings for the use of ‘other antidepresssants’ in depressed 
patients with co-existing CVDs are summarised in this section: 
 
• In addition to the SSRIs, bupropion and venlafaxine should be 
considered as first-line medications for the treatment of Depressive 
Disorders in patients, post-MI (Glassman et al., 1993). 
• In contrast to the SSRIs, venlafaxine and its active metabolite, termed O-
desmethylvenlafaxine, are not highly plasma protein bound (Andrews, 
Ninan & Nemeroff, 1996; Beliles et al., 1998) and may be used in patients 
receiving other drugs with extensive protein-binding properties, such as 
warfarin (Andrews et al., 1996).   
• Mirtazapine has minimal anticholinergic and anti-adrenergic properties 
and as a result, is associated with marginal cholinergic blocking side 
effects and orthostatic hypotension (Beliles et al., 1998).  However, 
mirtazapine has been shown to increase heart rate and reduce heart rate 
variability (Nelson, 1997).    
• Nefazodone reveals marginal adrenergic activity (and almost no 
cardiotoxicity) (Majeroni et al., 1998); and less anticholinergic activity than 
other antidepressants (Taylor et al., 1995). 
• Mirtazapine, venlafaxine and nefazodone do not cause inhibition of fast 
sodium channels and consequently do not slow intracardiac conduction 
(Nelson, 1997).  
• Trazodone has been linked to arrhythmias in patients with an existing 
Cardiac Disease State (Majeroni et al., 1998).   
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The possible drug-drug interactions that may result from the concurrent 
administration of antidepressants and agents acting on the Cardiovascular 
System are listed in Table 3.10. 
 
TABLE 3.10 
POSSIBLE DRUG-DRUG INTERACTIONS BETWEEN CARDIOVASCULAR 
SYSTEM AGENTS AND ANTIDEPRESSANTS 
 
Antidepressant 
Class 
Cardiovascular 
System Medication 
Administered 
Concomitantly  
Possible Outcome of Antidepressant-
Cardiovascular System Medication 
Drug-Drug Interaction 
TCAs 
Class I antiarrhythmics • The combination may increase cardiotoxicity 
(Majeroni et al., 1998). 
 
Clonidine • TCA may reduce clonidine’s antihypertensive 
effect (Majeroni et al., 1998). 
 
Diltiazem and verapamil • TCA levels may be elevated (Majeroni et al., 
1998; Kando et al., 2002). 
MAOIs 
 
Thiazide diuretics 
 
• The hypotensive effect may increase 
(Majeroni et al., 1998). 
MAOIs may be involved in potentially toxic reactions with tyramine-containing 
foods (wine, cheese, liver & yeast extract), which can lead to a hypertensive crisis 
(Majeroni et al., 1998). 
SSRIs 
Warfarin • The prothrombin time may rise (Majeroni et 
al., 1998). 
 
Propranolol • Fluvoxamine has been associated with a 
five-fold increase in plasma propranolol levels 
when these drugs are co-administered 
(Kando et al., 2002).   
 Diltiazem • Bradycardia may occur (Kando et al., 2002). 
Other Antidepressants: 
Nefazodone 
Digoxin • Plasma digoxin levels may be affected 
(Kando et al., 2002).   
Trazodone 
Digoxin • Trazodone may increase digoxin levels 
(Nemeroff, 1994; Kando et al., 2002). 
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It was previously stated that Hypertension is a prevalent chronic disease 
state amongst South Africans (Steyn et al., 2005; Heart Foundation - South 
Africa, 2006).  Furthermore, Hypertension is a frequently diagnosed 
comorbidity in depressed patients (Jonas et al., 1997; Meyer et al., 2004; 
Cankurtaran et al., 2005; Patten et al., 2005).  The following factors need to 
be considered when antidepressant treatments are initiated in depressed 
patients with co-existing Hypertension: 
 
• The interactions between antidepressants and antihypertensive 
medications may result in either a greater blood pressure lowering effect or 
alternatively, a suppressed effect of the antihypertensive treatment.  For 
example, antidepressants that have alpha receptor blocking effects (TCAs 
and trazodone) may enhance the blood pressure lowering effects of 
alpha-blockers (for example, prazocin) used for the treatment of 
Hypertension.  Conversely, the antihypertensive actions of the following 
treatments for Hypertension will be counteracted by TCAs:  guanethidine, 
clonidine and alpha-methyldopa.  This counteracting effect may possibly 
be explained by the following mechanisms:  desensitisation of the alpha2-
adrenergic receptor or inhibition of the uptake of the antihypertensive 
agent on a presynaptic level.  (Lucas, 1999; APA, 2000.) 
• Despite causing fewer anticholinergic effects than most TCAs, trazodone 
may result in postural hypotension (especially in the elderly) (Majeroni et 
al., 1998).  Additionally, the concurrent administration of antidepressants 
and certain antihypertensive therapies, such as diuretics, increases the 
risk of the TCAs, trazodone and MAOIs resulting in symptomatic 
orthostatic hypotension (Majeroni et al., 1998; APA, 2000). 
• Some beta-blockers (propranolol, in particular), methyldopa, clonidine and 
nifedipine are used in the treatment of Hypertension and may lead to the 
development of a co-existing Depressive Disorder (APA, 2000; 
Alexopoulos, 2005; Cankurtaran et al., 2005). 
• Fluvoxamine has been associated with a fivefold increase in plasma 
propranolol levels when these drugs are co-administered.  The 
concomitant administration of fluvoxamine and diltiazem may lead to 
bradycardia.  (Kando et al., 2002.) 
 
 103
• Bupropion and venlafaxine may raise blood pressure (Roose, Dalack, 
Glassman, Woodring, Walsh & Giardina, 1991; Stoudemire, 1996; 
Johnson et al., 2006).  Stoudemire (1996) found that venlafaxine’s effect 
on blood pressure was dose-related, in view of the fact that the incidence 
of Hypertension increased as follows with an increase in dosage:  3% 
(dosages below 100mg/day), 5% to 7% (dosages between 100mg and 
300mg/day) and 13% for dosages above 300mg/day.  Thus, it has been 
recommended that blood pressure monitoring be implemented in patients 
receiving daily dosages of greater than 200mg (MacHale, 2002). 
• MAOIs may lead to a hypertensive crisis when administered concurrently 
with tyramine-containing foods (Majeroni et al., 1998; Kando et al., 2002). 
 
As mentioned in Section 2.6.2.5, the relationship between cholesterol levels 
and Depressive Disorders has not been clearly established due to conflicting 
results from various studies.  Some studies have demonstrated that 
depressed patients had low cholesterol levels before treatment was initiated; 
followed by a ‘significant increase’ in plasma cholesterol levels (total) with 
recovery from the depressive episode (Sarchiapone, Roy, Camardese & De 
Risio, 2000).  On the other hand, other researchers have found that patients 
with both Generalised Anxiety Disorder and MDD had elevated total lipids, TG 
and low-density lipoprotein cholesterol levels; as well as reduced high-density 
lipoprotein cholesterol levels.  Additionally, it has been deduced that 
depressed patients with a comorbid Anxiety Disorder might exhibit an 
enhanced fatality risk from Coronary Artery Disease.  (Sevincok, Buyukozturk 
& Dereboy, 2001.)   
 
There has been limited research conducted with reference to the suitability of 
antidepressants in depressed patients with comorbid Dyslipidaemias.  
However, the following observations have been made:  
 
• Mirtazapine has been associated with the possibility of enhancing serum 
cholesterol levels in a few patients (Nicholas et al., 2003).   
• Current studies have shown that depressed patients with elevated 
cholesterol levels were ‘significantly more likely’ not to respond to 
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treatment with fluoxetine than individuals with non-elevated cholesterol 
levels (Nicholas et al., 2003).   
 
In contrast to the limited comorbidity findings pertaining to Lipid Disorders in 
depressed patients, there has been extensive research conducted regarding 
the management of Depressive Disorders in patients with comorbid Diabetes 
Mellitus.  The treatment considerations thereof will be discussed in the 
following section. 
 
3.4.1.4 Treatment of Depressive Disorders and Comorbid Diabetes  
Mellitus 
 
The following recommendations have been made regarding the management 
of co-existing Depressive Disorders and Diabetes Mellitus: 
 
3.4.1.4.1 Cognitive Behavioural Therapy (CBT)  
 
CBT aims to ‘correct maladaptive thought patterns’ (Frank, Kupfer, Perel, 
Cornes, Jarrett, Mallinger, Thase, McEachran & Grochocinski, 1990) and 
studies have proven this method to be an effective alternative to 
pharmacological therapy in depressed patients with Type II Diabetes Mellitus 
(Lustman et al., 1998). 
 
3.4.1.4.2 Antidepressant Treatment  
 
Tables 3.11 to 3.13 contrast the advantages and disadvantages of various 
antidepressants for the treatment of Depressive Disorders in patients with 
comorbid Diabetes Mellitus. 
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TABLE 3.11 
DISADVANTAGES AND ADVANTAGES OF TCAs IN DEPRESSED 
PATIENTS WITH COMORBID DIABETES MELLITUS 
 
Disadvantages Advantages 
• TCAs may result in weight gain and postural hypotension (APA, 
2000), which are risk factors for Diabetes Mellitus (Musselman et 
al., 2003; Katon, 2003; Cankurtaran et al., 2005).  
 
• The antiarrhythmic effects of TCAs and other related compounds 
limit the use of these medications in diabetic patients (Roose et 
al., 1992).   
 
• TCAs may cause a significant increase in serum glucose levels 
(up to 150%); enhance appetite (especially cravings for 
carbohydrate-containing foods); and decrease the metabolic rate 
(MacHale, 2002). 
 
• A study assessing the effects of antidepressants on Depressive 
Disorders and glucose regulation, found that while nortriptyline 
improved Depressive Disorders, it had an adverse effect on 
glucose control (Lustman, Griffith, Clouse, Freedland, Eisen, 
Rubin, Carney & McGill, 1997). 
 
• The following depressed patients are more susceptible to the 
exacerbation of Diabetes control by TCAs:  individuals with poorly 
managed Diabetes Mellitus or significant Cardiac or Renal 
Disease States (MacHale, 2002). 
 
• TCAs may increase the effect of sulfonylureas; which could 
possibly result in hypoglycaemia (Majeroni et al., 1998).  TCAs 
and MAOIs also enhance hypoglycaemic effects when co-
administered with insulin (Kando et al., 2002). 
 
• As a result of these disadvantages, TCAs are seldom used in 
diabetic patients with Depressive Disorders (Lustman et al., 2005).
• Despite the disadvantages 
mentioned alongside, in general, 
the TCAs are considered to be 
safe amongst depressed patients 
with well-controlled Diabetes 
Mellitus (MacHale, 2002).  In fact, 
TCAs, such as amitriptyline and 
imipramine, have been shown to 
be useful in patients with diabetic 
neuropathy (Max, Lynch, Muir, 
Shoaf, Smoller & Dubner, 1992; 
MacHale, 2002). 
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TABLE 3.12 
DISADVANTAGES AND ADVANTAGES OF SSRIs IN DEPRESSED 
PATIENTS WITH COMORBID DIABETES MELLITUS 
 
Disadvantages Advantages 
• Despite the benefits of using SSRIs in depressed 
patients with comorbid Diabetes Mellitus, fluoxetine 
has been associated with the following effects: 
greater likelihood of inducing hypoglycaemia 
(especially in patients with Type II Diabetes Mellitus) 
(MacHale, 2002); and certain side effects associated 
with the use of fluoxetine, namely sweating, tremor 
and nausea (SAMF, 2005), are similar to symptoms 
arising when hypoglycaemia is present; and this could 
lead to confusion and false interpretations of a 
hypoglycaemic event.  Therefore, in diabetic patients 
who have been prescribed fluoxetine, serum glucose 
levels should be monitored on a regular basis 
(MacHale, 2002). 
 
• Fluoxetine and fluvoxamine are inhibitors of the 
CYP450IIIA4 isoenzyme (Kando et al., 2002) and may 
therefore interfere with the metabolism of certain 
hypoglycaemic medications, such as pioglitazone and 
repaglinide.  In addition to this, some SSRIs 
(fluoxetine, fluvoxamine and sertraline) inhibit the 
CYP450IIC9 isoenzyme and may therefore alter the 
metabolism of hypoglycaemics (examples include the 
sulfonylureas:  tolbutamide and glimepiride) that 
require the same metabolic isoenzyme.  It is therefore 
evident that the abovementioned SSRIs may cause 
problems with hypoglycaemia in some depressed 
patients with comorbid Diabetes Mellitus.  
(Musselman et al., 2003.)  Having stated this, 
however, there have been no publications regarding 
specific reports of cases involving such drug-drug 
interactions (DeVane & Markowitz, 2002). 
• The SSRIs are preferred in diabetic patients 
with comorbid Depressive Disorders 
(Goodnick, 2001; Musselman et al., 2003; 
Gülseren, Gülseren, Hekimsoy & Mete, 2005) 
because the pharmacological profile is 
favourable and short-term use has not been 
associated with hyperglycaemia (unlike TCAs 
and MAOIs).   
 
• SSRIs may actually allow for better metabolic 
control by means of facilitating weight loss 
(MacHale, 2002), which consequently leads to 
improved insulin resistance (Van Tilburg, 
McCaskill, Lane, Edwards, Bethel, Feinglos & 
Surwit, 2001).  Potter van Loon and others 
(1992) reported that fluoxetine regulates the 
peripheral and hepatic actions of insulin in 
insulin-resistant, obese patients.  
 
• SSRIs may decrease serum glucose levels by 
up to 30% (MacHale, 2002). 
 
• Maintenance treatment with sertraline has 
been shown to sustain remission in depressed 
diabetic patients post-recovery, and as a 
result, improve glycosylated haemoglobin 
levels for a minimum of one year (Lustman, 
Clouse, Nix, Freedland, Rubin, McGill, 
Williams, Gelenberg, Ciechanowski & Hirsch, 
2006).   
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TABLE 3.13 
DISADVANTAGES AND ADVANTAGES OF ‘OTHER ANTIDEPRESSANTS’ 
IN DEPRESSED PATIENTS WITH COMORBID DIABETES MELLITUS 
 
Disadvantages Advantages 
• In terms of adverse metabolic effects, 
some of the newer antidepressants 
(mirtazapine in particular) have only 
been associated with weight gain 
(Fava, 2000; Sussman et al., 2001). 
 
• Like certain SSRIs, nefazodone also 
inhibits the CYP450IIIA4 isoenzyme, 
which may, as consequence, alter the 
metabolism of hypoglycaemic 
medications utilising the same 
enzyme (Kando et al., 2002). 
• In addition to the SSRIs, the following antidepressants may 
have considerable advantages in depressed patients with 
concomitant Diabetes Mellitus:  venlafaxine, bupropion, 
mirtazapine and nefazodone.  These antidepressants have 
been associated with fewer anti-adrenergic and cholinergic-
blocking actions and do not result in antiarrhythmic effects 
(Musselman et al., 2003). 
 
• Bupropion causes marginal inihibition of the CYP450 
isoenzymes and does not result in significant sexual 
dysfunction (Rowland, Myers, Culver & Davidson, 1997) or 
weight gain (Musselman et al., 2003). 
 
MAOIs may cause weight gain and postural hypotension (APA, 2000), which 
are risk factors for Diabetes Mellitus (Musselman et al., 2003; Katon, 2003; 
Cankurtaran et al., 2005).  At low dosages, MAOIs may enhance the diabetic 
patient’s sensitivity to insulin and oral hypoglycaemic drug treatments.  Higher 
doses of MAOIs, however, are associated with greater insulin resistance.  
(Majeroni et al., 1998.) Thus, MAOIs are not the antidepressants of choice in 
depressed patients with concomitant Diabetes Mellitus (Lustman et al., 2005). 
 
It is evident from the information presented in Tables 3.11 to 3.13 that 
pharmacological treatments need to be carefully selected for depressed 
patients with Diabetes Mellitus, since the possibility of drug-drug interactions 
and adverse effects need to be considered.   
 
3.4.1.4.3 Treatment of Diabetes Mellitus  
 
The treatment of Diabetes Mellitus will lead to improved glycaemic control, 
which has been associated with a better sense of well-being (Lustman et al., 
 
 108
2005).  Figure 3.2 depicts an algorithm proposed for the treatment of 
Depressive Disorders and comorbid Diabetes Mellitus. 
  
 
 
 
 
 
 
 
 
 
 
 
 
If glucose control goals 
are being met, follow up 
every 3 to 6 months. 
If glucose control goals are 
not being met, institute 
advanced antidiabetic 
therapy. 
If glucose control goals are 
not being met, institute 
advanced antidiabetic 
therapy. 
If glucose control goals are 
not being met, institute 
advanced antidiabetic 
therapy. 
Evaluate for Depressive 
Disorder as a contributor 
to poor metabolic control 
in any type of Diabetes. 
Treat clinically 
significant 
depressive 
episodes with 
psychotherapy or 
antidepressants. 
Determine Diabetes status goal: 
* FBG < 110-130 mg/dl 
** SBMG < 100-120 mg/dl 
*** A1C < 6.5% - 7% 
Initial intervention 
Evaluate for Depressive 
Disorder as a contributor 
to the development of 
Type II Diabetes. 
Consider 
maintenance 
psychotherapy or 
antidepressants 
for relapsing 
Depressive 
Disorders.
If glucose control goals 
are being met, follow up 
every 3 to 6 months. 
If glucose control goals 
are being met, follow up 
every 3 to 6 months. 
FIGURE 3.2 
TREATMENT ALGORITHM FOR THE COMBINED MANAGEMENT OF DEPRESSIVE 
DISORDERS AND COMORBID DIABETES MELLITUS (Source:  Adapted from Lustman et 
al., 2005) 
 
*  fasting blood glucose    ** self-monitoring of glucose 
***  glycosylated haemoglobin  
 
As discussed in Section 2.6.2.6, Depressive Disorders may play a role in the 
development and/or progression of Diabetes Mellitus.  Patients not meeting 
glucose control goals should be advised to adhere to a stepwise approach to 
adjust the current diabetes treatment (such as the example presented in 
Figure 3.2).  In addition, Depressive Disorders should be managed 
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concurrently; and patients with recurrent depressive episodes, should be 
offered maintenance treatment (Lustman et al., 2005).  Depressive Disorders 
impair glycaemic control (Lustman et al., 1992; Harpole et al., 2005; Lustman 
et al., 2005) and also inhibit all facets of the individual’s ability to function 
properly in daily life (Lustman et al., 1992).  The effective treatment of 
Depressive Disorders in diabetic patients may result in normalisation of 
neuroendocrine and immuno-inflammatory hyperactivation; better control of 
glucose levels; and improved compliance with regards to medication and diet 
regimens (Harpole et al., 2005).  
 
Since concurrent CVD drug therapy with antidepressants is often unavoidable, 
care should be taken to avoid drug-drug interactions.  However, this is not to 
say that therapy should be withheld from the patient as a consequence, 
because the treatment of Depressive Disorders in patients with concomitant 
CVDs has been shown to improve functionality and patient quality of life 
(Krishnan et al., 2002).  Instead, drug therapy should be carefully selected to 
suit the individual needs of the patient and to best minimise the possibility of 
unwanted drug-drug interactions.   
 
3.4.2 Treatment of Depressive Disorders and Comorbid Arthritis 
 
Studies have shown that improvement of depressive symptoms (through 
antidepressant therapy or psychotherapy) decreases arthritic pain and 
enhances functionality and patient quality of life (Lin et al., 2003).  Research 
has recently focused on attempting to establish a better understanding of the 
relationship between improved mood (as a result of antidepressant treatment 
or psychotherapy) and reduced pain.  The following theory has been 
proposed:  peripheral pain signals may be dulled by neurotransmitters, such 
as serotonin and noradrenaline, which may mediate the bidirectional feedback 
between a central pain modulation system and a peripheral pain stimulus, for 
example, the pain associated with arthritis (Fields, 2000; Hirakawa, Tershner, 
Fields & Manning, 2000).   
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SSRIs are first-line treatments for depressed patients with comorbid 
Rheumatological Disease States (Alpay et al., 2000).  Psychostimulants may 
be useful in depressed elderly patients with comorbid Arthritis because they 
may allow for lower dosages of analgesics to be used (Pickett, Masand & 
Murray, 1990). 
 
3.4.3 Treatment of Depressive Disorders in Menopausal Women 
 
Studies have focused on two treatment approaches for the management of 
Depressive Disorders in menopausal women, namely:  estrogen replacement 
therapy (ERT) and antidepressant medications (MacQueen & Chokka, 2004).  
Table 3.14 compares the role of ERT and antidepressants in the management 
of Depressive Disorders in women diagnosed with Menopause.  Other 
treatments for Depressive Disorders in peri- and postmenopausal women are 
being examined and include the use of hypnotic agents, such as zolpidem 
(Dorsey, Lee & Scharf, 2004).  The use of hypnotics for the treatment of 
Depressive Disorders has not been shown to be effective in the general 
population.  However, the benefit of using hypnotics for the treatment of 
Depressive Disorders during the menopausal transition may be related to the 
suggestion that such disorders occur as a consequence of sleep disruption, 
which has been associated with hot flushes.   (Cohen et al., 2005.) 
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TABLE 3.14 
USE OF ESTROGEN REPLACEMENT THERAPY AND ANTIDEPRESSANT 
MEDICATIONS IN DEPRESSED MENOPAUSAL WOMEN 
 
ESTROGEN REPLACEMENT THERAPY (ERT) Antidepressant Medications 
• Numerous researchers have demonstrated that 
estrogen alleviates somatic and mild depressive 
symptoms of Depressive Disorders in menopausal 
women (Schmidt, Nieman, Danaceau, Tobin, Roca, 
Murphy & Rubinow, 2000; Soares, Almeida, Cohen & 
Joffe, 2001; Gambacciani, Ciaponi, Cappagli, 
Monteleone, Benussi, Bevilacqua, & Genazzani, 2003).  
For example, two randomised placebo-controlled 
studies showed that the administration of transdermal 
estradiol (daily doses of 50 to 100 micrograms) 
produced partial or complete remission of depressive 
episodes in 60% to 75% of females receiving hormonal 
therapy for four to 12 weeks.  This contrasts with 20% 
to 30% of participants receiving placebo (Schmidt et al., 
2000; Soares et al., 2001). 
• ERT elicits a response within the first month of 
administration, however there is limited information 
available regarding the optimal duration of use of 
estrogen that is required to produce prolonged 
antidepressant effects (Cohen et al., 2005). 
• Large-scale studies, such as the Women’s Health 
Initiative Study (2002) resulted in much controversy 
regarding the use of ERT for any length of time.  It was 
established that the majority of women (should they be 
regarded as low risk for CVD and Breast Cancer) only 
require HRT for a four- to five-year period.  Thereafter, 
the increasing risk of CVDs and Breast Cancer 
becomes a concern (Cohen et al., 2005).   
• Research has demonstrated the 
efficacy of antidepressants in peri- and 
postmenopausal women (Joffe, 
Groninger, Soares, Nonacs & Cohen, 
2001; Soares, Poitras, Prouty, 
Alexander, Shifren & Cohen; 2003).   
Citalopram and mirtazapine have 
been efficacious as monotherapy or 
as an adjunct to ERT in the treatment 
of Depressive Disorders in peri- and 
postmenopausal women (Joffe et al., 
2001; Soares et al., 2003).  
• Antidepressants may assist in 
alleviating hot flushes (Rossouw, 
Anderson, Prentice, LaCroix, 
Kooperberg, Stefanick, Jackson, 
Beresford, Howard, Johnson, Kotchen 
& Ockene, 2002), which may affect up 
to 75% of women undergoing 
Menopause (Von Muhlen, Kritz-
Sliverstein & Barrett-Connor, 1995).   
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TABLE 3.14 
USE OF ESTROGEN REPLACEMENT THERAPY AND ANTIDEPRESSANT 
MEDICATIONS IN DEPRESSED MENOPAUSAL WOMEN (CONTINUED) 
 
ESTROGEN REPLACEMENT THERAPY (ERT) Antidepressant Medications 
• Some women choose not to take ERT and others are 
not able to do so because of contraindications to the 
use of estrogens, which include:  existing Breast 
Cancer or the occurrence of risks for Thrombo-embolic 
Disorders (Cohen et al., 2005).  For women who are 
unable to take ERT or who prefer not to do so, 
antidepressants are considered to be novel alternatives 
for the management of symptoms occurring during 
Menopause (Rossouw et al., 2002; Soares et al., 
2003). 
• In cases where hormonal therapy is 
contraindicated, antidepressants may 
be a useful alternative (Rossouw et al., 
2002; Soares et al., 2003).  Examples 
of antidepressants that have been 
shown to reduce hot flushes, include:  
venlafaxine (Barton, Loprinzi & 
Wahner-Roedler, 2001) and paroxetine 
(Stearns, Isaacs, Rowland, Crawford, 
Ellis, Kramer, Lawrence Hanfelt & 
Hayes, 2000).   
It has been proposed that ERT may actually enhance the actions of antidepressants in peri- and 
postmenopausal women (Schneider, Small & Clary, 2001; Soares et al., 2003).  For example, Soares and 
others (2003) found that remission rates were higher amongst depressed peri- and postmenopausal 
women receiving combination treatment with ERT and citalopram (84.6%) than amongst their female 
counterparts receiving only citalopram therapy (59%).  Similarly, a study conducted in 127 women (aged 
60 years and older) to evaluate whether ERT enhances the effects of sertraline, found superior 
improvements in the quality of life amongst women receiving ERT and sertraline, relative to those women 
receiving estrogen only (Schneider et al., 2001).  However, some antidepressants, such as fluoxetine 
(Amsterdam, Garcia-Espana, Fawcett, Quitkin, Reimherr, Rosenbaum & Beasley, 1999) and venlafaxine 
(Thase et al., 2001) have not been associated with an enhanced effectiveness when used in combination 
with ERT.   
 
3.4.4 Treatment of Depressive Disorders and Comorbid Hypothyroidism 
 
There is a paucity of research pertaining to the management of Depressive 
Disorders in patients with Thyroid Disorders.  At present, researchers are 
attempting to determine whether adjunctive thyroid hormone therapy, in the 
presence of antidepressant treatment (in euthyroid individuals), may enhance 
treatment response.  The most commonly employed method is potentiation 
with tri-iodothyronine (T3), but high dosages of thyroxine (T4) have also been 
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used in patients with treatment-resistant Depressive Disorders.  The various 
mechanisms of action of the thyroid hormones in the CNS include:  
modulating the expression of genes of different groups of proteins (some have 
physiological implications in Mood Disorders); and exerting an influence over 
the neurotransmission of serotonin and noradrenaline (which is one of the 
mechanisms of action of antidepressants).  (Danilo, Gloger, Valdivieso, Ivelic 
& Fardella, 2004.) When thyroid hormones are prescribed with a TCA, there is 
an increase in the therapeutic and potentially toxic effects of both medications 
(Kando et al., 2002).   
 
3.4.5 Treatment of Depressive Disorders and Comorbid Asthma 
 
Krommydas and others (2005) recently made the following hypothesis 
regarding the role of antidepressants in the management of Asthma:  
antidepressants could be expected to modify the underlying inflammatory 
process of Asthma; and might alter the control of the CNS over the respiratory 
and immune systems.  Some researchers have proposed a combined 
treatment approach that is geared towards addressing the physical, mental 
and social implications of suffering from Asthma (Miller & Wood, 1997; 
Koenig, 2000).  For instance, these same studies (Miller et al., 1997; Koenig, 
2000) suggested the following integrated treatment regimen for depressed 
patients with comorbid Asthma:  antidepressants with anticholinergic 
properties (for example, TCAs) may be used to treat both concomitant 
disease states.  This is useful since TCAs are effective in the treatment of 
Depressive Disorders (Arrol et al., 2005) and also prevent ACh-mediated 
bronchoconstriction (Koenig, 2000).  In addition to this, Koenig (2000) 
emphasises the important role of psychotherapy in the treatment of Asthma. 
 
MAOIs may interact with sympathomimetic agents (prescribed in asthmatic 
individuals to bring about bronchodilation) and fluvoxamine may increase 
theophylline levels (McCoy, 1996; Kando et al., 2002).  Due to the possible 
drug-drug interaction between theophylline and fluvoxamine, it is 
recommended that oral theophylline dosages be reduced when these two 
agents are concurrently prescribed (Beliles et al., 1998). Other 
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antidepressants appear to be safe when co-administered with asthma 
medication (APA, 2000).        
 
3.4.6 Treatment of Depressive Disorders and Comorbid Psychiatric and 
Neurological Disease States 
 
3.4.6.1 Comorbid Psychiatric Disease States 
 
Table 3.15 outlines the treatment recommendations for depressed patients 
with a co-existing Psychiatric Disorder. 
 
TABLE 3.15 
LITERATURE RECOMMENDATIONS FOR THE MANAGEMENT OF 
DEPRESSIVE DISORDERS WHEN PSYCHIATRIC DISORDERS CO-EXIST 
 
Psychiatric 
Comorbidity 
Treatment Recommendations 
Anxiety 
Disorders 
• The presence of anxiety symptoms or insomnia may necessitate the choice of an 
antidepressant with greater sedative properties (AHCPR, 1993). 
 
• Depressed patients with a co-existing Anxiety Disorder take a longer time to respond to 
antidepressant treatment and are associated with a higher risk of relapse than patients 
suffering from either disorder on its own.  This explains why patients presenting with 
Depressive Disorders and comorbid Anxiety Disorders may benefit from a longer 
duration of treatment.  (Hirschfeld, 2001.) 
 
• Martin and others (1995) made the following recommendations with regards to the 
treatment of Depressive Disorders in patients with a co-existing Anxiety Disorder:  
antidepressants with shorter half-lives should be used; treatment with such agents 
should be initiated at a lower dosage and then increased slowly; and antidepressants 
with pronounced anticholinergic effects (for example, amitriptyline) should be avoided. 
 
 
 
 
 
 
 115
TABLE 3.15 
LITERATURE RECOMMENDATIONS FOR THE MANAGEMENT OF 
DEPRESSIVE DISORDERS WHEN PSYCHIATRIC DISORDERS CO-EXIST 
(CONTINUED) 
 
Psychiatric 
Comorbidity 
Treatment Recommendations 
Anxiety 
Disorders 
• SSRIs, venlafaxine and bupropion have been shown to be effective first-line 
treatments in depressed patients with a co-existing Anxiety Disorder (Rudolph, Entsuah 
& Chitra, 1998; Rush, Trivedi, Carmody, Donahue, Houser, Bolden-Watson, Batey, 
Ascher & Metz, 2001), but it is the SSRIs that have become the most predominantly 
used first-line antidepressants for MDD and Anxiety Disorders (Hirschfeld, 2001). 
 
• Fava and colleagues (2000) found that the following SSRIs displayed equivalent 
antidepressant efficacy in the acute treatment of Depressive Disorders when a 
comorbid Anxiety Disorder was present:  paroxetine, fluoxetine and sertraline.  Of the 
SSRIs, paroxetine and sertraline are the most versatile in terms of the types of Anxiety 
Disorders that can be effectively treated with these drugs (Fava , Rosenbaum, Hoog, 
Tepner, Kopp & Nilsson, 2000). 
 
• Having said that the SSRIs are effective in the treatment of anxiety symptoms, however, 
some patients may experience more anxiety or agitation at the start of treatment with 
this class of antidepressants (Kando et al., 2002). 
 
• According to Beliles and Stoudemire (1998), many cardiologists prefer benzodiazepines 
for the treatment of Anxiety in patients with a co-existing CVD.   
Psychotic 
Disorders 
• Depressed patients with a co-existing Psychotic Disorder usually require the use of 
either a combination treatment (with an antidepressant and an antipsychotic) or ECT 
(Kando et al., 2002). 
 
• Bupropion should not be prescribed for depressed patients with a co-existing Psychotic 
Disorder because it may cause agitation or trigger psychosis (Beliles et al., 1998).  
 
• In patients diagnosed with Bipolar Disorder, the antidepressant must be carefully 
selected because of the risk of producing a state of mania.  The use of antiepileptic 
agents (such as carbamazepine or valproate) and lithium, may be effective either alone 
or in combination with an antidepressant.  (Majeroni et al., 1998.) 
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TABLE 3.15 
LITERATURE RECOMMENDATIONS FOR THE MANAGEMENT OF 
DEPRESSIVE DISORDERS WHEN PSYCHIATRIC DISORDERS CO-EXIST 
(CONTINUED) 
 
Psychiatric 
Comorbidity 
Treatment Recommendations 
Psychotic 
Disorders 
• The following drug-drug interactions have been reported with the concomitant use of 
antidepressants and antipsychotics: 
i) The drug-drug interaction between fluvoxamine and clozapine causes an 
increase in plasma clozapine levels and increases the risk of orthostatic 
hypotension and seizures (Kando et al., 2002). 
ii) Haloperidol may increase plasma concentrations of TCAs (Kando et al., 2002).  
On the other hand, SSRIs may increase the half-life of haloperidol (Majeroni et 
al., 1998). 
iii) The co-administration of TCAs and lithium may possibly result in a synergistic 
effect on lowering the seizure threshold (Kando et al., 2002). 
iv) Nefazodone has been found to reduce the clearance of haloperidol by 35% 
(Kando et al., 2002).   
v) The concomitant administration of lithium and fluoxetine may result in 
neurotoxic effects that present in the form of confusion, tremor, dizziness, ataxia 
and absence seizures.  Similarly, the co-administration of lithium and 
fluvoxamine may cause enhanced serotonergic effects (nausea, seizures and 
tremor).  (Kando et al., 2002.)   
More than 
One 
Depressive 
Disorder 
• Patient with comorbid MDD and Dysthymia have been shown to respond favourably to 
the use of SSRIs or TCAs (Friedman & Kocsis, 1996). 
 
• TCAs have been shown to be effective in inhibiting the autonomic manifestation of panic 
in depressed patients with comorbid Panic Disorder (Majeroni et al., 1998).  Conversely, 
bupropion may exacerbate symptoms associated with Panic Disorder (Young, 1996). 
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TABLE 3.15 
LITERATURE RECOMMENDATIONS FOR THE MANAGEMENT OF 
DEPRESSIVE DISORDERS WHEN PSYCHIATRIC DISORDERS CO-EXIST 
(CONTINUED) 
 
Psychiatric 
Comorbidity 
Treatment Recommendations 
More than 
One 
Depressive 
Disorder 
• If more than one antidepressant is prescribed for the treatment of multiple Depressive 
Disorders, the following antidepressant-antidepressant interactions may be observed: 
 
i) SSRIs may interact with MAOIs; causing potentially lethal reactions (APA, 
2000). 
In theory, the interaction between mirtazapine and MAOIs may result in a 
central serotonin syndrome (Kando et al., 2002).  
ii) SSRIs will increase TCAs levels (Majeroni et al., 1998; Kando et al., 2002).  
However, research has shown that citalopram may only cause moderate or no 
pharmacokinetic interactions when prescribed with TCAs (Kando et al., 2002).   
iii) SSRIs reduce the effect of bupropion (Majeroni et al., 1998). 
iv) Although MAOIs and TCAs may be more effective than monotherapy in patients 
with refractory Depressive Disorders, severe reactions have resulted with the 
concomitant administration of these antidepressants and include:  hypertensive 
crisis, seizures, hyperpyrexia and excitation (APA, 2000). 
 
3.4.6.2  Comorbid Neurological Disease States 
 
This section provides an outline of the treatment considerations for depressed 
patients with comorbid Epilepsy, Alzheimer’s Disease, Parkinson’s Disease 
and Post-Stroke Depressive Disorders, respectively. 
 
3.4.6.2.1 Epilepsy 
 
The following possibilities need to be excluded before antidepressant 
treatment is initiated in an epileptic patient (Kanner, 2003):  
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• occurrence of  a depressive episode following the cessation of an 
antiepileptic medication with mood-stabilising effects (examples include:  
carbamazepine, valproic acid and lamotrigine); and 
• devlopment of a depressive episode after a dosage increase of an 
antiepileptic drug with negative psychotropic effects (examples include:  
phenobarbital, tiagabine, vigabatrin and topiramate). 
 
When non-epileptic depressed individuals were prescribed antidepressant 
treatments, it was found that the following factors were associated with an 
enhanced risk of seizures (Rosenstein, Nelson & Jacobs, 1993): 
 
• elevated plasma concentrations of the antidepressants.  At therapeutic 
plasma levels, TCAs have not being associated with drug-induced 
seizures (only in patients noted to be slow metabolisers of TCAs).  
Furthermore, studies have found that TCAs administered alone or in 
combination with an SSRI in epileptic patients, did not worsen seizures 
(Blumer, 1991; Blumer, Montouris & Hermann, 1995).     
• rapid increases in antidepressant dosages; 
• co-administration of antidepressant treatments with other drugs 
possessing seizure-inducing properties; and 
• pathology in the CNS, abnormal electroencephalogram and a history 
(personal and family) of seizures.  
 
In light of the abovementioned findings, Kanner (2003) suggested that 
depressed patients should be commenced on low dosages of 
antidepressants, followed by small increments until the optimal clinical 
response has been achieved.  Studies have shown that many antidepressants 
may lower the seizure threshold in depressed patients with comorbid 
Epilepsy.  However, since the actual risk of antidepressants exacerbating 
seizures in depressed patients with comorbid Epilepsy is slight, initiation of 
treatment for Depressive Disorders should not be delayed (Kanner, 2003).  
For example, Tatum and others (2001) deduced that sertraline only resulted 
in a definite exacerbation of seizures in one percent of patients treated with 
this antidepressant.   
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Table 3.16 depicts the research findings pertaining to the administration of 
antidepressants in depressed patients with a co-existing Epileptic Disorder.   
 
TABLE 3.16 
RESEARCH FINDINGS REGARDING ANTIDEPRESSANT USE IN 
DEPRESSED PATIENTS WITH COMORBID EPILEPSY 
 
Antidepressant 
Class 
Treatment Implications for Depressed 
Patients with Comorbid Epilepsy  
Possible Antidepressant-
Antiepileptic Drug 
Interactions 
TCAs 
• Blumer (1991) and others (1995) advocated 
the use of low-dose TCAs in depressed 
epileptic patients, with imipramine being used 
most often, at dosages of 100mg to 150mg per 
day. 
• Concomitant administration of 
TCAs and phenytoin or 
carbamazepine may 
decrease plasma TCA levels 
and lower the seizure 
threshold (Kando et al., 
2002).  Valproate may 
increase plasma levels of 
certain TCAs, such as 
amitriptyline (Daily Drug 
Use, 2001). 
MAOIs 
• MAOIs have not been associated with seizures 
in depressed patients without Epilepsy (Curran 
& de Pauw, 1998).   
• The concurrent administration 
of MAOIs and carbamazepine 
is not recommended (SAMF, 
2005). 
SSRIs 
• SSRIs should be the antidepressant class 
considered for first-line use in depressed 
patients with comorbid Epilepsy (MacHale, 
2002; Kanner, 2003) because of the following:  
their safety in terms of tendency towards 
seizures; decreased likelihood of fatalities in 
overdoses; and their tolerable adverse effects 
(Kanner, 2003).  More specifically, Kanner 
(2003) recommends sertraline as the SSRI of 
choice because of marginal pharmacokinetic 
interactions with antiepileptic medications.     
• The concomitant 
administration of fluoxetine 
and carbamazepine, 
phenytoin or valproate, may 
result in increased plasma 
levels of the antiepileptic 
drugs, which can lead to 
symptoms of toxicity (Kando 
et al., 2002).   
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TABLE 3.16 
RESEARCH FINDINGS REGARDING ANTIDEPRESSANT USE IN 
DEPRESSED PATIENTS WITH COMORBID EPILEPSY (CONTINUED) 
 
Antidepressant 
Class 
Treatment Implications for Depressed 
Patients with Comorbid Epilepsy  
Possible Antidepressant-
Antiepileptic Drug 
Interactions 
SSRIs 
• Sertraline may be initiated at 25mg to 50mg 
daily, with increases in dosage of 50mg every 
three weeks until the desired clinical response 
is observed; or until the maximum dosage of 
200mg per day is reached; or adverse effects 
are troublesome (Kanner, 2003). 
 
• Citalopram does not inhibit the CYP450 
isoenzymes and can therefore be used as an 
alternative to sertraline (Kanner, 2003). 
• The co-administration of 
carbamazepine and 
fluvoxamine may possibly 
result in carbamazepine 
toxicity (Daily Drug Use, 
2001; Kando et al., 2002). 
• Phenytoin may increase 
blood levels of paroxetine 
(Daily Drug Use, 2001).  
Other 
Antidepressants 
• Trazodone has been found to reduce the 
frequency of seizures and improve depressive 
symptoms.  However, the clinical importance 
of this has not been precisely defined and 
improvements observed with the use of this 
drug may possibly be attributed to:  improved 
seizure control as a result of reduced 
emotional stress; the possibility of a direct 
anticonvulsant effect imparted by the 
antidepressant; the administration of low to 
moderate dosages of trazodone, with slow 
increments in the presence of antiepileptic 
medication; and possible drug interactions 
between antidepressant and antiepileptic 
medications, with the result of enhanced 
plasma levels of the anticonvulsant, which may 
result in better seizure control.  (Lowe, 2006). 
 
• Elevated phenytoin levels 
have been reported in 
patients treated with 
trazodone (Nemeroff, 1994; 
Kando et al., 2002; SAMF, 
2005). 
• Carbamazepine induces 
bupropion metabolism and 
may therefore reduce the 
levels of this antidepressant 
medication (Ketter, Jenkins, 
Schroeder, Pazzaglia, 
Marangell, George, Callahan, 
Hinton, Chao & Post, 1995). 
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TABLE 3.16 
RESEARCH FINDINGS REGARDING ANTIDEPRESSANT USE IN 
DEPRESSED PATIENTS WITH COMORBID EPILEPSY (CONTINUED) 
 
Antidepressant 
Class 
Treatment Implications for Depressed 
Patients with Comorbid Epilepsy  
Possible Antidepressant-
Antiepileptic Drug 
Interactions 
Other 
Antidepressants 
• It has been suggested that bupropion may 
lower the seizure threshold (Kanner, 2003).  
Thus, it is contraindicated in patients with a 
seizure disorder (SAMF, 2005).  The 
occurrence of seizures in patients receiving 
bupropion treatment seems to be related to 
dosage to a large extent (Kando et al., 2002).  
For example, the frequency of seizures has 
been highest in patients receiving bupropion 
treatment and has ranged between 0.40% 
and 2.19% in various studies (Lowe, 2006). 
 
• In addition to bupropion, maprotiline is one 
of the antidepressants with the most 
pronounced seizure-inducing capabilities and 
should therefore also be avoided in 
depressed patients with comorbid Epilepsy 
(Pisani, Spina & Oteri, 1999; Kando et al., 
2002).  Seizure risk increases with dosages 
exceeding recommended dosages; and with 
concurrent phenothiazine administration 
(Majeroni et al., 1998). 
 
• Depressive symptoms were found to diminish 
in epileptic patients (controlled Epilepsy) 
receiving venlafaxine at dosages ranging 
between 75mg and 225mg a day (Kanner, 
2003). 
• Ketter and others (1995) found 
that, unlike carbamazepine, 
valproate does not result in 
enhanced bupropion 
metabolism. 
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3.4.6.2.2 Alzheimer’s Disease 
 
Depressed patients with co-existing Alzheimer’s Disease may be effectively 
treated for Depressive Disorders by means of ECT (Dombrovski & Mulsant, 
2007).  Conversely, ECT causes confusion shortly after the application of 
therapy and may therefore increase the risk of confusion amongst depressed 
patients with comorbid CNS disease states (Zisselman et al., 2001).   
 
Tune (1998) recommended the use of SSRIs with a potential stimulant effect, 
such as sertraline and fluoxetine, for depressed patients with concomitant 
Alzheimer’s Disease.  Research has found that donepezil (a reversible 
cholinesterase inhibitor) was effective for the treatment of the affective and 
behavioural symptoms associated with Alzheimer’s Disease (Weiner, Martin-
Cook, Foster, Saine, Fontaine & Svetlik, 2000).  The anticholinergic side 
effects of the TCAs may exacerbate cognitive function in patients with 
dementia and neurological disease states (Taragano, Lyketsos, Mangone, 
Allegri & Comesana-Diaz, 1997).  
 
3.4.6.2.3 Parkinson’s Disease 
 
Numerous studies have shown that the following antidepressants are 
associated with improved depressive symptoms in patients with Parkinson’s 
Disease:  imipramine; desipramine; nortriptyline (Majeroni et al., 1998); 
SSRIs (Ceravolo, Nuti, Piccinni, Dell’Agnello, Bellini, Gambaccini, Dell’Osso, 
Murri & Bonucelli, 2000); and bupropion (Majeroni et al., 1998).  
 
The efficacy of TCAs in depressed patients with Parkinson’s Disease may be 
attributable to the anticholinergic effects of this class of antidepressants, 
which may potentially alleviate extrapyramidal symptoms.  A study conducted 
by Serrano-Duenas (2002), revealed that an average daily dosage of 
amitriptyline of 35.2mg, was effective in the management of Depressive 
Disorders in patients diagnosed with Parkinson’s Disease.  Nortriptyline 
appears to be the preferred TCA in depressed patients with co-existing 
Parkinson’s Disease because it has been studied more extensively than the 
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other agents in the same class (Vajda & Solinas, 2005).  Having mentioned 
the benefits of TCAs, however, the same advantageous contribution, namely, 
the anticholinergic effects, may possibly increase confusion amongst patients 
with Parkinson’s Disease (MacHale, 2002).  Furthermore, TCAs may lower 
plasma levels of levodopa (Kando et al., 2002), which is an agent commonly 
used for the management of Parkinson’s Disease.   
 
Existing tremor amongst patients with Parkinson’s Disease may be 
exacerbated by the use of SSRIs, particularly in those individuals receiving 
selegiline (MacHale, 2002).  The enhanced propensity towards extrapyramidal 
symptoms and serotonergic reactions, make the following antidepressants 
less suitable in patients who are receiving selegiline for the treatment of 
Parkinson’s Disease:  certain SSRIs, clomipramine and MAOIs (MacHale, 
2002).  The co-administration of fluoxetine or fluvoxamine and selegiline, for 
example, may exacerbate a serotonin syndrome or hypertensive crisis (Vajda 
et al., 2005).  The association between SSRIs and the occurrence of 
extrapyramidal side effects was evaluated by Caley (1997).  This study 
proposed that SSRIs exert inhibitory actions (caused by serotonin) on 
extrapyramidal dopamine activity, thus possibly leading to the exacerbation of 
extrapyramidal side effects in patients with Parkinson’s Disease.   
 
In contrast, in addition to its noradrenergic activity, bupropion inhibits the re-
uptake of dopamine on a presynaptic level and as a result, does not elicit 
extrapyramidal side effects (Vajda et al., 2005).  The antiparkinsonian 
dopamine agonist, pramipexole may improve depressive symptoms in 
patients with Depressive Disorders and comorbid Parkinson’s Disease. 
However, the use of pramipexole is limited because it causes somnolence, 
which proved to be problematic for patients’ driving.  (Vajda et al., 2005.)  
Depressed patients with comorbid Parkinson’s Disease, who failed to respond 
to lifestyle adjustments and antidepressant medications, may benefit from the 
use of ECT, which could temporarily reduce the rigidity and bradykinesia 
(associated with Parkinson’s Disease), and improve depressive symptoms 
(Vajda et al., 2005).  The treatment of Depressive Disorders in patients with 
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comorbid Parkinson’s Disease has been associated with improved cognitive 
function (Norman, Troster, Fields & Brooks, 2002). 
 
3.4.6.2.4 Post-Stroke Depressive Disorders 
 
The following factors should be considered when a decision needs to be 
made regarding the implementation of antidepressant therapy in Post-Stroke 
Depressive Disorders:  the age of the patient; epileptogenic potential and 
existing treatments (for example, anticoagulants or cardiac therapy) 
(MacHale, 2002). 
 
SSRIs are the drugs of choice for the treatment of Post-Stroke Depressive 
Disorders (Majeroni et al., 1998; MacHale, 2002).  Studies have shown that 
nortriptyline (Robinson, Schultz, Castillo, Kopel, Kosier, Newman, Curdue, 
Petracca, & Starkstein, 2000; MacHale, 2002) and trazodone (Carod-Artal, 
2006) had superior efficacy when compared with placebo for the treatment of 
Post-Stroke Depressive Disorders.   
 
3.4.7 Treatment of Depressive Disorders and Comorbid HIV-Disease 
 
HIV patients will benefit from the same treatments for Depressive Disorders 
as individuals without this disease state (Forstein et al., 2000).  Numerous 
researchers have found that drug treatments for Depressive Disorders in HIV-
infected patients have generally been safe and effective (Ferrando, Goldman 
& Charness, 1997; Rabkin, Wagner & Rabkin, 1999).  Nevertheless, the 
antiretroviral regimens and the severity of the HIV-Illness need to be taken 
into consideration before antidepressant therapy is initiated (Roy, 2006).  
Currently, there has been no particular antidepressant shown to be preferred 
or conversely, failed to work, in depressed patients with HIV.  Consequently, 
the focus has been geared towards identifying potential drug-drug interactions 
and side effects that the medically ill are more vulnerable to.  (Forstein et al., 
2000.) Possible drug interactions include:  competitive protein binding; CYP450 
enzyme inductive/inhibitory reactions; and possible alteration in the absorption 
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of antidepressants caused by the co-administered antiretroviral medications 
(Roy, 2006). 
 
The following factors should be considered for patients diagnosed with HIV:  
weight gain and constipation may be helpful in individuals with noticeable 
weight loss and diarrhoea; sedation could be useful in patients with insomnia; 
and neuropathic pain is common in the late stages of HIV and AIDS.  TCAs 
have been shown to exert a beneficial effect in the aforementioned instances.   
(Roy, 2006.) The SSRIs are more favourable in terms of patient tolerability, 
than the TCAs.  In addition, the SSRIs do not seem to result in undesirable 
immunosuppressive effects (Alexopoulos et al., 2002).  On the other hand, 
SSRIs have been reported to be involved in unwanted drug-drug interactions 
with antiretroviral medications (Tseng & Foisy, 1999).  Venlafaxine, 
mirtazapine and bupropion (sustained-release) seem to be effective; have 
comparable tolerability to SSRIs and TCAs; and are not involved in significant 
drug-drug interactions (Forstein et al., 2000).  In spite of this, the 
gastrointestinal side effects of venlafaxine may perturb some patients, since 
these effects are also commonly associated with the use of antiretroviral 
medications (Roy, 2006). 
 
Some studies have suggested the use of drugs which act on other physiologic 
mechanisms to treat symptoms of Depressive Disorders in HIV-infected 
individuals.  For example, dextroamphetamine has been used successfully as 
a quick-acting antidepressant in HIV patients with debilitating fatigue (Wagner 
& Rabkin, 2000).  Similarly, testosterone has been used to treat Depressive 
Disorders in males with comorbid HIV (Rabkin et al., 1999).    
 
Psychotherapy provides a means of focusing on the quality of life and 
emotional-related matters that are associated with HIV.  The treatment of 
Depressive Disorders may improve the physical and emotional status of 
individuals diagnosed with HIV.  (Roy, 2006.) Moreover, compliance with 
antiretroviral medication regimens is improved amongst patients treated with 
antidepressants (Yun, Maravi, Kobayashi, Barton & Davidson, 2005). 
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3.5 CONCLUSION 
 
This chapter summarised the literature findings pertaining to the management 
of Depressive Disorders in patients with specified comorbidities and illustrated 
that Depressive Disorders can be treated in these patients.  It is evident that 
there are many factors that need to be considered before antidepressant 
treatment is initiated.  In addition to the general recommendations that should 
be considered for depressed patients with specific chronic concomitant 
disease states, each individual needs to be evaluated as a separate entity, 
with an independent pharmacological and physiological profile.  The treatment 
of Depressive Disorders with antidepressants has been associated with a 
much greater probability of an improved clinical response in patients with 
various chronic comorbid disease states, than placebo (MacHale, 2002 
Hayes, 2004).  This emphasises the importance of conducting additional 
studies to confirm that the treatment of Depressive Disorders leads to an 
improvement in overall medical outcomes.  Such studies would allow for 
further investigation into the appropriateness of selected antidepressants in 
patients with particular chronic comorbid disease states.  This, in turn, will 
assist prescribers in making informed decisions regarding which 
antidepressant will be most suitable for individual patients, based on the 
nature of the co-existing disease states and medications already prescribed.   
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
METHODOLOGY 
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4.1 INTRODUCTION 
 
This pharmacoepidemiological study employs a retrospective drug utilisation 
review methodology.  The overall design of the study was quantitative and 
non-experimental.  Pharmacoepidemiology may be defined as ‘the study of 
the utilisation and effects of drugs in large numbers of people’.  Such a study 
lends from both pharmacology and epidemiology.  (International Society for 
Pharmacoepidemiology, 2007.) A drug utilisation review can be described as 
the systematic process of evaluating data on the prescribing, dispensing and 
consumption of medication in a particular group of patients (Lipton, Kreling & 
Hertz, 1999).  In this study, the group of patients under review consisted of 
individuals diagnosed with Depressive Disorders, who were registered with a 
chronic medical aid plan in South Africa.   The purpose of this review was to 
assess antidepressant drug therapy in both patients with solely Depressive 
Disorders, and in those depressed patients with one or more comorbid 
disease states.  The data were evaluated against predetermined and 
acceptable criteria and standards, thereby allowing for the identification of 
possible discrepancies in prescribing practice.  This chapter discusses the 
methods utilised to achieve the study objectives.  The methodology comprises 
of the following:  literature review; data collection; data verification; data 
analysis; statistical analysis; methods employed to conduct analyses; 
confidentiality; and limitations of the study. 
 
4.2 LITERATURE REVIEW 
 
The purpose of this study was to investigate the complex relationship that 
exists between chronic disease states and Depressive Disorders from a 
pharmacoepidemiological perspective.  It was therefore necessary to examine 
the published literature pertaining to the following:  aetiology and diagnosis of 
Depressive Disorders; prevalence of Depressive Disorders and factors 
affecting prevalence; nature and prevalence of commonly occurring chronic 
comorbid disease states; and the implications of being diagnosed with a 
disease state and comorbid Depressive Disorder.  Furthermore, it has been 
proposed that providing treatment for Depressive Disorders may give rise to 
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more ‘significant improvements’ in quality of life, physical and psychological 
functioning and disability; than bringing forth productive interventions for other 
chronic disease states (Noël et al., 2004).  For this reason, the management 
of Depressive Disorders, in the presence of commonly occurring comorbid 
disease states, needed to be conceptualised from a treatment perspective. 
 
An extensive literature review was conducted to obtain relevant information 
pertaining to the abovementioned topics.  This information search was 
initiated by a ScienceDirect® and Medline® search extending from February 
1995 to October 2006.  Literature published outside this time-frame was 
referred to where required.  Textbooks were also consulted where applicable. 
 
4.3 DATA COLLECTION  
 
This section provides a summary of the method employed to obtain data for 
this study and discusses the layout of the information supplied by the data 
source. 
 
4.3.1 Data Request 
  
Medscheme (Solutio Healthcare) is a Managed Healthcare Company that 
administers medical aid claims for a number of medical schemes in South 
Africa.  All records pertaining to depressed patients were requested from this 
company for the purposes of this study.  The company approved the request 
and the data, containing records extending from 1988/12/10 to 2005/04/01, 
were captured on 4 April 2005.  Data were requested in text format and 
imported into Microsoft Access® 2003, a database programme.   
 
4.3.2 Data Format  
 
The entire database comprised of 23 205 patients with 267 427 patient 
records on 4 April 2005.  A ‘patient record’ can be defined as a row dedicated 
to each new drug prescribed for a particular patient.  Therefore, one patient 
may have multiple records.  Table 4.1 outlines the different field headings 
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provided for each patient in the Microsoft Access® database.  Appendix A 
provides an example of the way in which the patient information was 
presented in the database. 
 
TABLE 4.1 
FIELD HEADINGS DISPLAYED IN THE ACCESS® DATABASE          
 
FIELD HEADING DESCRIPTION 
ID A unique identification number allocated to each patient.  
Gender 
The gender of each patient was specified using the letters ‘F’ and 
‘M’ for females and males, respectively. 
Age The age of each patient was shown as a number in years. 
Comm Date 
The commencement date provided the date on which a particular 
drug treatment was initiated in a patient.  The following format 
was used to record these dates:  yyyy/mm/dd. 
Term Date 
The termination date indicated the date on which a particular drug 
was stopped in a patient.  These dates were displayed in the 
same format as the commencement dates. 
ICD-10 
The International Statistical Classification of Diseases and 
Related Health Problems (ICD-10) is a diagnostic classification 
system that was developed by the WHO in collaboration with 10 
international centres.  It is the classification system for all general 
epidemiological purposes and allows for mortality statistics to be 
compared on an international level.  (Centres for Disease Control 
and Prevention, 2003.) The ICD-10 code presents each diagnosis 
as a code.  For example, Recurrent Depression is represented by 
the ICD-10 code F33.2.   
Diagnosis 
The diagnosis is not only assigned an ICD-10 code, but there is 
also a separate column, namely, ‘Diagnosis’ that includes a text 
description of the disease state.  For example, the ICD-10 code 
F32.9 will also be represented as ‘Depression’ in the Diagnosis 
column. 
Drug Name 
The trade name of every drug that has been authorised as 
chronic medication for a patient.  
Drug Strength 
The strength (or concentration) of the active ingredient/s present 
in each drug in milligrams.   
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TABLE 4.1  
FIELD HEADINGS DISPLAYED IN THE ACCESS® DATABASE 
(CONTINUED) 
 
FIELD HEADING DESCRIPTION 
NAPPI 
The NAPPI (National Pharmaceutical Pricing Index) code is the 
code used to classify medication.  Every trade name product has 
a specific NAPPI code.  For example, Trepiline® (one trade name 
for amitriptyline) has a NAPPI code of 771996.  
Drug Form 
The formulation of each drug, in other words, whether the drug is 
in tablet or capsule form, for instance, refers to the drug form. 
SEP price 
The single exit price (SEP) is the manufacturer’s or importer’s 
price (inclusive of value added tax) of one pack size of a drug 
product.  
Pack size 
The pack size indicates the quantity of the drug (in its particular 
formulation) contained in one pack size.  
Directions 
The dosage and frequency of the administration of each drug that 
is prescribed for a patient on a daily basis.  
January to 
December 
Each month of the year has a separate column indicating the 
quantity of each drug that was supplied to a patient in a given 
month.   
ATC_Description  The Anatomical-Therapeutic-Chemical (ATC) Classification 
System is used for the classification of drugs.  Drugs are divided 
into various groups depending on their chemical, pharmacological 
and therapeutic properties, as well as the organ or system on 
which they act.  The ‘ATC_Description’ displays the active 
ingredient/s contained in each drug.  In turn, the ‘ATC_Code’ 
presents the classification code for each drug (WHO, 2006). 
ATC_Code  
 
• The ATC Classification System divides drugs into groups at five different levels.  The first 
level (consisting of 14 main groups) describes the anatomical main group of the drug.  
The second and third levels depict the therapeutic/pharmacological subgroups; and the 
fourth and fifth levels classify the therapeutic/pharmacological subgroups and chemical 
substances, respectively.  For example, fluoxetine is classified as follows according to the 
five levels of the ATC Classification System:  N06AB03 (N = Nervous System [Level 
One]; N06 = Psychoanaleptics [Level Two]; N06A = Antidepressants [Level Three]; 
N06AB = SSRIs [Level Four]; and N06AB03 = fluoxetine [Level Five]).  (Guidelines for 
ATC Classification and DDD Assignment, 1996). 
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4.4 DATA VERIFICATION 
 
The dataset was verified to ensure that all of the information provided by the 
Managed Healthcare Company met certain predetermined criteria for the 
study.  This verification process will be discussed relative to the following: 
 
• Diagnosis;  and   
• Age and gender 
 
4.4.1 Diagnosis  
 
4.4.1.1 Depressed Patients 
 
Queries were run in Microsoft Access® and these were copied and transferred 
to Microsoft Excel® 2003 in order to perform analyses in a manner that 
allowed for easier data analysis.  During this initial verification process, it was 
established that 2 020 patients (8.71%) did not have a Depressive Disorder as 
one of their diagnoses.  Since only the medication records pertaining to 
patients with Depressive Disorders were of relevance to the study, these 
records were removed from the dataset.  There were 21 185* patients 
diagnosed with one or more Depressive Disorders and 253 836** records 
pertaining to these patients.   
* [23 205 – 2 020 = 21 185 patients] 
** [267 427 – 13 591 = 253 836 patient records] 
 
4.4.1.2 Ambiguous Diagnoses 
 
Upon further analysis of the patient records, it was noted that 25 of the male 
patients were on HRT and/or had Menopause as a diagnosis.  The drug 
treatments for all of these patients were evaluated and it was noted that 
female hormonal therapies, such as oestradiol, were prescribed.  To avoid 
confusion, these records were transferred to the Excel® storage folder and 
excluded from further analyses.  On the other hand, there were also six 
females with Benign Prostatic Hypertrophy as a diagnosis.  These records 
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were also transferred to the Excel® storage folder.  The total number of 
records remaining was 253 804*.   
* [253 836 - 32 = 253 804 patient records] 
 
4.4.1.3 Age and Gender 
 
It was decided that only those patients who were between the ages of 0 and 
100 years would be included in the study.   It was found that of the 21 185 
depressed patients, 14 (0.01%) had ages that did not fulfil the age inclusion 
criteria.  Of these 14 patients, eight had negative ages, three were over 100 
years of age, and three had no ages.  All of the records associated with the 14 
patients who did not fulfil the age criteria for the study were transferred to a 
separate Excel® storage folder.  Therefore, only the records of the remaining 
21 171 depressed patients (91.23%* of the patients in the original database) 
were analysed for the study.  There were no discrepancies with regard to 
gender.  The total number of patient records remaining (and therefore suitable 
for further analyses) was 253 692**. 
* [(21 171/23 205) x 100 = 91.23% of patients] 
** [253 804 – 112 = 253 692 patient records] 
 
4.5 DATA ANALYSES 
 
Data analyses were performed for the entire study population (21 171 
patients) firstly (Chapter 5), and then for patients diagnosed with one or more 
Depressive Disorders in the year, 2004 (Chapter 6).  All of the depressed 
patients in the database (who fulfilled the criteria stipulated in Section 4.4, 
namely:  21 171 patients), are referred to as the ‘entire study population’ or 
‘total study population’ throughout the study.  Similarly, depressed patients 
diagnosed with one or more Depressive Disorders in 2004 are labelled as the 
‘secondary study population’ (15 984 patient records, representing 6 150 
depressed patients).  The data analyses for the entire and secondary study 
populations were performed utilising Microsoft Access® 2003 and Microsoft 
Excel® 2003.  Sections 4.5.1 and 4.5.2 describe the processes involved in 
further preparing the data for analyses.  Thereafter, Sections 4.5.3 and 4.5.4 
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summarise the various levels that were analysed for the purposes of this 
study.  Section 4.5.5, in turn, describes the methods employed to conduct the 
analyses. 
 
4.5.1 Patient Demographics 
 
Due to the fact that the study included depressed patients of all ages, it was 
decided to group patients into age categories.  These age groupings allowed 
for comparisons to be made with regard to the following: 
 
i) disease states co-existing with Depressive Disorders; and 
ii) treatment of Depressive Disorders amongst the different age 
groups.   
 
Erik Erikson’s concept of the possible developmental stages present in the 
course of a person’s life provided the basis for the selection of the age 
categories in this study.  Erikson’s theory antagonised Freud’s belief that 
personality is determined solely by early experiences in childhood, and 
incorporates additional stages of development, such as adolescence, 
adulthood, and old age (Slater, 2003).  This theory claimed that the 
developmental pathway is determined by the interaction of the ‘body (genetic 
biological programming), mind (psychological), and cultural (ethos)’ influences 
(Harder, 2002).  Erikson divided the course of life from birth to death into eight 
developmental stages, which are presented in Table 4.2.  The ages selected 
by Erikson are an extension of Freud’s psychosexual stages of development.  
The theory makes the assumption that each person lives a full life, since 
every individual is expected to pass through all stages.  Each stage presents 
two opposing notions, one representing a supposed positive pole and the 
other a negative pole.  These ideas represent a conflict that, upon resolution, 
leads to a resultant ratio between the positive and the negative components.  
Erikson’s notion of identity is supported by the concepts of other psychologists 
such as Frankl (1963), Debats (1999), Maslow (1970) and Roger (1961).  
(Slater, 2003.) 
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TABLE 4.2  
ERIKSON’S EIGHT-STAGE THEORY OF LIFE-CYCLE DEVELOPMENT 
 
Stage Age Range Pairs of Opposing Notions 
Infancy Birth to 18 months Trust versus Mistrust 
Early Childhood 18 months to three years Autonomy Versus Shame 
Play Age Three to Five years Initiative Versus Guilt 
School Age Six to 12 Years Industry Versus Inferiority 
Adolescence 12 to 18 Years Identity Versus Identity Diffusion 
Young Adulthood 18 to 35 Years Intimacy Versus Isolation 
Middle Adulthood 35 to 55 or 65 Years Generavity Versus Stagnation 
Late Adulthood 55 or 65 Years to Death Integrity Versus Despair 
 
(Source:  Adapted from Slater, 2003 & Harder, 2002) 
 
The age groups selected for the study were as follows:   
 
• 0 to 17 years 
• 18 to 34 years 
• 35 to 54 years 
• 55 to 64 years  
• 65 years of age and older. 
 
The first five stages of Erikson’s model were combined into one age group 
because the patients under 18 years of age only made up 0.68% of the entire 
study population.  Many studies have shown that the prevalence of multiple 
chronic disease states is higher in those individuals aged 65 years or older 
(Harpole et al., 2004; Taylor et al., 2004).  Late adulthood was thus separated 
into two age groups so that comparisons could be made between the 
prevalence of Depressive Disorders and other comorbid disease states in the 
elderly (defined as individuals aged 65 years or older) (Yates et al., 2004) and 
in the younger age groups.  Individuals in the 0 to 17 and 35 to 54 year age 
groups were also referred to as the ‘young’ patients or ‘children and 
adolescents’ and ‘middle-aged’ patients, respectively, throughout the study. 
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4.5.2 Grouping of Diagnoses for Drug Utilisation Review 
 
4.5.2.1 The ICD-10 Coding System 
 
As discussed previously, the ICD is a standard classification system that is 
recognised on an international level.  It provides the diagnostic classifications 
for all general epidemiological purposes as well as numerous health 
management services.  For example, examination of the incidence and 
prevalence of disease states and evaluation of the general health 
circumstances of population groups.  This classification system allows for 
global comparisons to be made with regards to the ‘collection, processing, 
classification, and presentation of mortality statistics’.  (Centres for Disease 
Control and Prevention, 2003.) New versions of ICD are drawn-up periodically 
to ensure that developments in medical science are taken into consideration. 
 
Every system in the body is assigned an independent letter of the alphabet in 
the ICD-10 coding system.  This letter is then followed by a number between 
zero and 99, which represents a subcategory of the main system.  For 
example, Mental and Behavioural Disorders are expressed as codes ranging 
between F00 to F99.  More specifically, Mood Disorders are represented by 
codes that range between F30 and F39.  There will also be a decimal point 
after the third character (or second number), followed by one or more 
numbers.  There are many variations at the third numerical character level, so 
the code is often summarised at the second number level.  In other words, a 
depressive episode has been allocated the ICD-10 code F32.  This particular 
code represents all forms of depressive episodes, such as mild depressive 
episode (F32.0) or severe depressive episode without psychotic symptoms 
(F32.2).  Appendix B presents the various chapters and accompanying ICD-
10 codes and titles as they appear in the ICD-10 document, volume 1, version 
2003.   
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4.5.2.2 Diagnosis and ICD-10 Code Synchronisation 
 
Certain diagnoses in the database had the same ICD-10 code.  For example, 
‘Depression (major)’ and ‘Major Depression - No Psychosis’ are represented 
by the code F32.2 and are essentially describing the same Depressive 
Disorder.  In order to avoid duplication of identical disease state cases in a 
single patient, those diagnoses with comparable text descriptions and sharing 
the same ICD-10 codes, were adjusted in Microsoft Excel® to reflect the same 
diagnosis name.  A disease state case, simply termed ‘case’ throughout the 
study, refers to a single diagnosis and does not account for each episode of 
the same disease state as a separate entity.  In other words, a patient 
diagnosed with ‘Depression (major)’ may have multiple records pertaining to 
this diagnosis because of relapses and different therapies being used.  
However, ‘Depression (major)’ is only counted as one disease state case for 
that particular patient.  Table 4.3 displays the pairs of interchangeable disease 
states that had a common ICD-10 code and demonstrates how these 
diagnoses were handled to avoid duplication of identical disease state cases 
in a single patient.   
 
4.5.2.3 Grouping of Diagnoses for Drug Utilisation Review 
 
For the purposes of the drug utilisation review, it was decided that appropriate 
disease states would be grouped together in order to obtain results that 
provided a more comprehensive representation of the most prevalent disease 
states.  The code ranges present in the ICD-10 system provided the basis for 
the selection of such groupings.  Table 4.4 provides examples of disease 
states that were grouped together for the purposes of the study.  Appendix C 
presents a more detailed description of the disease state groupings 
conducted for the purposes of the study.   
 
 
 
 
 
 
 138
TABLE 4.3 
INTERCHANGEABLE DISEASE STATES WITH IDENTICAL ICD-10 
CODES 
 
Disease State Pairs 
(Diagnoses with the same ICD-10 code) 
ICD-10 
Code 
Data Verification Process 
In Excel® 
‘Affective Disorder’ and 
‘Mood Affective Disorder’ 
F38.8 All ‘Affective Disorder’ entries were 
changed to ‘Mood Affective 
Disorder’. 
‘Depression (major)’ and 
‘Major Depression - No Psychosis’ 
F32.2 All ‘Major Depression - No Psychosis’ 
entries were changed to ‘Depression 
(major)’. 
‘Recurrent Depression’ and 
‘Recurrent Depression - No 
Psychosis’ 
F33.2 All ‘Recurrent Depression - No 
Psychosis’ entries were changed to 
‘Recurrent Depression’. 
‘Cancer (non-specific)’ and 
‘Carcinoma’ 
C80 All ‘Cancer (non-specific)’ entries 
were changed to ‘Carcinoma’. 
‘Ischaemic Heart Disease’ and ‘IHD’ 
I25.9 All ‘IHD’ entries were changed to 
‘Ischaemic Heart Disease’. 
‘CVA’ and ‘Stroke’ 
I64 All ‘CVA’ entries were changed to 
‘Stroke’. 
‘Irritable Bowel Syndrome’ and 
‘Spastic Colon’ 
K58.9 All ‘Spastic Colon’ entries were 
changed to ‘Irritable Bowel 
Syndrome’. 
‘Cardiac Arrhythmia, Unspecified’ and 
‘Arrhythmias’ 
I49.9 All ‘Cardiac Arrhythmia, Unspecified’ 
entries were changed to 
‘Arrhythmias’. 
‘CCF’ and ‘Cardiac Failure’ 
I50.9 All ‘CCF’ entries were changed to 
‘Cardiac Failure’. 
‘Angina’ and ‘Angina Pectoris’ 
I20.9 All ‘Angina’ entries were changed to 
‘Angina Pectoris’. 
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TABLE 4.4 
GROUPING OF CHRONIC DISEASE STATES ACCORDING TO ICD-10 
DESCRIPTIONS AND CODES 
 
CHRONIC DISEASE STATES ICD-10 ICD-10 DESCRIPTION ICD-10 CODE 
  CODE    RANGE FOR 
      DESCRIPTION
Depression comprising of:    
Depression F32.9 
Mood Disorders F30 - F39 
Depression (major) F32.2 
Depression (mild) F32.0 
Depression with Psychosis F32.3 
Cyclothymia F34.0 
Dysthymia F34.1 
Mood Affective Disorder F38.8 
Neurotic Depression F34.1 
Recurrent Depression F33.2 
Depression (Post-natal) 
  
  
F53.0 
  
  
Behavioural Syndromes Associated  
with Physiological disturbances and  
Physical factors 
F50 - F59 
 
4.5.3 Study Population Analyses:  Entire Study Population 
 
Data pertaining to the entire and secondary study populations were 
retrospectively analysed using Microsoft Access® and Microsoft Excel® 2003.  
The following levels were evaluated for the entire study population: 
 
4.5.3.1 Characteristics of the Entire Study Population 
 
The distribution of age and gender for the entire study population (21 171 
patients), as well as for the individual specified age groups, was investigated.  
The distribution of depressed patients was compared with the corresponding 
percentages for non-depressed patients in the entire member database.  This 
was done in order to ascertain whether the depressed sample (study 
population) was representative of the age group distributions observed in the 
larger population.  Since all of the patients in the study population were 
depressed, the prevalence of the various Depressive Disorders in the 
selected age groups was established.  The relationship between the 
prevalence of Depressive Disorders and age or gender was then investigated. 
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4.5.3.2 Comorbidity Analysis 
 
The risk of developing a Depressive Disorder secondary to a chronic disease 
state or conversely, developing a chronic disease state secondary to a 
Depressive Disorder, has been evaluated by researchers for numerous years 
already (Katon, 2003).  Research has shown that patients with Depressive 
Disorders have a greater burden of comorbid disease states than their non-
depressed counterparts (Callahan et al., 1997).  The distribution of depressed 
patients regarding the number of chronic comorbid disease states, and the 
mean number of comorbidities per patient, according to gender, was 
determined for the entire study population and the age groups, independently.  
The most prevalent disease states co-existing with Depressive Disorders in 
females and males in the total study population, as well as for the separate 
age groups, were identified.  The relationship between the prevalence of the 
most commonly occurring chronic comorbid disease states and age was 
analysed for the entire study population.  The prevalence percentages of the 
commonly occurring comorbid disease states in females and males were 
contrasted for each of the age groups. 
 
4.5.4 Study Population Analyses:  Secondary Study Population 
 
Untreated Depressive Disorders become typically chronic and are expected to 
be second to CVDs in the global burden of disease by 2020 (Chapman et al., 
2005).  This emphasises the importance of ensuring that Depressive 
Disorders are adequately treated.  The main focus of the secondary study 
population analyses was to evaluate the drug treatments prescribed for the 
management of Depressive Disorders in 2004, taking into consideration the 
influence of prevalent co-existing disease states on drug selection.  More 
specifically, the following levels were investigated: 
 
4.5.4.1 Characteristics of the Secondary Study Population 
 
The age and gender distribution of the 6 150 patients, diagnosed with one or 
multiple Depressive Disorders in 2004, was examined.  Furthermore, the age 
 
 141
and gender distribution of the depressed patients in the selected age groups 
was established.  
 
The term ‘active ingredient’ refers to an individual chemical substance (as per 
Level Five of the ATC Classification System) prescribed and was used 
throughout the study to represent the various trade names for a particular 
active ingredient as a single entry.  For example, the active ingredient, 
fluoxetine (trade names include, but are not limited to:  Prozak®, Nuzak® and 
Sandoz-Fluoxetine®) may be prescribed in the form of different trade name 
products to the same patient, depending on the availability of the product at 
the selected drug provider, which may also vary from time to time.  Albeit 
being prescribed numerous times, however, fluoxetine was only counted once 
per patient.  Therefore, the active ingredient (as opposed to the trade name) 
was the deciphering determinant of prescribing frequency.  This was to 
ensure that a single active ingredient prescribed to one patient was only 
considered once.  The terms ‘active ingredient’, ‘medication’ and ‘drug’ were 
used interchangeably throughout the study.  
 
The number of active ingredients prescribed per patient, relative to gender, 
was established for the secondary study population as a whole, and patient 
distributions in this regard, were compared for the individual age groups.  The 
mean number of active ingredients prescribed per depressed patient was 
evaluated for all females and males in 2004.  The percentage frequencies of 
the most commonly prescribed agents were calculated for both genders, and 
were depicted according to the first, second, third and fourth levels of the ATC 
Classification System.  The suitability of the drug classes and individual 
agents, with reference to the most prevalent comorbidities identified in the 
entire study population, was discussed broadly at each of the selected levels 
of the ATC Classification System.  
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4.5.4.2 Analysis of Medications Prescribed for Depressive 
Disorders  
 
Medications prescribed for the management of Depressive Disorders in 2004, 
were evaluated for the secondary study population as an entirety, and for the 
different age groups, independently.  This evaluation included the following:  
patient distribution for the number of active ingredients prescribed for the 
treatment of Depressive Disorders per patient; mean number of active 
ingredients per patient; prescribing trends of the most prevalent medications 
(according to the third, fourth and fifth levels of the ATC Classification 
System); and general comments regarding the appropriateness of the most 
commonly prescribed agents in depressed patients, relative to the most 
prevalent chronic comorbid disease states identified in each age group.  
(These ‘prevalent chronic comorbid disease states‘ refer to the five most 
frequently diagnosed comorbidities identified per each age group for the entire 
study population).  Female and male prescribing frequencies were contrasted 
at each level of the ATC Classification System.  Furthermore, comparisons 
between the various age groups were made where applicable. 
 
Hypertension, HRT/Menopause, Lipid Disorders and Arthritis were the 
most commonly diagnosed chronic comorbid disease states in the entire 
study population.  The antidepressant prescribing trends for 2004, in adult 
patients (aged 18 years and older) diagnosed with Hypertension, Lipid 
Disorders and Arthritis, were investigated.  Since HRT/Menopause was a 
disease state that was diagnosed in females only, it was decided that the 
fourth most prevalent concomitant disease state, namely, Arthritis would be 
analysed instead.  In addition, seeing as though these comorbidities were not 
prevalent in children and adolescents, it was decided to exclude the 0 to 17 
year age group from these analyses.    
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4.5.5 Statistical Analyses and Methods Employed:  Entire and 
Secondary Study Populations 
 
This section provides an overview of the types of statistical tests used, 
followed by a description of the methods utilised to perform the analyses for 
the entire and secondary study populations. 
 
4.5.5.1 Statistical Analyses 
 
Microsoft Excel® 2003 and Statistica® Release 7 (2005) were utilised for the 
basic statistical analysis of the data.  The Descriptive Statistics Function in the 
Data Analysis Tool Package of Microsoft Excel® was used to perform 
calculations for mean values, 95% confidence intervals of these mean values, 
minimum and maximum values, and standard deviations.  Microsoft Excel® 
and the Basic Statistics and Table Function of Statistica® were used to 
conduct the following inferential tests: 
 
• The t-test and Cohen’s d Statistic 
The one- and two- sample t-tests (at a 95% confidence interval) were used 
to evaluate the differences in means between two groups.  As a result of 
the large sample sizes in this study, the practical significance of the 
differences in sample means, represented by the Cohen’s d Statistic, were 
calculated.  If the calculated d-value was found to be ≤ 0.2, the difference 
was not of practical significance.  Conversely, a calculated d-value > 0.2, 
signified a difference that was practically significant. 
 
• Chi-Square Test of Independence, Test of Goodness-of-fit and Test of 
Homogeneity 
For comparisons based on frequencies for nominal scale data, the Chi-
Square Test of Independence, Test of Goodness-of-fit and Test of 
Homogeneity were used.  Cramér’s V is based on the chi-square statistic 
and was calculated in order to ascertain whether a particular finding was of 
practical significance.  The degrees of freedom (d.f.) is a measure of the 
number of independent pieces of information on which the precision of a 
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parameter estimate is based.  The d.f. for an estimate equals the number 
of observations (values) minus the number of additional parameters 
estimated for that calculation.  For a finding to be practically significant, 
Cramér’s V needs to be equal to or greater than a predetermined value 
associated with a particular number of degrees of freedom.  Table 4.5 
depicts the minimum values for Cramér’s V (required to denote practical 
significance) that are associated with a specified number of degrees of 
freedom.       
 
TABLE 4.5 
MINIMUM VALUES OF CRAMÉR’S V REQUIRED FOR A FINDING TO BE 
SIGNIFICANT, RELATIVE TO DEGREES OF FREEDOM  
 
Degrees of Freedom 
Cramér’s V 
Small Medium Large 
1 * 0.10 ** 0.30 ** 0.50 ** 
2 0.07 0.21 0.35 
3 0.06 0.17 0.29 
 
* When the degrees of freedom equals one, Cramér’s V must be ≥ 0.10 in order to 
depict practical significance.   
** The following ranges for Cramér’s V (when d.f. = 1) are indicative of varying 
degrees of significance:  0.10 – 0.29 (small); 0.30 - 0.49 (medium); and ≥ 0.50 (large). 
 
• Pearson’s Product Moment Coefficient (Correlation Coefficient) 
The correlation coefficient is an interpretation of the extent to which the 
values of two variables are ‘proportional’ to each other.  Proportionality 
denotes a linear relationship between the two variables.  This means that 
the correlation is high if it can be approximated by a straight line that may 
be an upward (depicted by a positive value) or downward (depicted by a 
negative value) slope.  This line is termed the regression or least squares 
line.  The two variables are assumed to be measured on at least interval 
scales.  Therefore, Pearson’s Product Moment Coefficients were useful for 
correlations between the selected age groups analysed in this study.  Rcrit 
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is sample-size dependent and will be indicated where results are reported.   
An Rcrit value ≥ 0.316 is indicative of practical significance (0.316 equals to 
√0.1, which is the recommended r2 value that depicts practical 
significance).  Conversely, Rcrit < 0.316 means that the result is not 
practically significant.       
 
For tests pertaining to statistical significance, a calculated p-value of < .05, 
presented a finding that was significant at the 95% confidence interval.  In 
accordance with the recommended convention, the zero preceding the 
decimal point is omitted because 0 < p ≤ 1.  For the purposes of this study, a 
result that is found to be ‘significant’ is interpreted as being both statistically 
and practically significant.  Furthermore, in instances where statistical 
analyses involving Cramér's V yield ‘large’ values (refer to Table 4.5), findings 
may be reported as being ‘highly’ significant. 
 
4.5.5.2 Methods Employed to Perform Analyses 
 
Table 4.6 outlines the methods employed to conduct the aforementioned 
analyses (described in Sections 4.5.3 and 4.5.4) for the total and secondary 
study populations. 
 
4.6 CONFIDENTIALITY 
 
The Managed Healthcare Company provided each patient with a unique 
patient identification number and therefore no names were used.  The 
patients were not inconvenienced throughout the course of the study and 
stringent ethical considerations were adhered to in order to respect patient 
confidentiality.  This study involved the observation of prescribing patterns 
retrospectively, with no patient involvement.  Therefore, there were no 
alterations made to patient therapy.  The Nelson Mandela Metropolitan 
University’s Human Ethics Committee approved the proposal for this study 
regarding the methods utilised and for the protection of the identities of the 
patients partaking in the study. 
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TABLE 4.6 
DESCRIPTION OF ANALYSES AND METHODS EMPLOYED 
 
Description of Analyses Methods Utilised to Perform Analyses 
1) Basic demographic analyses were 
conducted with regard to age and gender 
distribution for both study populations.   
2) The number of chronic comorbid disease 
states and the mean number of 
comorbidities per depressed patient were 
determined for the entire study 
population. 
3) The most frequently occurring chronic 
disease states that were comorbid with 
Depressive Disorders were identified for 
the total study population.  
4) The number of active ingredients; as well 
as the mean number of active ingredients 
prescribed per patient, was investigated 
for the year, 2004. 
5) The most frequently prescribed 
medications for the treatment of 
Depressive Disorders in the secondary 
study population were identified.   
6) The antidepressant prescribing patterns 
for 2004, in depressed patients 
diagnosed with comorbid Hypertension, 
Lipid Disorders and Arthritis, were 
evaluated.  
• Graphs and tables were constructed in 
Microsoft Excel®. 
• Statistical Analyses performed in Microsoft 
Excel® 2003 and Statistica® Release 7, 2005 
included the use of the following: 
i) Descriptive Statistics Function in the Data 
Analysis Tool Package of Microsoft Excel® was 
used to perform calculations of means relating 
to the ages of the depressed patients; number 
of chronic comorbid disease states; and the 
number of active ingredients.  The 95% 
confidence intervals of these mean values, 
minimum and maximum values, and standard 
deviations were also determined. 
ii) Inferential tests:  the statistical tests described 
in Section 4.5.5.1 were used to investigate 
differences in prevalence patterns of commonly 
diagnosed chronic comorbid disease states, 
antidepressant prescribing trends, and mean 
values, relative to age and gender.  
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4.7 LIMITATIONS OF THE STUDY 
 
The most important limitations of the study are outlined in the following 
section: 
 
• The medications listed in the database were limited to those authorised as 
chronic medications.  This means that over-the-counter medications, such 
as alternative therapies, and acute courses of medications, were not 
recorded.  This is relevant because these agents may interact with other 
co-administered chronic medications. 
• Discussions pertaining to the appropriateness of selected antidepressant 
treatments in depressed patients, diagnosed with prevalent chronic 
comorbid disease states, were not based on observed clinical outcomes 
(since this information was not available) and needed to be confined to 
literature recommendations and the findings of previous studies.   
• According to the medical aid scheme’s chronic authorisation formulary, the 
following antidepressants are the ‘accepted treatments’ (refers to 
medications that ‘will be authorised without requesting additional clinical 
information’) for the management of Depressive Disorders:  fluoxetine, 
citalopram, imipramine, amitriptyline, and dothiepin (Solutio 
Comprehensive PMB Formulary, 2006).  This is relevant because the 
prescribing trends identified in this study would have been influenced by 
the abovementioned formulary recommendations. 
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CHAPTER 5 
RESULTS AND DISCUSSION: 
 
PREVALENCE OF DEPRESSIVE DISORDERS AND THE 
NATURE OF CHRONIC COMORBID DISEASE STATES IN 
DEPRESSED PATIENTS 
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5.1 CHARACTERISTICS OF THE STUDY POPULATION 
 
The study population was selected as described in Sections 4.3 and 4.4 (see 
Methodology).  This section of the results contrasts the following 
characteristics of the study population: 
 
• number of patients;  
• age and gender distribution of patients; and 
• diagnostic classification and prevalence of Depressive Disorders 
relative to age and gender. 
 
5.1.1 Number of Patients  
 
The total number of patients in the study population was 21 1711 and this 
consisted of 71.73% females and 28.27% males.    
 
5.1.2 Age and Gender Distribution of the Study Population 
 
Figure 5.1 depicts the age and gender distribution of the study population.  It 
is evident that the number of patients presenting with Depressive Disorders 
started to increase from the age of 27 years.  This finding is in accordance 
with the results published by Snowdon (2001) following a review of various 
global studies analysing the relationship between age and Depressive 
Disorders (diagnosed using DSM® criteria).  Snowdon reported that the rates 
of Depressive Disorders peak in age groups above 24 years in all instances.   
 
It can further be seen that the majority of the patients, both females (48.53%) 
and males (46.63%), were between the ages of 35 and 54 years.  It was 
found that almost half of the population, namely, 10 160 patients (47.99%) 
were between 35 and 54 years of age.  The remaining age groups consisted 
of the following percentages of patients:  0.68% (0 to 17 years); 8.15% (18 to 
34 years); 23.35% (55 to 64 years) and 19.83% (65 years and older).   
 
1 Entire member database (N = 191 854) = Depressed patients (N = 21 171) + Non-
depressed patients (N = 170 683)  
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FIGURE 5.1  
AGE AND GENDER DISTRIBUTION OF THE STUDY POPULATION (N = 21 171) 
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The highest prevalence of Depressive Disorders was evident amongst both 
females and males between the ages of 35 and 54 years (91.17%).   
 
It is noteworthy to mention that the study population was a sample (consisting 
of all of the depressed patients only) of the entire member database.  The age 
distribution of depressed patients (in other words, the entire study population) 
and all of the other patients in the larger population (non-depressed patients) 
are compared in Figure 5.2.   
 
0-17 18-34 35-54 55-64 ≥ 65
Depressed Study Population * 0.68 8.15 47.99 23.35 19.83
Non-depressed Population ** -8.6 -6.95 -39.86 -23.57 -21.03
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FIGURE 5.2 
AGE DISTRIBUTION OF DEPRESSED AND NON-DEPRESSED PATIENTS (N = 21 171 
AND 170 683, RESPECTIVELY) ACCORDING TO SELECTED AGE GROUPS 
 
*  This study population includes all of the patients with Depressive Disorders. 
**  The non-depressed population refers to patients without Depressive Disorders. 
 
It was established that, except for patients aged 0 to 17 years, the incidence 
of Depressive Disorders in the depressed study population was in accordance 
with that in the non-depressed population.  Furthermore, the age-related 
difference across the adult* age groups (includes the 18 to 34, 35 to 54, 55 to 
64 and 65 years and older age groups) between the depressed study 
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population (21 028** patients) and the non-depressed population of             
156 010*** patients, was not significant (Chi² = 215.27, d.f. = 3, p = < .0005, 
Cramér's V = 0.03).  Albeit these similarities, Figure 5.2 shows that the 
greatest difference between the age distribution of depressed and non-
depressed patients, occurs in the 35 to 54 year age group (approximately 8% 
higher for the depressed study population). 
* The adult age groups include those patients aged 18 years and older; therefore the 0 
to 17 year age group is excluded. 
** [Depressed adult population = 21 171 – 143 = 21 028] (Total number of depressed 
patients – Total number of depressed patients aged 0 to 17 years) 
*** [Non-depressed adult population = 170 683 – 14 673 = 156 010] (Total number of 
non-depressed patients – Total number of non-depressed patients aged 0 to 17 years) 
 
Figure 5.3 shows the representation of depressed patients in the age groups 
selected for this study.  It was noted that, except for depressed patients aged 
0 to 17 years, there were a greater number of females than males in each of 
the age groups.  However, this gender-related difference was not significant 
(Chi² = 89.16, d.f. = 4, p = <.0005, Cramér's V = 0.06).        
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Table 5.1 outlines the descriptive statistics for the ages of the depressed 
patients.  The mean age of the study population was calculated to be 52.80 
years.  The mean ages for females and males did not differ significantly at the 
99% confidence interval (t-test = 3.58, p < .1; Cohen’s d = 0.05). 
 
TABLE 5.1 
DESCRIPTIVE STATISTICS FOR THE AGES OF THE DEPRESSED 
PATIENTS (N = 21 171) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD * 
Females 
(n = 15 185) 
53.02 10 98 13.88 
Males  
(n = 5 986) 
52.25 7 97 14.74 
All Patients 
(N = 21 171) 
52.80 7 98 14.14 
 
* SD is the standard deviation. 
 
5.1.3 Diagnostic Classification and Prevalence of Depressive Disorders 
Relative to Age and Gender 
 
Table 5.2 outlines the diagnostic classification of Depressive Disorders in the 
various age groups (0 to 17 years; 18 to 34 years; 35 to 54 years; 55 to 64 
years and 65 years and older).  Triant (2002) stated that the ‘hallmark of 
Depressive Disorders’ is a mood change that results in extreme emotional 
distress and impairs the rhythm of daily activities.  It is evident from Table 5.2 
that Depression was the most commonly occurring Depressive Disorder in all 
of the age groups.  Prevalence percentages for Depression exceeded 75% for 
females and males in each age group.   
  
 
 
 
 154
TABLE 5.2 
DIAGNOSTIC CLASSIFICATION AND PREVALENCE OF DEPRESSIVE 
DISORDERS IN THE SELECTED AGE GROUPS (N = 21 171) 
 
Depressive 
Disorders 
ICD-10 
Code 
Gender * 
 
Prevalence Percentage (%) in Each Age Group 
0-17 yrs 18-34 yrs 35-54 yrs 
 
55-64 yrs ≥ 65 yrs 
 
nf ** = 55 nf = 1 193 
 
nf = 7 369 
 
nf = 3 582 
 
nf = 2 986 
 
nm *** = 88 nm = 533 nm = 2 791 nm = 1 361 nm = 1 213
Depression F32.9 
F 78.18 81.56 87.83 91.62 90.82 
M 84.09 80.11 88.07 89.35 92.33 
Depression  
(Major) F32.2 
F 21.82 29.25 19.68 19.68 13.04 
M 18.18 32.27 19.17 19.17 15.06 
Recurrent 
Depression F33.2 
F 5.45 3.52 4.29 4.29 5.22 
M 2.27 2.81 3.65 3.65 6.10 
Mood Affective  
Disorder F38.8 
F 7.27 0.75 0.65 0.36 0.33 
M 0 0.56 0.61 0.44 0.41 
Dysthymia F34.1 
F 0 0.17 0.45 0.36 0.44 
M 0 0 0.57 0.37 0.16 
Depression  
(Mild) F32.0 
F 0 0.42 0.50 0.47 0.30 
M 0 0.56 0.21 0.22 0.16 
Depression 
with Psychosis F32.3 
F 0 0.34 0.35 0.31 0.47 
M 0 0.75 0.36 0.37 0.16 
Affective  
Psychosis F39 
F 0 0 0.09 0.06 0.13 
M 0 0 0.07 0.15 0.25 
Depression  
(Post-natal) F53.0 
F 0 0.34 0.35 0.31 0.47 
M 0 0 0 0 0 
Neurotic  
Depression F34.1 
F 0 0 0 0.03 0.07 
M 0 0 0 0.07 0 
Cyclothymia F34.0 
F 0 0.08 0.01 0 0 
M 0 0 0 0 0 
 
*  F = Females and M = Males. 
** nf = Number of females per age group.  
*** nm = Number of males per age group. 
 
On the whole, the prevalence of Depression in females increased with an 
increase in age.  However, there was a slight decrease in prevalence from 
91.62% in females between the ages of 55 and 64 years to 90.82% in females 
aged 65 years and older.  In Jorm’s (2000) review of several large-scale adult 
epidemiological surveys, it was found that many studies showed an initial 
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increase in the prevalence of Depression across the age groups, followed by 
a decrease (for both genders).  Therefore, the prevalence of Depression 
amongst females in this study followed a similar trend to the results of multiple 
studies reviewed by Jorm (2000).  The prevalence pattern for Depression in 
males was found to firstly decrease slightly in patients aged 18 to 34 years, 
and then increase thereafter with an increase in age.   
 
It is noteworthy to mention that if Depression was the only Depressive 
Disorder considered in this study, then, overall (with the exception of slight 
decreases in prevalence percentages in females aged 65 years and older and 
males aged 18 to 34 years), the prevalence trend observed in individuals over 
18 years of age would be in agreement with the results of several other 
studies that have found a positive relationship between the prevalence of 
Depression and age (Mirowsky et al., 1992 [America]); Pillay et al., 1999 
[South Africa]); and Schnittker, 2005 [America]).  
 
For the entire member database (N = 191 854), the prevalence of Depressive 
Disorders was 11.88%.  More specifically, the prevalence percentages for the 
individual age groups were as follows:  0.97% (0 to 17 years); 12.70% (18 to 
34 years); 12.99% (35 to 54 years); 10.94% (55 to 64 years); and 10.47% (65 
years and older age group).  Figure 5.4 depicts the prevalence pattern for 
Depressive Disorders, relative to age and gender, in the depressed study 
population.  With regards to age, the results of this study are in agreement 
with Jorm’s (2000) findings, that is, that there is an initial increase (0 to 54 
years in this case) in the prevalence of Depressive Disorders across the age 
groups, followed by a decrease (after 54 years of age).  The literature 
contains many conflicting views regarding the relationship between age and 
the prevalence of Depressive Disorders.  There are, therefore, many 
deductions that have been made by other researchers in this regard, that may 
not concur with the age prevalence pattern observed in this study.  Schnittker 
(2005), for example, conducted a study in 22 293 Americans over the age of 
50 years and found that there was a steep incline in the prevalence of 
Depressive Disorders in late life; however, it is clear that there is in fact a 
decline in this particular study.  An earlier American study conducted by 
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Mirowsky and Ross (1992), in turn, found that middle-aged individuals were 
the least depressed and that those over 80 years were definitely the most 
depressed (sample size of 2 840 patients).  Yet another study, termed the 
ECA study (approximately 20 000 Americans aged 18 years or older) found 
that the rates of Depressive Disorders decreased with age (Narrow et al., 
2002).  As depicted in Figure 5.4, this study found middle-aged individuals to 
be the most depressed and those over 80 years of age (although not the least 
depressed as was the case in the ECA study) fell into the age group that 
exhibited only the third most prevalent number of depressed individuals.  
These findings are thus in conflict with those published by Mirowsky and Ross 
(1992) and Narrow and others (2002).  On the other hand, the results of 
Snowdon’s reviews (mentioned in Section 5.1.2) regarding the age ranges 
during which the prevalence of Depressive Disorders peak, are in closer 
agreement with the findings of this study.   
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FIGURE 5.4  
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It must be taken into account that South Africa is a middle income, developing 
country and it has been suggested that the prevalence of mental illnesses 
amongst South Africans is linked to the political and social history of the 
country.  For example, apartheid, high poverty and unemployment rates 
(estimated to be 30% and 50%, respectively) and the burden of HIV/AIDS 
amongst South Africans, all have a profound impact on mental health.  (Triant, 
2002.) Therefore, prevalence ranges will vary depending on the location and 
design of the study.  It can be expected that the prevalence patterns for 
Depressive Disorders amongst Americans, for instance, would differ from the 
ones evident in South Africa because of the political, social and medical 
differences (in terms of the higher prevalence of fatal disease states in South 
Africa) between the two countries.  Then again, even studies performed in the 
same countries have yielded inconsistent results (refer to the results of 
Mirowsky and Ross [1992]; Narrow and others [2002]; and Schnittker [2005], 
which were mentioned earlier in this section).  Thus, it should be considered 
that the trend identified in this particular study would be representative of the 
member base of the database under investigation. 
 
Conversely, the relationship between gender and prevalence of Depressive 
Disorders has been confidently defined and is much less controversial than 
the independent link between Depressive Disorders and age.  Except for the 0 
to 17 year age group, all of the other age groups yielded gender prevalence 
rates that were consistent with the results of many other previous studies.  
The literature states that the prevalence of Depressive Disorders is twice as 
high amongst females as their male depressed counterparts (Kamlet et al., 
1995; Kornstein, 2001; Kessler, 2003).  All of these studies were performed in 
individuals over the age of 18 years, which might have suggested a difference 
with regards to the gender relationship observed in younger individuals.  With 
the exception of the youngest age group of 0 to 17 years, the prevalence of 
Depressive Disorders in all of the age groups was approximately twice as high 
in females as in males.  In fact, the mean female to male prevalence ratio 
(excluding the 0 to 17 year age group) was calculated to be 2.57:1.  Figure 5.4 
further illustrates that the female and male populations followed similar trends 
with regards to the prevalence of Depressive Disorders and age.    
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5.2 EPIDEMIOLOGICAL ANALYSIS OF COMORBID DISEASE STATES 
IN DEPRESSED PATIENTS 
 
This section analyses the number of chronic comorbid disease states per 
depressed patient; and provides an overview of the most prevalent disease 
states co-existing with Depressive Disorders in the study population.  
Thereafter, each age group selected for the study will be analysed individually 
in terms of the following:  
 
• age and gender distribution; and 
• comorbidity analysis.  
 
5.2.1 Number of Chronic Comorbid Disease States per Depressed
 Patient 
 
Many studies have shown that the prevalence of multiple chronic comorbid 
disease states is on the rise.  For example, a Canadian study performed in 
660 females (mean age of 54.9 years) and 320 males (mean age of 58.2 
years) determined that 90% of the study population had more than one 
chronic disease state (Fortin, Bravo, Hudon, Vanasse & Lapointe, 2005).  In 
the year 2000, it was also estimated that 57 million Americans had more than 
one chronic disease state and that by 2020, this representation would 
increase to approximately 81 million (Anderson, 2002).  In addition, research 
has consistently shown that there is a bidirectional relationship between 
Depressive Disorders and numerous chronic medical disease states.  On the 
one hand, some studies have shown that depressed patients are more 
susceptible to the development of comorbid disease states than their non-
depressed counterparts (Barbee, 1998; Krishnan et al., 2000; Lespẻrance et 
al., 2000; Ohira et al., 2001; van Manen et al., 2002; Katon, 2003; Golden et 
al., 2004; Cankurtaran et al., 2005; Chapman et al., 2005).  For example, a 
study focusing on the existence of comorbidities with Depressive Disorders, 
determined the prevalence of any of eight chronic disease states (Arthritis, 
Hypertension, Diabetes Mellitus, CVD, Neurological Disease State, Lung 
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Disease, Cancer and Physical Handicap) to be 65% to 71% in depressed 
patients (Wells et al., 1991).  On the other hand, other studies deduced that 
individuals with chronic disease states had an elevated risk towards the 
development of a future Depressive Disorder.  (AHCPR, 1993; Lespẻrance et 
al., 1996; McCoy, 1996; Patten, 2001; Bosworth et al., 2003; Carnethon et al., 
2003; Kanner, 2003; Katon, 2003; Yates et al., 2004; Chapman et al., 2005; 
Patten et al., 2005).  For instance, Hirschfeld (2001) analysed various studies 
to determine the prevalence of Depressive Disorders in patients with common 
chronic disease states (such as Cancer, MI and Diabetes Mellitus) and 
predicted that 20% to 50% of these patients would develop a future 
Depressive Disorder. 
 
The number of chronic comorbid disease states per depressed patient in the 
study population was determined.  Table 5.3 and Figure 5.5 present the 
distribution percentages of patients diagnosed solely with one or more 
Depressive Disorders (number of chronic comorbid disease states equals to 
0); and patients who had a single or multiple co-existing disease states, 
according to age and gender, respectively. 
 
TABLE 5.3 
DISTRIBUTION OF THE NUMBER OF CHRONIC COMORBID DISEASE 
STATES PER DEPRESSED PATIENT IN THE SELECTED AGE GROUPS 
(N = 21 171) 
  
Age Group Number of Chronic Comorbid Disease States Per Patient Total (N = 21 171)0 1 2 3-5 6-9 ≥ 10 
0-17 yrs 
n 15 59 36 33 0 0 143 
% 10.49 41.26 25.17 23.08 0 0 100 
18-34 yrs 
n 293 611 422 361 21 18 1 726 
% 16.98 35.40 24.45 20.92 1.22 1.04 100 
35-54 yrs 
n 593 2 543 2 449 3 695 793 87 10 160 
% 5.84 25.03 24.10 36.37 7.81 0.86 100 
55-64 yrs 
n 86 663 919 2 283 835 157 4 943 
% 1.74 13.41 18.59 46.19 16.89 3.18 100 
≥ 65 yrs 
n 36 321 633 1 913 1 058 238 4 199 
% 0.86 7.64 15.08 45.56 25.20 5.67 100 
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Table 5.3 shows that there was a decrease in the percentage of depressed 
patients diagnosed with one or two chronic comorbid disease states across 
the age groups.  Conversely, there was an increase in the percentage of 
depressed patients diagnosed with six to nine or ten or more comorbidities 
with an increase in age.  Therefore, it is apparent that the incidence of chronic 
comorbid disease states increased with an increase in age.  This finding was 
significant (Chi² = 3 305.13, d.f. = 20, p= < .0005, Cramér's V = 0.23). 
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FIGURE 5.5 DISTRIBUTION OF THE NUMBER OF CHRONIC COMORBID DISEASE 
STATES PER FEMALE AND MALE DEPRESSED PATIENT (N = 21 171) 
 
It was noticeable that 92.52% of females and 94.29% of males (95.17% taking 
the genders together) had at least one chronic disease state co-existing with a 
Depressive Disorder.  Furthermore, the majority of depressed patients 
(71.70% of females and 70.62% of males) had between one and four 
comorbidities.  It was calculated that, in addition to Depressive Disorders, 
approximately a quarter (23.47%) of the patients were diagnosed with five or 
more concomitant disease states.  In terms of the distribution of patients 
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diagnosed with more than three co-existing disease states, there was a 
decline in the percentage of patients with an increase in the number of chronic 
disease states.  In Figure 5.5, the column representing more than 16 chronic 
comorbid disease states per depressed patient included all of those patients 
who had between 17 and 22 comorbidities (22 being the maximum number of 
co-existing disease states identified).  The distribution of females and males 
did not differ significantly in terms of the number of chronic comorbid disease 
states per patient (Chi² = 109.72, d.f. = 5, p = < .0005, Cramér's V = 0.07).  
The prevalence percentages pertaining to the number of comorbidities in 
patients of different ages will be discussed under the individual age groups 
later in this study. 
 
The descriptive statistics for the number of chronic comorbid disease states 
per depressed patient were calculated.  The results for females and males, 
individually and collectively, are summarised in Table 5.4.   
 
TABLE 5.4 
DESCRIPTIVE STATISTICS FOR THE NUMBER OF CHRONIC COMORBID 
DISEASE STATES PER DEPRESSED PATIENT IN THE STUDY 
POPULATION (N = 21 171) 
 
 NUMBER OF CHRONIC COMORBID DISEASE STATES 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 15 185) 
3.36 0 20 2.46 
Males  
(n = 5 986) 
2.99 0 22 2.26 
All Patients 
(N = 21 171) 
3.25 0 22 2.41 
 
It was found that, in addition to one or more Depressive Disorders, patients 
had a mean of approximately three comorbid disease states.  It was 
previously mentioned in the literature (see Section 2.5) that depressed 
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patients were diagnosed with a mean of two chronic medical disease states 
(Katon, 2003).  This is slightly less than the mean identified in this study, 
however, it should be noted that psychiatric comorbidities, such as Anxiety 
Disorders, for example, were also taken into consideration in this study.  The 
mean number of chronic comorbid disease states was greater for females 
than for males (mean difference of 0.37), but this gender-related difference 
was not significant (t-test = 10.15, p < .1; Cohen’s d = 0.15). 
 
5.2.2 Overview of the Most Prevalent Chronic Comorbid Disease States 
in the Study Population  
 
The most commonly occurring chronic comorbid disease states in the entire 
depressed study population are outlined in Figure 5.6. 
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FIGURE 5.6 MOST PREVALENT CHRONIC COMORBID DISEASE STATES IN THE 
STUDY POPULATION (N = 21 171)  
 
Figure 5.7 presents the co-existing chronic disease states found to be most 
prevalent in the total study population of depressed females.  Figure 5.8, in 
turn, illustrates the relationship between age and the prevalence of the most 
frequently occurring comorbidities in depressed females. 
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FIGURE 5.7 MOST PREVALENT CHRONIC COMORBID DISEASE STATES IN 
DEPRESSED FEMALES (n = 15 185) 
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FIGURE 5.8 
PREVALENCE OF CHRONIC COMORBID DISEASE STATES RELATIVE TO AGE  
IN DEPRESSED FEMALES (n = 15 185) 
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According to Figure 5.8, except for HRT/Menopause, there was an increase 
in the prevalence of chronic comorbid disease states in depressed females 
with an increase in age.  In particular, the observed correlations (for age and 
the prevalence of specific chronic comorbid disease states in females) of 
0.983, 0.993, 0.981 and 0.988 for Hypertension, Arthritis, Lipid Disorders 
and Hypothyroidism, respectively, were all significant (For α = .05 and n = 5, 
rCRIT = 0.88).  In addition, it was discovered that the prevalence of the 
aforementioned chronic comorbidities in females increased by the following 
percentages per year:  1.06% [Hypertension]; 0.44% [Arthritis]; 0.41% [Lipid 
Disorders]; and 0.25% [Hypothyroidism].  This is in accordance with the 
findings of numerous other studies conducted throughout the world, that have 
identified a positive relationship between age and the prevalence of chronic 
disease states (van den Akker, Buntinx, Metsemakers, Roos & Knottnerus, 
1998 [Europe]; Australian Institute of Health and Welfare, 2001 [Australia];  
van Manen, Bindels, IJzermans, van der Zee, Bottema & Schadé, 2001 
[Amsterdam]; Wolff, Starfield & Anderson, 2002 [America]; Fortin et al., 2005 
[Canada]; Harpole et al., 2005 [Canada]; Lovell, 2006 [America]).   
 
The findings of the Women’s Health Initiative study (2002), conducted in       
10 000 females between 50 and 79 years of age, who were taking estrogen 
and progestin treatment for one year (Rossouw et al., 2002), had a global 
impact on the prescribing of HRT and prompted numerous organisations to 
consider safety issues with respect to the use of HRT in postmenopausal 
women.  The American College of Obstetricians and Gynaecologists and the 
North American Menopause Society, in particular, recommend HRT for the 
treatment of menopausal symptoms, however, advise against the prolonged 
use of this therapy.  In addition to this, both organisations do not recommend 
that HRT be used solely for the prevention of CVD or Osteoporosis.  (Berg & 
US Preventive Services Task Force, 2002.) Given that females over 65 years 
of age are less likely to be experiencing menopausal symptoms (when 
compared with the 55 to 64 year age group), this could possibly explain why 
the use of HRT amongst females aged 65 years and older was lower than the 
use in females between 55 and 64 years of age.   
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The chronic comorbid disease states identified to be most prevalent in the 
depressed male study population are depicted in Figure 5.9.  Thereafter, the 
relationship between age and the most commonly occurring co-existing 
chronic disease states in depressed males is outlined in Figure 5.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
P
re
va
le
nc
e 
Pe
rc
en
ta
ge
 (%
)
Chronic Comorbid Disease States
Prevalence in Males (%) 53.99 30.25 22.34 14.80 14.63
Hyper -     
tension
Lipid       
Disorders
Thrombo-
embolic 
Diabetes 
Mellitus
Allergic 
Rhinitis
 
FIGURE 5.9 MOST PREVALENT CHRONIC COMORBID DISEASE STATES IN 
DEPRESSED MALES (n = 5 986) 
 
According to Figure 5.10, the prevalence of Allergic Rhinitis in the male 
study population was found to have decreased with age.  The observed 
negative correlation of 0.935 was significant (which may be interpreted as a 
proportional decline in the prevalence of Allergic Rhinitis with an increase in 
age) and the prevalence of Allergic Rhinitis in males was calculated to have 
decreased by 0.53% per year (For α = .05 and n = 5, rCRIT = 0.88).  This 
finding is in agreement with previous research that has established the 
prevalence of Allergic Rhinitis to be higher amongst younger individuals 
(Australian Institute of Health and Welfare, 2001; Dahl, Andersen, Chivato, 
Valovirta & de Monchy, 2004).   
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FIGURE 5.10 
PREVALENCE OF CHRONIC COMORBID DISEASE STATES RELATIVE TO AGE  
IN DEPRESSED MALES (n = 5 986) 
 
Conversely, it was clear that there was a rise in the prevalence of 
Hypertension and Thrombo-embolic Prophylaxis in males, with an 
increase in age.  The incline across the age groups yielded significant positive 
correlation values for both Hypertension (0.952) and Thrombo-embolic 
Prophylaxis (0.979) (For α = .05 and n = 5, rCRIT = 0.88).  Except for a 
marginal decrease in the 65 years and older age group (difference of 0.46% 
relative to the 55 to 64 year age group), the prevalence of Diabetes Mellitus 
also increased with age.  Lipid Disorders occurred most frequently in 
depressed males aged 55 to 64 years.  The prevalence of Lipid Disorders 
increased with age in patients aged 0 and 64 years.  Subsequently, there was 
a decline (2.68% less than the 55 to 64 year age group) in the elderly 
depressed population.  On the whole, however, there was a rise in the 
prevalence of Hypertension, Lipid Disorders, Thrombo-embolic Prophylaxis 
and Diabetes Mellitus across the age groups.   
 
The results shown in Figures 5.6, 5.7 and 5.9 are consistent with many other 
studies conducted on a global level.  For example, Fortin and others (2005) 
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found the following disease states to be most prevalent amongst a Canadian 
study population with multiple chronic disease states:  Hypertension, 
Hyperlipidaemia and Rheumatologic Disease States.  Furthermore, the 
literature presents numerous positive correlations between Depressive 
Disorders and the following disease states:  Hypertension (Jonas et al., 
1997; Dorsey et al., 2002; Kessler et al., 2003b; Meyer et al., 2004; 
Cankurtaran et al., 2005; Patten et al., 2005);  Arthritis (Marsh, 1997; Kessler 
et al., 2003b);  Menopause (Cohen et al., 2006); Diabetes Mellitus (Lustman 
et al., 1997; Kovacs et al., 1997; Anderson et al., 2001; Pincus et al., 2001; 
Kanner, 2003; Cankurtaran et al., 2005); Thyroid Disorders (Burmeister et 
al., 2001; Patten et al., 2005; Thomsen et al., 2005; Gülseren et al., 2006); 
Allergic Rhinitis (Cuffel et al., 1999); Lipid Disorders (Kinder et al., 2004; 
Nakao et al., 2004; Petrlova et al., 2004) and Thrombo-embolic Prophylaxis 
(Frasure-Smith et al., 1995; Musselman et al., 1998; Krishnan et al., 2000; 
Nemeroff et al., 2000).   
 
Natural menopause is said to occur between 40 and 60 years of age 
(Dvornyk, Long, Liu, Zhao, Shen, Recker & Deng, 2005).  Seeing as though 
40.95% of the population consisted of females between the ages of 40 and 60 
years, it was not surprising to have identified HRT/Menopause as one of the 
most frequently diagnosed chronic conditions in females for this study.  The 
most prevalent chronic comorbid disease states in each age group will be 
discussed in more detail in the section to follow.   
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5.3 Age Group Analysis:  0 to 17 Years 
 
5.3.1 Age and Gender Distribution of Depressed Patients 
 
Table 5.5 outlines the age and gender analysis of the 143 patients between 0 
and 17 years of age.  It was noted that the majority of females were 17 years 
of age (30.91%) and that most of the males were 15 years of age (21.59%).  A 
total of 104 of the patients (72.73%) were between the ages of 14 and 17 
years.   
 
TABLE 5.5 
DESCRIPTIVE STATISTICS FOR THE AGES OF THE PATIENTS:  AGE 
GROUP 0 TO 17 YEARS (n = 143) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 55) 
15.29 10 17 1.73 
Males  
(n = 88) 
14.15 7 17 2.40 
All Patients 
(n = 143) 
14.59 7 17 2.23 
 
Various studies have shown that the prevalence rates of Depressive 
Disorders in children and adolescents range between 0.2% and 1.8% (mean 
equals to 1%) (Cohen, Cohen, Kasen, Velez, Hartmark, Johnson, Rojas, 
Brook & Streuning, 1993; Costello, Angold, Burns, Stangl, Tweed, Erkanli, & 
Worthman, 1996; Ford, Goodman & Meltzer, 2003).  The 0 to 17 year age 
group consisted of 0.68% of the study population, which concurs with the 
prevalence rates for Depressive Disorders in children and adolescents as 
described in the literature.  Furthermore, when the expected mean prevalence 
percentage of 1% was compared with the observed rate of 0.68%, it was 
found that the difference was not significant (Chi² = 22.52, d.f. = 1, p = <.0005, 
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Cramér's V = 0.03).  A study performed in Britain by Ford and others (2003) 
was conducted in 10 438 children and the researchers estimated that one in 
ten children suffer from at least a single DSM-IV® disorder that is likely to 
require treatment. 
 
As mentioned previously, patients aged 0 to 17 years constituted the only age 
group that was not in agreement with previous studies regarding the 
relationship between gender and prevalence of Depressive Disorders.  This 
age group consisted of 38.46% females and 61.54% males (female to male 
ratio is 0.63:1), which indicated an almost inverse gender relationship to the 
predictable trends observed in the other age groups (mean for female to male 
ratio for depressed patients aged 18 years and older is 2.57:1).  When a 50:50 
distribution for both genders was assumed, it was deduced that the 
dominance of males over females, was significant (although small) for the 0 to 
17 year age group (Chi² = 7.62, d.f. = 1, p = .006; Cramér's V = 0.23).  There 
has been limited research regarding the gender differences in child and 
adolescent Depressive Disorders.  It has been suggested that the gender 
differences recognised in adults may also be applied to children and 
adolescents (Weller, Kloos, Kang & Weller, 2006).  Studies have found that 
the prevalence of Depressive Disorders is higher amongst girls than boys 
(Costello, Mustillo, Erkanli, Keeler & Angold, 2003; Maharajh, Ali & Konings, 
2006).  These same studies also deduced that there are more girls over 12 to 
13 years of age who suffer from clinical Depressive Disorders than boys of the 
corresponding ages.  Although there were a greater number of depressed 
boys than there were depressed girls in the 0 to 17 year age group, it is 
noteworthy that the prevalence of Depressive Disorders amongst girls over 13 
years of age was higher (87.27%) than in boys over 13 years of age (63.63%).  
These findings are therefore in agreement with the results of the 
aforementioned studies.   
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5.3.2 Comorbidity Analysis 
 
5.3.2.1 Number of Chronic Comorbid Disease States per Depressed  
 Patient 
 
Table 5.6 provides a representation of the descriptive statistics for the number 
of chronic disease states co-existing with Depressive Disorders per patient in 
the 0 to 17 year age group.  Depressed young males were diagnosed with a 
significantly greater mean number of chronic comorbidities than their female 
counterparts (t-test = 1.75, p < .1; Cohen’s d = 0.294). 
   
TABLE 5.6 
DESCRIPTIVE STATISTICS FOR THE NUMBER OF CHRONIC COMORBID 
DISEASE STATES PER DEPRESSED PATIENT IN THE 0 TO 17 YEAR 
AGE GROUP (n = 143) 
 
 NUMBER OF CHRONIC COMORBID DISEASE STATES 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 55) 
1.51 0 4 1.14 
Males  
(n = 88) 
1.86 0 5 1.21 
All Patients 
(N = 143) 
1.73 0 5 1.19 
 
The distribution of depressed patients, with regard to the number of chronic 
comorbidities, is depicted in Table 5.7.  Only 10.49% of the young patients 
had a Depressive Disorder as their sole diagnosis.  It was thus established 
that 89.51% of the patients had at least one more chronic disease state in 
addition to a Depressive Disorder.  The majority of patients aged 0 to 17 years 
(41.26%) had one co-existing chronic disease state.  Just over a quarter of the 
depressed patients (25.17%) had two comorbidities and 23.08% of them had 
three or more chronic co-existing disease states.  It was noted that 4.55% of 
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depressed males in this young age group were diagnosed with five 
comorbidities.  The distribution of the young patients, regarding the number of 
co-existing chronic disease states, did not differ significantly for females and 
males (Chi² = 6.75, d.f. = 4, p = .240). 
   
TABLE 5.7 
NUMBER OF CHRONIC COMORBID DISEASE STATES PER PATIENT:  
AGE GROUP 0 TO 17 YEARS 
 
NUMBER OF CHRONIC 
COMORBID DISEASE STATES 
NUMBER OF PATIENTS (%) 
FEMALES MALES BOTH GENDERS 
0 9 6 15 
  (16.36) (6.82) (10.49) 
1 24 35 59 
  (43.64) (39.77) (41.26) 
2 11 25 36 
  (20) (28.41) (25.17) 
3 7 13 20 
  (12.73) (14.77) (13.99) 
4 4 5 9 
  (7.27) (5.68) (6.29) 
5 0 4 4 
  (0) (4.55) (2.80) 
TOTAL NUMBER OF PATIENTS  55 88 143 
(%) (100) (100) (100) 
 
5.3.2.2 Most Prevalent Chronic Comorbid Disease States 
 
The comorbidities presenting most frequently in female patients between 0 
and 17 years of age are shown in descending order (in terms of prevalence 
percentage) in Table 5.8.  The most frequently diagnosed chronic comorbid 
disease states in young depressed females were Allergic Rhinitis, Asthma, 
ADHD, Epilepsy and Acne.  The percentage column in Table 5.8 does not 
add up to 100% because it must be taken into account that the patients may 
have more than one chronic co-existing disease state.   
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TABLE 5.8  
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
FEMALE PATIENTS AGED 0 TO 17 YEARS (n = 55) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
    FEMALE PATIENTS WITH 
    COMORBID DISEASE STATES 
    (n = 55) 
1 Allergic Rhinitis 34.55 
2 Asthma 20 
3 
Attention Deficit and Hyperactivity 
Disorder (ADHD) 12.73 
3 Epilepsy  12.73 
3 Acne 12.73 
4 Anxiety Disorders 5.45 
4 Eczema 7.27 
4 Bipolar Disorders  5.45 
4 Hypothyroidism 5.45 
5 Urinary Incontinence 3.64 
5 Tourette Syndrome 3.64 
5 Diabetes Mellitus 3.64 
 
Table 5.9 summarises the most frequently diagnosed chronic comorbid 
disease states in depressed males between the ages of 0 and 17 years.   
 
TABLE 5.9  
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
MALE PATIENTS AGED 0 TO 17 YEARS (n = 88) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
   MALE PATIENTS WITH 
   COMORBID DISEASE STATES 
   (n = 88) 
1 Allergic Rhinitis 46.59 
1 ADHD 46.59 
2 Asthma 29.55 
3 Epilepsy  11.36 
4 Acne 6.82 
5 Psychotic Disorders 4.55 
 
The disease states that were found to be most prevalent in males were similar 
to those identified in females.  For example, in males, Allergic Rhinitis, 
Asthma, ADHD, Epilepsy and Acne also featured along with the most 
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common disease states co-existing with Depressive Disorders.  Allergic 
Rhinitis and ADHD presented most often in depressed males, with each 
disease state yielding a prevalence of 46.59%.  More specifically, it was 
calculated that either one or both of these chronic disease states were 
diagnosed in 75% of depressed males aged 0 to 17 years.  This observation 
was highly significant, when the distribution for the number of males 
diagnosed with ADHD or Allergic Rhinitis, relative to the corresponding 
number of males not affected by either disease state, was assumed to be 
50:50 (Chi² = 22, d.f. = 1, p = < .0005, Cramér's V = 0.50). 
 
Figure 5.11 contrasts the concomitant disease states evident in depressed 
female and male patients in the age group 0 to 17 years.  Females had a 
greater number of multiple disease states with identical prevalence rates 
when compared to males.  For example, the fifth most prevalent chronic co-
existing disease state in males was occupied by Psychotic Disorders, 
whereas in females there were three disease states ranked fifth, namely:  
Urinary Incontinence, Tourette Syndome and Diabetes Mellitus.   
 
ADHD was diagnosed in a significantly greater number of male depressed 
patients when compared with females (Chi² = 17.41, d.f. = 1, p = < .0005, 
Cramér's V = 0.35).  This disease state has been found to occur more readily 
in males than females and female to male ratios have ranged from 1:2 to 1:9, 
depending on the type of ADHD present (DSM-IV-TR®, 2000).  The female to 
male ratio for this study was 1:3.66 and thus, presents a gender-difference 
ratio that falls within the range stipulated by the DSM-IV-TR®, 2000.  Anxiety 
Disorders were prevalent in depressed females and were ranked as the 
seventh most commonly occurring concomitant disease states in depressed 
males.  It is well-known that Depressive Disorders commonly co-exist with 
Anxiety and Disruptive Behavioural Disorders (Avenevoli, Stolar, Li, Dierker, 
Ries Merikangas & 2001).  Similarly, both Anxiety Disorders and ADHD have 
been associated with a higher prevalence of comorbid Depressive Disorders 
(Angold, Erkanli & Costello, 1999; Cuffe, Moore & McKeown, 2005).  
However, researchers have speculated that this might not have been 
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accurately reported since the symptoms of both Depressive Disorders and 
ADHD are known to overlap (de Mesquita & Gilliam, 1994).   
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FIGURE 5.11 
PREVALENCE OF CHRONIC COMORBID DISEASE STATES (ACCORDING TO GENDER) 
IN DEPRESSED PATIENTS BETWEEN THE AGES OF 0 AND 17 YEARS (n = 143) 
 
The prevalence of ADHD in America and Australia has been estimated to be 
between 1.7% and 16% in childhood and adolescence (six to 17 years) 
(Sawyer, Arney, Baghurst, Clark, Graetz, Kosky, Nurcombe, Patton, Prior, 
Raphael, Rey, Whaites & Zubrich, 2001).  More recently, the American 
National Health Interview Survey, which involved 10 367 children between the 
ages of four and 17 years, determined the prevalence of ADHD to be 1.77% in 
females and 4.19% in males (Cuffe et al., 2005).  It should be considered that 
Cuffe and others did not distinguish between depressed and non-depressed 
patients.  On comparison of the results of this study (for depressed males) 
and the findings of Cuffe and others (2005), regarding the prevalence of 
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ADHD in young males, it was apparent that the percentage prevalence 
calculated in this study was more than ten times greater than the 
corresponding percentage observed in the American National Health Interview 
Survey (46.59% for this study versus 4.19%).  Therefore, the co-existence of 
a Depressive Disorder could have possibly be an influencing variable in terms 
of the higher prevalence of ADHD identified in this study, relative to the 
American study.    
 
Acne was identified as a common disorder in both female and male patients 
in this age group.  Acne is a highly prevalent disorder in adolescents (Ayer & 
Burrows, 2006).   
 
Allergic Rhinitis was the most frequently diagnosed comorbidity in both 
genders.  The International Study of Asthma and Allergy in Children (ISAAC) 
found the prevalence of Allergic Rhinitis to be approximately 15% amongst 
South African children.  This was comparable to prevalence results observed 
in other countries, such as:  America, Australia, Brazil, France and Germany.  
(ISAAC Steering Committee, 1998.) There have been few studies published 
on the prevalence of mental disorders in patients with comorbid Allergic 
Rhinitis.  This could possibly be due to the fact that Allergic Rhinitis is a less 
disabling condition than some of the other disease states that have been 
frequently studied, such as Diabetes Mellitus and CVDs.  The prevalence of 
Allergic Rhinitis in the 0 to 17 year age group was 34.55% amongst females 
and 46.59% amongst males.  A South African study conducted in a 
Bloemfontein Hospital in 771 children between 0 and 12 years of age, found 
the prevalence of Allergic Rhinitis to be higher in males than in females 
(female to male prevalence ratio of 0.63:1) (Mercer, van der Linde & Joubert, 
2002).  This is similar to the female to male prevalence ratio of 0.46:1 
observed in this study for patients aged 0 to 17 years.  Allergic Rhinitis has 
been found to be associated with depressive and anxiety symptoms.  Some 
psychosocial symptoms of Allergic Rhinitis include reduced appetite, chronic 
fatigue, irritability and moodiness, and these may be likened to symptoms of 
Depressive Disorders and Anxiety (Marshall, 1993).  On the other hand, 
researchers have suggested that immune dysfunction, resulting from impaired 
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functioning of the HPA axis (evident in depressed patients) may lead to the 
development of an Allergic Disorder (Cuffel et al., 1999). 
 
The prevalence of Allergic Rhinitis in both females and males between 0 and 
17 years of age was calculated to be 41.96%, which is about 2.50 times 
greater than the results obtained for South African children in the ISAAC 
study.  This finding was highly significant (Chi² = 81.51, d.f. = 1, p = < .0005, 
Cramér's V = 0.75).  The higher prevalence in this study may suggest that 
there is an association between Depressive Disorders and Allergic Rhinitis.  
Having said this however, due to failure of previous studies to yield consistent 
results (Gaitens, Kaplan & Freigang, 1998), the link between Allergic Rhinitis 
and Depressive Disorders is still not precisely known.   
 
Research has identified a pronounced link between Allergic Rhinitis and 
Asthma and the observed trends in this regard, have indicated that the 
development of Asthma is preceded by a history of Allergic Rhinitis (Leynaert, 
Neukirch, Demoly & Bousquet, 2000).  The literature has calculated the 
prevalence of Allergic Rhinitis to be approximately 80% to 90% in patients 
suffering from Asthma (Leynaert et al., 2000).  Asthmatic children with 
concomitant Allergic Rhinitis have been found to incur greater drug costs and 
to visit general practitioners more frequently than children without Allergic 
Rhinitis (Thomas, Kocevar, Zhang, Yin & Price, 2005).  Tables 5.8 and 5.9 
show that Asthma and Allergic Rhinitis followed each other closely in terms of 
prevalence rank, with both conditions having featured amongst the most 
prevalent disease states that were comorbid with Depressive Disorders.  
Furthermore, the prevalence of Allergic Rhinitis in patients with Asthma was 
calculated and it was found that in addition to Depressive Disorders, 72.97% 
(which is slightly below the 80% to 90% range stipulated by the literature) of 
young depressed asthmatic patients had Allergic Rhinitis as well.  Studies 
have consistently shown that asthmatic patients exhibit a higher prevalence of 
Depressive Disorders than non-asthmatic patients (Mancuso et al., 2000; 
Pincus et al., 2001; Kanner, 2003; Cankurtaran et al., 2005; Opolski et al., 
2005), so it was not surprising to have identified Asthma as one of the more 
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frequently occurring concomitant chronic disease states in the young 
depressed patients. 
 
It was mentioned previously that the risk of developing Epilepsy is four to six 
times greater if there is a history of a Depressive Disorder (Kanner, 2003).  
Epilepsy was identified in 12.73% of the female depressed patients and 
11.36% of the male depressed patients between the ages of 0 and 17 years.  
Numerous studies conducted in young individuals have identified a higher 
prevalence of Depressive Disorders in epileptic patients when compared with 
their non-epileptic counterparts (Thome-Suza, Kuczynski, Assumpcão, 
Rzazek, Fuentes, Fiore & Valente, 2004; Caplan, Siddarth, Gurbani, Hanson, 
Sankar & Shields, 2005). 
 
A recent study analysed data from the 1998 Medical Expenditure Panel 
Survey, which involved 24 072 Americans in the community, and found 
Respiratory Diseases and Behavioural Disorders to be the most prevalent 
disease states in children (Anderson & Horvath, 2004).  Similarly, for this 
study, these disease states were also frequently diagnosed in South African 
children aged 0 to 17 years. 
 
5.4 Age Group Analysis:  18 to 34 Years 
 
5.4.1 Age and Gender Distribution of Depressed Patients 
 
The age-related descriptive statistics for the 1 726 patients in the 18 to 34 
year age group are shown in Table 5.10.  In total, depressed patients between 
18 and 34 years of age made up 8.15% of the study population.  The majority 
of the patients in this group, namely 14.08%, were 33 years old (15.26% of 
females and 11.44% of males).   
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TABLE 5.10 
DESCRIPTIVE STATISTICS FOR THE AGES OF THE PATIENTS:  AGE 
GROUP 18 TO 34 YEARS (n = 1 726) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 1 193) 
28.71 18 34 4.84 
Males  
(n = 533) 
27.47 18 34 5.26 
All Patients 
(n = 1 726) 
28.33 18 34 5.00 
 
There were a significantly greater number of depressed females than males 
(assumed distribution of 50:50) in the 18 to 34 year age group (Chi² = 252.38, 
d.f. = 1, p = < .0005, Cramér's V = 0.38).  The female to male prevalence ratio 
for Depressive Disorders was 2.24:1.  This is in agreement with many other 
studies that have determined the prevalence of Depressive Disorders to be 
approximately twice as high in females as in males (Kamlet et al., 1995; 
Kornstein, 2001; Kessler, 2003).  There was a significant gender-related 
difference between the mean ages of females and males (t-test = 4.77, p < .1; 
Cohen’s d = 0.248). 
 
5.4.2 Comorbidity Analysis 
 
5.4.2.1 Number of Chronic Comorbid Disease States per Depressed  
 Patient 
 
The descriptive statistics for the number of chronic co-existing disease states 
per depressed patient in the 18 to 34 year age group are outlined in Table 
5.11.  The mean number of chronic comorbid disease states did not differ 
significantly for females and males (t-test = 1.44, p < .1; Cohen’s d = 0.073).     
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TABLE 5.11 
DESCRIPTIVE STATISTICS FOR THE NUMBER OF CHRONIC COMORBID 
DISEASE STATES PER DEPRESSED PATIENT IN THE 18 TO 34 YEAR 
AGE GROUP (n = 1 726) 
 
 NUMBER OF CHRONIC COMORBID DISEASE STATES 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 1 193) 
1.77 0 12 1.59 
Males  
(n = 533) 
1.66 0 9 1.27 
All Patients 
(n = 1 726) 
1.74 0 12 1.50 
 
The means for the number of comorbidities per female (1.77) or male (1.66) 
depressed patient were similar to the values obtained for patients between the 
ages of 0 and 17 years, namely, 1.51 for females and 1.86 for males.  The 
prevalence distribution for the number of chronic comorbid disease states per 
depressed patient aged 18 to 34 years is outlined in Table 5.12.   
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TABLE 5.12 
NUMBER OF CHRONIC COMORBID DISEASE STATES PER PATIENT:  
AGE GROUP 18 TO 34 YEARS 
 
NUMBER OF CHRONIC 
COMORBID DISEASE STATES 
NUMBER OF PATIENTS (%) 
FEMALES MALES BOTH GENDERS 
0 209 84 293 
  (17.52) (15.76) (16.98) 
1 420 191 611 
  (35.21) (35.83) (35.40) 
2 276 146 422 
  (23.13) (27.39) (24.45) 
3 159 69 228 
  (13.33) (12.95) (13.21) 
4 65 29 94 
  (5.45) (5.44) (5.45) 
5 29 10 39 
  (2.43) (1.88) (2.26) 
6 15 1 16 
  (1.26) (0.19) (0.93) 
7 5 2 7 
  (0.42) (0.38) (0.41) 
8 7 0 7 
  (0.59) (0) (0.41) 
9 3 1 4 
  (0.25) (0.19) (0.23) 
10 3 0 3 
  (0.25) (0) (0.17) 
11 1 0 1 
  (0.08) (0) (0.06) 
12 1 0 1 
  (0.08) (0) (0.06) 
TOTAL NUMBER OF PATIENTS   1 193 533 1 726 
(%) (100) (100) (100) 
 
5.4.2.2 Most Prevalent Chronic Comorbid Disease States 
 
Table 5.13 presents the chronic disease states diagnosed most frequently 
with Depressive Disorders in female patients between the ages of 18 and 34 
years. 
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TABLE 5.13 
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
FEMALE PATIENTS AGED 18 TO 34 YEARS (n = 1 193) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
    FEMALE PATIENTS WITH 
    COMORBID DISEASE STATES 
    (n = 1 193) 
1 Allergic Rhinitis 24.39 
2 Asthma 16.35 
3 Acne 14.75 
4 Hypertension 14.25 
5 Hypothyroidism 9.72 
6 Epilepsy 9.30 
7 Diabetes Mellitus 7.29 
8 Bipolar Disorders  5.87 
9 Migraine 5.53 
10 Arthritis 5.03 
 
It is evident that Allergic Rhinitis and Asthma were the two chronic comorbid 
disease states that were diagnosed most frequently in depressed females 
aged 18 to 34 years.  This was also the case for females between the ages of 
0 and 17 years (refer to Table 5.8).   
 
There is little information documented on the prevalence of Acne in adult age 
groups.  An earlier (1979) large-scale British community study was conducted 
by Cunliffe and Gould in order to determine the prevalence of Acne in 
adolescents and adults.  The highest prevalence percentages, namely, 23% 
for females and 35% for males, were observed in 18-year-old participants.  In 
this study, for patients between the ages of 18 and 34 years, Acne was most 
prevalent amongst 21-year-old females (13.07% of females) and 20-year-old 
males (17.31% of males).  A relationship between age and prevalence of 
Acne could not be determined because percentages fluctuated unpredictably 
with an increase in age.  With regard to gender-related differences, Acne was 
dominant in females, relative to males (Chi² = 54.61, d.f. = 1, p = <.0005, 
Cramér's V = 0.48).  It was calculated that females constituted 73.90% of 
patients diagnosed with Acne.  A more recent British study, involving 427 
females and 322 males over the age of 25 years, found the prevalence of 
Acne to be 12% for females and 3% for males (Goulden, Stables & Cunliffe, 
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1999).  This could suggest that Acne affects a greater proportion of adult 
females than adult males.  It needs to be mentioned that the prevalence 
studies conducted by Cunliffe and others (1979) and Goulden and colleagues 
(1999) did not analyse the relationship between Acne and Depressive 
Disorders.  Several qualitative studies, however, have proposed that there 
may be an association between the two disease states (Mallon, Newton, 
Klassen, Stewart-Brown, Ryan & Finlay, 1999; Klassen, Newton & Mallon, 
2000).   
 
The prevalence of Migraine in females aged 18 to 34 years was calculated to 
be 5.53%.  A link between Depressive Disorders and Migraine Headaches 
has been noted by researchers (Merikangas, Angst & Isler, 1990; Patten, 
2001; Molgat & Patten, 2005).  Examples include:   
 
• A study conducted in Switzerland in individuals in their late twenties 
(sample size of just under 500 participants) found Migraine to be a 
commonly occurring comorbid disease state in depressed patients 
(Merikangas et al., 1990).   
• Another more current study, using a large-scale probability sample 
(sample size in excess of 130 000) from the CCHS, determined the 
prevalence of MDD to be higher in Migraine sufferers (17.60%) than in the 
general population (7.40%) and in those patients with other chronic 
disease states (7.80%) (Molgat et al., 2005).   
 
Table 5.14 summarises the most frequently occurring chronic concomitant 
disease states in depressed males aged 18 to 34 years.  Depressive 
Disorders have been shown to occur frequently in patients with 
Schizophrenia (Maggini & Raballo, 2005; Moller, 2005).  In Italy, Maggini and 
Raballo (2005) calculated the prevalence of Depressive Disorders in 161 
schizophrenic patients (between the ages of 18 and 65 years) to be 29.8%.  
Furthermore, research has shown that Schizophrenia is slightly more common 
in males than in females (DSM-IV-TR®, 2000).  According to the DSM-IV-TR® 
(2000), the diagnosis ‘Psychotic Disorders’ includes the following disorders:  
Schizophrenia, Schizophreniform Disorder, Delusional Disorder, Brief 
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Psychotic Disorder, Shared Psychotic Disorder, Psychotic Disorder Due to a 
General Medical Condition, Substance-Induced Psychotic Disorder and 
Psychotic Disorder Not Otherwise Specified.  Due to the fact that the 
database did not specify the exact Psychotic Disorders, it can be assumed 
that this diagnosis includes all Psychotic Disorders except Schizophrenic 
Disorders, since such disorders were listed separately.  When these disease 
states were considered collectively, Psychotic Disorders were diagnosed in 
14.07% of male depressed patients between 18 and 34 years of age.   
 
TABLE 5.14 
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
MALE PATIENTS AGED 18 TO 34 YEARS (n = 533) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
   MALE PATIENTS WITH 
   COMORBID DISEASE STATES 
   (n = 533) 
1 Allergic Rhinitis 30.21 
2 Asthma 15.76 
3 Hypertension 12.57 
4 Epilepsy  10.51 
5 Psychotic Disorders 8.07 
6 Arthritis  7.88 
7 Lipid Disorders 6.19 
8 Schizophrenic Disorders 6 
9 Bipolar Disorders  4.32 
10 Anxiety Disorders 3.94 
 
Lipid Disorders were identified as chronic disease states that were frequently 
comorbid with Depressive Disorders in adult males between the ages of 18 
and 34 years (6.19%).  According to the literature, some studies have 
demonstrated that Depressive Disorders are associated with an increase in 
lipid levels (Kinder et al., 2004; Nakao et al., 2004; Petrlova et al., 2004).  
Although Lipid Disorders did not feature as one of the 10 most commonly 
diagnosed chronic disease states in depressed females in this age group, it is 
noteworthy that the prevalence percentage of 4.36% is not much less than the 
percentages obtained for some of the other disease states listed in Table 
5.13.  It is to be expected that the prevalence of Lipid Disorders is lower in 
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females than in males, because females have comparatively higher HDL 
cholesterol levels (Heart Foundation - South Africa, 2006).  It was discovered 
that this gender-related difference regarding the prevalence of Lipid Disorders 
(assumed distribution to be equal for females and males; namely 50:50), was 
significant (Chi² = 4.25, d.f. = 1, p = .039, Cramér's V = 0.22).     
 
Figure 5.12 contrasts the most prevalent concomitant chronic disease states 
in depressed females and males aged 18 to 34 years.  In 1998, the first South 
African National Demographic and Adult Health Survey was carried out in    
13 827 individuals aged 15 years and older.  The gender distribution was 59% 
females and 41% males.  The prevalence of Hypertension was determined to 
be 23.4% and 23.7% in female and male South Africans, respectively.  This is 
thought to represent an estimate of an additional three million South Africans.  
(Steyn, Gaziano, Bradshaw, Laubscher & Fourie, 2001.) Moreover, the South 
African Heart Foundation estimates that one in four South Africans between 
15 and 64 years of age have Hypertension (Heart Foundation - South Africa, 
2006).  The prevalence of Diabetes Mellitus in South African adults has been 
calculated by epidemiological studies to range between 4.7% and 13% (Omar, 
Seedat, Motala, Dyer & Becker, 1993; Levitt, Unwin, Bradshaw, Kitange, 
Mbanya, Mollentze, Omar, Motala, Joubert, Masuki & Machibya, 2000).  
Another study that was conducted by the research team in the South African 
Demographic and Health Survey evaluated the use of prescribed medications 
for frequently occurring chronic conditions (Hypertension, Diabetes Mellitus, 
Hyperlipidaemia, Tuberculosis, Asthma and COPD) amongst South Africans 
aged 15 years and older.  More than 15% of South African adults were found 
to be taking drugs for Asthma, Hypertension and Diabetes Mellitus.  (Steyn 
et al., 2005.) The results of these large-scale studies indicate that 
Hypertension, Asthma and Diabetes Mellitus are prevalent chronic disease 
states in South Africans.  Figure 5.12 shows that all three of these disease 
states were frequently diagnosed in the 18 to 34 year age group.  The 
prevalence percentages of these disease states were as follows:  13.73% 
(Hypertension); 16.16% (Asthma) and 6.14% (Diabetes Mellitus). 
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FIGURE 5.12  
PREVALENCE OF CHRONIC COMORBID DISEASE STATES (ACCORDING TO GENDER) 
IN DEPRESSED PATIENTS BETWEEN THE AGES OF 18 AND 34 YEARS (n = 1 726) 
 
Many studies have recognised elevated rates of Depressive Disorders in 
patients with Allergic Rhinitis and Asthma (Rubin, 1993); Hypertension 
(Jonas et al., 1997; Dorsey et al., 2002; Kessler et al., 2003b; Meyer et al., 
2004; Cankurtaran et al., 2005; Patten et al., 2005); Epilepsy (Indaco et al., 
1992; Baker et al., 1996; Kanner, 2003); Psychotic Disorders (Maggini et al., 
2005; Moller, 2005); Acne (Mallon et al., 1999; Klassen et al., 2000); 
Hypothyroidism (Burmeister et al., 2001; Thomsen et al., 2005); Lipid 
Disorders (Kinder et al., 2004; Nakao et al., 2004; Petrlova et al., 2004); 
Diabetes Mellitus (Kovacs et al., 1997; Lustman et al., 1997; Anderson et al., 
2001; Pincus et al., 2001; Kanner, 2003; Cankurtaran et al., 2005); Migraine 
(Moldin et al., 1993; Patten, 2001); Arthritis (Marsh, 1997; Taal et al., 1997; 
Kessler et al., 2003b) and Anxiety Disorders (Kessler et al., 1996; Barbee, 
1998; Bhagwanjee, Parekh, Paruk, Petersen & Subedar, 1998; Triant, 2002; 
Kessler et al., 2003b). 
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The following disease states occurred commonly in both genders for this age 
group:  Allergic Rhinitis, Asthma, Hypertension, Diabetes Mellitus, 
Epilepsy, Bipolar Disorders, Hypothyroidism and Arthritis.  The literature 
has provided the following evidence for an association between Depressive 
Disorders and these disease states:  
 
• It is well-known that a Depressive Disorder is one of the most frequently 
occurring mental disease states in allergic patients (Rubin, 1993).  For 
example, a drug utilisation review performed in more than 600 000 
Americans (85 298 with allergies and 555 907 without allergies) 
determined the prevalence of Depressive Disorders to be 12% in 
individuals with allergies and 7.6% in participants with no allergies (Cuffel 
et al., 1999).  Allergic Rhinitis has been distinguished as a prevalent 
comorbid disease state in both age groups discussed thus far. 
• Research has consistently shown that patients with Asthma display a 
higher prevalence of Depressive Disorders than non-depressed patients 
(Mancuso et al., 2000; Pincus et al., 2001; Kanner, 2003; Cankurtaran et 
al., 2005; Opolski et al., 2005).  Mancuso and others (2000) estimated that 
almost half of patients diagnosed with Asthma, experience concomitant 
depressive symptoms.   
• In addition to the association between Depressive Disorders and Allergic 
Rhinitis, it has also been mentioned that there is a strong link between 
Allergic Rhinitis and Asthma (Leynaert et al., 2000).  The prevalence of 
Allergic Rhinitis in asthmatic patients was found to be 43.73% in the 18 to 
34 year age group.  This is significantly less than the 80% to 90% 
prevalence range (mean equals to 85%) stipulated by Leynaert and 
colleagues (2000) (Chi2 = 372.75, d.f = 1, p = < .005, Cramér’s V = 1.16, 
for an expected percentage of 85%).  In addition, the difference between 
the prevalence percentages (for Allergic Rhinitis in patients with Asthma) 
observed in the 0 to 17 and 18 to 34 year age groups of this study, was 
significant (Chi2 = 120.96, d.f = 1, p = < .005, Cramér’s V = 0.66).  This is 
to be expected because the prevalence of Allergic Disorders has been 
shown to decrease with age (Australian Institute of Health and Welfare, 
2001; Dahl et al., 2004).   
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• Studies performed in young adults with Arthritis (between 16 and 30 
years of age) found Depressive Disorders to be ‘an important emotional 
outcome’ (Taal et al., 1997).  More specifically, a large-scale Canadian 
study involving just over 115 000 individuals (aged 18 years and older), 
determined the prevalence of MDD to be 15.7% in patients with Arthritis 
(Patten et al., 2005).  Conversely, the prevalence of Arthritis in depressed 
patients between 18 and 34 years of age was calculated to be 5.91% for 
this study (5.03% for females and 7.88% for males).   
• Depressive Disorders have been shown to be common concomitant 
disease states in diabetic patients and recent studies have shown that 
more than a quarter of patients diagnosed with Diabetes Mellitus are 
affected (Anderson et al., 2001; Egede, Zheng & Simpson, 2002).   
• Depressive Disorders are the most prevalent Psychiatric Disorders in 
epileptic individuals (Kanner, 2003).  Of the 1 726 depressed patients 
between 18 and 34 years of age, 9.68% were found to have a co-existing 
Epileptic Disorder.  Many studies have been conducted in individuals 
with controlled Epilepsy and the prevalence of Depressive Disorders was 
found to range between 3% and 9% amongst these patients (Baker et al., 
1996; O’Donoghue et al., 1999).  
• Individuals with Hypothyroidism have been shown to display a greater 
risk towards the development of Depressive Disorders (Thomsen et al., 
2005). 
• It was previously mentioned in the literature (see Section 2.1) that Bipolar 
Disorder is a recurrent Affective Disorder that presents itself in the form of 
one or many episodes of mania or mixed manic and depressive episodes.  
Since Depressive Disorders are a feature of this Psychiatric Disease State, 
it was not surprising to note that Bipolar Disorder was prevalent in both 
females and males of this age group.  It has been shown that Bipolar 
Disorder is equally prevalent amongst females and males (DSM-IV-TR®, 
2000).  Females were found to exhibit a slightly higher prevalence (5.87%) 
of Bipolar Disorders than males (4.32%).  The average age of onset of 
Bipolar Disorder is 20 years (DSM-IV-TR®, 2000).  This could explain why 
this disorder was found to occur most commonly in the 18 to 34 year age 
group. 
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On comparison of the results for females between the ages of 0 and 17 years 
(see Table 5.8) with those obtained for females aged 18 to 34 years (refer to 
Table 5.13), it was evident that the following chronic disease states were 
diagnosed most frequently in depressed females:  Allergic Rhinitis, Asthma, 
Acne, Hypothyroidism, Epilepsy, Diabetes Mellitus and Bipolar 
Disorders.  Similarly, for depressed males, the following chronic comorbid 
disease states were common to the 0 to 17 (refer to Table 5.9) and 18 to 34 
(see Table 5.14) year age groups:  Allergic Rhinitis, Asthma, Epilepsy and 
Psychotic Disorders. 
 
5.5 Age Group Analysis:  35 to 54 Years 
 
5.5.1 Age and Gender Distribution of Depressed Patients 
 
The majority of the patients in the study population (47.99%) were between 35 
and 54 years of age.  Table 5.15 summarises the age-related descriptive 
statistics for middle-aged patients.   
   
TABLE 5.15 
DESCRIPTIVE STATISTICS FOR THE AGES OF THE PATIENTS:  AGE 
GROUP 35 TO 54 YEARS (n = 10 160) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 7 369) 
46.02 35 54 5.39 
Males  
(n = 2 791) 
45.93 35 54 5.43 
All Patients 
(n = 10 160) 
46.00 35 54 5.40 
 
The female to male prevalence ratio for Depressive Disorders was 2.64:1, 
which is 1.32 times greater than the 2:1 ratio that has been consistently 
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presented in the literature (Kamlet et al., 1995; Kornstein, 2001; Kessler, 
2003).  This gender-related dominance of middle-aged females was 
significant (Chi² = 2 062.80, d.f. = 1, p = < .0005, Cramér's V = 0.45).  The 
mean ages of females and males in the 35 to 54 year age group were not 
significantly different (t-test = 0.77, p < .1; Cohen’s d = 0.02). 
 
5.5.2 Comorbidity Analysis 
 
5.5.2.1 Number of Chronic Comorbid Disease States per Depressed  
 Patient 
 
Table 5.16 presents the descriptive statistics regarding the number of chronic 
comorbid disease states per depressed middle-aged patient.  The means for 
the number of chronic comorbid disease states per female and male patient 
did not differ significantly (t-test = 5.17, p < .1; Cohen’s d = 0.11).   
   
TABLE 5.16 
DESCRIPTIVE STATISTICS FOR THE NUMBER OF CHRONIC COMORBID 
DISEASE STATES PER DEPRESSED PATIENT IN THE 35 TO 54 YEAR 
AGE GROUP (n = 10 160) 
 
 NUMBER OF CHRONIC COMORBID DISEASE STATES 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 7 369) 
2.76 0 20 2.03 
Males  
(n = 2 791) 
2.54 0 14 1.85 
All Patients 
(n = 10 160) 
2.70 0 20 1.98 
 
The prevalence distribution for the number of chronic comorbid disease states 
per depressed patient, aged between 35 and 54 years, is outlined in Table 
5.17.  
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TABLE 5.17 
NUMBER OF CHRONIC COMORBID DISEASE STATES PER PATIENT:  
AGE GROUP 35 to 54 YEARS 
 
NUMBER OF CHRONIC COMORBID
DISEASE STATES 
NUMBER OF PATIENTS (%) 
FEMALES MALES BOTH GENDERS 
0 415 178 593 
  (5.63) (6.38) (5.84) 
1 1 772 771 2 543 
  (24.05) (27.62) (25.03) 
2 1 778 671 2 449 
  (24.13) (24.04) (24.10) 
3 1 355 501 1 856 
  (18.39) (17.95) (18.27) 
4 886 309 1 195 
  (12.02) (11.07) (11.76) 
5 478 166 644 
  (6.49) (5.95) (6.34) 
6 284 87 371 
  (3.85) (3.12) (3.65) 
7 166 55 221 
  (2.25) (1.97) (2.18) 
8 111 20 131 
  (1.51) (0.72) (1.29) 
9 56 14 70 
  (0.76) (0.50) (0.69) 
10 25 9 34 
  (0.34) (0.32) (0.33) 
11 15 6 21 
  (0.20) (0.21) (0.21) 
12 13 3 16 
  (0.18) (0.11) (0.16) 
13 6 0 6 
  (0.08) (0) (0.06) 
14 4 1 5 
  (0.05) (0.04) (0.05) 
15 TO 20 5 0 5 
  (0.07) (0) (0.05) 
TOTAL NUMBER OF PATIENTS  
(%) 
7 369 2 791 10 160 
(100) (100) (100) 
 
With reference to Table 5.17, it is apparent that only 5.84% of the patients 
between the ages of 35 and 54 years had a Depressive Disorder as the sole 
diagnosis.  This is almost half of the percentage obtained for the 0 to 17 year 
age group (10.49% with one diagnosis) and almost one third of the 
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percentage calculated for the 18 to 34 year age group (16.98% with one 
diagnosis).  Similarly, the distribution of middle-aged depressed patients, with 
one chronic co-existing disease state, namely 25.03%, was noticeably less 
than the corresponding percentages for younger patients with the same 
number of disease states.  Conversely, with a higher number of chronic 
comorbidities, the percentage distributions were greater than for the 
respective values obtained for the two younger age groups.  For example, 
depressed patients with more than five concomitant disease states accounted 
for the following percentages in each age group:  0% (0 to 17 years); 2.26% 
(18 to 34 years); and 8.66% (35 to 54 years).  Therefore, it is evident that the 
number of chronic comorbid disease states increased with age.  The patient 
distribution for the number of comorbidities was not significantly different for 
middle-aged females and males (Chi² = 26.82, d.f. = 1, p = < .0005, Cramér's 
V = 0.05). 
 
5.5.2.2 Most Prevalent Chronic Comorbid Disease States 
 
Table 5.18 lists the most prevalent comorbid disease states in middle-aged 
females with Depressive Disorders.  The South African National Demographic 
and Adult Health Survey (referred to in Section 5.4.2.2) determined the 
prevalence of Hypertension to be 23.4% in the female study population 
(approximately 8 157 females aged 15 years and older) (Steyn et al., 2001).  
The prevalence of Hypertension in this group of depressed females was 
almost double (45.23%) the prevalence percentage observed in the South 
African National Demographic and Adult Health Survey.  Furthermore, the 
prevalence of Hypertension amongst all of the depressed females in the study 
population (n = 15 185) was 52.43%.   
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TABLE 5.18 
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
FEMALE PATIENTS AGED 35 TO 54 YEARS (n = 7 369) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
    FEMALE PATIENTS WITH 
    COMORBID DISEASE STATES 
    (n = 7 369) 
1 Hypertension 45.23 
2 HRT/Menopause 38.47 
3 Allergic Rhinitis 16.64 
4 Hypothyroidism 14.78 
5 Arthritis  13.53 
6 Asthma 11.63 
7 Lipid Disorders 10.64 
8 Diabetes Mellitus 10.63 
9 Anxiety Disorders 7.48 
10 Thrombo-embolic Prophylaxis 6.99 
 
Dvornyk and others (2005) suggested that Menopause occurs between the 
ages of 40 and 60 years in females.  The median age for Menopause is said 
to be 51 years of age (Burt & Stein, 2002).  In the 35 to 54 year age group, 
the mean and median ages for Menopause were calculated to be 48.97 years 
(SD is 4.28) and 50 years, respectively.  The median age, therefore, was 
similar to the age presented by Burt and Stein (2002) in the literature.  It has 
been reported that there is a greater risk for the development of Depressive 
Disorders in females during Perimenopause (transition period [five to six 
years] from usual ovarian cycles to total cessation of menstruation) and 
Menopause (Cohen et al., 2006).  Of the menopausal females in this age 
group, 84.90% were between 45 (value obtained by subtracting six years from 
the median age for Menopause in order to estimate perimenopausal age) and 
54 years of age. 
 
The most prevalent concomitant disease states in depressed males between 
the ages of 35 and 54 years are shown in Table 5.19.   
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TABLE 5.19 
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
MALE PATIENTS AGED 35 TO 54 YEARS (n = 2 791) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
   MALE PATIENTS WITH 
   COMORBID DISEASE STATES 
   (n = 2 791) 
1 Hypertension 51.31 
2 Lipid Disorders 27.12 
3 Allergic Rhinitis 15.98 
4 Diabetes Mellitus 14.73 
5 Thrombo-embolic Prophylaxis 14.22 
6 Arthritis  9.71 
7 Asthma 9.35 
8 Gout 9.28 
9 Anxiety Disorders 7.31 
10 Epilepsy 6.70 
 
Hypertension was also diagnosed frequently in middle-aged males, with a 
prevalence of 51.31%.  In 1998, the prevalence of Hypertension in the male 
population for the South African National Demographic and Adult Health 
Survey (approximately 5 669 males) was 23.7% (Steyn et al., 2001), which is 
less than half of the percentage obtained for depressed South African males 
in the entire study population (5 986), namely 53.97%.  The prevalence 
percentages for Hypertension in depressed females and males, aged 35 to 54 
years, differed significantly from the results of the South African National 
Demographic and Adult Health Survey, which did not consider the influence of 
Depressive Disorders on Hypertension prevalence (females:  Chi² = 1 959.17, 
d.f. = 1, p = < .0005, Cramér's V = 0.52; and males:  Chi² = 1 176.39, d.f. = 1, 
p = < .0005, Cramér's V = 0.65).  This could possibly indicate that there is a 
greater incidence of Hypertension amongst depressed patients.  This would 
be in concordance with many other studies that have highlighted an 
association between Depressive Disorders and Hypertension (Jonas et al., 
1997; Dorsey et al., 2002; Kessler et al., 2003b; Meyer et al., 2004; 
Cankurtaran et al., 2005; Patten et al., 2005).  However, it must be considered 
that the greater prevalence percentages of Hypertension noted in this study 
for females and males, relative to the corresponding percentages for the 
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South African National Demographic and Adult Health Survey, may have also 
been influenced in part by the different settings of the two studies.  For 
example, all of the patients in this study were registered with a Managed 
Healthcare Company to claim chronic medication; whereas the South African 
National Demographic and Adult Health Survey consisted of a cohort of 
randomly selected South Africans.      
 
Some researchers have suggested that the results pertaining to the 
relationship between Depressive Disorders and Hypertension have been 
inconsistent as a result of the failure of studies to consider the influence of 
Anxiety Disorders (Bosworth et al., 2003).  Due to the pronounced link 
between Anxiety and Depressive Disorders (Kessler et al., 1996; Barbee, 
1998; Bhagwanjee et al., 1998; Triant, 2002; Kessler et al., 2003b), it is 
important to precisely define this interrelationship in order to assess the 
relationship between Depressive Disorders and Hypertension more accurately 
(Bosworth et al., 2003).  Table 5.19 shows that 7.31% of male depressed 
patients in this age group had comorbid Anxiety Disorders.  In females, the 
prevalence of comorbid Anxiety Disorders was similar, namely, 7.48%.  Triant 
(2002) found that Psychiatric Disease States commonly co-existed and 
suggested that patients with one disease state have a greater risk of 
developing other Psychiatric Disorders.   
 
The onset of Gout often presents in middle age and it is a disease state that 
has been shown to be more prevalent in males (Johnstone, 2005).  In 
agreement with the literature, Gout was identified as a commonly occurring 
disease state amongst middle-aged males, with a prevalence of 9.28%.  It 
was also established that just over a third of males diagnosed with Gout 
(3.68%), had Gouty Arthritis.  Gout has also been associated with many other 
chronic disease states such as Diabetes Mellitus and Hypertension (Mikuls, 
Farrar, Bilker, Fernandes, Schumacher & Saag, 2005).  Of the 360 patients 
with Gout in this age group, 16.67% and 68.61% had Diabetes Mellitus or 
Hypertension, respectively.  Furthermore, it was calculated that 14.44% of 
depressed patients with Gout, had both Diabetes Mellitus and Hypertension. 
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The concomitant disease states presenting most often in female and male 
depressed patients in the 35 to 54 year age group, are contrasted in Figure 
5.13.   
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FIGURE 5.13  
PREVALENCE OF CHRONIC COMORBID DISEASE STATES (ACCORDING TO GENDER) 
IN DEPRESSED PATIENTS BETWEEN THE AGES OF 35 AND 54 YEARS (n = 10 160) 
 
The literature has provided an abundance of evidence for a link between 
Depressive Disorders and the prevalent disease states outlined in Figure 
5.13, namely:  Hypertension (Jonas et al., 1997; Dorsey et al., 2002; Kessler 
et al., 2003b; Meyer et al., 2004; Cankurtaran et al., 2005; Patten et al., 2005); 
Allergic Rhinitis (Cuffel et al., 1999); Hypothyroidism (Burmeister et al., 
2001; Thomsen et al., 2005); Menopause (Cohen et al., 2006); Arthritis 
(Marsh, 1997; Taal et al., 1997; Kessler et al., 2003b); Asthma (Mancuso et 
al., 2000; Pincus et al., 2001; Kanner, 2003; Cankurtaran et al., 2005; Opolski 
et al., 2005); Lipid Disorders (Kinder et al., 2004; Nakao et al., 2004; 
Petrlova et al., 2004); Diabetes Mellitus (Kovacs et al., 1997; Lustman et al., 
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1997; Anderson et al., 2001; Pincus et al., 2001; Kanner, 2003; Cankurtaran 
et al., 2005); Thrombo-embolic Prophylaxis (Frasure-Smith et al., 1995; 
Musselman et al., 1998; Krishnan et al., 2000; Nemeroff et al., 2000); 
Epilepsy (Indaco et al., 1992; Baker et al., 1996; Kanner, 2003); and Anxiety 
Disorders (Kessler et al., 1996; Barbee, 1998; Bhagwanjee et al., 1998; 
Triant, 2002; Kessler et al., 2003b). 
 
As for the 0 to 17 and 18 to 34 year age groups, Allergic Rhinitis was a 
common comorbidity in middle-aged depressed patients, with prevalence 
percentages of 16.62% for females and 15.94% for males.  Moreover, 
Asthma also occurred frequently in both genders, affecting 11.63% of 
females and 9.35% of males.  It was calculated that 38.46% of patients with 
Asthma, also had comorbid Allergic Rhinitis.   
 
A study that was conducted in Amsterdam investigated the prevalence of 23 
disease states in 290 patients with Chronic Airway Obstruction (including 
both COPD and Asthma) and a control group of 421 individuals (all over 40 
years of age).  The prevalence of Depressive Disorders in patients with 
Chronic Airway Obstruction, between the ages of 40 and 55 years, was 
calculated to be 20%.  (van Manen et al., 2001.) Conversely, for this study 
11.77% of depressed patients between 35 and 54 years of age had comorbid 
Chronic Airway Obstruction.  Therefore, the results of this study and the one 
conducted by van Manen and others (2001) could point towards the existence 
of a possible bidirectional relationship between Depressive Disorders and 
COPD or Asthma. 
  
On a global level, Lipid Disorders are commonly diagnosed chronic disease 
states.  For example, the WHO MONICA Project (Mulitinational MONitoring of 
Trends and Determinants in CArdiovascular Disease), involving approximately 
ten million females and the same number of males, was a study that involved 
obtaining data on cardiovascular risk factors in the following countries:   
Switzerland, Czech Republic, Lithuania, China, Russia, United States, Italy, 
Belgium, France, UK, Denmark, Germany, Australia, Canada, Sweden, 
Iceland, Finland, New Zealand, Spain, Poland and Yugoslavia (age range of 
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participants was 25 to 64 years).  The prevalence of moderate to high total 
cholesterol levels (greater than 5.20 mmol/l) ranged from 55% to 78% 
amongst females and 49% to 87% amongst males (Publications from the 
WHO MONICA Project, 1999).  In South Africa, Lipid Disorders are also highly 
prevalent (Steyn et al., 2005).  For instance, according to the South African 
Heart Foundation, 80% of westernised South Africans have 
Hypercholesterolaemia (Heart Foundation - South Africa, 2006).  Additionally, 
it has been estimated that 4.5 million South Africans with Hyperlipidaemia are 
at risk of developing atherosclerotic-related disease states, such as MI and 
Angina (Steyn et al., 2005).  Lipid Disorders were diagnosed in 10.76% of 
females and 27.41% of males with Depressive Disorders in this age group.  
Research has shown that depressed patients have higher plasma levels of 
clotting factors (for example, factor VII and factor X) than non-depressed 
individuals (Musselman et al., 1996, Krishnan et al., 2000; Doulalas, Rallidis, 
Gialernios, Moschonas, Kougioulis, Rizos, Tselegaridis, Kremastinos, 2005).  
This is noteworthy to mention at this stage because certain clotting factors, 
such as factors VII and X, have been positively associated with TG and 
cholesterol levels (Morishita, Jokaji & Matsuda, 1995; Doulalas et al., 2004). 
 
Hypothyroidism was diagnosed in 14.78% of depressed females between 35 
and 54 years of age.  It was also established that Lipid Disorders occurred 
frequently in this age group.  This is relevant because high cholesterol levels 
have been associated with Hypothyroidism.  For example, the Third National 
Health and Nutrition Examination Survey, Phase Two (1991 to 1994) 
conducted in America, found that individuals with Hypothyroidism were eight 
times more likely to have a high cholesterol level (over 6.20 mmol/l) than 
participants with normal thyroid function (Morris, Bostom, Jacques, Selhub & 
Rosenberg, 2001).  The prevalence of Lipid Disorders in middle-aged 
depressed patients with Hypothyroidism was calculated to be 16.32%.   
 
In addition to the association between Depressive Disorders and 
Hypertension or Lipid Disorders, research has also shown that Hypertension 
and Hypercholesterolaemia commonly co-exist.  For example, two large-scale 
studies conducted in England and America (11 199 and 371 221 participants, 
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respectively), determined the prevalence percentages for the comorbid 
existence of Hypertension and Hypercholesterolaemia, to range between 15% 
and 31% (Eaton, Feldman, Assaf, McPhillips, Hume, Lasater, Levinson & 
Carleton, 1994; Johnson, Pietz, Battleman & Beyth, 2004).  In the 35 to 54 
year age group of depressed patients, 13.11% of females and 28.88% of 
males with Hypertension were found to have had a co-existing Lipid Disorder.  
When genders were considered collectively, it was deduced that 17.67% of 
depressed patients with Hypertension had a concomitant Lipid Disorder.  This 
prevalence percentage concurs with the range depicted by the 
aforementioned studies. 
 
Diabetes Mellitus affects many South Africans (Omar et al., 1993; Steyn et 
al., 2001).  Also, studies have consistently shown that Diabetes Mellitus is 
strongly linked with Depressive Disorders (Kovacs et al., 1997; Lustman et al., 
1997; Anderson et al., 2001; Pincus, et al., 2001; Kanner, 2003; Cankurtaran 
et al., 2005).  Thus, it could be predicted that Diabetes Mellitus would be 
amongst the most prevalent co-existing disease states in middle-aged 
females (10.63%) and males (14.73%).  Researchers have demonstrated an 
elevated prevalence of Hypertension and Lipid Disorders in diabetic patients.  
For this age group, it was determined that 7.79% and 2.84% of depressed 
patients with Diabetes Mellitus, had comorbid Hypertension and Lipid 
Disorders, respectively.   
 
It was noted that 6.99% of females and 14.22% of males were receiving 
Thrombo-embolic Prophylaxis.  With reference to the literature, Depressive 
Disorders are associated with enhanced platelet aggregation and this may 
increase the risk of Thrombosis and Infarction (Frasure-Smith et al., 1995; 
Musselman et al., 1998; Krishnan et al., 2000; Nemeroff et al., 2000).  Some 
of the other risk factors for Thrombo-embolic Disease States include:  
increasing age, Stroke, long periods of immobility, history of Venous 
Thrombo-embolism (VTE), Cancer and treatment thereof, Obesity, trauma 
(particularly hip, pelvic or leg fractures), Varicose Veins, Cardiac Dysfunction, 
Pregnancy and estrogen therapy (Geerts, Heit, Clagett, Pineo, Colwell, 
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Anderson & Wheeler, 2001).  The following points were noted for the 35 to 54 
year age group: 
 
• Of the females in this age group, 23.91% were prescribed HRT.  This is 
relevant because estrogen therapy is a risk factor for Thrombotic 
Disorders. 
• The prevalence of Thrombotic Disorders was only 0.72%, so the risk 
posed by a history of a VTE is marginal. 
• There were 18 patients who had suffered a Stroke.  A history of Stroke 
enhances the individual’s risk for the development of a future 
Thrombotic Disorder (Geerts et al., 2001). 
• Geerts and others (2001) also identified Cardiac Dysfunction as a 
strong risk factor for future Thrombosis.  Hypertension was a prevalent 
CVD, occurring in 46.90% of depressed patients in this age group.   
 
The following chronic disease states were prevalent amongst depressed 
females aged 18 to 54 years:  Allergic Rhinitis, Asthma, Hypertension, 
Hypothyroidism, Diabetes Mellitus and Arthritis.  Similarly, for depressed 
males aged 18 to 54 years, the following chronic comorbid disease states 
were frequently diagnosed:  Allergic Rhinitis, Asthma, Hypertension, 
Arthritis, Lipid Disorders and Anxiety Disorders. 
 
5.6 Age Group Analysis:  55 to 64 Years 
 
5.6.1 Age and Gender Distribution of Depressed Patients 
 
The descriptive statistics regarding the ages of the patients between 55 and 
64 years are outlined in Table 5.20.  Similar to the results for the 35 to 54 year 
age group (2.64:1), the female to male prevalence ratio for patients aged 55 to 
64 years, was 2.63:1.  When an even gender distribution was assumed, it was 
noted that there was a significantly greater proportion of females than males 
in this age group (Chi² = 997.94, d.f. = 1, p = < .0005, Cramér's V = 0.45).  As 
shown in Table 5.20, the mean ages of depressed females and males did not 
differ significantly (t-test = 1.13, p < .1; Cohen’s d = 0.04). 
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TABLE 5.20 
DESCRIPTIVE STATISTICS FOR THE AGES OF THE PATIENTS:  AGE 
GROUP 55 TO 64 YEARS (n = 4 943) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 3 582) 
59.03 55 64 2.81 
Males  
(n = 1 361) 
58.93 55 64 2.81 
All Patients 
(n = 4 943) 
59.00 55 64 2.81 
 
5.6.2 Comorbidity Analysis 
 
5.6.2.1 Number of Chronic Comorbid Disease States per Depressed  
 Patient 
 
Table 5.21 summarises the descriptive statistics pertaining to the number of 
chronic concomitant disease states per depressed patient aged 55 to 64 
years.  The difference between the mean values obtained for females and 
males was found to be significant (t-test = 7.99, p < .1; Cohen’s d = 0.25).   
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TABLE 5.21 
DESCRIPTIVE STATISTICS FOR THE NUMBER OF CHRONIC COMORBID 
DISEASE STATES PER DEPRESSED PATIENT IN THE 55 TO 64 YEAR 
AGE GROUP (n = 4 943) 
 
 NUMBER OF CHRONIC COMORBID DISEASE STATES 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 3 582) 
3.98 0 19 2.49 
Males  
(n = 1 361) 
3.35 0 19 2.37 
All Patients 
(N = 4 943) 
3.81 0 19 2.48 
 
In turn, Table 5.22 provides an overview of the distribution of depressed 
patients between 55 and 64 years of age, with one or multiple concomitant 
chronic disease states.  It was calculated that 84.85% of the patients in this 
age group, had at least two other concomitant disease states in addition to a 
Depressive Disorder.  It is noticeable that depressed males were associated 
with a lower number of chronic co-existing disease states than their female 
counterparts.  Similarly, females were more likely than males to be diagnosed 
with three or more comorbidities.  Thus, it was established that the number of 
chronic comorbid disease states was significantly related to gender for the 55 
to 64 year age group (Chi² = 125.67, d.f. = 5, p = < .0005, Cramér's V = 0.16).   
 
Table 5.22 further reinforces the observation of a greater number of chronic 
comorbidities with an increase in age, because only 1.74% of the depressed 
patients had no other disease states (compared to prevalence percentages 
ranging between 5.84% and 16.98% for the 0 to 17, 18 to 34 and 35 to 54 
year age groups).  Furthermore, 20.07% of the depressed patients between 
55 and 64 years of age had more than five co-existing chronic disease states.  
This contrasts with the smaller percentages obtained for the younger age 
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groups, namely: 0%, 2.26% and 8.66% for the 0 to 17, 18 to 34 and 35 to 54 
year age groups, respectively.   
   
TABLE 5.22 
NUMBER OF CHRONIC COMORBID DISEASE STATES PER PATIENT:  
AGE GROUP 55 TO 64 YEARS (n = 4 943) 
 
NUMBER OF CHRONIC COMORBID 
DISEASE STATES 
NUMBER OF PATIENTS (%) 
FEMALES MALES BOTH GENDERS 
0 29 57 86 
  (0.81) (4.19) (1.74) 
1 418 245 663 
  (11.67) (18.00) (13.41) 
2 637 282 919 
  (17.78) (20.72) (18.59) 
3 727 255 982 
  (20.30) (18.74) (19.87) 
4 598 182 780 
  (16.69) (13.37) (15.78) 
5 397 124 521 
  (11.08) (9.11) (10.54) 
6 276 75 351 
  (7.71) (5.51) (7.10) 
7 192 57 249 
  (5.36) (4.19) (5.04) 
8 98 33 131 
  (2.74) (2.42) (2.65) 
9 84 20 104 
  (2.35) (1.47) (2.10) 
10 54 10 64 
  (1.51) (0.73) (1.29) 
11 21 11 32 
  (0.59) (0.81) (0.65) 
12 22 8 30 
  (0.61) (0.59) (0.61) 
13 7 0 7 
  (0.20) (0) (0.14) 
14 9 1 10 
  (0.25) (0.07) (0.20) 
15 to 19 13 1 14 
  (0.36) (0.07) (0.28) 
TOTAL NUMBER OF PATIENTS  3 582 1 361 4 943 
(%) (100) (100) (100) 
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5.6.2.2 Most Prevalent Chronic Comorbid Disease States 
 
Table 5.23 lists the chronic disease states presenting most frequently in 
depressed female patients between the ages of 55 and 64 years.  Marsh 
(2001) performed a drug utilisation review in 84 627 South African 
hypertensive patients (mean age of 59.34 years for females and 58.04 years 
for males).  The most commonly occurring chronic comorbid disease states 
amongst hypertensive females (56.50% of sample size) were:  
HRT/Menopause, Diabetes Mellitus (Type II), Arthritis, Hypothyroidism, 
Hypercholesterolaemia, Osteoporosis, Depression and Asthma.  Additionally, 
the prevalence of comorbid Depression was calculated to be 6.56% in 
hypertensive females.  The mean age for females in this age group of the 
study was 59.03 years, which is comparable to the mean age for Marsh’s 
study (2001).  It is notable that, of the chronic disease states determined to be 
prevalent amongst the hypertensive females (Marsh, 2001); the following 
were also found to occur commonly in depressed South African females, aged 
55 to 64 years, for this study:  HRT/Menopause, Diabetes Mellitus, 
Arthritis, Hypothyroidism, Osteoporosis and Lipid Disorders.  Moreover, 
Hypertension was diagnosed in 62.09% of depressed females in this age 
group. 
 
It was deduced that 20.35% of depressed females between the ages of 55 
and 64 years had comorbid Hypothyroidism.  This is greater than the 
prevalence percentages observed in depressed females in the younger age 
groups (14.78% in the 35 and 54 year age group and 9.72% in the 18 to 34 
year age group).  It was previously mentioned that Lipid Disorders have 
been associated with Hypothyroidism (Morris et al., 2001).  Of the depressed 
females with Hypothyroidism, 30.79% were found to have also been 
diagnosed with a co-existing Lipid Disorder. 
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TABLE 5.23 
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
FEMALE PATIENTS AGED 55 TO 64 YEARS (n = 3 582) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
    FEMALE PATIENTS WITH 
    COMORBID DISEASE STATES 
    (n = 3 582) 
1 HRT/Menopause 76.13 
2 Hypertension 62.09 
3 Arthritis 23 
4 Lipid Disorders 22.75 
5 Hypothyroidism 20.35 
6 Thrombo-embolic Prophylaxis 14.96 
7 Osteoporosis 12.93 
8 Allergic Rhinitis 11.03 
9 Calcium Supplementation 10.86 
10 Diabetes Mellitus 10.78 
 
It is believed that Osteoporosis is the most frequently occurring bone disease 
in humans, affecting both females and males (Mauck & Clarke, 2006).  
Scientific evidence has shown that Calcium and Vitamin D Supplementation is 
vital in the management of Osteoporosis.  It is recommended that the 
following individuals take Calcium and Vitamin D Supplementation:  older 
females and males; as well as other individuals who may have a high risk of 
Calcium and Vitamin D deficiencies; patients diagnosed with Osteoporosis 
and who are taking anabolic and antiresorptive therapies and patients who 
are on glucocorticoid treatment.  (Boonen, Vanderschueren, Haentjens & Lips, 
2006.) Table 5.23 shows that 12.93% of depressed females in this age group 
had Osteoporosis.  It was calculated that 31.97% of these patients were 
receiving Calcium Supplementation.  In America it is recommended that 
most females and males over 50 years of age should receive Calcium 
Supplementation (Gass & Dawson-Huges, 2006).  However, in this study, only 
7.89% of depressed patients over 50 years of age (938 out of 11 750 patients 
aged 51 years or older) were prescribed Calcium Supplementation.  
 
It is worth mentioning that 80% of the chronic disease states identified to be 
prevalent amongst middle-aged depressed females (refer to Table 5.18) were 
also commonly occurring disease states in depressed females aged 55 to 64 
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years (see Table 5.23).  Therefore, the following chronic disease states were 
most prevalent in depressed females between 35 and 64 years of age:  
Hypertension; Allergic Rhinitis; Hypothyroidism; Arthritis; Lipid 
Disorders; Thrombo-embolic Prophylaxis and Diabetes Mellitus.  This 
concurs with numerous literature studies that have recognised an enhanced 
prevalence of the specified disease states in depressed patients (references 
of these studies were provided in Section 5.5.2.2).  Osteoporosis was an 
additional prevalent disease state in depressed females aged 55 to 64 years 
(but not amongst the most commonly diagnosed in middle-aged depressed 
females).  The literature has also identified an association between this 
chronic disease state and Depressive Disorders (Cankurtaran et al., 2005).  
Except for Allergic Rhinitis, the prevalence percentages for all of the other 
comorbid disease states (common to both age groups) were higher in 
depressed females aged 55 to 64 years, relative to their middle-aged 
counterparts. 
 
Table 5.24 presents the most frequently diagnosed chronic co-existing 
disease states in depressed males aged 55 to 64 years.  Marsh (2001) found 
the following disease states to be most prevalent in South African males with 
Hypertension (mean age of 58.04 years and male sample size of 36 589):  
Arthritis, Diabetes Mellitus (Type I and II), Hypercholesterolaemia and 
Hyperlipidaemia, Asthma, Hyperuricaemia, IHD and Thrombo-embolic 
Prophylaxis.  With reference to Table 5.24, it is apparent that all of the 
disease states found to be prevalent in the study by Marsh (2001) were also 
commonly diagnosed in depressed South African males between 55 and 64 
years of age for this study.  
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TABLE 5.24  
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
MALE PATIENTS AGED 55 TO 64 YEARS (n = 1 361) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
   MALE PATIENTS WITH 
   COMORBID DISEASE STATES 
   (n = 1 361) 
1 Hypertension 64.73 
2 Lipid Disorders 40.93 
3 Thrombo-embolic Prophylaxis 29.68 
4 Diabetes Mellitus 17.85 
5 Arthritis 13.81 
6 Gout 12.78 
7 Ischaemic Heart Diseases 11.24 
8 Allergic Rhinitis 9.33 
9 Anxiety Disorders 8.96 
10 Asthma 7.57 
 
It has been stated that Gout is the most common form of inflammatory 
Arthritis in males over 40 years of age (Roubenoff, 1990).  Research has also 
shown that the prevalence of Gout is higher amongst males than females 
(Johnstone, 2005).  For example, the female to male prevalence ratio for Gout 
was calculated to be 1:3.6 in a large-scale epidemiological study (1.7 million 
participants) conducted in the UK by Mikuls and others (2005).  Gout has 
been frequently coupled with many other chronic disease states (Mikuls et al., 
2005).  Diabetes Mellitus and Hypertension, in particular, were found to be 
prevalent amongst depressed patients with Gout in this age group.  More 
specifically, 19.86% of depressed patients with Gout, had Diabetes Mellitus 
and 79.09% had Hypertension.  Furthermore, 18.82% of depressed patients 
with Gout were found to have had both Diabetes Mellitus and Hypertension.   
 
Ischaemic Heart Diseases were diagnosed in 11.24% of depressed males in 
this age group.  Numerous studies have ascertained that Depressive 
Disorders are a risk-factor for IHD (Frasure-Smith et al., 1995; Nemeroff et al., 
2000).  Additionally, it is well-known that depressed patients show greater 
platelet reactivity than non-depressed individuals (Musselman et al., 1996; 
Nemeroff et al., 2000).  Nemeroff and others (2000) suggested that platelet 
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dysfunction plays a vital role in enhancing the predisposition of depressed 
patients towards the development of IHD. 
 
Similar to the trend observed in females, it was found that 80% of the chronic 
disease states that occurred frequently in middle-aged depressed males were 
also the most commonly diagnosed comorbidities in depressed males aged 
55 to 64 years.  Moreover, Hypertension and Lipid Disorders (in that order) 
were the most prevalent disease states amongst depressed males between 
35 and 64 years of age.  References regarding numerous studies that have 
identified an elevated prevalence of these chronic disease states 
(Hypertension, Lipid Disorders, Thrombotic Disorders, Diabetes Mellitus, 
Arthritis, Gout, Asthma and Anxiety Disorders) in depressed patients aged 
35 to 64 years, have already been reviewed in Section 5.5.2.2. 
 
Figure 5.14 compares the most prevalent chronic disease states in depressed 
females and males in the 55 to 64 year age group.  Figure 5.14 marks Lipid 
Disorders as prevalent concomitant disease states in depressed females and 
males of this age group.  Lipid Disorders occurred more commonly in males 
(40.93%) than females (22.75%), as was observed in the younger age groups.  
This is in accordance with many other studies that have also found Lipid 
Disorders to occur more frequently in males than in females (Nakao et al., 
2004; Heart Foundation - South Africa, 2006).  However, according to the 
Heart Foundation of South Africa, with the onset of Menopause, the low-
density lipoprotein levels increase in females and the risk for Lipid Disorders is 
believed to be equivalent to that of males.   Lipid Disorders are diagnosed 
often in South African females and males (Heart Foundation - South Africa, 
2006).  Furthermore, research has demonstrated an elevated blood lipid level 
profile in depressed patients, relative to their non-depressed counterparts 
(Carnethon et al., 2004; Nakao et al., 2004; Petrlova et al., 2004). 
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FIGURE 5.14  
PREVALENCE OF CHRONIC COMORBID DISEASE STATES (ACCORDING TO GENDER) 
IN DEPRESSED PATIENTS BETWEEN THE AGES OF 55 AND 64 YEARS (n = 4 943) 
 
Hypertension and Lipid Disorders have occurred commonly in depressed 
patients aged 18 years and older in this study so far.  Besides these 
independent associations with Depressive Disorders, it is well-established that 
Hypertension and Lipid Disorders commonly co-exist (Eaton et al., 1994; 
Johnson et al., 2004).  The results for individuals between 55 and 64 years of 
age were similar to the findings observed by Eaton (and others in 1994) and 
Johnson (and others in 2004), because Lipid Disorders were diagnosed in 
31.11% of hypertensive patients with Depressive Disorders.  
 
Thrombo-embolic Prophylaxis was prescribed to 14.96% of females and 
29.68% of males between 55 and 64 years of age.  These percentages are 
more than twice the respective values obtained for patients aged 35 and 54 
years, namely 6.99% of females and 14.22% of males.  This is to be 
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expected, since this age group presents with a greater number of risk factors 
for Thrombotic Disorders.   
 
Diabetes Mellitus affected 10.78% of depressed females and 17.85% of 
depressed males in this age group.  It is apparent that Diabetes Mellitus has 
been a frequently occurring chronic disease state comorbid with Depressive 
Disorders in all of the age groups discussed this far, with prevalence 
percentages on the rise with an increase in age.  Diabetes Mellitus has been 
associated with a greater prevalence of Hypertension and Lipid Disorders 
(Eaton et al., 1994).  The prevalence of these disease states in depressed 
diabetic patients aged 55 to 64 years was determined to be 80.29% 
(Hypertension) and 44.04% (Lipid Disorders).  Furthermore, it was calculated 
that 88.08% of the depressed diabetic patients had Hypertension or a Lipid 
Disorder or both.  This is marginally less than the results obtained by Eaton 
and others (1994), where 92% of patients with Diabetes Mellitus (59 900 
participants, but mental disorders not considered) were found to have 
comorbid Hypertension or a Lipid Disorder or both.  
 
It is notable that 60% of the most prevalent disease states (determined 
independently for females and males and shown in Tables 5.23 and 5.24, 
respectively) were common to both genders.  This means that the following 
disease states were prevalent in both depressed females and males between 
the ages of 55 and 64 years:  Hypertension, Arthritis, Lipid Disorders, 
Thrombo-embolic Prophylaxis, Diabetes Mellitus and Allergic Rhinitis. 
 
5.7 Age Group Analysis:  65 Years of Age and Older 
 
5.7.1 Age and Gender Distribution of Depressed Patients 
  
It has been estimated that 15% of Americans aged 65 years and older 
experience depressive symptoms that are clinically significant   (Lebowitz, 
1996).  Studies conducted in earlier and recent times have demonstrated that 
the prevalence of Depressive Disorders increases with age amongst those 
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aged 65 years and older (Kramer, German, Anthony, Van Korff & Skinner, 
1985; Roberts, Kaplan, Shema & Strawbridge, 1997).  On the other hand, 
some studies have shown that the prevalence of Depressive Disorders 
decreases with age (Barry, Fleming, Manwell, Copeland & Appel, 1998; 
Narrow et al., 2002).  In this study, middle-aged patients were the most 
depressed.  Due to the conflicting findings of various researchers regarding 
the prevalence of Depressive Disorders in the elderly, Snowdon (2001) 
suggested that even if the prevalence of Depressive Disorders is found to be 
higher amongst the youth and middle-aged individuals, there might be a 
second peak in old age.  A study performed in 2 732 elderly American 
individuals determined the prevalence of current Depressive Disorders to be 
10.6% for females and 5.7% for males (Barry et al., 1998).  This compares 
closely with the results of this study because the prevalence of Depressive 
Disorders in patients aged 65 years and older was 14.10% for females and 
5.73% for males.   
 
The age descriptive statistics for elderly depressed patients are summarised 
in Table 5.25.  Depressed patients aged 65 years and older consisted of 
71.11% females and 28.89% males.  This presents a female to male 
prevalence ratio of 2.46:1.  Therefore, it can be seen that the distribution of 
elderly females and males was not equal; and this difference was found to be 
significant (Chi² = 748.64, d.f. = 1, p = < .0005, Cramér's V = 0.42).  The mean 
age of 293 depressed elderly patients participating in a study to evaluate the 
relationship between Depressive Disorders and Hypertension, was 70.30 
years (Bosworth et al., 2003).  This is similar to the mean age of 73.32 years 
for the 65 years and older age group in this study.  More recently, 
Cankurtaran and others (2005) conducted a study in 1 255 elderly Turkish 
patients between 60 and 108 years of age (273 patients with Depressive 
Disorders:  193 females and 80 males) with a mean age of 71.40 years for 
females and 72.50 years for males (mean age for entire sample:  71.80 years 
of age).  These mean ages were comparable to the corresponding ages for 
elderly patients in this study (see Table 5.25).  The gender-related difference 
for the mean ages of depressed elderly females and males was not significant 
(t-test = 2.45, p < .1; Cohen’s d = 0.08).   
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TABLE 5.25 
DESCRIPTIVE STATISTICS FOR THE AGES OF THE PATIENTS:  AGE 
GROUP 65 YEARS OF AGE AND OLDER (n = 4 199) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 2 986 ) 
73.48 65 98 6.67 
Males  
(n = 1 213) 
72.93 65 97 6.20 
All Patients 
(n = 4 199) 
73.32 65 98 6.54 
 
5.7.2 Comorbidity Analysis 
 
5.7.2.1 Number of Chronic Comorbid Disease States per Depressed  
 Patient 
 
Table 5.26 presents the descriptive statistics regarding number of chronic 
comorbid disease states per depressed patient in the 65 years and older age 
group.  A study specific to American elderly patients with Depressive 
Disorders (1 081 patients with a mean age of 72 years) found the mean 
number of chronic comorbid disease states to be four (Lin et al., 2003).  The 
mean number of chronic comorbidities for depressed elderly patients in this 
study (4.61) was similar to the results of Lin and others (2003).  The mean 
number of chronic co-existing disease states did no differ significantly 
amongst elderly females and males (t-test = 5.09, p < .1; Cohen’s d = 0.17).  
The mean number of chronic comorbidities per depressed patient has 
increased as follows across the age groups:  1.73 (0 to 17 years); 1.74 (18 to 
34 years), 2.70 (35 to 54 years); 3.81 (55 to 64 years) and 4.61 (65 years and 
older).  This confirms the existence of a positive association between age and 
number of chronic disease states in this study.  
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TABLE 5.26 
DESCRIPTIVE STATISTICS FOR THE NUMBER OF CHRONIC COMORBID 
DISEASE STATES PER DEPRESSED PATIENT IN THE 65 YEARS AND 
OLDER AGE GROUP 
 
 NUMBER OF CHRONIC COMORBID DISEASE STATES 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n =2 986) 
4.75 0 19 2.79 
Males  
(n = 1 213) 
4.27 0 22 2.67 
All Patients 
(N = 4 199) 
4.61 0 22 2.76 
 
It is well-established that Depressive Disorders commonly co-exist with other 
chronic disease states, particularly in the elderly (McCoy, 1996; Taylor et al., 
2004).  In addition to changes in mood, behaviour and ideation, Depressive 
Disorders in the elderly are linked to peripheral body changes, such as 
Obesity around the abdominal area, reduced bone density, Hypercortisolemia 
and greater risk for the development of Hypertension and Type II Diabetes 
Mellitus (Brown, Varghese & McEwen, 2004).   
 
Table 5.27 outlines the percentage distribution of depressed patients in this 
age group with one or multiple chronic comorbid disease states.  It has been 
suggested that 88% of individuals aged 65 years and older have one or 
multiple chronic disease states.  Moreover, it has also been estimated that 
25% of these patients will have more than four chronic disease states.  
(Hoffman et al., 1996.) For this study, 99.14% of depressed patients aged 65 
years and older had at least one chronic comorbidity.  Furthermore, 44.03% of 
depressed patients in this age group had more than four chronic comorbid 
disease states.   
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TABLE 5.27 
NUMBER OF CHRONIC COMORBID DISEASE STATES PER PATIENT:  
AGE GROUP 65 YEARS AND OLDER 
 
NUMBER OF CHRONIC COMORBID 
DISEASE STATES 
NUMBER OF PATIENTS (%) 
FEMALES MALES BOTH GENDERS 
0 19 17 36 
  (0.64) (1.40) (0.86) 
1 208 113 321 
  (6.97) (9.32) (7.64) 
2 428 205 633 
  (14.33) (16.90) (15.08) 
3 494 218 712 
  (16.54) (17.97) (16.96) 
4 457 191 648 
  (15.30) (15.75) (15.43) 
5 398 155 553 
  (13.33) (12.78) (13.17) 
6 303 99 402 
  (10.15) (8.16) (9.57) 
7 216 69 285 
  (7.23) (5.69) (6.79) 
8 163 69 232 
  (5.46) (5.69) (5.53) 
9 113 26 139 
  (3.78) (2.14) (3.31) 
10 80 18 98 
  (2.68) (1.48) (2.33) 
11 37 13 50 
  (1.24) (1.07) (1.19) 
12 19 9 28 
  (0.64) (0.74) (0.67) 
13 18 4 22 
  (0.60) (0.33) (0.52) 
14 16 2 18 
  (0.54) (0.16) (0.43) 
15 to 22 17 5 22 
  (0.57) (0.41) (0.52) 
TOTAL NUMBER OF PATIENTS (%) 2 986 1 213 4 199 
  (100) (100) (100) 
 
It is evident that the results for this age group are higher than the estimates 
made by Hoffman and others (1996) regarding the prevalence of one or more 
chronic disease states in elderly individuals.  This could possibly indicate that 
depressed elderly patients are prone to a greater number of chronic 
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comorbidities than their non-depressed counterparts.  This is in accordance 
with many studies that have demonstrated a high prevalence of common 
chronic disease states in depressed individuals (Wells et al., 1991; Frasure-
Smith et al., 1995; Lespẻrance et al., 2000; Katon, 2003).  Table 5.27 shows 
that the distribution trends for depressed females and males, regarding the 
number of chronic comorbidities per patient, were similar.  A chi-square test 
was used to confirm that this gender-related difference was not significant 
(Chi² = 31.21, d.f. = 5, p = < .0005, Cramér's V = 0.09).   
 
5.7.2.2 Most Prevalent Chronic Comorbid Disease States 
 
Table 5.28 provides an outline of the most prevalent chronic disease states in 
depressed elderly females.  As for the 18 to 34, 35 to 54 and 55 to 64 year 
age groups, Hypothyroidism was diagnosed frequently in elderly depressed 
females.  It was noted that 33.42% of depressed patients with Hypothyroidism 
in this age group, also had a concomitant Lipid Disorder.  This is relevant 
because an association between these two disease states has been 
established (Morris et al., 2001). 
 
TABLE 5.28 
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
FEMALE PATIENTS AGED 65 YEARS AND OLDER (n = 2 986) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
  FEMALE PATIENTS WITH 
   COMORBID DISEASE STATES 
   (n = 2 986) 
1 Hypertension 74.82 
2 HRT/Menopause 57.13 
3 Arthritis  30.68 
4 Lipid Disorders 28.67 
5 Thrombo-embolic Prophylaxis 26.39 
6 Hypothyroidism 23.14 
7 Osteoporosis 18.99 
8 Ischaemic Heart Diseases 11.02 
9 Calcium Supplementation 10.48 
10 Diabetes Mellitus 10.28 
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There is a positive correlation between bone loss and age, so the prevalence 
of Osteoporosis has been shown to increase with age (Australian Institute of 
Health and Welfare, 2001).  Similarly, for this study, the prevalence of 
Osteoporosis increased from 12.93% in females aged 55 and 64 years, to 
18.99% in females aged 65 years and older.  In terms of the relationship 
between age and the prevalence of Osteoporosis in females across the 
selected age groups, the observed correlation of 0.943 was significant.  In 
addition, the prevalence of Osteoporosis was found to have increased by 
0.28% per year (For α = .05 and n = 5, rCRIT = 0.88).  Bone loss occurring after 
Menopause (within the first 10 years following Menopause) is believed to be a 
chief contributing factor towards the enhanced prevalence of osteoporotic 
fractures (Elliott & O’Connell, 2002).  It was calculated that 26.81% of elderly 
females with Osteoporosis were receiving Calcium Supplementation. 
 
The following disease states were prevalent in depressed females aged 18 
years and older:  Hypertension, Hypothyroidism, Arthritis and Diabetes 
Mellitus.  Additionally, it was found that, except for Allergic Rhinitis, all of the 
other commonly occurring chronic disease states diagnosed in females 
between 55 and 64 years of age were also prevalent in the elderly age group.  
These disease states included the following:  Hypertension, 
HRT/Menopause, Arthritis, Lipid Disorders, Hypothyroidism, Thrombo-
embolic Prophylaxis, Osteoporosis, Calcium Supplementation and 
Diabetes Mellitus.   
 
Chronic comorbid disease states featuring most commonly in depressed 
elderly males are listed in Table 5.29.  Studies have consistently reported a 
higher prevalence of Gout in males (particularly over 40 years of age), relative 
to females (Roubenoff, 1990; Johnstone, 2005).  A large-scale 
pharmacoepidemiological study conducted in the UK using data from the 
General Practice Research Database (a population-based database that 
collects information from general practices) calculated the prevalence of Gout 
to be almost 7% in males over 65 years of age (Mikuls et al., 2005).  For this 
study, Gout was present in 16.49% of depressed patients aged 65 years and 
older.  The difference between the prevalence percentage for Gout in this 
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study and the one conducted by Mikuls and others (2005) was found to be 
significant (Chi² = 167.74, d.f. = 1, p = < .0005, Cramér's V = 0.37).  There is a 
paucity of research regarding the relationship between Depressive Disorders 
and Gout.  It is thus difficult to ascertain whether the higher prevalence of 
Gout in depressed South African males (when compared with the British study 
population where Depressive Disorders were not considered) can be 
attributed, in part, to the concomitant Depressive Disorders evident in this 
study population or the actual location of the study.  
 
TABLE 5.29 
COMORBIDITIES PRESENTING MOST FREQUENTLY IN DEPRESSED 
MALE PATIENTS AGED 65 YEARS AND OLDER (n = 1 213) 
 
RANK CHRONIC DISEASE STATES PERCENTAGE (%) OF DEPRESSED 
  MALE PATIENTS WITH 
  COMORBID DISEASE STATES 
  (n = 1 213) 
1 Hypertension 70.16 
2 Thrombo-embolic Prophylaxis 43.03 
3 Lipid Disorders 38.25 
4 Arthritis 19.54 
5 Ischaemic Heart Diseases 17.64 
6 Diabetes Mellitus 17.39 
7 Gout 16.49 
8 COPD 11.29 
9 Asthma 10.55 
10 Anxiety Disorders 8.41 
 
Diabetes Mellitus and Hypertension are chronic disease states that have 
been shown to co-exist frequently with Gout (Mikuls et al., 2005).  For this age 
group, of the depressed patients with Gout, 84.62% were also diagnosed with 
Hypertension and 19.92% with Diabetes Mellitus.  Additionally, it was 
calculated that 18.34% of patients with Gout, had both Hypertension and 
Diabetes Mellitus.  It was therefore evident that these patients had a minimum 
of four chronic disease states (Depressive Disorder, Gout, Hypertension and 
Diabetes Mellitus). 
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It was discovered that 11.29% of depressed patients aged 65 years and older 
had comorbid COPD.  A study conducted in 162 patients with COPD (mean 
age of 65.6 years) and 359 controls (mean age of 66.2 years) deduced that 
patients with severe COPD exhibited a 2.5 times greater risk of developing 
Depressive Disorders than controls (van Manen et al., 2002).  
 
Males in the 35 to 54, 55 to 64 and 65 years and older age groups have eight 
prevalent chronic disease states in common, namely:  Hypertension, Lipid 
Disorders, Diabetes Mellitus, Thrombo-embolic Prophylaxis, Arthritis, 
Asthma, Gout and Anxiety Disorders.  The most prevalent co-existing 
disease states in depressed elderly females and males are contrasted in 
Figure 5.15.   
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FIGURE 5.15 
PREVALENCE OF CHRONIC COMORBID DISEASE STATES (ACCORDING TO GENDER) 
IN DEPRESSED PATIENTS AGED 65 YEARS AND OLDER (n = 4 199) 
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Research has consistently identified an association between the prevalent 
chronic disease states identified in depressed patients aged 65 years and 
older in this study and Depressive Disorders:  Hypertension  (Jonas et al., 
1997; Dorsey et al., 2002; Kessler et al., 2003b; Meyer et al., 2004; 
Cankurtaran et al., 2005; Patten et al., 2005); Menopause (Cohen et al., 
2006); Lipid Disorders (Carnethon et al., 2004; Nakao et al., 2004; Petrlova 
et al.,  2004); Thrombo-embolic Prophylaxis (Frasure-Smith et al., 1995; 
Musselman et al., 1998; Krishnan et al., 2000; Nemeroff et al., 2000); 
Arthritis (Marsh, 1997; Taal et al., 1997; Kessler et al., 2003b); 
Hypothyroidism (Burmeister et al., 2001; Thomsen et al., 2005); 
Osteoporosis (Cankurtaran et al., 2005); Diabetes Mellitus (Kovacs et al., 
1997; Lustman et al., 1997; Anderson et al., 2001; Ischaemic Heart Disease 
(Nemeroff et al., 2000); Asthma (Mancuso et al., 2000; Pincus et al., 2001; 
Kanner, 2003; Cankurtaran et al., 2005; Opolski et al., 2005); COPD (van 
Manen et al., 2002) and Anxiety Disorders (Kessler et al., 1996; Barbee, 
1998; Bhagwanjee et al., 1998; Triant, 2002; Kessler et al., 2003b). 
 
The prevalence of Hypertension was 73.47% for depressed patients aged 65 
years and older.  Cankurtaran and others (2005) determined the prevalence of 
Hypertension to be 77.3% amongst 273 elderly depressed patients, which is 
similar to the percentage calculated for this age group of the study population. 
Furthermore, the prevalence of Lipid Disorders was calculated to be 33.29% 
in depressed hypertensive patients (30.93% for females and 39.48% for 
males).   
 
A recent study conducted in 1 801 depressed individuals over the age of 60 
years, found that more than half of the patients had Hypertension or Arthritis 
(Harpole et al., 2005).  Similarly, Lin and colleagues (2003) deduced that 
more than half of patients with late-life Depressive Disorders reported a 
comorbid disease state or treatment for Arthritis.  The high prevalence of co-
existing Arthritis in elderly depressed patients has been demonstrated in many 
other studies too (Unűtzer et al., 2000; Australian Institute of Health and 
Welfare, 2001).  It was calculated that 56.63% of the depressed elderly 
patients had comorbid Hypertension or Arthritis.  This is in agreement with the 
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findings of Lin and colleagues (2003) and Harpole and others (2005), since 
more than half of the depressed patients had comorbid Arthritis. 
 
With reference to Tables 5.28 and 5.29, it is noticeable that 26.39% and 
43.03% of elderly depressed females and males, respectively, were receiving 
Thrombo-embolic Prophylaxis.  It is well-known that depressed patients are 
more likely to have a Thrombotic Disorder than individuals without Depressive 
Disorders (Frasure-Smith et al., 1995; Musselman et al., 1998; Krishnan et al., 
2000; Nemeroff et al., 2000).  For example, a study performed in a sample of 
depressed individuals over 65 years of age without CHD, found that 
Depressive Disorders were linked to elevated fibrinogen and Factor VIIc 
levels (both coagulation promoters) in these patients (Kop, Gottdiener, 
Tangen, Fried, McBurnie, Walston, Newman, Hirsch & Tracy, 2002).  Many 
other studies have also reported elevated levels of coagulation factors in 
patients with Depressive Disorders, when compared to those evident in their 
non-depressed counterparts (Musselman et al., 1996; Panagiotakos, 
Pitsavos, Chrysohoou, Tsetsekou, Papageorgiou, Christodoulou & Stefanadis, 
2004).    
 
According to the guidelines for the prevention and treatment of Thrombo-
embolic Disease, although age itself is a risk factor for the development of 
VTE, being 65 years or older does not indicate a high enough risk for 
Thrombo-embolic Prophylaxis in the elderly, unless other risk factors are also 
present.  However, it must be remembered that, in addition to their age, 
depressed females on HRT exhibit another risk factor for the development of 
VTE.  (Agus, Allegra, Arpaia, Botta, Cataldi, Gasbarro, Mancini, Bonifacio & 
Todini, 2001.) Of the 2 986 females in this age group, 37.24% were on HRT.  
This represents a greater percentage of females than the 35 to 54 year age 
group (23.91% of females on HRT), but is less than the percentage of females 
aged 55 to 64 years (48.16%).  Despite the lower percentage of patients on 
HRT (compared with the 55 to 64 year age group), the prevalence of 
Thrombo-embolic Prophylaxis was found to be highest in the 65 years of age 
and older age group.  The following risk factors placed the elderly depressed 
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patients at a higher risk for the development of a Thrombotic Disorder, relative 
to younger patients: 
 
• Age is a risk factor for Thrombotic Disorders (Geerts et al., 2001), so 
patients aged 65 years and older will exhibit a greater risk than younger 
individuals. 
• The prevalence of Thrombotic Disorders in this age group was 1.98%, 
which is marginally higher than the 35 to 54 and 55 to 64 year age groups 
(0.72% and 1.25%, respectively).  This means that depressed elderly 
patients were at a greater risk for the development of a VTE, since a 
history of such an episode increases the predisposition towards a future 
Thrombotic Disorder (Geerts et al., 2001). 
• There were 70 depressed patients in this age group who had been 
diagnosed with a Stroke.  This contrasts with only 28 depressed patients in 
the 55 to 64 year age group and 18 in the 35 to 54 year age group.  A 
higher prevalence of Stroke has been associated with an enhanced risk for 
a Thrombotic Disorder (Geerts et al., 2001), thus, elderly individuals in this 
study were more susceptible towards a VTE.    
• Another risk factor for Thrombotic Disorders is Cardiac Dysfunction 
(Geerts et al., 2001).  The prevalence of Hypertension amongst depressed 
patients in this study has increased across the age groups as follows:  
1.40% (0 to 17 years of age); 13.73% (18 to 34 years of age); 46.90% (35 
to 54 years of age); 62.82% (55 and 64 years of age) and 73.47% (65 
years and older).  The observed correlation of 0.976 for the prevalence of 
Hypertension across the age groups was significant.  In fact, the 
prevalence of Hypertension was calculated to have increased by 1.06% 
per year (For α = .05 and n = 5, rCRIT = 0.88).  In terms of the risk 
presented by Cardiac Dysfunction, depressed patients aged 65 years and 
older exhibited the greatest prevalence of Hypertension in this study and 
as a result, may be more susceptible towards the development of future 
Thrombotic Disorders than the younger age groups. 
• It was calculated that 1.07% of females and 1.65% of males with 
Depressive Disorders in this age group also had Cancer.  The prevalence 
percentage for both genders was 1.24% and this was 1.59 and 4.58 times 
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IHD was identified as a commonly occurring concomitant disease state in both 
depressed females (11.02%) and males (17.64%) in this age group.  Many 
researchers have shown that Depressive Disorders pose an independent risk 
for the onset and progression of a CVD (Frasure-Smith et al., 1995; Wulsin et 
al., 2003).  Depressive Disorders have been coupled with many important 
cardiac risk factors, such as Diabetes Mellitus and Hypertension (Carney et 
al., 2002; Katon, 2003).  It was clear that these disease states were prevalent 
amongst depressed patients aged 18 years and older in this study.  In 
addition, overall, the prevalence of Diabetes Mellitus and Hypertension was 
found to increase across the age groups.  This is applicable because there 
would be a greater risk contributed by these disease states towards the 
development of a CVD in the elderly than in the younger age groups. 
 
The observation that Diabetes Mellitus occurred frequently in depressed 
patients in all of the age groups may suggest that there is a correlation 
between this chronic disease state and Depressive Disorders.  This possible 
association would be in agreement with numerous other studies that have 
recognised a relationship between Depressive Disorders and Diabetes 
Mellitus (Kovacs et al., 1997; Lustman et al., 1997; Anderson et al., 2001; 
Pincus et al., 2001; Kanner, 2003; Cankurtaran et al., 2005; Lustman et al., 
2005). 
 
Over and above the association that exists between Diabetes Mellitus and 
Depressive Disorders, research has found that diabetic patients also exhibit a 
high prevalence of Hypertension and Lipid Disorders (Eaton et al., 1994).  
Eaton and others (1994), calculated the prevalence of comorbid Hypertension 
and Lipid Disorders to be 65.03% amongst 31 154 diabetic males over 65 
years of age.  This is greater than half of the prevalence percentage (30.18%) 
for comorbid Hypertension and Lipid Disorders observed in the non-diabetic 
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male population aged 65 years and older.  It was calculated that 88.61% and 
42.47% of diabetic patients in this age group had comorbid Hypertension or a 
Lipid Disorder, respectively.  Of the depressed patients with Diabetes Mellitus 
in this age group, 93.49% of females and 94.31% of males, were found to 
have comorbid Hypertension or a Lipid Disorder or both (93.82% for both 
genders).  This compares with the results of Eaton and others (1994), since 
92% of diabetic patients in the literature study were found to have had either 
Hypertension or a Lipid Disorder or both disease states.   
 
It was also determined that 11.16% of depressed asthmatic females had 
comorbid Allergic Rhinitis.  It is evident that on the whole, the prevalence of 
Asthma and Allergic Rhinitis (when disease states are considered 
independently and collectively) has decreased with an increase in age.  Figure 
5.16 shows this inverse relationship.   
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FIGURE 5.16 
PREVALENCE OF COMORBID ALLERGIC RHINITIS AND ASTHMA IN DEPRESSED 
PATIENTS FOR THE SELECTED AGE GROUPS 
 
This observation of a decrease in the prevalence of Allergic Rhinitis and 
Asthma with an increase in age concurs with other studies that have found a 
higher prevalence of Asthma and Allergic Rhinitis in younger individuals than 
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in the elderly (Australian Institute of Health and Welfare, 2001; Dahl et al., 
2004).  The decrease in the prevalence of Allergic Rhinitis across the age 
groups, in those patients diagnosed with or without Asthma, yielded a 
significant negative correlation of 0.965 and 0.942, respectively  (For α = .05 
and n = 5, rCRIT = 0.88).  However, because of a marginal incline in the 
prevalence of Asthma from 9.29% for patients aged 55 to 64 years to 10.03% 
for the 65 years and older age group, the observed negative correlation of 
0.865 (which was only 0.015 less than rCRIT) was not significant (For α = .05 
and n = 5,   rCRIT = 0.88).     
 
On the contrary, the prevalence of comorbid Hypertension, Lipid Disorders 
and Arthritis increased with age, as is depicted in Figure 5.17.  For example, it 
was determined that the prevalence percentages in the 65 years and older 
age group, were 5.35 and 6.39 times greater for Hypertension and Lipid 
Disorders, respectively, than the 18 to 34 year age group.   
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FIGURE 5.17 
PREVALENCE OF COMORBID HYPERTENSION, LIPID DISORDERS AND ARTHRITIS IN 
DEPRESSED PATIENTS FOR THE SELECTED AGE GROUPS 
 
Many studies have concluded that increasing age is associated with a greater 
prevalence of common chronic disease states, such as Hypertension and 
Arthritis (van den Akker et al., 1998; Australian Institute of Health and Welfare, 
 
  
224
2001; van Manen et al., 2001; Wolff et al., 2002; Anderson et al., 2004; Fortin 
et al., 2005; Harpole et al., 2005; Lovell, 2006).   
 
5.8 CONCLUSION 
 
This study is in agreement with the literature, which has consistently found 
that depressed patients exhibit a high prevalence of other chronic disease 
states.  In addition to the complex relationship between Depressive Disorders 
and chronic disease states, there are also interrelationships that exist 
between chronic disease states such as Hypertension and Lipid Disorders, for 
example.  These associations, in turn, have major implications for the 
management of Depressive Disorders and the treatment of concomitant 
chronic disease states. 
 
 
 
 
 
CHAPTER 6 
RESULTS AND DISCUSSION: 
 
APPROPRIATENESS OF ANTIDEPRESSANT PRESCRIBING 
PATTERNS IN THE PRESENCE OF PREVALENT CHRONIC 
COMORBID DISEASE STATES  
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6.1 CHARACTERISTICS OF THE SECONDARY STUDY POPULATION 
 
The secondary study population may be defined as all the patients diagnosed 
with one or more Depressive Disorders in 2004 (refer to Section 4.5 of the 
Methodology). 
 
The first section of this chapter will describe the following characteristics of the 
secondary study population: 
  
• number of patients; 
• age and gender distribution of patients; 
• number of active ingredients prescribed per patient; 
• most frequently prescribed active ingredients; and  
• analysis of medications prescribed for Depressive Disorders. 
 
6.1.1 Number of Patients 
 
There were 6 150 patients in the secondary study population and this 
consisted of 71.89% females and 28.11% males.  This is similar to the 
distribution trends observed for depressed females and males in the entire 
study population (consisting of 21 171 patients); namely, 71.73% females and 
28.27% males (see Section 5.1.1). 
 
6.1.2 Age and Gender Distribution of the Secondary Study Population 
 
The age and gender distribution of the secondary study population is depicted 
in Figure 6.1.  In 2004, the majority of depressed females and males were 
between the ages of 35 and 54 years.  This was also the case for the entire 
study population.  Furthermore, distribution percentages for the 35 to 54 year 
age group of the entire study population were comparable to the results 
depicted in Figure 6.1 (for the secondary study population), namely, 48.53% 
and 46.63% for females and males, respectively (see Section 5.1.2).   
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As for the entire study population, the distribution of females and males did 
not differ significantly across the age groups for the secondary study 
population (Chi² = 24.31, d.f. = 4, p = <.0005, Cramér's V = 0.06).  
Additionally, the entire and secondary study populations displayed similar 
patterns pertaining to the distribution of patients according to age (Chi² = 95,  
d.f. = 4, p = <.0005; Cramér's V = 0.07). 
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FIGURE 6.1 
AGE AND GENDER DISTRIBUTION OF THE SECONDARY STUDY POPULATION  
(N = 6 150) 
 
The mean ages for depressed females and males in the secondary study 
population are outlined in Table 6.1.  The mean age for all of the depressed 
patients was calculated to be 53.01 years.  A study utilising data from the 
National Ambulatory Medical Care Survey (89 424 adult primary care visits) in 
order to evaluate antidepressant prescribing trends in the US, found the mean 
age of the participants to be 53.3 years in 2000 (Pirraglia, Stafford & Singer, 
2003), which is comparable to the mean age of patients in this study for 2004.  
There was no significant gender-related difference in mean ages for the 
secondary study population (t-test = 0.43, p < .1; Cohen’s d = 0.01). 
   
 
 228
TABLE 6.1 
DESCRIPTIVE STATISTICS FOR THE AGES OF DEPRESSED PATIENTS 
IN THE SECONDARY STUDY POPULATION (N = 6 150) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 4 421) 
53.06 10 97 14.95 
Males  
(n = 1 729) 
52.87 7 97 15.75 
All Patients 
(N = 6 150 ) 
53.01 7 97 15.18 
 
6.1.3 Number of Active Ingredients Prescribed per Patient  
 
Figure 6.2 displays the percentage distribution for the number of different 
active ingredients prescribed per patient in the secondary study population.  
The majority of the patients, namely, 34.90% of females and 36.61% of males, 
were prescribed only one active ingredient.  In other words, taking the 
genders together, 35.38% of the patients were prescribed a single medication 
during 2004.  A total of 77.35% of the patients were prescribed between one 
and three different active ingredients.  This means that less than a quarter of 
the depressed patients (22.65%) were taking four or more different 
medications concurrently for one or multiple chronic disease states.  The 
findings of a South African study conducted by Steyn and others (2005), 
evaluating the use of prescribed medications for commonly occurring chronic 
conditions, also showed that the majority of patients were prescribed one 
active ingredient.  Thereafter, there was a decline in the patient distribution 
percentages with an increase in the number of active ingredients prescribed 
per patient.  Similarly for this study, there was an inverse relationship between 
distribution and number of active ingredients prescribed per patient. 
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FIGURE 6.2 
DISTRIBUTION OF THE NUMBER OF DIFFERENT ACTIVE INGREDIENTS PRESCRIBED 
PER PATIENT (N = 6 150) 
 
It is evident from Figure 6.2 that the overall distribution percentages were 
similar for females and males in the secondary study population.  The 
prevalence percentages regarding the number of active ingredients prescribed 
for patients in the various age groups are represented in Figure 6.3.  This 
figure shows that for all of the age groups (with the exception of the 0 to 17 
year age group, which demonstrated a greater prevalence of patients on two 
active ingredients), most of the depressed patients were prescribed only one 
active ingredient.  It is also apparent that patients aged 65 years and older 
exhibited a higher prevalence of a greater number of active ingredients than 
the younger age groups.  For example, the prevalence percentages for the 
various age groups pertaining to the use of three or more active ingredients 
per patient, were as follows:  28.57% (0 to 17 years); 27.80% (18 to 34 years); 
34.82% (35 to 54 years); 44.58% (55 to 64 years); and 50.96% (65 years and 
older). 
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FIGURE 6.3 
DISTRIBUTION OF THE NUMBER OF DIFFERENT ACTIVE INGREDIENTS PRESCRIBED 
PER PATIENT IN EACH OF THE AGE GROUPS (N = 6 150) 
 
The descriptive statistics for the number of active ingredients prescribed per 
patient in 2004 are depicted in Table 6.2.  The mean number of active 
ingredients prescribed per patient did not differ significantly for females and 
males (t-test = 0.15, p < .1; Cohen’s d = 0.01). 
 
TABLE 6.2 
MEAN NUMBER OF ACTIVE INGREDIENTS PER PATIENT (N = 6 150) 
 
 NUMBER OF ACTIVE INGREDIENTS 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 4 421) 
2.60 1 18 1.88 
Males  
(n = 1 729) 
2.59 1 16 1.96 
All Patients 
(N = 6 150 ) 
2.60 1 18 1.90 
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6.1.4 Overview of the Most Frequently Prescribed Medications in the 
Secondary Study Population  
 
The most commonly prescribed medications for females and males in the 
secondary study population were grouped according to the following levels of 
the ATC Classification System (as described in Section 4.5.4.1 of the 
Methodology): 
 
• first level (anatomical main group); 
• second level (therapeutic main group); 
• third level (pharmacological subgroup); and 
• fourth level (therapeutic subgroup) (Guidelines for ATC 
Classification and DDD Assignment, 1996).   
 
6.1.4.1 Percentage Frequency of Medications Prescribed According to 
the ATC Classification System, First Level 
 
Figure 6.4 categorises the agents prescribed to females and males according 
to the first level of the ATC Classification System.   
 
According to Figure 6.4, Nervous System agents were the most frequently 
prescribed (52.42% for females and 54.64% for males).  This could be 
expected since all of the patients were diagnosed with one or more 
Depressive Disorders.  Thereafter, Cardiovascular System agents comprised 
19.22% and 23.42% of the medications prescribed for females and males, 
respectively.  Collectively, agents falling into the following groups of the first 
level of the ATC Classification System accounted for 94.69% (94.17% for 
females and 96.03% for males) of all the medications prescribed in 2004:  
Nervous System; Cardiovascular System; Alimentary Tract and Metabolism; 
Genito Urinary System and Sex Hormones; Respiratory System; Blood and 
Blood Forming Organs and the Musculo-skeletal System.  
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FIGURE 6.4 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS ACCORDING TO THE FIRST LEVEL OF THE ATC CLASSIFICATION SYSTEM (N = 6 150) 
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The following chronic disease states were found to be most prevalent in the 
entire depressed study population (refer to Section 5.2.2):  Hypertension 
(females and males); HRT/Menopause (females); Arthritis (females); 
Hypothyroidism (females); Lipid Disorders (females and males); Thrombo-
embolic Prophylaxis (males); Diabetes Mellitus (males); and Allergic 
Rhinitis (males).  Except for Hypothyroidism, all of the abovementioned 
chronic comorbid disease states are associated with treatment agents falling 
into one of the ATC Classification System (First Level) groups, distinguished 
to be prevalent amongst the agents prescribed for the secondary study 
population.  
 
Figure 6.4 illustrates that on the whole, the prescribing frequency of 
medications for females and males was similar.  The only noteworthy 
difference is the prescribing frequency of agents belonging to the Genito 
Urinary System and Sex Hormones Group.  It was calculated that this group 
was responsible for 6.88% of all of the agents prescribed to depressed 
females in the secondary study population.  This contrasts with the prescribing 
frequency for males, which was found to be 0.36%.  Menopause in females 
occurs between 40 and 60 years of age (Dvornyk et al., 2005).  Seeing as 
though 52.34% of the females in the secondary study population were 
between these ages,  it could be predicted that there would be a greater 
prescribing frequency of agents falling into the Genito Urinary System and 
Sex Hormones Group for females, in comparison to their male counterparts.  
 
6.1.4.2 Percentage Frequency of Medications Prescribed According to 
the ATC Classification System, Second Level 
 
The distribution of agents, according to the second level of the ATC 
Classification System, is presented in Figure 6.5.   
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FIGURE 6.5 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS ACCORDING TO THE SECOND LEVEL OF THE ATC CLASSIFICATION SYSTEM (N = 6 150)
 
 235
The following therapeutic main groups were found to be prescribed most often 
to the secondary study population:  psychoanaleptics (44.41%), agents acting 
on the renin-angiotensin system (6.30%), sex hormones and modulators of 
the genital system (4.73%), psycholeptics (4.07%) and serum lipid reducing 
agents (4%).  It was not surprising to note that psychoanaleptics were the 
most frequently prescribed agents for both females (44.40%) and males 
(44.42%), since all of the patients were prescribed medications for the 
treatment of one or more Depressive Disorders.   
 
It was previously mentioned that Hypertension and Diabetes Mellitus were 
commonly diagnosed disease states in South Africans (Omar et al., 1993; 
Levitt et al., 2000; Steyn et al., 2001; Steyn et al., 2005).  In addition, 
numerous studies have shown a strong association between a higher 
prevalence of Hypertension (Jonas et al., 1997; Dorsey et al., 2002; Kessler 
et al., 2003b; Meyer et al., 2004; Cankurtaran et al., 2005; Patten et al., 2005) 
and Diabetes Mellitus (Kovacs et al., 1997; Lustman et al., 1997; Anderson 
et al., 2001; Pincus et al., 2001; Kanner, 2003; Cankurtaran et al., 2005) in 
depressed patients, when compared with their non-depressed counterparts.  
Figure 6.5 demonstrates that diabetic medications and blood pressure 
lowering agents (for example:  agents acting on the renin-angiotensin system, 
beta blocking agents and diuretics) were frequently prescribed to the 
secondary study population.  It could be argued that the agents acting on the 
renin-angiotensin system, beta blocking agents and diuretics may not have 
been used solely as antihypertensive therapies.  However, it was calculated 
that the majority of the agents acting on the Cardiovascular System (66.23%) 
were prescribed for the treatment of Hypertension.   
 
Lipid Disorders also occur frequently amongst South Africans (Steyn et al., 
2005; Heart Foundation - South Africa, 2006) and the results for this study 
(conducted in 21 171 South Africans) identified a similar trend (see Section 
5.2.2).  In addition, depressed patients have been shown to be more prone to 
the development of Hyperlipidaemia than non-depressed individuals 
(Carnethon et al., 2004; Nakao et al., 2004; Petrlova et al., 2004).  Taking 
both of these factors into account, it was not a surprise to find that serum lipid 
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reducing agents constituted one of the more prevalent therapeutic main 
groups in the secondary study population.  Research has identified a higher 
prevalence of Lipid Disorders in males than in females (Nakao et al., 2004; 
Heart Foundation - South Africa, 2006) and this was also the trend observed 
for patients with Lipid Disorders in the entire study population.  This could 
explain the higher percentage frequency of serum lipid reducing agents 
amongst males (5.91%), when compared with females (3.26%).   
 
Many studies have demonstrated that depressed patients have an enhanced 
risk for the development of Thrombosis or Infarction as a result of a greater 
degree of platelet aggregation that has been associated with Depressive 
Disorders (Frasure-Smith et al., 1995; Musselman et al., 1998; Krishnan et al., 
2000; Nemeroff et al, 2000).  Moreover, Steyn and others (2001) estimated 
that almost half a million South Africans with Hyperlipidaemia exhibit a risk for 
the development of an atherosclerotic-related disease state.  Therefore, 
seeing as though there were more males on serum lipid reducing agents than 
females, it could be predicted that there would be a greater prescribing 
frequency of antithrombotic agents in males (4.19%), relative to females 
(2.19%). 
 
In addition to Hypertension, Diabetes Mellitus and Lipid Disorders, the 
elevated prevalence of the following disease states in depressed patients was 
discussed in Chapter five (Sections 5.3.2.2, 5.4.2.2, 5.5.2.2, 5.6.2.2 and 
5.7.2.2):  Hypothyroidism; Menopause; Thrombo-embolic Prophylaxis; 
Epilepsy; Asthma and Psychotic Disorders.  It was thus predictable to 
identify thyroid therapy, sex hormones and modulators of the genital system, 
antithrombotic agents, antiepileptics, throat preparations and psycholeptics, 
as being the therapeutic main groups prescribed most often to the depressed 
patients during 2004. 
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6.1.4.3 Percentage Frequency of Medications Prescribed According to 
the ATC Classification System, Third Level 
 
The pharmacological subgroup classification of the medications prescribed 
can be represented according to the third level of the ATC Classification 
System; the distribution of which is outlined in Figure 6.6. 
 
Given that all of the patients in the secondary study population were 
depressed, it was not unforeseen to have identified antidepressants as the 
most commonly prescribed pharmacological subgroup (44.15%).  For 
females, the second most frequently prescribed pharmacological subgroup 
was the estrogens (4.51%).  It was previously calculated that more than half of 
the depressed female patients receiving treatment in 2004 fell within the age 
range during which Menopause is said to occur (Dvornyk et al., 2005).  
Furthermore, it could be expected that estrogens would be frequently 
prescribed because these agents are a subgroup of two other main groups 
that were already identified as being commonly prescribed, namely, the 
Genito Urinary System and Sex Hormones Group (ATC Classification System, 
First Level) and sex hormones and modulators of the genital system (ATC 
Classification System, Second Level).  On the other hand, cholesterol and 
triglyceride reducers were the second most frequently prescribed 
pharmacological subgroups for depressed males in 2004.  This was 
predictable because serum lipid reducing agents were commonly prescribed 
to the secondary population; particularly for depressed males. 
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PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS ACCORDING TO THE THIRD LEVEL OF THE ATC CLASSIFICATION SYSTEM (N = 6 150) 
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The other pharmacological subgroups prescribed most often to depressed 
patients in 2004 were used predominantly for the management of the 
following chronic disease states:  Hypertension and other CVDs, Arthritis, 
Diabetes Mellitus (Type II), Asthma, Epilepsy, Psychotic Disorders and 
COPD.  This is in accordance with the literature, which has consistently 
shown that there is a strong association between the abovementioned chronic 
disease states and Depressive Disorders.  Additionally, these disease states 
were found to occur commonly in the various age groups for this study 
(Sections 5.3.2.2, 5.4.2.2, 5.5.2.2, 5.6.2.2 and 5.7.2.2). 
 
6.1.4.4 Percentage Frequency of Medications Prescribed 
According to the ATC Classification System, Fourth Level 
 
The ten most frequently prescribed agents for depressed patients in 2004, 
relative to the fourth level of the ATC Classification System, are listed in Table 
6.3.  It is evident that in both depressed females and males, various 
antidepressants constituted the three most frequently prescribed agents in the 
secondary study population.  Collectively, SSRIs, non-selective monoamine 
re-uptake inhibitors and other antidepressants (examples include:  mianserin, 
trazodone, mirtazapine, venlafaxine and duloxetine) comprised 43.28% 
(43.46% for females and 42.82% for males) of all of the agents prescribed in 
2004.  
 
Natural and semisynthetic estrogens, plain, were one of the most commonly 
prescribed medications for depressed females, however (as would be 
presumed), these agents were not prescribed to any male patients.  Although 
to a greater extent in males, HMG CoA (3-hydroxy-3-methylglutaryl-coenzyme 
A) reductase inhibitors and Angiotensin converting enzyme (ACE) inhibitors 
were commonly prescribed to both genders in the secondary study population.   
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TABLE 6.3 
PERCENTAGE PRESCRIBING FREQUENCY OF THE MOST COMMONLY PRESCRIBED AGENTS ACCORDING TO THE ATC 
CLASSIFICATION SYSTEM, FOURTH LEVEL
ATC Classification System, Fourth Level ATC Code 
Rank  
(All Patients) 
Percentage of All Actives Prescribed (%) 
Females Rank 
(Females) 
Males Rank 
(Males) 
SSRIs N06AB 1 28.70 1 28.30 1 
Non-Selective Monoamine Re-uptake Inhibitors N06AA 2 9.02 2 7.14 3 
Other Antidepressants N06AX 3 5.75 3 7.38 2 
HMG CoA Reductase Inhibitors G03CA 4 3.15 5 5.73 4 
ACE Inhibitors, Plain C10AA 5 3.10 6 4.97 5 
Natural and Semisynthetic Estrogens, Plain C09AA 6 4.51 4 0  
Platelet Aggregation Inhibitors Excluding Heparin H03AA 7 1.75 8 3.26 6 
Thyroid Hormones B01AC 8 2.62 7 0.76  
Beta-Blocking Agents, Selective C07AB 9 1.74 9 1.47 7 
Other Antiepileptics N03AX 10 1.57 10 1.47 8 
Dihydropyridine Derivatives C08CA  1.10  1.32 10 
Benzamides N05AL  1.06  1.36 9 
Other Pharmacological Subgroups    35.96  36.84  
Total (%)     100  100  
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6.1.5 Analysis of Medications Prescribed for Depressive Disorders 
 
This section of the results involves an analysis of the medications prescribed 
for the treatment of Depressive Disorders in the secondary study population 
(N = 6 150) and includes: 
 
• an overview of the number of active ingredients prescribed for the 
treatment of Depressive Disorders per patient; and 
• an overview of the medications prescribed, according to the third, 
fourth and fifth Levels of the ATC Classification System, 
respectively. 
 
6.1.5.1 Number of Active Ingredients Prescribed per Patient in the 
Secondary Study Population for the Treatment of Depressive 
Disorders  
 
The distribution percentages regarding the number of active ingredients 
prescribed per patient, for the treatment of Depressive Disorders in 2004, are 
outlined in Figure 6.7.  Most of the patients (81.09% for females and 81.49% 
for males) were prescribed only a single therapy.  The dominance of single 
treatment prescribing (versus two or three or more agents) was highly 
significant (Chi² = 6 459.96, d.f. = 2, p = < .0005, Cramér's V = 0.72).  
Percudani and others (2004) yielded similar results on evaluating the 
prevalence and distribution of medications prescribed for Depressive 
Disorders in an Italian study population (404 238 participants were prescribed 
one or more medications for Depressive Disorders).  It was found that 87.17% 
and 88.23% of depressed females and males respectively, were prescribed a 
single antidepressant treatment (Percudani, Barbui, Fortino & Petrovich, 
2004).  Patients with multiple concomitant disease states are presumably 
prescribed more than one medication for the simultaneous management of 
different comorbidities and as a result, drug-drug interactions are more likely.  
Therefore, it was positive to have established that the majority of patients 
were prescribed monotherapies for the management of Depressive Disorders.  
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FIGURE 6.7 
DISTRIBUTION OF THE NUMBER OF DIFFERENT ACTIVE INGREDIENTS PRESCRIBED 
PER PATIENT FOR THE TREATMENT OF DEPRESSIVE DISORDERS (N = 6 150) 
 
Table 6.4 outlines the mean number of active ingredients prescribed per 
patient for the pharmacological management of Depressive Disorders in the 
secondary study population.  The mean number of active ingredients was 
identical for females and males.   
 
TABLE 6.4 
MEAN NUMBER OF ACTIVE INGREDIENTS FOR THE TREATMENT OF 
DEPRESSIVE DISORDERS (N = 6 150) 
 
 NUMBER OF ACTIVE INGREDIENTS 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 4 421) 
1.24 1 7 0.56 
Males  
(n = 1 729) 
1.24 1 6 0.58 
All Patients 
(N = 6 150 ) 
1.24 1 7 0.56 
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6.1.5.2 Overview of the Medications Prescribed for Depressive 
Disorders in the Secondary Study Population According to The 
ATC Classification System, Third Level 
 
Figure 6.8 distinguishes the prescribing trends of the most prevalent 
pharmacological subgroups for Depressive Disorders in 2004.   
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FIGURE 6.8 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE THIRD LEVEL OF THE ATC CLASSIFICATION SYSTEM 
(N = 6 150) 
 
* The sum of the prescribing frequencies for females and males do not total 100% 
because other classes of medications (for example, anxiolytics) and agents with a non 
Nervous System Classification (due to possible errors in the data capturing process)  
constituted 0.33% (for females) and 0.42% (for males) of the total number of active 
ingredients prescribed for Depressive Disorders. 
** Four females were prescribed antidepressants in combination with psycholeptics.  
 
It was not surprising to have identified the antidepressants as the most 
frequently prescribed pharmacological subgroup amongst the depressed 
patients.  This is in agreement with a South African study conducted in 2 640 
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depressed patients (aged 65 years and older), which deduced that in 2002, 
86.0% of the medications prescribed for Depressive Disorders were 
antidepressants (Bellingan, 2004).  Furthermore, when the distribution for 
each of the specified ATC Classification System, Third Level Groups (namely, 
antidepressants and combinations; antipsychotics and antiepileptics) was 
assumed to be equal, it was found that the dominance of antidepressant 
prescribing was highly significant (Chi² = 11 700.08, d.f. = 2, p = < .0005, 
Cramér's V = 0.88).   
 
6.1.5.3 Overview of the Medications Prescribed for Depressive 
Disorders in the Secondary Study Population According to The 
ATC Classification System, Fourth Level 
 
The prescribing frequency of medications for the treatment of Depressive 
Disorders, based on the fourth level of the ATC Classification System, is 
summarised in Figure 6.9.  It is evident that the different classes of 
antidepressants were not evenly prescribed to the depressed patients.  In fact, 
it was established that this difference in prescribing frequency was highly 
significant (Chi² = 4 956.17, d.f. = 3, p = <.0005; Cramér's V = 0.47).  
According to the NICE Guidelines (2004) for the management of Depression 
in Primary and Secondary Care, SSRIs should be the antidepressants of 
choice; followed by a different SSRI or mirtazapine as a second-line agent, if 
first-line therapy fails.  It was deduced that SSRIs were the most frequently 
prescribed medications for the treatment of Depressive Disorders (60.03% for 
females and 58.76% for males).  This concurs with the recommendations of 
the NICE Guidelines (2004); and numerous studies that have found that, 
relative to other medications, the SSRIs were the most commonly prescribed 
agents in depressed patients (Truter et al., 1996; Way, Young, Opland, 
Whitehouse & Hughes, 1999; Pirraglia et al., 2003; Bellingan, 2004 [for 2002]; 
Percudani et al., 2004; Van Schalkwyk, 2005 [for 2002 and 2003]).  For 
example, a large-scale retrospective drug utilisation review was conducted in 
over 200 000 Americans, who initiated antidepressant treatment through a 
national managed care organisation (primary care prescribers) and its 
behavioural health subsidiary (psychiatrists).  This study found that 67% and 
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64% of all antidepressant prescriptions written out by primary care providers 
and psychiatrists, respectively, were for SSRIs.  (Way et al., 1999.) Similarly, 
another American study carried out by Pirraglia and others (2003), calculated 
that SSRIs comprised 65% of all antidepressants prescribed to a depressed 
study population. 
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FIGURE 6.9 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE FOURTH LEVEL OF THE ATC CLASSIFICATION SYSTEM 
(N = 6 150) 
 
* The non-selective monoamine re-uptake inhibitors included the following agents:  
maprotiline (1.22%) and TCAs (98.78%). 
** Other therapeutic subgroups represent other medications that were not commonly 
prescribed for the management of Depressive Disorders, for example:  various 
antiepileptics (such as lamotrigine); antipsychotics (such as thioxathine derivatives); 
psycholeptics and psychoanaleptics in combination (such as antidepressants in 
combination with psycholeptics); and beta blocking agents (such as propranolol).  
 
In terms of South African studies conducted in depressed patients, two recent 
drug utilisation reviews (mean ages of patients:  72.9 years [Bellingan, 2004] 
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and 43.43 years [Van Schalkwyk, 2005]) identified SSRIs as the most 
commonly prescribed antidepressant class.  In 2002, for instance, the 
prescribing frequency of SSRIs was 48.4% (Bellingan, 2004) and 51.47% 
(Van Schalkwyk, 2005).  The results of the aforementioned studies compare 
closely with the prescribing frequency of SSRIs observed in this study for 
2004, namely, 59.67%.  Figure 6.9 demonstrates that females and males 
displayed similar prescribing frequencies of the antidepressant classes.  This 
was confirmed by the statistical finding that there was no significant gender-
related difference in this regard (Chi² = 22.80, d.f. = 3, p = < .0005; Cramér's 
V = 0.05). 
 
Hypertension was set apart as the leading chronic comorbid disease state in 
both depressed females and males in the entire study population (prevalence 
of 52.87%; refer to Section 5.2.2).  Similarly, comorbid Hypertension was 
prevalent in the secondary study population, having been diagnosed in 
45.46% of depressed patients.  The concurrent administration of 
antidepressants and antihypertensives may increase the risk of the TCAs 
resulting in orthostatic hypotension (APA, 2000).  Therefore, it was noteworthy 
that the non-selective monoamine re-uptake inhibitors (which consisted 
predominantly of TCAs) were commonly prescribed (19.23%) in 2004, albeit 
the high prevalence of Hypertension identified in the secondary study 
population.     
 
Research has demonstrated that females exhibit a better response to SSRIs 
than males (Kornstein, Schatzberg, Thase, Yonkers, McCullough, Keitner, 
Gelenberg, Davis, Harrison & Keller, 2000).  Although the prescribing 
frequency of SSRIs was marginally higher for females than for males during 
2004, the difference was not significant (Chi² = 1.02, d.f. = 1, p = >.05).  On 
the other hand, males have been shown to respond better to TCAs than their 
female counterparts (Kornstein et al., 2000; Yonkers, 2003).  For this study, 
however, the prescribing frequency of TCAs was lower for males relative to 
the corresponding percentage for females. 
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SSRIs and TCAs accounted for 76.64% of all of the antidepressants 
prescribed.  This correlates with the results of another South African drug 
utilisation review conducted in 2 117 depressed patients.  This study found 
that, collectively, SSRIs and TCAs constituted 75% of the total 
antidepressants prescribed (Truter et al., 1996).  More recently, Van 
Schalkwyk (2005) determined the combined prescribing frequency of SSRIs 
and TCAs in a depressed study population to be 82%.  In addition, Bellingan 
(2004) compared the prescribing trends of antidepressant therapies for the 
years:  1996 and 2002.  This study identified a difference in the prescribing 
trends of SSRIs, relative to TCAs, with time.  In 1996, TCAs were prescribed 
more frequently than SSRIs (prescribing frequency of 52.9% for TCAs and 
34.8% for SSRIs); however, this relationship was reversed in 2002; with TCAs 
having been prescribed less frequently than SSRIs (27.1% for TCAs and 
48.4% for SSRIs).  The increase in prescribing of SSRIs over the years, from 
the advent of this class of drugs in 1988, has been demonstrated in numerous 
studies conducted universally (Stafford, MacDonald & Finkelstein, 2001; 
Pirraglia et al., 2003).         
 
‘Other antidepressants’ include the following antidepressants (ATC code):    
duloxetine (N06AX20), mianserin (N06AX3), mirtazapine (N06AX11), 
nefazodone (N06AX06), reboxetine (N06AX18), trazodone (N06AX05) and 
venlafaxine (N06AX16).  The prescribing frequency of these antidepressants 
(collectively) was calculated to be 12.81%.  Of all the medications prescribed 
for the treatment of Depressive Disorders during 2004, 72.48% could be 
accounted for by the SSRIs and ‘other antidepressants’.  This finding is 
positive because SSRIs or newer antidepressants (such as, venlafaxine) are 
recommended as first-line or second-line drugs of choice for the treatment of 
Depressive Disorders (APA, 2002; NICE Guidelines, 2004).   
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6.1.5.4 Overview of the Medications Prescribed for Depressive 
Disorders in the Secondary Study Population According to The 
ATC Classification System, Fifth Level 
 
The prescribing frequencies of the individual agents used for the management 
of Depressive Disorders in the secondary study population are listed in Table 
6.5.  Fluoxetine was the most frequently prescribed antidepressant during 
2004, with a prescribing frequency of 25.43%.  This is similar to the findings of 
the study conducted by Truter and others (1996), which calculated the 
prescribing frequency of fluoxetine (identified as the antidepressant prescribed 
most often) to be 21.90% amongst the depressed South African population 
sample.  In a more current South African drug utilisation review, Van 
Schalkwyk (2005) evaluated antidepressant prescribing patterns in depressed 
patients (2 803 and 3 267 patients receiving at least one antidepressant 
treatment during 2002 and 2003, respectively) and found fluoxetine to be most 
commonly prescribed in both years (23.07% in 2002 and 26.48% in 2003).  
The findings of Van Schalkwyk (2005), pertaining to fluoxetine prescribing 
frequencies (for 2003, in particular), are similar to the corresponding 
percentage observed in this study for 2004, namely 25.43%.  
 
Citalopram was prescribed to almost a quarter (23.69%) of the depressed 
patients.  This is a promising finding as a result of the following:  of the SSRIs, 
citalopram and sertraline have the most favourable pharmacokinetic profiles, 
which include:  short to intermediate half-lives; no clinically relevant active 
metabolites; linear kinetics; and poor potential for drug-drug interactions 
(Hirschfeld, 2001).  This is applicable since, according to Beliles and 
Stoudemire (1998), an antidepressant with a reasonably short half-life is 
preferred in a patient with co-existing disease states.  In theory, this allows the 
physician to change antidepressant treatments quickly in instances where 
drug interactions are problematic.  Then again, in practice, antidepressants 
such as paroxetine (short half-life relative to other SSRIs), elicit withdrawal 
reactions upon rapid cessation of treatment.  (Beliles et al., 1998.) Paroxetine 
was prescribed to 9.63% of the depressed patients.   
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TABLE 6.5 
PATIENT DISTRIBUTION AND PRESCRIBING FREQUENCIES FOR 
MEDICATIONS USED FOR THE TREATMENT OF DEPRESSIVE 
DISORDERS IN ALL PATIENTS (N = 6 150) 
 
 
Drug Treatment for 
Depressive Disorder 
ATC 
Code N * 
% Of Total 
Medications Prescribed 
for Depressive Disorders 
% Of Depressed Patients 
(N = 6 150) ** 
Fluoxetine N06AB03 1 937 25.43 31.50 
Citalopram N06AB04 1 457 19.13 23.69 
Amitriptyline N06AA09 799 10.49 12.99 
Paroxetine N06AB05 592 7.77 9.63 
Venlafaxine N06AX16 559 7.34 9.09 
Sertraline N06AB06 286 3.75 4.65 
Dothiepin N06AA16 265 3.48 4.31 
Escitalopram N06AB10 212 2.78 3.45 
Mirtazapine N06AX11 203 2.67 3.30 
Antiepileptics *** N03A 216 2.84 3.51 
Sulpiride N05AL01 156 2.05 2.54 
Moclobemide N06AG02 135 1.77 2.20 
Trimipramine N06AA06 94 1.23 1.53 
Mianserin N06AX03 91 1.19 1.48 
Trazodone N06AX05 81 1.06 1.32 
Imipramine N06AA02 74 0.97 1.20 
Fluvoxamine N06AB08 61 0.80 0.99 
Clomipramine N06AA04 44 0.58 0.72 
Other Antipsychotics *** N05A 247 3.24 4.02 
All Other 
Antidepressants # N06A 82 1.08 1.33 
Other Agents ##  26 0.34 0.42 
TOTAL  7617 100   
* N = The total number of patients who were prescribed a particular medication for the 
treatment of one or more Depressive Disorders. 
** One patient may be on more than one antidepressant; therefore, the column does 
not add up to 100%. 
*** The sum of the number of patients who were prescribed individual agents within the 
class of medications listed.  ‘Other Antipsychotics’ include all antipsychotic treatments 
prescribed, except for sulpiride. 
# This includes all of the other antidepressants, categorised as agents with the ATC 
Classification System code of N06, that were not amongst the more prevalent agents 
listed in Table 6.5. 
## ‘Other agents’ includes medications (not classified as antidepressants) that were 
not prescribed frequently, for example:  benzodiazepine derivatives, such as 
bromazepam.  
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Amitriptyline was the third most frequently prescribed antidepressant in the 
secondary study population.  It was also the most prescribed TCA; and this is 
similar to the observations of several other drug utilisation studies that have 
analysed antidepressant prescribing trends (Stafford et al., 2001; Bellingan, 
2004; Van Schalkwyk, 2005).   
 
According to Table 6.5, sulpiride accounted for 2.05% of the treatments 
prescribed for Depressive Disorders.  This antipsychotic was separated from 
the other agents in the same class (ATC code:  N05) because it was 
prescribed more frequently.  Research has shown that low dosages of 
sulpiride may be effective for the treatment of Depressive Disorders (Uchida, 
Takeuchi, Suzuki, Nomura, Watanabe & Kashima, 2005).   
 
The prescribing frequencies of medications for females and males in the 
secondary study population are contrasted in Figure 6.10.  This figure depicts 
similar prescribing frequencies for females and males. The drug consumption 
patterns regarding patients of different ages will be discussed under the 
individual age groups later in this chapter. 
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FIGURE 6.10 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS ACCORDING TO THE FIFTH LEVEL OF THE ATC 
CLASSIFICATION SYSTEM (N = 6 150) 
 
 252
6.2 AGE GROUP ANALYSIS 
 
This section evaluates the following aspects pertaining to each age group of 
the secondary study population: 
 
• age and gender distribution; 
• medications prescribed for Depressive Disorders (according to the 
third, fourth and fifth levels of the ATC Classification System); and 
• antidepressant prescribing patterns relative to the most prevalent 
chronic comorbid disease states identified in each age group.  The 
discussions pertaining to the appropriateness of antidepressant 
selection for 2004, relative to the most commonly occurring 
comorbidities identified in the entire study population (Sections 
6.2.1.3, 6.2.2.3, 6.2.3.3, 6.2.4.3 and 6.2.5.3), will provide general 
comments in this regard. 
 
Thereafter, the antidepressant prescribing trends according to age and the 
three most prevalent chronic comorbid disease states in adult depressed 
patients (aged 18 years and older) will be investigated more specifically.   
 
6.2.1 Age Group 0 to 17 Years 
 
6.2.1.1 Age and Gender Distribution 
 
The descriptive statistics for the ages of the patients between 0 and 17 years 
are presented in Table 6.6.  The mean age of females was found to be 
significantly higher than the mean age of males for the 0 to 17 year age group 
(t-test = 2.27, p < .1; Cohen’s d = 0.58).  Van Schalkwyk (2005) analysed 
antidepressant prescribing trends in South African patients aged 18 years and 
younger, who were prescribed at least one antidepressant in 2002 and 2003 
(n = 176 in 2002 and n = 185 in 2003) and also found the mean age of 
females to be higher than males in both years.   
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Most of the patients (33.93%) were 17 years of age.  It was previously noted 
(see Section 5.3.1) that the gender distribution trend observed in patients 
aged 0 to 17 years for the entire study population, was contrary to those 
observed in all of the other age groups; as well as with the findings of the 
literature regarding the relationship between gender and the prevalence of 
Depressive Disorders.  Similarly, for 2004, there were more depressed males 
(51.79%) than females (48.21%) in the youngest age group.  However, unlike 
the findings for the entire study population, the distribution of males and 
females did not differ significantly when an even distribution was assumed for 
both genders (Chi² = 0.07, d.f. = 1, p = >.05).   
 
TABLE 6.6 
DESCRIPTIVE STATISTICS FOR THE AGES OF DEPRESSED PATIENTS:  
AGE GROUP 0 TO 17 YEARS (n = 56) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 27) 
15.67 10 17 1.59 
Males  
(n = 29) 
14.28 7 17 2.79 
All Patients 
(n = 56) 
14.95 7 17 2.38 
 
6.2.1.2 Analysis of Medications Prescribed for Depressive Disorders:  
Age Group 0 to 17 Years 
 
6.2.1.2.1 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Third Level 
 
The ATC Classification System, Third Level breakdown for the 0 to 17 year 
age group is outlined in Figure 6.11.  There were only three pharmacological 
subgroups utilised for the treatment of Depressive Disorders, namely:  
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antidepressants, antiepileptics and antipsychotics.  The dominance of 
antidepressant prescribing, relative to the other pharmacological subgroups, 
was significant (Chi² = 92.24, d.f. = 2, p = < .0005, Cramér's V = 0.82 when 
the prescribing frequency of each of the specified pharmacological subgroups 
was assumed to be 33.33%).  Van Schalkwyk (2005) identified antiepileptics 
as the most frequently prescribed CNS agents, after antidepressants, in 
young patients.  For this study, antiepileptics and antipsychotics were both 
second to antidepressants (in terms of prescribing frequency) and collectively 
constituted 11.76% (5.88% for each) of the medications prescribed to patients 
between 0 and 17 years of age for the treatment of Depressive Disorders. 
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PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE THIRD LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 0 TO 17 YEARS (n = 56) 
 
6.2.1.2.2 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fourth Level 
 
Figure 6.12 compares the frequency of the most commonly prescribed 
therapeutic subgroups for the treatment of Depressive Disorders in females 
and males aged 0 to 17 years, in 2004.  The difference in the prescribing 
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frequency of the SSRIs, relative to the other specified therapeutic subgroups 
(considered collectively), was not significant (Chi² = 2.88, d.f. = 1, p = >.05, 
Cramér's V = 0.47).   
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FIGURE 6.12 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE FOURTH LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 0 TO 17 YEARS (n = 56) 
 
* Maprotiline was not prescribed to patients in the 0 to 17 year age group; therefore the 
non-selective monoamine reuptake inhibitors were all TCAs. 
** ‘Other therapeutic subgroups’ includes medications that were not commonly 
prescribed for the management of Depressive Disorders, for example:  benzamides. 
 
For both genders, the SSRIs were prescribed most frequently, followed by the 
TCAs.  According to Kando and others (2002), since there are currently no 
definitive treatments for Depressive Disorders in children and adolescents, the 
TCAs and SSRIs continue to be practical antidepressant choices.  
Furthermore, it has been suggested that the unfavourable side-effect profile 
and failed efficacy of TCAs in children, may leave the SSRIs as the only 
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available antidepressant agents suitable for use in young depressed patients 
(Whittington et al., 2004).  However, it must be noted that SSRIs have been 
associated with the possibility of increasing the risk of suicide in children and 
adolescents (Whittington et al., 2004; NICE Guidelines, 2005).   
 
The results of two other South African drug utilisation reviews found the TCAs 
to be the most frequently prescribed antidepressant class in young patients 
(Kairuz et al., 2003; Van Schalkwyk, 2005).  These findings differ from the 
most common therapeutic subgroup identified in this study, namely, the 
SSRIs.  This may indicate a shift towards a greater use of SSRIs; and concurs 
with other research that has demonstrated a rise in the prescribing frequency 
of SSRIs in young depressed patients (Hayes, 2004).  The observations of 
this study for the 0 to 17 year age group are in agreement with the literature, 
which recommends the use of SSRIs in young people, because of their 
proposed efficacy and superior tolerability, when compared with other 
antidepressants (Hayes, 2004).  Conversely, toxicity in overdose with TCAs, 
has been shown to be fatal (Kerr et al., 2001) and because suicide is a major 
concern amongst adolescents, SSRIs are a comparatively safer treatment 
option (Kando et al., 2002). 
 
Similar to the results of Van Schalkwyk (2005) for 2002 and 2003, this study 
found that TCAs were prescribed more commonly to male depressed patients 
in 2004 (refer to Figure 6.12), who, according to previous research findings, 
have been shown to respond better to this class of antidepressants than 
females (Kornstein et al., 2000; Yonkers, 2003).  Albeit this finding, it was 
established that this gender difference was not significant for young patients in 
2004 (Chi² = 0.09, d.f. = 1, p = >.05). 
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6.2.1.2.3 Analysis of Medications Prescribed for Depressive Disorders 
According to The ATC Classification System, Fifth Level 
 
The frequencies of the various medications prescribed for the management of 
Depressive Disorders in patients aged 0 to 17 years of age, are depicted in 
Table 6.7.   
 
TABLE 6.7 
PATIENT DISTRIBUTION AND PRESCRIBING FREQUENCIES FOR 
MEDICATIONS USED FOR THE TREATMENT OF DEPRESSIVE 
DISORDERS:  AGE GROUP 0 TO 17 YEARS (n = 56) 
 
Treatment for 
Depressive Disorder 
 
ATC Code 
 n * 
% Of Total 
Medications Prescribed 
for Depressive Disorders 
% of Depressed Patients 
(n = 56) ** 
Fluoxetine N06AB03 18 26.47 32.14 
Citalopram N06AB04 18 26.47 32.14 
Amitriptyline N06AA09 7 10.29 12.50 
Venlafaxine N06AX16 5 7.35 8.93 
Imipramine N06AA02 4 5.88 7.14 
Antiepileptics *** N03 4 5.88 7.14 
Antipsychotics *** N05 4 5.88 7.14 
Paroxetine N06AB05 2 2.94 3.57 
Escitalopram N06AB10 2 2.94 3.57 
Fluvoxamine N06AB08 1 1.47 1.79 
Moclobemide N06AG02 1 1.47 1.79 
Mirtazapine N06AX11 1 1.47 1.79 
Duloxetine N06AX20 1 1.47 1.79 
 TOTAL   68 100%  
* n = The total number of patients who were prescribed a particular medication for the 
treatment of one or more Depressive Disorders. 
** One patient may be on more than one antidepressant; therefore, the column does 
not add up to 100%. 
*** The sum of the number of patients who were prescribed individual agents within the 
class of medications listed.   
 
Fluoxetine and citalopram were the most commonly prescribed agents for 
young patients in the secondary study population.  Collectively, these two 
agents accounted for over half of the total medications prescribed for 
Depressive Disorders.  Fluoxetine is the only SSRI approved by the US FDA 
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for the treatment of Depressive Disorders in children (Hayes, 2004).  
However, the CSM (a British expert working group) stated that child and 
adolescent psychiatrists are able to prescribe other SSRIs in specific 
situations (NICE Guidelines, 2004).  It is well-known that citalopram has a 
favourable pharmacokinetic profile, which means that it is associated with few 
drug-drug interactions (Hirschfeld, 2001).  In addition, fluoxetine and 
citalopram are generally coupled with less discontinuation or withdrawal 
symptoms (NICE Guidelines, 2004).   
 
Table 6.7 identifies amitriptyline as the third most frequently prescribed agent 
in the 0 to 17 year age group.  This was also the case for the South African 
drug utilisation study performed by Van Schalkwyk (2005) for both years of 
the analysis.  Venlafaxine was also one of the more commonly prescribed 
medications, with a prescribing frequency of 7.35%.  The use of venlafaxine, 
as a first-line agent for the treatment of Depressive Disorders in children, is 
increasing (Chan, Rey & Hazell, 2002).   
 
Figure 6.13 compares the most frequently prescribed antidepressants in 
females and males aged 0 to 17 years.  It is evident that, except for citalopram 
and imipramine, which were prescribed more frequently to male depressed 
patients than their female counterparts, the frequencies of the other common 
agents were similar for both genders.  Studies have shown that males exhibit 
a superior tolerability towards imipramine than females (NICE Guidelines, 
2004).  Furthermore, imipramine has been approved by the FDA for the 
management of Enuresis in children (Kando et al., 2002).  This is relevant 
because Enuresis was diagnosed more frequently in young males in the 
entire study population than females; and could possibly explain the higher 
prescribing frequency of imipramine amongst males aged 0 to 17 years.  In 
Section 3.3.1, the possible enhanced relative noradrenergic to serotonergic 
activity in children and adolescents was discussed.  Research has 
demonstrated that citalopram displays the greatest selectivity for inhibiting the 
re-uptake of serotonin over noradrenaline (Owens, Morgan, Plot & Nemeroff, 
1997).  Consequently, this may prove to be a useful antidepressant in young 
patients.   
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FIGURE 6.13 
FREQUENCY OF THE MOST COMMONLY PRESCRIBED ANTIDEPRESSANTS FOR 
DEPRESSIVE DISORDERS (BY GENDER) ACCORDING TO THE FIFTH LEVEL OF THE 
ATC CLASSIFICATION SYSTEM:  AGE GROUP 0 TO 17 YEARS (n = 56) 
 
6.2.1.3 Antidepressant Prescribing Patterns Relative to the Most 
Prevalent Comorbidities:  Age Group 0 to 17 Years 
 
Studies have consistently shown that children with MDD often have multiple 
comorbidities (Daly & Wilens, 1998).  In Section 5.3.2.2, the most prevalent 
concomitant disease states in young depressed patients were identified:  
Allergic Rhinitis, ADHD, Asthma, Epilepsy and Acne.  The most frequently 
prescribed treatments for the management of Depressive Disorders in the 0 to 
17 year age group will be discussed with reference to their appropriateness in 
patients with the abovementioned chronic co-existing disease states: 
 
• Despite the concerns regarding TCA use (anticholinergic effects and 
cardiotoxicity), this class of antidepressants may be beneficial in 
depressed children and adolescents with comorbidities (Son et al., 2000), 
such as ADHD and Asthma (Dopheide & Theesen, 2002).  In fact, TCAs 
have been considered as second-line agents (after stimulants) for the 
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treatment of ADHD (Dopheide et al., 2002).  Moreover, in depressed 
patients with comorbid Asthma, TCAs prevent ACh-mediated 
bronchoconstriction (Koenig, 2000) and are effective for the treatment of 
Depressive Disorders (Arrol et al., 2005). 
• With reference to the literature, Asthma and Allergic Rhinitis are chronic 
disease states that are often comorbid with Depressive Disorders 
(Leynaert et al., 2000) and this study yielded a similar finding (refer to 
Sections 5.3.2.2, 5.4.2.2, 5.5.2.2 and 5.6.2.2).  The complexity of treating 
co-existing Depressive Disorders, Asthma and Allergic Rhinitis, stems from 
the fact that TCAs are useful in depressed patients with Asthma (Arrol et 
al., 2005), however, anticholinergic side effects may be a problem if co-
administered with antihistamines (SAMF, 2005), which are first-line agents 
for the management of Allergic Rhinitis (May, 2002).  For example, 
amitriptyline, which was the most frequently prescribed TCA in the young 
patients, has extensive anticholinergic properties (SAMF, 2005) and is 
more likely to elicit adverse anticholinergic side effects (relative to other 
TCAs with lower propensities towards inducing such effects). 
• ADHD was identified as a prevalent concomitant disorder in young male 
depressed patients in particular (prevalence of ADHD:  12.73% for females 
and 46.59% for males).  Taking into consideration that imipramine is one 
of the recommended first-line agents for the treatment of Depressive 
Disorders and comorbid ADHD (Dopheide et al., 2002); and that it has 
been associated with a greater tolerability in males (NICE Guidelines, 
2004), it was not surprising to have recognised a higher prescribing 
frequency of this TCA amongst males, than their female counterparts.  
Birmaher and others (1998) recommend the use of venlafaxine in young 
patients with MDD and comorbid ADHD, thus, it was positive to note that 
this agent was frequently prescribed.    
• SSRIs should be first-line treatments for depressed patients with comorbid 
Epilepsy (MacHale, 2002; Kanner, 2003).  More specifically, citalopram 
(which was prescribed to over a quarter of the young patients) is one of the 
preferred SSRIs in depressed patients with Epilepsy (Kanner, 2003). 
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6.2.2 Age Group 18 to 34 Years 
 
6.2.2.1 Age and Gender Distribution 
 
Table 6.8 outlines the age-related descriptive statistics for patients between 
18 and 34 years in the secondary study population.   
 
TABLE 6.8 
DESCRIPTIVE STATISTICS FOR THE AGES OF DEPRESSED PATIENTS:  
AGE GROUP 18 to 34 YEARS (n = 615) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 433) 
27.88 18 34 5.03 
Males  
(n = 182) 
26.79 18 34 5.31 
All Patients 
(n = 615) 
27.56 18 34 5.13 
 
There were significantly more females than males in this age group (for an 
assumed 50:50 gender distribution, Chi² = 102.44, d.f. = 1, p = <.0005, 
Cramér's V = 0.41).  Similar to the findings for patients aged 18 to 34 years in 
the total study population (see Section 5.4.1), the majority of the patients in 
the same age group for the secondary study population, were 33 years of age 
(12.85%).  The mean ages for females and males in this age group were 
found to differ significantly (t-test = 2.43, p < .1; Cohen’s d = 0.21). 
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6.2.2.2 Analysis of Medications Prescribed for Depressive Disorders: 
Age Group 18 to 34 Years 
 
6.2.2.2.1 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Third Level 
 
The prescribing frequencies of the various ATC Classification System, Level 
Three agents are depicted in Figure 6.14.   
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FIGURE 6.14 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE THIRD LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 18 to 34 YEARS (n = 615) 
 
* The sum of the prescribing frequencies for females and males do not add up to 100% 
because other classes of medications (for example, anxiolytics) accounted for 0.35% 
(females) and 0.42% (males) of the total number of active ingredients prescribed for 
Depressive Disorders. 
 
As expected, antidepressants were prescribed significantly more frequently 
than the other pharmacological subgroups for the treatment of Depressive 
Disorders in patients aged 18 to 34 years (prescribing frequencies were 
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assumed to be evenly distributed:  Chi² = 1 126.21, d.f. = 2, p = <.0005, 
Cramér's V = 0.83).  Epilepsy (for females and males) and Psychotic 
Disorders (for males) were amongst the most prevalent co-existing disease 
states in depressed patients between 18 and 34 years of age for the total 
study population.  Therefore, it could be predicted that augmentation therapy, 
in the form of antiepileptics and antipsychotics, would be among the more 
common pharmacological subgroups prescribed for Depressive Disorders in 
the presence of these co-existing chronic disease states. 
 
6.2.2.2.2 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fourth Level 
 
The therapeutic subgroups prescribed most often for the treatment of 
Depressive Disorders in females and males in the 18 to 34 year age group, 
are contrasted in Figure 6.15.  Similar to the results for the 0 to 17 year age 
group, SSRIs were the most frequently prescribed agents.  This finding was 
significant (assumed prescribing frequency of 50:50 for SSRIs versus all other 
agents prescribed:  Chi² = 85.29, d.f. = 1, p = <.0005, Cramér's V = 0.32).  
This is in agreement with research recommendations stating that SSRIs are 
considered to be first-line agents for the treatment of Depressive Disorders in 
adults.  This is because SSRIs have a favourable tolerability profile; reduced 
potential for cardiovascular side effects; and superior safety in cases of 
overdose, relative to the TCAs.  (Judd et al., 1999; NICE Guidelines, 2004; 
Nemeroff, 2006.) Conversely, the prescribing frequency of the TCAs in this 
age group was less than half of the respective percentage for patients 
between 0 and 17 years of age (16.18% for 0 to 17 year age group versus 
7.64% for the 18 to 34 year age group).   
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PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE FOURTH LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 18 TO 34 YEARS (n = 615) 
 
* Maprotiline was not prescribed to patients in the 18 to 34 year age group; therefore 
the non-selective monoamine re-uptake inhibitors were all TCAs. 
** ‘Other therapeutic subgroups’ includes medications that were not commonly 
prescribed for the management of Depressive Disorders, for example:  benzamides. 
 
It was positive to deduce that ‘other antidepressants’ were prescribed more 
frequently than the TCAs (10.97% for ‘other antidepressants’ and 7.64% for 
TCAs), since these agents could offer considerable advantages to the older 
treatments in terms of a more favourable side effect profile associated with 
their use (Majeroni et al., 1998).  It is worth mentioning that MAO A Inhibitors 
were prescribed more regularly than TCAs to male patients in 2004 
(prescribing frequencies of 5% for MAO A Inhibitors and 4.58% for TCAs).  
The literature has demonstrated that MAOIs are not as useful for the 
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treatment of Depressive Disorders as some of the other available 
antidepressants (Balon et al., 1999).  However, MAOIs may be beneficial in 
patients with refractory Depressive Disorders (Nemeroff, 2006) and this could 
possibly explain their use in patients aged 18 to 34 years. 
 
6.2.2.2.3 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fifth Level 
 
The details pertaining to the individual agents prescribed for the 18 to 34 year 
age group for the management of Depressive Disorders in 2004, are outlined 
in Table 6.9.  The following observations were made with regard to the 
medication prescribing trends for the 18 to 34 year age group: 
 
• Fluoxetine, citalopram and paroxetine were all commonly prescribed 
SSRIs.   
• Venlafaxine, which was prescribed to 9.43% of the patients, and its active 
metabolite, are not extensively protein bound (unlike the SSRIs) (Andrews, 
et al., 1996; Beliles et al., 1998), and may be useful in patients already 
prescribed other highly protein bound medications. 
• The prescribing frequency of escitalopram was 5.06%.  Like citalopram, 
research has demonstrated that escitalopram is not likely to partake in 
pharmacokinetic interactions that are clinically significant (Kando et al., 
2002). 
• As for the 0 to 17 year age group, amitriptyline (which has pronounced 
anticholinergic effects) was the most commonly prescribed TCA in patients 
aged 18 to 34 years.  In spite of this, amitriptyline had a lower prescribing 
frequency in this age group, relative to the respective percentage for the 
younger age group (10.29% for the 0 to 17 year age group and 4.81% for 
the 18 to 34 year age group). 
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TABLE 6.9 
PATIENT DISTRIBUTION AND PRESCRIBING FREQUENCIES FOR 
MEDICATIONS USED FOR THE TREATMENT OF DEPRESSIVE 
DISORDERS:  AGE GROUP 18 TO 34 YEARS (n = 615) 
 
Treatment for 
Depressive Disorder 
ATC Code 
 n * 
% Of Total 
Medications Prescribed 
for Depressive Disorders 
% of Depressed Patients 
(n = 615) ** 
Fluoxetine N06AB03 238 29.35 38.70 
Citalopram N06AB04 166 20.47 26.99 
Venlafaxine N06AX16 58 7.15 9.43 
Paroxetine N06AB05 55 6.78 8.94 
Antiepileptics *** N03 48 5.92 7.80 
Antipsychotics *** N05 41 5.06 6.67 
Escitalopram N06AB10 41 5.06 6.67 
Amitriptyline N06AA09 39 4.81 6.34 
Moclobemide N06AG02 31 3.82 5.04 
Sertraline N06AB06 30 3.70 4.88 
Mirtazapine N06AX11 15 1.85 2.44 
Dothiepin N06AA16 10 1.23 1.63 
Trimipramine N06AA06 9 1.11 1.46 
Fluvoxamine N06AB08 7 0.86 1.14 
Reboxetine N06AX18 6 0.74 0.98 
Trazodone N06AX05 5 0.62 0.81 
Imipramine N06AA02 3 0.37 0.49 
Mianserin N06AX03 3 0.37 0.49 
Duloxetine N06AX20 2 0.25 0.33 
Lofepramine N06AA07 1 0.12 0.16 
Other Agents ##   3 0.37 0.49 
 TOTAL   811 100%  
* n = The total number of patients who were prescribed a particular medication for the 
treatment of one or more Depressive Disorders. 
** One patient may be on more than one antidepressant; therefore, the column does 
not add up to 100%. 
*** The sum of the number of patients who were prescribed individual agents within the 
class of medications listed.   
## ‘Other agents’ includes medications (not classified as antidepressants) that were 
not prescribed frequently, for example:  benzodiazepine derivatives, such as 
bromazepam.  
 
The most frequently prescribed antidepressants in females and males aged 
18 to 34 years are compared in Figure 6.16.  It is evident that the prescribing 
frequencies of venlafaxine, paroxetine and moclobemide were higher in 
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depressed males than females.  On the other hand, amitriptyline was more 
commonly prescribed to depressed females.  
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FIGURE 6.16 
FREQUENCY OF THE MOST COMMONLY PRESCRIBED ANTIDEPRESSANTS FOR 
DEPRESSIVE DISORDERS (BY GENDER) ACCORDING TO THE FIFTH LEVEL OF THE 
ATC CLASSIFICATION SYSTEM:  AGE GROUP 18 TO 34 YEARS (n = 615) 
 
6.2.2.3 Antidepressant Prescribing Patterns Relative to the Most 
Prevalent Comorbidities:  Age Group 18 to 34 Years 
 
When the total study population was analysed, it was established that 
depressed patients between 18 and 34 years of age were most commonly 
diagnosed with the following concomitant chronic disease states:  Allergic 
Rhinitis, Asthma, Acne, Hypertension and Epilepsy (refer to Section 
5.4.2.2).   
 
The SSRIs are the antidepressants of choice for the management of 
Depressive Disorders in the presence of comorbid Hypertension (Guck et al., 
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2001; MacHale, 2002; Hayes, 2004); and Epilepsy (MacHale, 2002; Kanner, 
2003).  Kanner (2003) stated that citalopram may be used instead of sertraline 
(which is not one of the medical aid scheme’s ‘accepted’ chronic treatments’ 
for Depressive Disorders and thus, explains the low prescribing frequency of 
this antidepressant) in epileptic patients since it is not involved in the 
inhibition of CYP450 isoenzymes.  It was therefore promising to have found 
that citalopram was prescribed regularly to the 18 to 34 year age group of the 
secondary study population.  Conversely, fluoxetine and paroxetine, which 
were also commonly prescribed, may be involved in drug-drug interactions 
with antiepileptics (Kando et al., 2002).   
 
Antidepressants with anticholinergic effects, such as TCAs, are favoured for 
the management of Depressive Disorders and concomitant Asthma (Koenig, 
2000).  It was previously established that for the entire study population, there 
was an inverse relationship between the prevalence of comorbid Asthma and 
age (refer to Section 5.7.2.2, Figure 5.16).  The lower prescribing frequency of 
the TCAs (when compared with the corresponding percentage for the 0 to 17 
year age group) could be related to the higher prevalence of concomitant 
Asthma in the younger age group. 
 
6.2.3 Age Group 35 to 54 Years 
 
6.2.3.1 Age and Gender Distribution 
 
Table 6.10 presents the descriptive statistics for the ages of the patients 
between 35 and 54 years.  The 35 to 54 year age group included the highest 
number of patients in both the total and secondary study populations.  The 
mean ages of middle-aged females and males did not differ significantly for 
the secondary study population (t-test = 0.41, p < .1, Cohen’s d = 0.02).  It 
was calculated that 73.97% of middle-aged depressed patients were females 
and 26.03% were males.  This gender-related difference was found to be 
significant (Chi² = 622.16, d.f. = 2, p = <.0005, Cramér's V = 0.48). 
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TABLE 6.10 
DESCRIPTIVE STATISTICS FOR THE AGES OF DEPRESSED PATIENTS:  
AGE GROUP 35 TO 54 YEARS (n = 2 708) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 2 003) 
45.96 35 54 5.46 
Males  
(n = 705) 
46.06 35 54 5.39 
All Patients 
(n = 2 708) 
45.98 35 54 5.44 
 
6.2.3.2 Analysis of Medications Prescribed for Depressive Disorders: 
Age Group 35 to 54 Years 
 
6.2.3.2.1 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Third Level 
 
The frequency of the pharmacological subgroups prescribed for patients 
between 35 and 54 years of age, is shown in Figure 6.17.  As for the younger 
age groups, antiepileptics, antipsychotics and antidepressants were 
prescribed most often.  It is clear that antidepressants were prescribed more 
commonly than the other subgroups.  In fact, this difference was highly 
significant (Chi² = 4 000.40, d.f. = 2, p = <.0005, Cramér's V = 0.89).  It was 
observed that the prescribing frequency of antidepressants increased with age 
as follows (taking the genders together):  88.24% (0 to 17 year age group); 
88.68% (18 to 34 year age group) and 91.89% (35 to 54 year age group).  
Conversely, the prescribing frequency of antiepileptics and antipsychotics 
decreased with an increase in age.  This may be attributed to the higher 
prevalence of Psychotic Disorders and Epilepsy that was recognised in the 
younger age groups, relative to middle-aged patients, in the total study 
population (see Sections 5.3.2.2, 5.4.2.2 and 5.5.2.2).   
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FIGURE 6.17 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE THIRD LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 35 TO 54 YEARS (n = 2 708) 
 
* The sum of the prescribing frequencies for females and males do not add up to 100% 
because other classes of medications (for example, anxiolytics) accounted for 0.20% 
(for females) and 0.33% (for males) of the total number of active ingredients prescribed 
for Depressive Disorders. 
 
6.2.3.2.2 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fourth Level 
 
The distribution of the therapeutic subgroups for the 35 to 54 year age group, 
in terms of the prescribing frequencies, is shown in Figure 6.18.  The trend 
noticed for the prescribing frequency of the SSRIs has remained constant 
throughout the age groups; comprising over half of the medications for 
Depressive Disorders in each of the age groups discussed so far.  More 
specifically, the greater prescribing frequency of the SSRIs, when compared 
with the sum of the frequencies of the other therapeutic subgroups, in middle-
aged individuals in 2004, was significant (Chi² = 193.55, d.f. = 1, p = <.0005, 
Cramér's V = 0.24). 
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FIGURE 6.18 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE FOURTH LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 35 to 54 YEARS (n = 2 708) 
 
* The non-selective monoamine re-uptake inhibitors included the following agents:  
maprotiline (0.77%) and TCAs (99.23%). 
** ‘Other therapeutic subgroups’ includes medications that were not commonly 
prescribed for the management of Depressive Disorders, for example:  benzamides. 
 
6.2.3.2.3 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fifth Level 
 
Table 6.11 describes the frequencies of agents prescribed for the treatment of 
Depressive Disorders in the 35 to 54 year age group in 2004.  Fluoxetine, 
citalopram, amitriptyline, venlafaxine and paroxetine were most commonly 
prescribed.  As was evident in the younger age groups, fluoxetine, citalopram 
and paroxetine were the most frequently prescribed SSRIs in middle-aged 
depressed patients.   
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TABLE 6.11 
PATIENT DISTRIBUTION AND PRESCRIBING FREQUENCIES FOR 
MEDICATIONS USED FOR THE TREATMENT OF DEPRESSIVE 
DISORDERS:  AGE GROUP 35 TO 54 YEARS (n = 2 708) 
 
 
Treatment for 
Depressive Disorder ATC Code n * 
% Of Total 
Medications Prescribed 
for Depressive Disorders 
% Of Depressed Patients 
(n = 2 708) ** 
Fluoxetine N06AB03 933 27.32 34.45 
Citalopram N06AB04 645 18.89 23.82 
Amitriptyline N06AA09 351 10.28 12.96 
Venlafaxine N06AX16 275 8.05 10.16 
Paroxetine N06AB05 263 7.70 9.71 
Antipsychotics *** N05 168 4.92 6.20 
Sertraline N06AB06 135 3.95 4.99 
Escitalopram N06AB10 105 3.07 3.88 
Antiepileptics *** N03 101 2.96 3.73 
Dothiepin N06AA16 94 2.75 3.47 
Mirtazapine N06AX11 74 2.17 2.73 
Moclobemide N06AG02 68 1.99 2.51 
Trazodone N06AX05 35 1.02 1.29 
Trimipramine N06AA06 34 1.00 1.26 
Fluvoxamine N06AB08 33 0.97 1.22 
Mianserin N06AX03 28 0.82 1.03 
Imipramine N06AA02 18 0.53 0.66 
Clomipramine N06AA04 15 0.44 0.55 
Duloxetine N06AX20 12 0.35 0.44 
Reboxetine N06AX18 10 0.29 0.37 
Lofepramine N06AA07 6 0.18 0.22 
Maprotiline N06AA21 4 0.12 0.15 
Other Agents ##  8 0.23 0.30 
TOTAL  3 415 100%  
* n = The total number of patients who were prescribed a particular medication for the 
treatment of one or more Depressive Disorders. 
** One patient may be on more than one antidepressant; therefore, the column does 
not add up to 100%. 
*** The sum of the number of patients who were prescribed individual agents within the 
class of medications listed.   
## ‘Other agents’ includes medications (not classified as antidepressants) that were 
not prescribed frequently, for example:  benzodiazepine derivatives, such as 
bromazepam.  
 
In turn, Figure 6.19 presents the frequencies of the antidepressants 
prescribed most often to females and males between 35 and 54 years of age 
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during 2004.  Fluoxetine, citalopram, amitriptyline, venlafaxine and paroxetine 
were commonly prescribed antidepressants for the 18 to 34 and 35 to 54 year 
age groups.   
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FIGURE 6.19 
FREQUENCY OF THE MOST COMMONLY PRESCRIBED ANTIDEPRESSANTS FOR 
DEPRESSIVE DISORDERS (BY GENDER) ACCORDING TO THE FIFTH LEVEL OF THE 
ATC CLASSIFICATION SYSTEM:  AGE GROUP 35 to 54 YEARS (n = 2 708) 
 
6.2.3.3 Antidepressant Prescribing Patterns Relative to the Most 
Prevalent Comorbidities:  Age Group 35 to 54 Years 
 
The following chronic disease states were set apart from the rest in depressed 
females aged 35 to 54 years in the entire study population:  Hypertension, 
HRT/Menopause, Allergic Rhinitis, Hypothyroidism and Arthritis.  
Similarly, in depressed males of the same age group, the following comorbid 
disease states were most prevalent:  Hypertension, Lipid Disorders, 
Allergic Rhinitis, Diabetes Mellitus and Thrombo-embolic Prophylaxis. 
 
In terms of the choice of the most frequently prescribed agents (namely:  
fluoxetine, citalopram, amitriptyline, venlafaxine and paroxetine) in middle-
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aged depressed patients with the aforementioned comorbidities, the following 
comments may be made:  
 
• Numerous researchers have ascertained that the SSRIs are the 
antidepressants of choice in depressed patients with the following 
concomitant chronic disease states:  Hypertension (Guck et al., 2001; 
MacHale, 2002; Hayes, 2004); HRT/Menopause (Stearns et al., 2000); 
Arthritis (Alpay et al., 2000); Diabetes Mellitus (Goodnick, 2001; 
Musselman et al., 2003; Gülseren et al., 2005); and Thrombo-embolic 
Prophylaxis (Roose et al., 1998).  Thus, it was positive to have found that 
this class of antidepressants dominated in terms of prescribing frequency 
in middle-aged depressed patients. 
• Certain antidepressants have been associated with the improvement of hot 
flushes in menopausal females, for example:  venlafaxine (Barton et al., 
2001) and paroxetine (Stearns et al., 2000).  Furthermore, an American 
study conducted by Soares and colleagues (2003) concluded that 
citalopram was effective when prescribed on its own or together with ERT 
for the treatment of Depressive Disorders in peri- and postmenopausal 
females (age range of participants:  40 to 57 years).  
• In patients with Hypothyroidism, the coadministration of thyroid 
hormones and TCAs, such as amitriptyline, may possibly result in 
enhanced toxic effects of both classes of medications (Kando et al., 2002).  
This is pertinent because amitriptyline was frequently prescribed in 
patients aged 35 to 54 years, especially in females. 
• Despite the SSRIs being the recommended first-line agents in depressed 
diabetic patients (Goodnick, 2001; Musselman et al., 2003; Gülseren et 
al., 2005), fluoxetine, in particular, has been associated with the following 
negative effects in terms of the management of comorbid Diabetes 
Mellitus:  enhanced propensity to cause hypoglycaemia (MacHale, 2002); 
certain side effects associated with its use (such as tremor and sweating) 
may cause misinterpretation of a hypoglycaemic state; and drug-drug 
interactions with particular oral hypoglycaemics (Musselman et al., 2003).  
Likewise, TCAs are seldom used in diabetic patients (Lustman et al., 
2005); however, amitriptyline may be useful in patients with diabetic 
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neuropathy (MacHale, 2002).  It has been proposed that venlafaxine may 
offer significant advantages to the SSRIs with regard to the management 
of Depressive Disorders in diabetic patients (Musselman et al., 2003). 
• Studies have found that SSRIs have antiplatelet and endothelium-
protective properties (Serebruany et al., 2003).  Therefore, researchers 
have suggested that SSRIs may exert further antiplatelet effects in patients 
already receiving Thrombo-embolic Prophylaxis (Roose et al., 1998).  In 
particular, the effect of sertraline on platelet function has been shown to 
contest cardiovascular morbidity and mortality (Serebruany et al., 2001).  
In view of the fact that sertraline was not one of the ‘accepted treatments’ 
listed on the chronic formulary of the medical aid scheme, it was not 
surprising to note the low prescribing frequency of this SSRI in middle-
aged patients.  
 
6.2.4 Age Group 55 to 64 Years 
 
6.2.4.1 Age and Gender Distribution 
 
Table 6.12 summarises the descriptive statistics for the ages of patients in the 
55 to 64 year age group.   
   
TABLE 6.12 
DESCRIPTIVE STATISTICS FOR THE AGES OF DEPRESSED PATIENTS:  
AGE GROUP 55 TO 64 YEARS (n = 1 411) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 991) 
59.24 55 64 2.78 
Males  
(n = 420) 
59.00 55 64 2.76 
All Patients 
(n = 1 411) 
59.17 55 64 2.78 
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There were significantly more females than males in the 55 to 64 year age 
group (Chi² = 231.07, d.f. = 1, p = <.0005, Cramér's V = 0.40).  The gender-
related difference for the mean ages of females and males, however, was not 
significant (t-test = 1.48, p < .1; Cohen’s d = 0.09). 
 
6.2.4.2 Analysis of Medications Prescribed for Depressive Disorders: 
Age Group 55 to 64 Years 
 
6.2.4.2.1 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Third Level 
 
Figure 6.20 provides an outline of the most frequently prescribed 
pharmacological subgroups in patients between 55 and 64 years of age for 
the secondary study population.  It was calculated that 92.59% of the 
medications prescribed for the management of Depressive Disorders were 
antidepressants.  This result was highly significant (Chi² = 1 934.21, d.f. = 2,  
p = <.0005, Cramér's V = 0.91).  The same trend was observed for all of the 
younger age groups discussed thus far.   
 
In patients aged 18 years and older, the prescribing frequency of 
antipsychotics and antiepileptics was found to decrease with an increase in 
age.  For example, the prescribing frequency of antipsychotics has decreased 
as follows across the age groups:  5.06% (18 to 34 year age group); 4.92% 
(35 to 54 year age group); and 4.69% (55 to 64 year age group).  This further 
reinforces the high prevalence of comorbid Psychotic or Epileptic Disorders 
in depressed patients younger than 18 years of age.  This finding is in 
concurrence with previous studies that have established a high prevalence of 
concomitant Behavioural Disorders and Epileptic Disorders in young 
patients with Depressive Disorders (Thome-Suza et al., 2004; Caplan et al., 
2005).  
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FIGURE 6.20 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE THIRD LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 55 TO 64 YEARS (n = 1 411) 
 
* The sum of the prescribing frequencies for females and males do not add up to 100% 
because other classes of medications (for example, anxiolytics) accounted for 0.93% 
(for females) and 0.20% (for males) of the total number of active ingredients prescribed 
for Depressive Disorders. 
** Three females were prescribed antidepressants in combination with psycholeptics. 
 
6.2.4.2.2 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fourth Level 
 
The various therapeutic subgroups prescribed for patients aged 55 to 64 
years are contrasted in Figure 6.21.  SSRIs were prescribed significantly more 
frequently than the other subgroups (Chi² = 51.27, d.f. = 1, p = <.0005, 
Cramér's V = 0.17).  It is apparent that the distribution of the therapeutic 
subgroups is very similar for the 35 to 54 and 55 to 64 year age groups (refer 
to Figures 6.18 and 6.21).  The only noticeable difference was the increase in 
the prescribing frequency of non-selective monoamine re-uptake inhibitors, 
particularly in females (16.12% and 22.07% for the 35 to 54 and 55 to 64 year 
age groups, respectively). 
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FIGURE 6.21 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE FOURTH LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 55 TO 64 YEARS (n = 1 411) 
 
* The non-selective monoamine re-uptake inhibitors included the following agents:  
maprotiline (0.88%) and TCAs (99.12%). 
** ‘Other therapeutic subgroups’ includes medications that were not commonly 
prescribed for the management of Depressive Disorders, for example:  benzamides. 
 
6.2.4.2.3 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fifth Level 
 
The frequencies of the agents prescribed for the treatment of Depressive 
Disorders in the 55 to 64 year age group are listed in Table 6.13.   
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TABLE 6.13 
PATIENT DISTRIBUTION AND PRESCRIBING FREQUENCIES FOR 
MEDICATIONS USED FOR THE TREATMENT OF DEPRESSIVE 
DISORDERS:  AGE GROUP 55 TO 64 YEARS (n = 1 411) 
 
Treatment for 
Depressive Disorder ATC Code n * 
% Of Total 
Medications Prescribed 
for Depressive Disorders 
% Of Depressed Patients 
(n = 1 411) ** 
Fluoxetine N06AB03 445 26.39 31.54 
Citalopram N06AB04 292 17.32 20.69 
Amitriptyline N06AA09 201 11.92 14.25 
Paroxetine N06AB05 151 8.96 10.70 
Venlafaxine N06AX16 117 6.94 8.29 
Antipsychotics *** N05AA01 79 4.69 5.60 
Dothiepin N06AA16 64 3.80 4.54 
Sertraline N06AB06 62 3.68 4.39 
Mirtazapine N06AX11 43 2.55 3.05 
Antiepileptics *** N03 34 2.02 2.41 
Escitalopram N06AB10 33 1.96 2.34 
Trimipramine N06AA06 31 1.84 2.20 
Trazodone N06AX05 26 1.54 1.84 
Moclobemide N06AG02 23 1.36 1.63 
Imipramine N06AA02 20 1.19 1.42 
Clomipramine N06AA04 17 1.01 1.20 
Mianserin N06AX03 15 0.89 1.06 
Fluvoxamine N06AB08 7 0.42 0.50 
Duloxetine N06AX20 5 0.30 0.35 
Lofepramine N06AA07 5 0.30 0.35 
Maprotiline N06AA21 3 0.18 0.21 
Reboxetine N06AX18 1 0.06 0.07 
Other Agents ##  12 0.71 0.85 
TOTAL  1 686 100  
* n = The total number of patients who were prescribed a particular medication for the 
treatment of one or more Depressive Disorders. 
** One patient may be on more than one antidepressant; therefore, the column does 
not add up to 100%. 
*** The sum of the number of patients who were prescribed individual agents within the 
class of medications listed.   
## ‘Other agents’ includes medications (not classified as antidepressants) that were 
not prescribed frequently, for example:  benzodiazepine derivatives, such as 
bromazepam.  
 
Tables 6.11 and 6.13 show that fluoxetine, citalopram, amitriptyline, 
paroxetine and venlafaxine were the most commonly prescribed agents in 
 
 280
both the 35 to 54 and 55 to 64 year age groups.  The most prescribed 
antidepressants in females and males between 55 and 64 years of age are 
compared in Figure 6.22. 
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FIGURE 6.22 
FREQUENCY OF THE MOST COMMONLY PRESCRIBED ANTIDEPRESSANTS FOR 
DEPRESSIVE DISORDERS (BY GENDER) ACCORDING TO THE FIFTH LEVEL OF THE 
ATC CLASSIFICATION SYSTEM:  AGE GROUP 55 TO 64 YEARS (n = 1 411) 
 
6.2.4.3 Antidepressant Prescribing Patterns Relative to the Most 
Prevalent Comorbidities:  Age Group 55 to 64 Years 
 
In Section 5.6.2.2, the most prevalent concomitant chronic disease states in 
depressed females and males aged 55 to 64 years, for the total study 
population, were determined.  The following disease states were found to 
occur commonly:  Hypertension (females and males), HRT/Menopause 
(females), Lipid Disorders (females and males); Arthritis (females and 
males), Thrombo-embolic Prophylaxis (females and males), 
Hypothyroidism (females) and Diabetes Mellitus (males).  Except for 
Allergic Rhinitis, all of the other frequently diagnosed chronic disease states in 
middle-aged depressed patients were the same as those found to occur most 
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often in depressed patients between 55 and 64 years of age.  In addition, the 
agents prescribed the most frequently to middle-aged and 55 to 64 year old 
patients (fluoxetine, citalopram, amitriptyline, paroxetine and venlafaxine) 
were identical.  Therefore, the appropriateness of these agents in patients 
with Hypertension, HRT/Menopause, Lipid Disorders, Thrombo-embolic 
Prophylaxis, Hypothyroidism and Diabetes Mellitus has already been 
discussed in Section 6.2.3.3.  
    
6.2.5 Age Group 65 Years of Age and Older 
 
6.2.5.1 Age and Gender Distribution 
 
Table 6.14 outlines the age descriptive statistics for elderly patients in the 
secondary study population.  As was the case for all of the other adult age 
groups, there were significantly more females than males aged 65 years and 
older (for an assumed 50:50 distribution:  Chi² = 317.54, d.f. = 1, p = <.0005, 
Cramér's V = 0.48).     
   
TABLE 6.14 
DESCRIPTIVE STATISTICS FOR THE AGES OF DEPRESSED PATIENTS:  
AGE GROUP 65 YEARS OF AGE AND OLDER (n = 1 360) 
 
 AGE (IN YEARS) 
GENDER MEAN MINIMUM MAXIMUM SD 
Females 
(n = 967) 
73.75 65 97 6.79 
Males  
(n = 393) 
73.49 65 97 6.60 
All Patients 
(n = 1 360) 
73.67 65 97 6.73 
 
Bellingan (2004) determined the mean age of elderly depressed South African 
females and males to be 72.9 and 73 years, respectively, in 2002 (48 330 
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participants).  This is comparable to the mean ages obtained for patients aged 
65 years and older in this study for the secondary study population.  The 
gender-related difference for the mean ages of elderly depressed patients did 
not differ significantly (t-test = 0.63, p < .1; Cohen’s d = 0.04).   
 
6.2.5.2 Analysis of Medications Prescribed for Depressive Disorders: 
Age Group 65 Years of Age and Older 
 
6.2.5.2.1 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Third Level 
 
The most prevalent pharmacological subgroups in patients aged 65 years and 
older are depicted in Figure 6.23.   
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FIGURE 6.23 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE THIRD LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 65 YEARS OF AGE AND OLDER (n = 1 360) 
 
* The sum of the prescribing frequencies for females and males do not add up to 100% 
because other classes of medications (for example, anxiolytics) accounted for 0.34% 
(for females) and 0.85% (for males) of the total number of active ingredients prescribed 
for Depressive Disorders. 
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According to Figure 6.23, antidepressants were prescribed the most for the 
treatment of Depressive Disorders in elderly patients.  This finding was highly 
significant (Chi² = 1 729.45, d.f. = 2, p = <.0005, Cramér's V = 0.86) and 
concurs with the findings regarding the most frequently prescribed subgroups 
in all of the younger age groups (see Figures 6.11, 6.14, 6.17 and 6.20).  
Antipsychotics were the second most commonly prescribed agents (6.78% of 
elderly patients); which is in accordance with the results of the drug utilisation 
review conducted by Bellingan (2004) for the year, 2002 (8.1%).  Additionally, 
the prescribing frequency of antiepileptics for this study in 2004 (1.77% for 
females and males collectively) was also found to be comparable to the 
corresponding percentage obtained by Bellingan (2004), namely 1.7%. 
 
6.2.5.2.2 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fourth Level 
 
The prescribing trends of the major therapeutic subgroups for the treatment of 
Depressive Disorders, in patients aged 65 years and older, are highlighted in 
Figure 6.24.  SSRIs were distinguished as the therapeutic subgroup 
prescribed most often to elderly depressed patients in 2004.  This was 
followed by the non-selective monoamine re-uptake inhibitors and ‘other 
antidepressants’, respectively.  This antidepressant prescribing pattern 
parallels the results of the study by Bellingan (2004), which identified the 
same three therapeutic subgroups (in the identical order of rank) as the most 
commonly prescribed agents during 2002. 
 
When a 50:50 prescribing frequency was assumed (SSRIs relative to other 
therapeutic subgroups), it was established that the SSRIs constituted the 
dominant antidepressant class (Chi² = 50.81, d.f. = 1, p = <.0005, Cramér's   
V = 0.18).  SSRIs are first-line agents for the treatment of Depressive 
Disorders in the elderly (Hayes, 2004).  Moreover, current research has 
demonstrated the efficacy and safety of certain SSRIs in elderly patients with 
Depressive Disorders and concomitant chronic disease states.  Therefore, it is 
promising that more than half of both elderly females and males were 
prescribed an SSRI.   
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FIGURE 6.24 
PRESCRIBING FREQUENCY OF ACTIVE INGREDIENTS FOR DEPRESSIVE DISORDERS 
ACCORDING TO THE FOURTH LEVEL OF THE ATC CLASSIFICATION SYSTEM:  AGE 
GROUP 65 YEARS OF AGE AND OLDER (n = 1 360) 
 
* The non-selective monoamine re-uptake inhibitors included the following agents:  
maprotiline (2.41%) and TCAs (97.59%). 
** ‘Other therapeutic subgroups’ includes medications that were not commonly 
prescribed for the management of Depressive Disorders, for example:  benzamides. 
 
TCAs were also frequently prescribed to depressed elderly patients.  This is of 
concern because these antidepressants are not first-line agents for the 
treatment of Depressive Disorders in the elderly (Gareri, Stilo, Bevacqua, 
Mattace, Ferreri & De Sarro, 1998).  It is more likely for an elderly patient who 
is prescribed a TCA to experience anticholinergic effects and orthostatic 
hypotension, than a younger depressed patient (APA, 2000; MacHale, 2002).  
This is noteworthy because it has been reported that orthostatic hypotension 
enhances the risk of falls and hip fractures (Kairuz et al., 2005).  Furthermore, 
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TCAs have been described as ‘potentially inappropriate’ for use in elderly 
patients (Beers, 1997).  
 
6.2.5.2.3 Analysis of Medications Prescribed for Depressive Disorders 
According to the ATC Classification System, Fifth Level 
 
Table 6.15 lists the treatments prescribed for the management of Depressive 
Disorders in the 65 years and older age group, according to the fifth level of 
the ATC Classification System.  
 
Citalopram was the most frequently prescribed antidepressant in the elderly.  
This is a positive finding because citalopram has one of the most favourable 
pharmacokinetic profiles (Kando et al., 2002).  The major benefit of this 
property is the reduced likelihood of drug-drug interactions with citalopram.  
Drug interactions are a major concern in patients with multiple comorbidities 
and complex medication regimens involving different treatments (Kairuz et al., 
2005).  Given that this study identified a positive relationship between age and 
the number of chronic disease states (see Section 5.2.1), it is apparent that 
elderly patients, specifically, would benefit from the use of citalopram.  
Additionally, research has demonstrated that chronic treatment with 
citalopram is well tolerated and effective in terms of preventing recurrent 
depressive episodes in the elderly (Klysner, Bent-Hansen, Hansen, Lunde, 
Pleidrup, Poulsen, Andersen & Petersen, 2002).  Similar to the results of this 
study, Bellingan (2004) found citalopram to be the most commonly prescribed 
SSRI in 2002 (and second only to amitriptyline, when all of the other 
medications, for the treatment of Depressive Disorders, were also 
considered); followed by fluoxetine and paroxetine.   
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TABLE 6.15 
PATIENT DISTRIBUTION AND PRESCRIBING FREQUENCIES FOR 
MEDICATIONS USED FOR THE TREATMENT OF DEPRESSIVE 
DISORDERS:  AGE GROUP 65 YEARS OF AGE AND OLDER (n = 1 360) 
 
Treatment for 
Depressive Disorder ATC Code n * 
% Of Total 
Medications Prescribed 
for Depressive Disorders 
% of Depressed Patients 
(n = 1 360) ** 
Citalopram N06AB04 336 20.53 24.71 
Fluoxetine N06AB03 303 18.51 22.28 
Amitriptyline N06AA09 201 12.28 14.78 
Paroxetine N06AB05 121 7.39 8.90 
Antipsychotics *** N05 111 6.78 8.16 
Venlafaxine N06AX16 104 6.35 7.65 
Dothiepin N06AA16 97 5.93 7.13 
Mirtazapine N06AX11 70 4.28 5.15 
Sertraline N06AB06 59 3.60 4.34 
Mianserin N06AX03 45 2.75 3.31 
Escitalopram N06AB10 31 1.89 2.28 
Antiepileptics *** N03 29 1.77 2.13 
Imipramine N06AA02 29 1.77 2.13 
Trimipramine N06AA06 20 1.22 1.47 
Trazodone N06AX05 15 0.92 1.10 
Fluvoxamine N06AB08 13 0.79 0.96 
Clomipramine N06AA04 12 0.73 0.88 
Moclobemide N06AG02 12 0.73 0.88 
Maprotiline N06AA21 9 0.55 0.66 
Lofepramine N06AA07 5 0.31 0.37 
Tranylcypromine N06AF04 2 0.12 0.15 
Reboxetine N06AX18 2 0.12 0.15 
Duloxetine N06AX20 2 0.12 0.15 
Nefazodone N06AX06 1 0.06 0.07 
Other Agents ##  8 0.49 0.59 
TOTAL  1 637 100%  
 
* n = The total number of patients who were prescribed a particular medication for the 
treatment of one or more Depressive Disorders. 
** One patient may be on more than one antidepressant; therefore, the column does 
not add up to 100%. 
*** The sum of the number of patients who were prescribed individual agents within the 
class of medications listed.   
## ‘Other agents’ includes medications (not classified as antidepressants) that were 
not prescribed frequently, for example:  benzodiazepine derivatives, such as 
bromazepam.  
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It has been recommended that an antidepressant that is not associated with 
changes in weight may be preferable in elderly depressed patients (Kairuz et 
al., 2005).  Treatment of Depressive Disorders with paroxetine is more likely 
to result in weight gain (Bourin et al., 2001) and fluoxetine has been linked 
with appetite suppression (Kairuz et al., 2005).  Contrary to the suggestions of 
Kairuz and others (2005), the American Psychiatric Association (2000) 
encourages the use of agents that have been coupled with weight gain, since 
weight loss is a problem in elderly individuals.   
 
Bellingan (2004) evaluated the safety and suitability of various SSRIs 
(citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) in the elderly, 
by means of comparing relative ratings for certain drug selection criteria (such 
as:  plasma half-lives, the presence of active metabolites and inhibitory 
potential on the CYP450 system).  The higher the rating value, the less 
appropriate the SSRI is deemed to be for use in elderly depressed patients.  
Based on the criteria analysed, it was deduced that citalopram and fluoxetine 
were the ‘most appropriate’ and ‘least appropriate’ SSRIs, respectively, for 
elderly patients.   
 
Amitriptyline was a commonly prescribed agent in patients aged 65 years and 
older during 2004.  This finding does not correlate with research 
recommendations, which discourage the use of amitriptyline in elderly patients 
with Depressive Disorders (Alexopoulos et al., 2001) because it has 
pronounced anticholinergic effects and is more likely to cause orthostatic 
hypotension (SAMF, 2005).  Seeing as though amitriptyline was the least 
expensive TCA at the time of the analysis, the decision to prescribe this drug 
may have been influenced by attempts to save costs.  Since secondary 
amines, such as desipramine and nortriptyline are not available in South 
Africa, Bellingan (2004) recommends the use of lofepramine or dothiepin in 
elderly depressed patients, rather than amitriptyline, when a TCA needs to be 
used.  It is concerning to note that lofepramine, which is associated with fewer 
adverse effects than most of the other TCAs (refer to Table 3.4 in Section 
3.2.3.2), was last, in terms of prescribing frequency, when compared with all 
of the other agents within the same class.  However, despite the low 
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prescribing frequency of lofepramine, it was promising to note that dothiepin 
was the second most frequently prescribed TCA.  The preference of dothiepin 
over lofepramine could possibly be attributed to the fact that dothiepin (unlike 
lofepramine) was one of the ‘accepted treatments’ listed by the medical aid 
scheme for the management of Depressive Disorders.  In addition, dothiepin 
was cheaper at the time of prescribing.   
 
Venlafaxine was also frequently prescribed to elderly depressed patients in 
2004.  This is in agreement with the literature, which has advised the use of 
venlafaxine either as a first-line agent in elderly individuals with severe 
Depressive Disorders; or instead of SSRIs, in patients who fail to respond 
(Alexopoulos et al., 2001).  It was noticed that mirtazapine (also categorised 
as one of the ‘other antidepressants’) was prescribed most frequently to 
depressed patients aged 65 years and older, relative to the other age groups.  
Mirtazapine may be useful in the elderly because it has been associated with 
weight gain (APA, 2000).  Venlafaxine and mirtazapine seem to be effective; 
have comparable tolerability to SSRIs and TCAs; and are not involved in 
significant drug-drug interactions (Forstein et al., 2000). 
 
The gender-related frequencies of the most commonly prescribed 
antidepressants in patients aged 65 years and older are differentiated in 
Figure 6.25.   
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FIGURE 6.25 
FREQUENCY OF THE MOST COMMONLY PRESCRIBED ANTIDEPRESSANTS FOR 
DEPRESSIVE DISORDERS (BY GENDER) ACCORDING TO THE FIFTH LEVEL OF THE 
ATC CLASSIFICATION SYSTEM:  AGE GROUP 65 YEARS OF AGE AND OLDER  
(n = 1 360)  
 
6.2.5.3 Antidepressant Prescribing Patterns Relative to the Most 
Prevalent Comorbidities:  Age Group 65 Years of Age and 
Older 
 
For depressed females aged 65 years and older in the entire study population, 
the following comorbidities were diagnosed most frequently:  Hypertension, 
HRT/Menopause, Arthritis, Lipid Disorders and Thrombo-embolic 
Prophylaxis.  Correspondingly, in depressed elderly males, the same disease 
states (with the exception of HRT/Menopause and the addition of Ischaemic 
Heart Diseases) were found to occur commonly.  The SSRIs are first-line 
antidepressants for depressed patients with the abovementioned 
comorbidities (Roose et al., 1998; Alpay et al., 2000; Stearns et al., 2000; 
Guck et al., 2001; MacHale, 2002; Hayes, 2004).  The benefits of the SSRIs, 
collectively; and the most frequently prescribed antidepressants, 
independently (citalopram, fluoxetine amitriptyline, venlafaxine and 
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paroxetine), have already been discussed with regard to their efficacy and 
tolerability in depressed patients with the aforementioned prevalent 
comorbidities (refer to Section 6.2.3.2).  Consistent with the trends for all of 
the other age groups, sertraline was not frequently prescribed in patients aged 
65 years and older.  This is concerning because it may offer the following 
benefits for elderly depressed patients with concomitant disease states:  less 
likely to induce orthostatic hypotension (APA, 2000) than other 
antidepressants (for example, TCAs); has been shown to be safe, effective 
and well tolerated in elderly patients with a vascular comorbidity (Krishnan et 
al., 2001); and like citalopram, has a more favourable pharmacokinetic profile 
than most of the other SSRIs (Hirschfeld, 2001).   
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6.3 ANTIDEPRESSANT PRESCRIBING TRENDS RELATIVE TO 
PREVALENT CHRONIC COMORBID DISEASE STATES ACROSS 
THE ADULT AGE GROUPS  
 
For the entire adult study population, the three most prevalent co-existing 
chronic disease states in depressed patients were determined to be 
Hypertension, HRT/Menopause and Lipid Disorders (see Section 5.2.2, 
Figure 5.6).  Seeing as though HRT/Menopause was a disease state that was 
diagnosed in females only, it was decided that the fourth most prevalent 
concomitant disease state, namely, Arthritis would be considered instead.  
This section evaluates the prescribing trends of antidepressants in adult 
depressed patients with comorbid Hypertension, Lipid Disorders and Arthritis, 
for 2004.  
 
In Sections 5.2.1 and 5.2.2, the relationship between the prevalence of 
commonly occurring comorbidities in the entire depressed study population 
and age, was briefly analysed; and it was established that there was an 
increase in the prevalence of Hypertension, Lipid Disorders and Arthritis with 
an increase in age.  Similarly, a positive relationship was noticed between age 
and the prevalence of the aforementioned chronic disease states in the 
secondary study population.  Figure 6.26 depicts this prevalence incline 
across the adult age groups.  For α = .05 and n = 4, the observed correlations 
of 0.977 and 0.983 for Hypertension and Arthritis, respectively, depicted a 
significant increase in the prevalence of these chronic comorbid disease 
states with age (rCRIT = 0.95).  However, the observed correlation for the 
relationship between age and Lipid Disorders (0.911) was not significant (For 
α = .05 and n = 4, rCRIT = 0.95).  This is because there was a slight decrease 
in the prevalence of Lipid Disorders in the elderly age group, when compared 
with the corresponding percentage for patients aged 55 to 64 years. 
 
Figures 6.27 to 6.29, in turn, present the prescribing trends of TCAs, SSRIs 
and ‘other antidepressants’, respectively, in depressed adult patients 
diagnosed with co-existing Hypertension, Lipid Disorders or Arthritis.  The 
values shown in these figures represent the percentage of depressed patients 
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with the specified chronic comorbidity, who were prescribed TCAs (Figure 
6.27), SSRIs (Figure 6.28) and ‘other antidepressants’ (Figure 6.29). 
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FIGURE 6.26  
PREVALENCE OF COMORBID HYPERTENSION, LIPID DISORDERS AND ARTHRITIS IN 
THE SECONDARY ADULT STUDY POPULATION (n = 6 094) 
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FIGURE 6.27  
PERCENTAGE OF DEPRESSED ADULT PATIENTS WITH COMORBID HYPERTENSION, 
LIPID DISORDERS OR ARTHRITIS WHO WERE PRESCRIBED TCAs  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
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FIGURE 6.28  
PERCENTAGE OF DEPRESSED ADULT PATIENTS WITH COMORBID HYPERTENSION, 
LIPID DISORDERS OR ARTHRITIS WHO WERE PRESCRIBED SSRIS  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
According to Figures 6.26 to 6.28, on the whole, there was an increase in the 
distribution of depressed patients with comorbid Hypertension, Lipid Disorders 
and Arthritis who were prescribed TCAs, with an increase in age and 
prevalence of these chronic comorbid disease states.  However, only the 
observed correlation of 0.951 for depressed patients with comorbid Lipid 
Disorders, who were prescribed TCAs, was found to depict a significant 
linear relationship across the age groups (For α = .05 and n = 4, rCRIT = 0.95).  
In contrast, except for depressed patients with Arthritis, the distribution of 
SSRIs was inversely related to age and prevalence of Hypertension and Lipid 
Disorders.  The following observations were made regarding the prescribing 
trends of TCAs and SSRIs, relative to the prevalence patterns of the specified 
chronic comorbid disease states: 
 
• SSRIs have been recommended as the antidepressants of choice in 
depressed patients with multiple comorbidities, such as, Hypertension 
(Guck et al., 2001; MacHale, 2002; Hayes, 2004); and Arthritis (Alpay et 
al., 2000).  Therefore, it could be expected that there would be an increase 
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• When compared with other antidepressants, SSRIs are more effective and 
safer in patients with a CVD (APA, 2000).  More precisely, research has 
demonstrated that SSRIs may restore heart rate variability and decrease 
activation of platelets; the consequences of which lead to a lower risk of a 
cardiovascular event (Yeragani, Jampala, Sobelewski, Kay & Igel, 1999; 
Serebruany et al., 2003).  In addition, the effects of SSRIs on blood 
pressure, heart rate and conduction, have been described as being 
‘clinically benign’ (Roose et al., 1998; Glassman et al., 2002; MacHale, 
2002; Hayes, 2004).  Conversely, TCAs elicit pronounced effects on the 
Cardiovascular System, which include changes in the heart rate and 
rhythm, electrical conduction, myocardial contractility and blood pressure 
(Roose et al., 1992).  Consequently, it could be assumed that the 
favourable cardiovascular effects of the SSRIs would be coupled with a 
greater distribution of patients in the age groups displaying higher 
prevalence rates of CVDs, such as Hypertension and Lipid Disorders, but 
this is not the case for the secondary study population.  Figure 6.28 shows 
the age-related decline in the percentage of depressed patients, with co-
existing Hypertension or Lipid Disorders, who received SSRI treatment for 
Depressive Disorders.  Furthermore, the correlation value of 0.950 
observed for depressed hypertensive patients, who were prescribed 
SSRIs, was significant.  This means that there was a proportional decline 
in the distribution of depressed patients with concomitant Hypertension, 
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• TCAs may be used as adjuvant medications for the management of 
chronic pain disorders, such as Arthritis (Cavalieri, 2005).  This is 
noteworthy to mention because the positive relationship between the 
prevalence of Arthritis and age was coupled with a greater distribution of 
patients on TCAs across the age groups.  But, according to Figure 6.27, 
there was a marginal decrease in the percentage of elderly depressed 
patients with comorbid Arthritis who were prescribed TCAs, when 
compared with the 55 to 64 year age group.  This is promising because the 
use of TCAs in the elderly has been referred to as ‘potentially 
inappropriate’ (Beers, 1997).  Despite the possible use of TCAs in chronic 
pain management; as mentioned previously, this class of antidepressants 
is not recommended as a first-line antidepressant for the treatment of 
Depressive Disorders (Quitkin, 2002), especially in the elderly (Gareri et 
al., 1998).  Additionally, SSRIs are the recommended first-line agents for 
the treatment of Depressive Disorders in patients with concomitant 
Rheumatologic Disease States (Alpay et al., 2000).   
 
With reference to the prescribing trends of the ‘other antidepressants’ in 
depressed patients with comorbid Hypertension and Lipid Disorders across 
the age groups, Figure 6.29 demonstrates that patients aged 18 to 34 years 
had the highest distribution percentages.  This could be attributed to the fact 
that this age group had the least number of patients diagnosed with these 
comorbid disease states, in comparison with the other age groups.  For 
example, the number of depressed patients with comorbid Lipid Disorders 
was as follows for the adult age groups:  30 (18 to 34 years), 454 (35 to 54 
years), 446 (55 to 64 years) and 422 (65 years and older).  Thus, for 
comparative purposes, Table 6.16 depicts the proportion of patients with the 
specified chronic comorbidity, who were prescribed an agent categorised as 
one of the ‘other antidepressants’, as a function of the total number of patients 
per disease state receiving this class of antidepressants.  For instance, it can 
be seen that 145 (or 38.56%) of the total number of hypertensive patients 
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receiving treatment with ‘other antidepressants’, were 65 years of age and 
older. 
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FIGURE 6.29  
PERCENTAGE OF DEPRESSED ADULT PATIENTS WITH COMORBID HYPERTENSION, 
LIPID DISORDERS OR ARTHRITIS WHO WERE PRESCRIBED ‘OTHER 
ANTIDEPRESSANTS’ (nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
TABLE 6.16 
DISTRIBUTION OF DEPRESSED PATIENTS WITH PREVALENT CHRONIC 
COMORBID DISEASE STATES WHO WERE PRESCRIBED ‘OTHER 
ANTIDEPRESSANTS’  
 
Age Group 
Number of Patients with Specified Chronic Comorbid Disease State 
Hypertension 
(n = 2 791) 
Lipid Disorders 
(n = 1 352) 
Arthritis 
(n = 874) 
n % n % n % 
18-34 yrs 8 2.13 7 3.65 4 3.60 
35-54 yrs 126 33.51 49 25.52 24 21.62 
55-64 yrs 97 25.80 69 35.94 38 34.23 
≥ 65 yrs 145 38.56 67 34.90 45 40.54 
Total 376 100 192 100 111 100 
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Overall, it is apparent that the elderly age group was coupled with the greatest 
distribution of patients who were prescribed ‘other antidepressants’ in 2004.  
This is a promising finding because, after the SSRIs, the other individual 
agents recommended for use in elderly patients with Depressive Disorders 
are all classified as ‘other antidepressants’, based on the ATC Classification 
System, Fourth Level (Hayes, 2004).  Furthermore, newer antidepressants 
may offer considerable advantages to the older agents for the treatment of 
Depressive Disorders when other chronic disease states co-exist.   
 
Figure 6.30 categorises the individual TCAs in terms of the percentage of 
depressed patients with co-existing Hypertension, Lipid Disorders and 
Arthritis, who were prescribed these agents.   
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FIGURE 6.30 
PERCENTAGE OF DEPRESSED ADULT PATIENTS WITH COMORBID HYPERTENSION, 
LIPID DISORDERS OR ARTHRITIS WHO WERE PRESCRIBED INDIVIDUAL TCAs 
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
Amitriptyline was the most commonly prescribed TCA in 2004 for depressed 
patients diagnosed with comorbid Hypertension, Lipid Disorders or Arthritis.  
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Of the TCAs, amitriptyline has the most prominent anticholinergic properties 
and has been associated with pronounced sedative and hypotensive effects 
(Kando et al., 2002).  The relative potentials of the individual TCAs, in terms of 
anticholinergic effects, sedation and orthostatic hypotension, were compared 
in Section 3.2.3.2.  It is noticeable that the secondary amines and 
lofepramine, exhibit the lowest hypotensive, anticholinergic and sedative 
properties, when compared with the other TCAs.  As a result, these TCAs 
would be preferred in depressed patients with chronic comorbidities because 
of superior tolerability profiles.  Secondary amines are not available in South 
Africa, so the prescribing frequency of lofepramine should be analysed.  
Figure 6.16 marks lofepramine as the least prescribed TCA in depressed 
patients with any of the specified chronic comorbid disease states.  However, 
dothiepin was the second most commonly prescribed TCA.  This is positive, 
since dothiepin has been shown to display comparable efficacy to 
amitriptyline, but with a more favourable side effect profile (Barbui et al., 
2001). 
 
Figure 6.30 distinguishes amitriptyline and dothiepin as the TCAs that were 
prescribed the most.  Figures 6.31 and 6.32 summarise the distribution 
percentages for depressed patients (diagnosed with the selected chronic 
comorbid disease states) who were prescribed amitriptyline and dothiepin, 
respectively, across the adult age groups.   
 
With regard to age and the distribution of patients who were prescribed 
amitriptyline in 2004, the observed correlations of 0.433, 0.569 and [0.676] 
(negative correlation) for Hypertension, Lipid Disorders and Arthritis, 
respectively, were not significant (For α = .05 and n = 4, rCRIT = 0.95).  This 
signifies that the relationship between age and the proportion of patients who 
were prescribed amitriptyline was not linear.  There was no significant 
difference regarding the prescribing frequency of amitriptyline within each age 
group for the selected comorbidities (Chi² = 7.88, d.f. = 6, p = > .05).  
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FIGURE 6.31 
PERCENTAGE OF DEPRESSED ADULT PATIENTS (ACCORDING TO SELECTED AGE 
GROUPS) WITH COMORBID HYPERTENSION, LIPID DISORDERS OR ARTHRITIS WHO 
WERE PRESCRIBED AMITRIPTYLINE  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
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FIGURE 6.32 
PERCENTAGE OF DEPRESSED ADULT PATIENTS (ACCORDING TO SELECTED AGE 
GROUPS) WITH COMORBID HYPERTENSION, LIPID DISORDERS OR ARTHRITIS WHO 
WERE PRESCRIBED DOTHIEPIN  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
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It was positive to note that dothiepin was prescribed most often to patients 
aged 65 years and older, with concomitant Hypertension, Lipid Disorders and 
Arthritis in this study, since it has been recommended as one of the preferred 
TCAs for use in elderly South African patients diagnosed with Depressive 
Disorders (Bellingan, 2004).  The distribution of depressed patients (with the 
selected chronic comorbid disease states), regarding the prescribing of 
individual SSRIs in 2004, is presented in Figure 6.33.   
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FIGURE 6.33  
PERCENTAGE OF DEPRESSED ADULT PATIENTS WITH COMORBID HYPERTENSION, 
LIPID DISORDERS OR ARTHRITIS WHO WERE PRESCRIBED INDIVIDUAL SSRIs 
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
With regards to Figure 6.33, fluoxetine was prescribed to the majority of 
depressed patients with the specified chronic comorbid disease states.  This 
is of concern for the following reasons: 
 
• Fluoxetine has a long half-life in comparison with many other 
antidepressants (Kando et al., 2002).  Research has shown that 
antidepressants with short half-lives are favoured in depressed patients 
with concomitant disease states (Beliles et al., 1998). 
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• CVD patients with Depressive Disorders will presumably be taking other 
medications, particularly antihypertensives and serum lipid reducing 
agents (Davies, Jackson, Potokar & Nutt, 2004).  This is worth mentioning 
because of the possibility of pharmacokinetic interactions between certain 
SSRIs and these Cardiovascular System medications.  Antihypertensive 
therapies and serum lipid reducing agents were identified as prevalent 
medications prescribed to the secondary study population.  Fluoxetine is a 
potent inhibitor of the CYP450IID6 enzyme system and could therefore 
increase the concentration of Cardiovascular System drugs, such as 
propranolol, which are metabolised by the same system.  It was calculated 
that 15.71% of patients who were receiving beta blocker therapy in 2004, 
were prescribed propranolol.  After atenolol (36.74% of patients prescribed 
beta blocker treatment), propranolol was the most commonly prescribed 
beta blocker.  In spite of this, it was promising to note that atenolol was 
more frequently prescribed than propranolol because it undergoes minimal 
hepatic metabolism and thus, is less likely to elicit drug-drug interactions 
(Beliles et al., 1998).  Fluoxetine also inhibits the CYP450IIIA4 system to a 
large degree and may consequently lead to elevated levels of simvastatin, 
amlodipine and nifedipine (also metabolised by CYP450IIIA4); which are 
agents commonly prescribed for patients diagnosed with Hypertension or 
a Lipid Disorder.  It was determined that 8.44% of patients in the 
secondary study population were prescribed one or more of these agents. 
• It was previously stated that depressed individuals with elevated 
cholesterol levels, were ‘significantly’ less likely to respond to fluoxetine 
treatment than patients without these disease states (Nicholas et al., 
2003).  The enhanced prevalence of Lipid Disorders that has consistently 
been depicted in South African individuals (Steyn et al., 2005; Heart 
Foundation - South Africa, 2006); coupled with the high prescribing 
frequency of fluoxetine identified in various South African drug utilisation 
reviews (Truter et al., 1996; Van Schalkwyk, 2005); emphasise the 
importance of conducting similar studies to Nicholas and others (2003), in 
order to establish whether there is a discernable relationship between  
treatment response to fluoxetine and comorbid Hypercholesterolaemia. 
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Research has shown that antidepressants with short half-lives, such as 
citalopram and paroxetine, are preferred in depressed patients with 
concomitant disease states (Beliles et al., 1998).  Furthermore, citalopram has 
a comparatively lower inhibitory effect on the CYP450 enzymes than fluoxetine 
and paroxetine (Hirschfeld, 2001; Kanner, 2003), so it is a favourable choice 
in patients with a CVD.  Therefore, it was promising to have distinguished 
citalopram as one of the more commonly prescribed SSRIs to depressed 
patients with the specified comorbities.  Figures 6.34 and 6.35 outline the 
patient distribution percentages for the most commonly prescribed SSRIs, 
namely, fluoxetine and citalopram, for each age group.      
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FIGURE 6.34 
PERCENTAGE OF DEPRESSED ADULT PATIENTS (ACCORDING TO SELECTED AGE 
GROUPS) WITH COMORBID HYPERTENSION, LIPID DISORDERS OR ARTHRITIS WHO 
WERE PRESCRIBED FLUOXETINE  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
According to Figure 6.34, over half of the depressed patients aged 18 to 34 
years, with a comorbid Lipid Disorder, were prescribed fluoxetine.  
Considering the possible association between elevated cholesterol levels and 
a failure to respond to treatment with fluoxetine (Nicholas et al., 2003), this 
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may be a potential concern.  Nevertheless, it was positive to note a decline in 
the percentage of patients who were prescribed fluoxetine with an increase in 
age.  In terms of the decline in the distribution of depressed patients with 
comorbid Lipid Disorders who were prescribed fluoxetine, with an increase in 
age, the observed multiple correlation for the polynomial regression of order 
two was 0.981 and thus, significant (For α = .05 and n = 4, rCRIT = 0.95).  
Therefore, the decrease in the prescribing frequency of fluoxetine was age-
dependent.  Similarly, the observed negative correlations of 0.986 and 0.988 
for depressed patients with concomitant Hypertension and Arthritis, 
respectively, receiving fluoxetine treatment, were indicative of significant linear 
declines in fluoxetine prescribing with an increase in age (For α = .05 and n = 
4, rCRIT = 0.95).  This means that fluoxetine was the least prescribed SSRI for 
patients aged 65 years and older.  This is a positive finding since, relative to 
other SSRIs, fluoxetine is the ‘least appropriate’ for use in elderly patients 
(Bellingan, 2004).   
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FIGURE 6.35 
PERCENTAGE OF DEPRESSED ADULT PATIENTS (ACCORDING TO SELECTED AGE 
GROUPS) WITH COMORBID HYPERTENSION, LIPID DISORDERS OR ARTHRITIS WHO 
WERE PRESCRIBED CITALOPRAM  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
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The prescribing trend of citalopram was similar for the specified comorbidities 
across the age groups, that is, there was an initial increase in the patient 
distribution percentages from the 18 to 34 to 35 to 54 year age groups; 
followed by a decrease in patients aged 55 to 64 years; and then a final 
incline in elderly depressed patients.  Depressed patients aged 65 years and 
older in the secondary study population, displayed the highest prevalence of 
co-existing Hypertension.  Citalopram has a favourable pharmacokinetic 
profile (Hirschfeld, 2001).  Hence, it was positive to have identified the 
greatest incidence of citalopram prescribing amongst depressed hypertensive 
patients, to be in the elderly.   
 
The percentage of depressed patients diagnosed with concomitant 
Hypertension, Lipid Disorders or Arthritis, who received treatment with one or 
more of the individual ‘other antidepressants’, is outlined in Figure 6.36.   
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FIGURE 6.36  
PERCENTAGE OF DEPRESSED ADULT PATIENTS WITH COMORBID HYPERTENSION, 
LIPID DISORDERS OR ARTHRITIS WHO WERE PRESCRIBED INDIVIDUAL ‘OTHER 
ANTIDEPRESSANTS’ (nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
Venlafaxine and mirtazapine were the most commonly prescribed ‘other 
antidepressants’ in adult depressed patients during 2004, for all of the chronic 
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comorbid disease states depicted in Figure 6.36.  According to Forstein and 
others (2000), venlafaxine and mirtazapine are effective; exhibit similar 
tolerability profiles to SSRIs and TCAs; and are not involved in significant 
drug-drug interactions.  Duloxetine, reboxetine and nefazodone are also ‘other 
antidepressants’, but these agents were not prescribed to any of the 
depressed patients with comorbid Hypertension, Lipid Disorders or Arthritis, in 
2004.  Figures 6.37 and 6.38 outline the percentages of depressed patients 
with the specified concomitant disease states (per age group), who were 
receiving venlafaxine or mirtazapine treatment, respectively, during 2004. 
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FIGURE 6.37 
PERCENTAGE OF DEPRESSED ADULT PATIENTS (ACCORDING TO SELECTED AGE 
GROUPS) WITH COMORBID HYPERTENSION, LIPID DISORDERS OR ARTHRITIS WHO 
WERE PRESCRIBED VENLAFAXINE  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
Figure 6.37 demonstrates a decrease in the proportion of depressed 
hypertensive patients who were prescribed venlafaxine, with an increase in 
age.  The observed multiple correlation for the polynomial regression of order 
two was 0.998 (For α = .05 and n = 4, rCRIT = 0.95) and may be interpreted as 
a significant age-dependent decline in the distribution of depressed 
hypertensive patients who were prescribed venlafaxine.  Venlafaxine has 
 
 306
been linked with an increase in blood pressure (Roose et al., 1991; 
Stoudemire, 1996; Johnson et al., 2006).  Although this effect has been 
proposed to be related to dosage (MacHale, 2002), it may have influenced the 
decision to prescribe this antidepressant to hypertensive patients.  This could 
explain the reduced prescribing frequency of this antidepressant in the 55 to 
64 and 65 years and older age groups, which were associated with the 
highest prevalence percentages of Hypertension. 
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FIGURE 6.38 
PERCENTAGE OF DEPRESSED ADULT PATIENTS (ACCORDING TO SELECTED AGE 
GROUPS) WITH COMORBID HYPERTENSION, LIPID DISORDERS OR ARTHRITIS WHO 
WERE PRESCRIBED MIRTAZAPINE  
(nHYPERTENSION = 2 796, nLIPID DISORDERS = 1 352, nARTHRITIS = 874) 
 
As is evident in Figure 6.38, with the exception of depressed patients 
diagnosed with co-existing Lipid Disorders and Arthritis in the 18 to 34 year 
age group, there was a positive relationship between age and the distribution 
of patients prescribed mirtazapine for all of the selected chronic comorbidities.  
This is promising as mirtazapine has been coupled with marginal 
anticholinergic side effects and orthostatic hypotension (Beliles et al., 1998), 
which makes this antidepressant more favourable in terms of the tolerability 
profile (when compared with some of the older agents) for elderly depressed 
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patients, in particular.  However, mirtazapine has been associated with an 
increase in serum cholesterol levels (APA, 2000).  Therefore, it may be useful 
to monitor these levels in depressed patients with Hyperlipidaemic Disorders.  
 
Table 6.17 summarises the distribution percentages of individual SSRIs, 
TCAs and ‘other antidepressants’ for depressed patients diagnosed with one 
or more of the specified chronic comorbidities, namely Hypertension, Lipid 
Disorders and Arthritis.  In other words, the disease states are not considered 
independently (as was the case for the rest of the analyses performed for 
Section 6.3), but rather, collectively.  For example, a single patient may have 
been diagnosed with comorbid Hypertension and Arthritis, but this particular 
patient is only accounted for once.   
 
TABLE 6.17 
DISTRIBUTION FOR ANTIDEPRESSANTS PRESCRIBED IN DEPRESSED 
PATIENTS WITH COMORBID HYPERTENSION, LIPID DISORDERS AND 
ARTHRITIS (n = 3 552) 
 
Antidepressant ATC Code 
Number and Percentage (%) of Depressed Patients with 
Specified Chronic Comorbid Disease states (n = 3 552) * 
n % 
Fluoxetine N06AB03 1 133 31.90 
Citalopram N06AB04 794 22.35 
Amitriptyline N06AA09 577 16.24 
Paroxetine N06AB05 354 9.97 
Venlafaxine N06AX16 289 8.14 
Dothiepin N06AA16 170 4.79 
Sertraline N06AB06 150 4.22 
Mirtazapine N06AX11 111 3.13 
Escitalopram N06AB10 104 2.93 
Trimipramine N06AA06 59 1.66 
Mianserin N06AX03 55 1.55 
Imipramine N06AA02 45 1.27 
Trazodone N06AX05 42 1.18 
Fluvoxamine N06AB08 33 0.93 
Clomipramine N06AA04 28 0.79 
Lofepramine N06AA07 10 0.28 
 
* There were 3 552 depressed patients diagnosed with either one or more of the 
following chronic comorbid disease states:  Hypertension, Lipid Disorders and 
Arthritis. 
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It was concerning that fluoxetine and amitriptyline were prescribed to almost 
half of the depressed patients (48.14%) with the selected prevalent 
concomitant disease states.  This contrasts with only 27.14% of patients who 
were prescribed citalopram or dothiepin, which are amongst the preferred 
SSRIs and TCAs, respectively.  The medical aid scheme’s chronic 
authorisation formulary has deemed all of these agents (fluoxetine, 
amitriptyline, citalopram and dothiepin) as ‘accepted treatments’ for the 
management of Depressive Disorders.  Therefore, the greater distribution of 
depressed patients who received fluoxetine (31.90%) or amitriptyline 
(16.24%), when compared with the corresponding percentages for citalopram 
(22.35%) and dothiepin (4.79%), respectively, could possibly be attributed to 
the lower cost associated with the former agents. 
    
6.4 CONCLUSION 
 
The antidepressant prescribing trends for depressed patients in 2004 were 
critically evaluated in this chapter.  Emphasis was placed on the judicious 
selection of antidepressants, based on side effect profiles, avoidance of 
potentially toxic drug interactions and consideration for the specific nature, 
and implications thereof, of prevalent chronic comorbid disease states.  In the 
past, the selection of antidepressants was limited to the almost sole 
availability of the TCAs.  In recent times, however, newer medications, such 
as the majority of the SSRIs and venlafaxine, have greatly simplified the 
treatment of Depressive Disorders in patients with comorbities.  Thus, it was 
promising that these agents featured amongst the most frequently prescribed 
antidepressants for the secondary study population.  However, fluoxetine and 
amitriptyline are not ideal choices in depressed patients with comorbidities, so 
it was concerning that these antidepressants were commonly prescribed in all 
of the specified age groups for 2004.  Moreover, citalopram and dothiepin, 
which are preferable antidepressants in depressed patients with chronic 
comorbid disease states, were ‘accepted treatments’ on the medical aid 
scheme’s chronic authorisation formulary.  Albeit this, the prescribing 
frequencies of these agents were superseded by fluoxetine and amitriptyline.       
 
 
 
 
 
CHAPTER 7 
 
CONCLUSION: 
SUMMARY AND RECOMMENDATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 310
7.1 STUDY IN REVIEW 
 
Studies have shown that the prevalence of Depressive Disorders in adults 
seems to be on the rise in many countries (Murray et al., 1996; Kessler et al., 
2003a).  It is important to enhance the awareness of these inclined 
prevalence trends because generally speaking, on a physical, mental and 
emotional level, depressed individuals function at lower levels than patients 
suffering from 11 other common chronic disease states (Wells et al., 1999).  
Moreover, untreated Depressive Disorders typically assume a chronic course 
and are expected to be second only to Heart Disease in terms of the global 
burden of disease by 2020 (Chapman et al., 2005).  This is further 
compounded by the findings of numerous studies that have consistently 
recognised an enhanced prevalence of chronic disease states amongst 
depressed patients, relative to their non-depressed counterparts (Wells et al., 
1991; Barbee, 1998; Krishnan et al., 2000; Lespẻrance et al., 2000; Ohira et 
al., 2001; van Manen et al., 2002; Katon, 2003; Golden et al., 2004; 
Cankurtaran et al., 2005).  The co-existence of chronic disease states in 
depressed patients further complicates the treatment of the Depressive 
Disorder and warrants careful selection of suitable antidepressants.  This 
study provided information on the prevalence of chronic comorbid disease 
states and antidepressant prescribing trends in a depressed South African 
study population (21 171 depressed patients).  General comments were made 
regarding the suitability of antidepressant prescribing trends during 2004, 
relative to the most commonly diagnosed chronic co-existing disease states  
(6 150 depressed patients).  Emphasis was placed on the appropriateness of 
antidepressant therapy in depressed patients who were diagnosed with the 
three most prevalent chronic comorbid disease states identified in the study, 
namely:  Hypertension, Lipid Disorders and Arthritis.  The purpose of this 
focus was to enable recommendations to be made regarding the treatment of 
Depressive Disorders in patients with specific chronic comorbid disease 
states. 
 
There are limited studies published in South Africa that address the 
management of Depressive Disorders in patients with chronic comorbid 
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disease states.  For this reason, it is essential to critically evaluate and record 
antidepressant prescribing trends in depressed South African patients with 
one or more co-existing disease states.   
 
7.2 SUMMARY OF MAIN FINDINGS 
 
The empirical analyses of this study were presented in two chapters 
(Chapters five and six).  The observed findings pertaining to each chapter will 
be summarised independently in this section.  The first results chapter 
investigated the prevalence of Depressive Disorders and the nature of chronic 
comorbid disease states in a depressed study population.  The second results 
chapter evaluated antidepressant prescribing patterns in the presence of 
prevalent chronic comorbid disease states in 2004 specifically. 
 
7.2.1 Prevalence of Depressive Disorders and Nature of Chronic 
Comorbid Disease States 
 
The findings relating to the following objectives of the study are reviewed in 
this section:   
 
• to establish the prevalence of Depressive Disorders relative to age and 
gender in the study population; 
• to provide an overview of the number of chronic comorbid disease 
states per depressed patient in the study population;  
• to investigate the prevalence and nature of chronic comorbid disease 
states in depressed patients; 
• to determine the prevalence and nature of chronic comorbid disease 
states in specified age groups; and 
• to investigate the impact of age on the chronic comorbid disease state 
prevalence. 
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7.2.1.1 Prevalence of Depressive Disorders Relative to Age and 
Gender in the Study Population 
 
With the exception of patients aged 0 to 17 years, the age distribution of 
patients with Depressive Disorders was in accordance with the larger 
population from which the depressed sample was drawn.  For the entire study 
population, the following trends were identified regarding the prevalence of 
Depressive Disorders:  
 
• The greatest prevalence of Depressive Disorders was evident in middle-
aged individuals (47.99%). 
• There were more female patients diagnosed with a Depressive Disorder 
(of the 21 171 depressed patients, 71.73% were females and 28.27% 
were males). 
• Of the Depressive Disorders, Depression was most frequently diagnosed 
across all of the selected age groups.  Excluding elderly females, there 
was an increase in the prevalence of Depression with an increase in age.  
For males aged 35 years and older, the prevalence of Depression 
increased with age.   
 
7.2.1.2 Overview of the Number of Chronic Comorbid Disease States 
per Depressed Patient 
 
The distribution trends and descriptive statistics, pertaining to the number of 
chronic co-existing disease states per depressed patient, established the 
following: 
 
• The incidence of chronic comorbid disease states was found to have 
increased significantly with an increase in age (Chi² = 3 305.13, d.f. = 20,  
p = < .0005, Cramér's V = 0.23). 
• The distribution of females and males, regarding the number of chronic 
comorbid disease states per depressed patient, did not differ significantly 
(Chi² = 109.72, d.f.= 5, p = < .0005, Cramér's V = 0.07). 
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• Most of the depressed females (71.70%) and males (70.62%) were 
diagnosed with one to four comorbidities. 
• There was a declining trend concerning the percentage of patients 
diagnosed with more than three co-existing disease states. 
• The mean number of chronic comorbid disease states per depressed 
patient in the study population was 3.25.  There was an increase in the 
mean number of chronic disease states with an increase in age. 
 
7.2.1.3 Prevalence and Nature of Chronic Comorbid Disease States in 
Depressed Patients 
 
The following comorbidities were associated with an enhanced prevalence in 
the entire depressed study population:   
 
• Hypertension, HRT/Menopause, Lipid Disorders, Arthritis, Thrombo-
embolic Prophylaxis, Hypothyroidism, Allergic Rhinitis, Diabetes 
Mellitus, Asthma and Anxiety Disorders. 
• For depressed females, Hypertension, HRT/Menopause, Arthritis, 
Hypothyroidism and Lipid Disorders were the most prevalent comorbid 
disease states.  Similarly, for depressed males, Hypertension, Lipid 
Disorders, Thrombo-embolic Prophylaxis, Diabetes Mellitus and 
Allergic Rhinitis were the most commonly diagnosed comorbidities.  
 
7.2.1.4 Prevalence and Nature of Chronic Comorbid Disease States in 
Specified Age Groups 
 
The most prevalent chronic comorbid disease states in depressed patients in 
the specified age groups are depicted in Table 7.1. 
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TABLE 7.1 
PREVALENT DISEASE STATES FOR EACH AGE GROUP 
 
Age Group 
Three Most Prevalent Chronic Comorbid Disease States  
in Depressed Patients 
Females * Males * 
0 to 17 Years 
1) Allergic Rhinitis 
2) Asthma 
3) ADHD, Epilepsy and Acne ** 
1) Allergic Rhinitis, ADHD ** 
2) Asthma 
3) Epilepsy 
18 to 34 Years 
1) Allergic Rhinitis 
2) Asthma 
3) Acne 
1) Allergic Rhinitis 
2) Asthma 
3) Hypertension 
35 to 54 Years 
1) Hypertension 
2) HRT/Menopause 
3) Allergic Rhinitis 
1) Hypertension 
2) Lipid Disorders 
3) Allergic Rhinitis 
55 to 64 Years 
1) HRT/Menopause 
2) Hypertension 
3) Arthritis 
1) Hypertension 
2) Lipid Disorders 
3) Thrombo-embolic Prophylaxis 
65 Years and 
Older 
1) Hypertension 
2) HRT/Menopause 
3) Arthritis 
1) Hypertension 
2) Thrombo-embolic Prophylaxis 
3) Lipid Disorders 
 
* Disease states are listed in descending rank, with ‘1’ indicating the most prevalent disease 
state in a particular age group.  
** Multiple disease states are depicted in cases where prevalence percentages are equal. 
 
7.2.1.5 Impact of Age on the Chronic Comorbid Disease State 
Prevalence 
 
The relationship between age and comorbid disease states in the depressed 
study population was evaluated and the following was evident: 
 
• There was an increase in the prevalence of Hypertension, Arthritis, 
Hypothyroidism, Lipid Disorders and Thrombo-embolic Prophylaxis 
with an increase in age.  More specifically, the incline in the prevalence of 
Hypertension, Arthritis, Lipid Disorders and Hypothyroidism in 
depressed females, was calculated to be proportionately related to age 
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(For α = .05 and n = 5, rCRIT = 0.88).  Likewise, for depressed males with 
comorbid Hypertension and Thrombo-embolic Prophylaxis, the 
increase in prevalence of these disease states with an increase in age, 
was significant (For α = .05 and n = 5, rCRIT = 0.88). 
• The prevalence of Allergic Rhinitis and Asthma (when disease states 
were considered independently and collectively) decreased with age.  
Furthermore, the decline in the prevalence of Allergic Rhinitis across the 
age groups, in those patients diagnosed with or without Asthma, was 
found to be significant (For α = .05 and n = 5, rCRIT = 0.88).   
 
7.2.2 Appropriateness of Antidepressant Prescribing Patterns in the 
Presence of Prevalent Chronic Comorbid Disease States  
 
The drug analysis component of this study involved an evaluation of the 
antidepressants prescribed to patients diagnosed with one or more 
Depressive Disorders in the year, 2004.  This section outlines the results with 
regard to the following objectives of the study:    
 
• to provide an overview of the number of active ingredients prescribed 
per depressed patient; 
• to evaluate the frequency of the most commonly prescribed 
medications in depressed patients in 2004; 
• to provide an overview of the treatments prescribed for the 
management of Depressive Disorders in the secondary study 
population; 
• to review the treatments prescribed for the management of Depressive 
Disorders in the specified age groups for 2004; and 
• to investigate changes in antidepressant prescribing patterns relative to 
the prevalence of commonly occurring chronic comorbid disease states 
in adult depressed patients. 
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7.2.2.1 Overview of the Number of Active Ingredients Prescribed per 
Depressed Patient 
 
An analysis of the distribution of patients regarding the number of active 
ingredients prescribed, revealed the following: 
 
• The majority of patients (35.38%) were prescribed a single active 
ingredient.  Furthermore, 77.35% of depressed patients were prescribed 
between one and three different active ingredients.  Thus, 22.65% of 
patients received four or more medications concurrently. 
• The distribution percentages for the number of active ingredients 
prescribed per depressed patient were similar for females and males. 
• The distribution of patients was found to be inversely related to the number 
of active ingredients prescribed per patient.   
• Elderly depressed patients exhibited a higher prevalence of a greater 
number of active ingredients than the younger age groups. 
• The mean number of active ingredients prescribed per patient was 2.60 for 
females and 2.59 for males (genders considered collectively:  2.60). 
 
7.2.2.2 Overview of the Frequency of the Most Commonly Prescribed 
Medications in Depressed Patients in 2004 
 
On examination of the most frequently prescribed medications in depressed 
patients in 2004, the following was observed: 
 
• The third level analysis of the ATC Classification System identified 
antidepressants as the most commonly prescribed pharmacological 
subgroups in depressed females (44.20%) and males (44.02%).  
Thereafter, estrogens and cholesterol and triglyceride reducers were 
prescribed most frequently to depressed females and males, respectively.  
The prevalent pharmacological subgroups amongst the depressed 
patients in 2004 were used predominantly for the management of the 
following chronic disease states:  HRT/Menopause, Lipid Disorders, 
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Arthritis, Epilepsy, Hypertension and other CVDs, Psychotic 
Disorders, Asthma, COPD and Diabetes Mellitus (Type II). 
• SSRIs, non-selective monoamine re-uptake inhibitors, and ‘other 
antidepressants’ comprised 43.28% of all of the agents prescribed in 2004, 
according to the fourth level of the ATC Classification System. 
 
7.2.2.3 Overview of the Treatments Prescribed for the Management of 
Depressive Disorders in the Secondary Study Population 
 
The treatments prescribed specifically for the treatment of Depressive 
Disorders were investigated and the following was established:  
 
• There was a significantly higher distribution of depressed patients who 
were prescribed a single therapy for the treatment of Depressive Disorders 
in 2004, relative to the corresponding percentages for two or three or more 
agents (Chi² = 6 459.96, d.f. = 2, p = < .0005, Cramér's V = 0.72). 
• The mean number of active ingredients prescribed was 1.24 for both 
females and males. 
• The majority of depressed patients (91.52%) were prescribed 
antidepressants for the treatment of Depressive Disorders (ATC 
Classification System, Level Three).  This was discovered to be highly 
significant (Chi² = 11 700.08, d.f. = 2, p = < .0005, Cramér's V = 0.88).   
• According to the fourth level of the ATC Classification System, SSRIs were 
prescribed most often for the treatment of Depressive Disorders (60.03% 
for females and 58.76% for males).  SSRIs and TCAs comprised 76.64% 
of the total antidepressants prescribed.  The prescribing frequency of 
SSRIs and TCAs was greater amongst depressed females than their male 
counterparts. 
• Fluoxetine was prescribed to the greatest number of patients in the 
secondary study population (31.50%).  This was followed by citalopram, 
which was prescribed to 23.69% of depressed patients. 
• Of the TCAs, amitriptyline was prescribed most often (10.49%). 
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7.2.2.4 Overview of the Treatments Prescribed for the Management of 
Depressive Disorders in the Specified Age groups 
 
The most frequently prescribed antidepressants for depressed patients in the 
specified age groups are depicted in Table 7.2. 
 
TABLE 7.2 
MOST COMMONLY PRESCRIBED ANTIDEPRESSANTS IN EACH AGE 
GROUP 
 
Age Group 
Three Most Frequently Prescribed Antidepressants 
in Depressed Patients during 2004 * 
0 to 17 Years 
1) Fluoxetine, citalopram ** 
2) Amitriptyline 
3) Venlafaxine 
18 to 34 Years 
1) Fluoxetine 
2) Citalopram 
3) Venlafaxine 
35 to 54 Years 
1) Fluoxetine 
2) Citalopram 
3) Amitriptyline 
55 to 64 Years 
1) Fluoxetine 
2) Citalopram 
3) Amitriptyline 
65 Years and Older 
1) Citalopram 
2) Fluoxetine 
3) Amitriptyline 
 
* Antidepressants are listed in descending rank of prescribing frequencies, with ‘1’ indicating 
the most commonly prescribed antidepressant in a particular age group.  
** Multiple antidepressants are depicted in cases where prevalence percentages are equal. 
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7.2.2.5 Antidepressant Prescribing Trends in Depressed Patients 
Diagnosed with the Most Prevalent Chronic Comorbid Disease 
States 
 
Hypertension, Lipid Disorders and Arthritis were identified as the most 
prevalent chronic comorbid disease states in depressed patients for the entire 
study population.  Furthermore, it was established that, on the whole, the 
prevalence of comorbid Hypertension, Lipid Disorders and Arthritis increased 
with age.  The following antidepressant prescribing trends, relative to the 
calculated prevalence percentages for the aforementioned comorbidities in 
the secondary study population, were recognised: 
 
• Overall, there was an increase in the distribution of depressed patients 
who were prescribed TCAs, with an increase in age and prevalence of 
these chronic comorbid disease states.  However, only the observed 
correlation for TCA prescribing in depressed patients with co-existing 
Lipid Disorders was found to depict a proportional incline across the age 
groups (For α = .05 and n = 4, rCRIT = 0.95).  Also, there was a slight 
decrease in the percentage of elderly depressed patients with comorbid 
Arthritis, who were prescribed TCAs, when compared with the 55 to 64 
year age group.    
• Conversely, there was a decrease in the distribution of patients who were 
prescribed SSRIs with age and prevalence of Hypertension and Lipid 
Disorders.  The decrease in SSRI prescribing amongst depressed 
hypertensive patients with an increase in age, was significant (For α = .05 
and n = 4, rCRIT = 0.95).     
• Elderly patients were associated with the greatest distribution of patients 
who were prescribed ‘other antidepressants’ in 2004.   
• Amitriptyline was the most commonly prescribed TCA in 2004 for 
depressed patients diagnosed with comorbid Hypertension, Lipid 
Disorders and Arthritis.  Following amitriptyline, dothiepin was prescribed 
most frequently to these patients.  In addition, dothiepin was prescribed 
most often to elderly depressed patients with concomitant Hypertension, 
Lipid Disorders or Arthritis.    
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• Fluoxetine was prescribed to the majority of depressed patients with the 
specified chronic comorbid disease states.  There was a decrease in the 
distribution of patients who were prescribed fluoxetine across the age 
groups.  For α = .05 and n = 4, the observed correlations for this decline 
were significant for depressed patients with comorbid Hypertension 
[0.986], Lipid Disorders [0.981] and Arthritis [0.988] (rCRIT = 0.95).   
• Citalopram was also a commonly prescribed SSRI.  Elderly depressed 
patients exhibited the greatest patient distribution percentage with regard 
to citalopram prescribing in patients with comorbid Hypertension, relative 
to the other age groups.   
• Venlafaxine and mirtazapine were the most commonly prescribed ‘other 
antidepressants’ in the adult secondary study population for all of the 
specified chronic comorbid disease states. 
• There was a significant age-dependent decline in the distribution of 
depressed hypertensive patients who were prescribed venlafaxine 
[observed correlation of 0.998] (For α = .05 and n = 4, rCRIT = 0.95).      
• Most of the depressed patients diagnosed with one or more of the 
specified chronic comorbid disease states (48.14%) were receiving 
treatment with fluoxetine or amitriptyline.  This contrasts with only 27.14% 
of patients who were prescribed citalopram or dothiepin. 
 
7.3 RECOMMENDATIONS 
 
This pharmacoepidemiological evaluation has yielded useful information 
pertaining to the research topic and makes it possible to offer the following 
recommendations: 
 
• In order to obtain a better understanding of the complex relationship that 
exists between Depressive Disorders and chronic comorbid disease 
states, new initiatives should focus on placing equal weighting on the 
investigation of psychiatric and physical disease states.  This differs to the 
approach of current studies that have concentrated on a single domain 
only, namely, either the Depressive Disorder or physical disease state. 
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• Prescribers and pharmacists should consider the factors influencing the 
choice of antidepressant therapy in a depressed patient with one or more 
specified chronic comorbid disease states (as discussed in Sections 3.1 
and 3.4).  In addition, these factors should be contemplated against the 
‘accepted treatments’ offered by the patient’s medical aid scheme’s 
chronic authorisation formulary.  Collaboration between prescribers and 
pharmacists will facilitate the individualised selection process for each 
depressed patient.  
• Fluoxetine and amitriptyline are not considered the antidepressants of 
choice in depressed patients with comorbidities.  Age in itself is a risk 
factor for many of the chronic disease states that have been consistently 
linked with Depressive Disorders.  Fluoxetine and amitriptyline should not 
be used in patients aged 65 years and older because these agents have 
been deemed the ‘least appropriate’ SSRI and TCA, respectively, in 
elderly depressed patients.  For these reasons, the use of citalopram and 
dothiepin, which have preferable side effect and pharmacokinetic profiles 
to fluoxetine and amitriptyline, should be considered instead, particularly in 
cases where these agents are listed as ‘accepted treatments’ on the 
chronic authorisation formulary of the patient’s medical aid. 
• Prescribers are often reluctant to initiate antidepressant therapy in 
depressed patients with co-existing disease states.  This stems from 
reservations regarding the possible exacerbation of the comorbidity that 
may occur as a consequence of the medication’s side effects and the 
possibility of drug-drug interactions.  Therefore, the benefits of 
psychotherapy (which is devoid of adverse effects and drug interactions) 
for the treatment of Depressive Disorders, in patients with particular 
chronic comorbid disease states, should not be underestimated.     
• The concerns of prescribers, regarding the use of pharmacotherapy in 
depressed patients with comorbidities, should be addressed by 
pharmacists because the successful treatment of Depressive Disorders 
has been shown to improve outcomes associated with chronic comorbid 
disease states (Noël et al., 2004).  The pharmacist should discuss the 
benefits of newer antidepressants (for example, bupropion and 
mirtazapine are well tolerated and do not increase morbidity) with the 
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prescriber so that an informed decision can be made in the best interests 
of the patient.   
• Prescribers and pharmacists should inform Managed Healthcare 
Companies of the possible advantages of utilising antidepressants (in 
depressed patients with chronic co-existing disease states) that are not 
‘accepted treatments’ on the medical aid’s chronic authorisation formulary.  
For example, sertraline has been shown to offer multiple benefits to 
depressed patients with chronic concomitant disease states; particularly in 
those patients with cardiovascular comorbidities.  Such a liaison between 
prescribers or pharmacists and the Managed Healthcare Company, will 
allow for the possible addition of useful antidepressants to the medical 
aid’s chronic authorisation formulary, which may assist in improving the 
management of Depressive Disorders when chronic disease states co-
exist. 
• Similar pharmacoepidemiological studies, relating to comorbidity research 
in depressed patients, should be conducted in South Africa.  The 
implementation of such studies may further explore the possibility of 
alternative treatment approaches.  For instance, an investigation into the 
benefits of a potential shift towards a more aggressive treatment strategy 
for the Depressive Disorder, as opposed to simply focusing on increasing 
the dosages of the therapies prescribed for the chronic comorbid disease 
states.  The rationale for exploring a potential shift of this nature can be 
explained by the fact that providing adequate treatment for Depressive 
Disorders has been shown to produce more significant improvements in 
quality of life than eliciting productive interventions for other chronic 
disease states (Noël et al., 2004).  Therefore, similar studies will reveal 
antidepressant prescribing trends in depressed patients with specific 
comorbidities.  In addition, reporting of empirical analyses should relate to 
specific chronic comorbid disease states because the type of comorbidity 
will influence the selection of antidepressant therapy.  Such studies will 
offer valuable information to prescribers and pharmacists; which can then 
be utilised to improve the treatment of Depressive Disorders in patients 
with particular chronic comorbid disease states. 
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7.4 CONCLUSION 
 
Research has shown that the effects of Depressive Disorders and chronic 
comorbid disease states on symptom burden, functionality and quality of life, 
are synergistic (Berardi et al., 2002).  Consequently, it is vital to recognise the 
role that Depressive Disorders have to play in the aetiology, course and 
outcomes associated with chronic disease states.  The primary aim of this 
study was to investigate the relationship between Depressive Disorders and 
the most frequently diagnosed chronic comorbid disease states in a 
depressed South African study population; and to comment on the 
appropriateness of antidepressants chosen for these patients.  The 
relationship between Depressive Disorders and commonly occurring chronic 
comorbid disease states is complex.  In addition to the intricate relationship 
between Depressive Disorders and chronic disease states (Chapman et al., 
2005), there are also interrelationships that exist between chronic disease 
states, which, in turn, have major implications for the management of 
Depressive Disorders and the treatment of chronic comorbid disease states.   
 
It has been postulated that providing treatment for Depressive Disorders can 
result in more significant improvements in quality of life, physical and 
psychological functioning, and disability, than eliciting useful interventions for 
other chronic disease states (Noël et al., 2004).  This highlights the need for 
further drug utilisation reviews of this nature.  The antidepressant prescribing 
trends observed in this study revealed potential areas of intervention.  Thus, 
recommendations were made with the goal of optimising and individualising 
antidepressant drug prescribing in depressed patients with chronic co-existing 
disease states. 
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EXEMPLAR OF THE DATA RECEIVED IN 2005 
 
ID Gender Age Comm Date 
Term 
Date ICD10 Diagnosis Drug Name
Drug 
Strength Nappi
Drug 
Form
SEP 
price
Pack 
size Directions
103349 F 50 19990609 20021029 I10 Hypertension COZAAR 50MG 818739 TAB 189.13 30 1 daily
103349 F 50 19961111 19990609 E11.9 Diabetes type 
2 noninsulin 
dep
DAONIL 5MG 717452 TAB 102.71 30 2 MANE 1 
NOCTE 
103349 F 50 20010613 20021029 G40.9 Epilepsy 
(unspecified) 
NEURONTIN 300MG 807451 CAP 352.72 100 2 bd 
103349 F 50 20021029  G40.9 Epilepsy 
(unspecified) 
TOPAMAX 50MG 822523 TAB 357.25 60 1 bd 
103349 F 50 20010613 20021029 G43.9 Migraine ZOMIG 2.5MG 845213 TAB 122.29 3 as directed
103349 F 50 20021029 20030403 F32.9 Depression TYDAMINE 50MG 772356 CAP 118.83 30 1 nocte
103349 F 50 19990609 20010613 E11.9 Diabetes type 
2 noninsulin 
dep
AMARYL 4MG 831573 TAB 212.22 30 1 daily 
103349 F 50 19961111 19990609 I10 Hypertension COVERSYL 4MG 785121 TAB 114 30 1 daily 
103349 F 50 19990609 20021029 I10 Hypertension ADALAT XL 60MG 793132 SRT 225.41 28 1 daily 
104237 F 56 20020422  N95.1 HRT PREMARIN 0.625MG 756733 TAB 72.63 28 1 daily
104237 F 56 19961112 19990810 F32.9 Depression AROPAX 20MG 791571 TAB 218.14 28 1 DAILY
104237 F 56 20010827  E11.9 Diabetes type 
2 noninsulin 
dep
GLUCOBAY 50MG 808156 TAB 152.7 90 1 tds
104237 F 56 19990803 20000804 F32.9 Depression EGLONYL 50MG 722375 CAP 57.32 30 1 daily
104237 F 56 20020422  N95.1 HRT PREMARIN 0.3MG 756725 TAB 62.31 28 1 daily
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EXEMPLAR OF THE DATA RECEIVED IN 2005 (CONTINUED) 
 
ID Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec ATC_Description ATC_Code 
103349 30 30 30 30 30 30 30 30 30 30 30 30 Losartan C09CA01 
103349 90 90 90 90 90 90 90 90 90 90 90 90 glibenclamide A10BB01 
103349 120 120 120 120 120 120 120 120 120 120 120 120 Gabapentin N03AX12 
103349 60 60 60 60 60 60 60 60 60 60 60 60 Topiramate N03AX11 
103349 3 3 3 3 3 3 3 3 3 3 3 3 Zolmitriptan N02CC03 
103349 30 30 30 0 0 0 0 0 0 30 30 30 Trimipramine N06AA06 
103349 30 30 30 30 30 30 30 30 30 30 30 30 glimepiride A10BB12 
103349 30 30 30 30 30 30 30 30 30 30 30 30 Perindopril C09AA04 
103349 30 30 30 30 30 30 30 30 30 30 30 30 Nifedipine C08CA05 
104237 28 28 28 28 28 28 28 28 28 28 28 28 Conjugated estrogens G03CA57 
104237 30 30 30 30 30 30 30 30 30 30 30 30 Paroxetine N06AB05 
104237 90 90 90 90 90 90 90 90 90 90 90 90 acarbose A10BF01 
104237 30 30 30 30 30 30 30 30 30 30 30 30 Sulpiride N05AL01 
104237 28 28 28 28 28 28 28 28 28 28 28 28 Conjugated estrogens G03CA57 
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ICD-10 CODES AND TITLES 
 
Chapter Blocks 
(Codes) 
Title 
I A00 – B99 Certain Infectious and Parasitic Diseases 
II C00 – D48 Neoplasms 
III D50 – D89 Diseases of the Blood and Blood-forming Organs and Certain 
Disorders involving the Immune Mechanism 
IV E00 – E90 Endocrine, Nutritional and Metabolic diseases 
V F00 – F99 Mental and Behavioural disorders 
VI G00 – G99 Diseases of the Nervous System 
VII H00 – H59 Diseases of the Eye and Adnexa 
VIII H60 – H95 Diseases of the Ear and Mastoid process 
IX I00 – I99 Diseases of the Circulatory system 
X J00 – J99 Diseases of the Respiratory system 
XI K00 – K93 Diseases of the Digestive system 
XII L00 – L99 Diseases of the Skin and Subcutaneous tissue 
XIII M00 – M99 Diseases of the Musculoskeletal System and Connective Tissue 
XIV N00 – N99 Diseases of the Genitourinary System 
XV O00 – O99 Pregnancy, childbirth and the puerperium 
XVI P00 – P96 Certain Conditions originating in the Perinatal Period 
XVII Q00 – Q99 Congenital Malformations, Deformations and Chromosomal 
Abnormalities 
XVIII R00 – R99 Symptoms, Signs and Abnormal Clinical Laboratory Findings, Not 
Elsewhere Classified 
XIX S00 – T98 Injury, Poisoning and Certain Consequences of External Causes 
XX V01 – Y98 External Causes of Morbidity and Mortality 
XXI Z00 – Z99 Factors Influencing Health Status and Contact with Health Services 
XXII U00 – U99 Codes for Special Purposes 
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GROUPING OF CHRONIC DISEASE STATES ACCORDING TO ICD-10 
DESCRIPTIONS AND CODES 
 
CHRONIC DISEASE STATES ICD-10 ICD-10 DESCRIPTION ICD-10 CODE 
  CODE    RANGE FOR 
      DESCRIPTION
Cancer (CA) comprising of:       
CA oesophagus C15 
Digestive Organs C15 - C26 CA colon C18 
CA pancreas C25 
CA accessory sinuses C31 
Respiratory and Intrathoracic Regions C30 - C 39 CA bronchus,lung C34 
CA mesothelioma C45 Mesothelial and Soft Tissue C45 - C49 
CA breast C50 Breast C50 
CA cervix uteri C53 
Female Genital Organs C51 - C58 CA ovary C56 
CA female genital organs other C57 
CA prostate C61 Male Genital Organs C60 - C63 
CA bladder C67 Urinary Tract C64 - C68 
CA unspecified sites C80 Malignant Neoplasms of Ill-defined, 
C76 - C80 Cancer (non-specific) C80 secondary and unspecified sites 
Carcinoma C80   
Myeloma,plasma cell CA C90 Malignant Neoplasms, stated or 
presumed to be primary, of lymphoid,  
 haematopoietic and related tissue 
C81 - C96 CA haematopoietic other 
  
C96 
    
CA unspecified sites uncertain 
  
D48.9 
  
Neoplasms of Uncertain or Unknown  
Behaviour  
D37 - D48 
Diabetes mellitus comprising of:       
Diabetes mellitus (unspecified) E14 
Diabetes Mellitus E10 - E14 Diabetes type 1 insulin dependent E10.9 
Diabetes type 2 noninsulin dependent E11.9 
Lipid disorders comprising of:       
Hypercholesterolaemia E78.1 
Metabolic Disorders E70 - E90 Hyperlipidaemia E78.0 
Hypertriglyceridaemia E78.5 
Familial hyperlipidaemia E78.4 
Depression comprising of:    
Depression F32.9 
Mood Disorders F30 - F39 
Depression (major) F32.2 
Depression (mild) F32.0 
Depression with psychosis F32.3 
Dysthymia F34.1 
Mood affective disorder F38.8 
Neurotic depression F34.1 
Recurrent depression F33.2 
Depression (post natal) 
  
  
F53.0 
  
  
Behavioural Syndromes Associated  
with Physiological disturbances and  
Physical factors 
F50 - F59 
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GROUPING OF CHRONIC DISEASE STATES ACCORDING TO ICD-10 
DESCRIPTIONS AND CODES (CONTINUED) 
 
CHRONIC DISEASE STATES ICD-10 ICD-10 DESCRIPTION ICD-10 CODE 
      RANGE FOR 
      DESCRIPTION
Epilepsy comprising of:       
Epilepsy (atonic) G40.3 
Episodic and Paroxysmal Disorders G40 - G47 
Epilepsy (clonic) G40.3 
Epilepsy (generalised convulsive) G40.3 
Epilepsy (generalised nonconvulsive) G40.3 
Epilepsy (Grand mal) G40.6 
Epilepsy (major) G40.3 
Epilepsy (minor) G40.3 
Epilepsy (Petit mal) G40.7 
Epilepsy (psychomotor) G40.2 
Epilepsy (temporal lobe) G40.2 
Epilepsy (tonic/clonic) G40.3 
Epilepsy (unspecified) G40.9 
Epilepsy (myoclonic) G40.3 
Epilepsy (parTransient ischaemic 
attacks) G40.1 
Status epilepticus G41 
Epilepsy (partial) G40.1 
Acne comprising of:       
Acne L70 
Disorders of the Skin Appendages L60 - L75 
Acne (nodulocystic) L70.0 
Acne Conglobata L70.1 
Acne rosacea L70.8 
Acne Vulgaris L70.0 
Arthritis comprising of:    
Arthritis (not specific) M13.9 
Inflammatory Polyarthropathies M05 - M14 
Gouty arthritis M10.0 
Juvenile arthritis M08.9 
Osteo-arthritis M15.0 
Polyarthritis M13.0 
Psoriatic arthritis M07.0 
Rheumatoid - Arthritis M06.9 
HRT/Menopause    
HRT  N95.1 Noninflammatory Disorders of Female  
Genital Tract 
N80 - N98 
Menopause N95.1 
 
 
 
 
 
 395
 
 
 
 
APPENDIX D 
 
GLOSSARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 396
A1C     Glycosylated haemoglobin 
ACE     Angiotensin converting enzyme 
Ach     Acetylcholine 
ADHD Attention Deficit and Hyperactivity Disorder 
AHCPR    Agency for Health Care Policy and 
Research 
AHRQ Agency for Health Care Research and 
Quality  
AIDS     Acquired Immunodefiency Syndrome 
APA     American Psychiatric Association 
ATC     Anatomical-Therapeutic-Chemical  
BMI Body mass index 
CA Cancer 
CBT Cognitive Behavioral Therapy 
CCHS Canadian Community Health Survey 
CHD     Coronary Heart Disease 
CHF     Congestive Heart Failure 
CI     Confidence interval 
CNS     Central Nervous System 
Comm Date    Commencement date 
COPD     Chronic Obstructive Pulmonary Disease 
CRH     Corticotropin releasing hormone 
CSM     Committee on Safety of Medicines  
CVD     Cardiovascular Disease 
CYP450    Cytochrome P450 
d.f     Degrees of freedom 
DDD     Defined daily dosage 
dl     decilitre  
DSM®    Diagnostic and Statistical Manual of  
Mental Disorders 
DSM-IV-TR® Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, text revision 
ECA     Epidemiologic Catchment Area 
ECT     Electroconvulsive Therapy 
 397
ERT     Estrogen replacement therapy 
F     Female 
FDA     Food and Drug Administration  
FEV1     Forced expiratory volume in one second 
FBG     Fasting blood glucose 
GABA    Gamma-aminobutyric acid 
HAART    Highly active antiretroviral therapy 
HbA1c     Glycosylated haemoglobin 
HMG CoA     3-hydroxy-3-methylglutaryl-coenzyme A 
HIV     Human Immunodefiency Virus 
HPA     Hypothalamic-Pituitary-Adrenal  
HRT     Hormone replacement therapy 
ICD      International Statistical Classification of  
Diseases and Related Health Problems 
ICD-10    International Statistical Classification of  
Diseases and Related Health Problems,  
Tenth Revision  
ID     Identification number 
IHD     Ischaemic Heart Disease 
IPT     Interpersonal Therapy 
ISAAC    International Study of Asthma and Allergy in  
Children 
kg     Kilogram 
l     litre 
m     metre 
M     Male 
MAOI     Monoamine oxidase inhibitor 
MDD     Major Depressive Disorder 
MDE     Major depressive episode 
mg     milligram 
MI     Myocardial Infarction 
mmol     millimol  
MONICA Mulitinational MONitoring of Trends and 
Determinants in CArdiovascular Disease 
 398
MRI     Magnetic resonance imaging 
NAPPI National Pharmaceutical Pricing Index  
NCS     National Comorbidity Survey 
NCS-R    National Comorbidity Survey Replication 
NEMESIS Netherlands Mental Health Survey and 
Incidence Study 
NICE     National Institute for Clinical Excellence 
NIMH     National Institute of Mental Health 
SADHART    Sertraline Heart Attack Randomised Trial 
SAMF     South African Medicines Formulary 
SBMG    Self-monitoring of blood glucose 
SD     Standard deviation 
SEP     Single exit price 
SSRI     Selective serotonin re-uptake inhibitor 
T3     Tri-iodothyronine 
T4     Thyroxine 
TADS Treatment for Adolescents with Depression 
Study 
TCA     Tricyclic antidepressant 
Term Date    Termination date 
TG     Triglyceride 
UK     United Kingdom 
US     United States  
VTE     Venous Thrombo-embolism 
WHO     World Health Organization 
8-OH-dG    8-hydroxydeoxyguanosine 
 
